0001185185-18-000924.txt : 20180516 0001185185-18-000924.hdr.sgml : 20180516 20180516172028 ACCESSION NUMBER: 0001185185-18-000924 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 82 FILED AS OF DATE: 20180516 DATE AS OF CHANGE: 20180516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioSig Technologies, Inc. CENTRAL INDEX KEY: 0001530766 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 264333375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-224985 FILM NUMBER: 18840911 BUSINESS ADDRESS: STREET 1: 12424 WILSHIRE BLVD. STREET 2: SUITE 745 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: (310) 820-8100 MAIL ADDRESS: STREET 1: 12424 WILSHIRE BLVD. STREET 2: SUITE 745 CITY: LOS ANGELES STATE: CA ZIP: 90025 S-1 1 biosigtech-s1051018.htm S-1

As filed with the Securities and Exchange Commission on May 16, 2018
 
SEC File No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM S-1
 

 
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933


BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
3845
 
26-4333375
(State or other jurisdiction of
incorporation or organization)
 
(Primary Standard Industrial
Classification Code Number)
 
(I.R.S. Employer Identification No.)
 
12424 Wilshire Blvd., Suite 745
Los Angeles, CA 90025
(512) 329-2643
(Address, including zip code, and telephone number,
 including area code, of registrant’s principal executive offices)
 
Kenneth Londoner
Chief Executive Officer
12424 Wilshire Blvd., Suite 745
Los Angeles, CA 90025
(512) 329-2643
(Name, address, including zip code, and telephone number,
 including area code, of agent for service)

Copies of all communications, including communications sent to agent for service, should be sent to:

Rick A. Werner, Esq.
Haynes and Boone, LLP
30 Rockefeller Plaza, 26th Floor
New York, New York 10112
Tel. (212) 659-7300
Fax (212) 884-8234



 
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.  

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b–2 of the Exchange Act.
(Check one):

Large accelerated filer  
Accelerated filer  
 
 
Non-accelerated filer  
Smaller reporting company  
(Do not check if a smaller reporting company)
 
 
 
Emerging growth company
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

Calculation of Registration Fee
 
Title of Each Class of Securities to be Registered
 
Amount to be
Registered(1)
   
Proposed
Maximum Offering
Price per Share
   
Proposed
Maximum Aggregate
Offering Price
   
Amount of
Registration Fee
 
Common Stock, $0.001 par value per share
   
1,294,392
   
$
1.84
   (2)  
$
2,381,681.28
   
$
296.52
 
Common Stock underlying Warrants
   
683,334
   
$
1.84
   (2)  
$
1,257,334.56
   
$
156.54
 
Total
   
1,977,726
   
$
1.84
   (2)  
$
3,639,015.84
   
$
453.06
 
 
(1)
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares of common stock offered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions. 
(2)
Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based upon the average of the high and low sales price of the common stock on May 15, 2018, as reported on the OTCQB.

 
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.


The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED May 16, 2018


PRELIMINARY PROSPECTUS
 
BioSig Technologies, Inc.
 
Up to 1,294,392 Shares of Common Stock Underlying Series E Convertible Preferred Stock and up to 683,334 Shares of Common Stock Underlying Warrants
 
 
This prospectus relates to the resale of up to (i) 1,000,000 shares of common stock to be offered by the selling stockholders upon the conversion of 1,000 shares of our Series E Convertible Preferred Stock, at a conversion price of $1.50 per share, (ii) 294,392 shares of our common stock issuable as a make-whole dividend of 7% per annum upon the conversion of our Series E Convertible Preferred Stock and (iii) 683,334 shares of our common stock to be offered by the selling stockholders upon the exercise of outstanding common stock purchase warrants. 
 
Our common stock trades in the over-the-counter market and is quoted on the OTCQB tier of the OTC Markets Group, Inc. under the symbol “BSGM.” Only a limited public market currently exists for our common stock. On May 15, 2018, the last reported sale price of our shares of common stock on the OTCQB was $1.85 per share. 
 
We will not receive any of the proceeds from the sale of common stock by the selling stockholders. However, we will receive proceeds from the exercise of the warrants if the warrants are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes. All expenses of registration incurred in connection with this offering are being borne by us, but all selling and other expenses incurred by the selling stockholders will be borne by the selling stockholders.

We qualify as an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012, or JOBS Act, and have elected to comply with certain reduced public company reporting requirements in this and future filings.

Investing in our common stock is highly speculative and involves a high degree of risk. You should carefully consider the risks and uncertainties in the section entitled “Risk Factors” beginning on page 3 of this prospectus before making a decision to purchase our stock.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is               , 2018





TABLE OF CONTENTS

 
Page
1
3
16
17
17
 18
26
40
44
47
48
50
53
67
68
68
68
68
69
 
You should rely only on the information contained in this prospectus.  We have not authorized any other person to provide you with different information.  If anyone provides you with different or inconsistent information, you should not rely on it.  We are not making an offer to sell these securities in any jurisdiction where offer or sale is not permitted.  You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus.  Our business, financial condition, results of operations and prospects may have changed since that date.
 
Information contained on our website is not part of this prospectus.
 
 

PROSPECTUS SUMMARY
 
The following summary highlights information contained elsewhere in this prospectus. It may not contain all the information that may be important to you. You should read this entire prospectus carefully, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our historical financial statements and related notes included elsewhere in this prospectus, or any accompanying prospectus supplement before making an investment decision. In this prospectus, unless the context requires otherwise, all references to “we,” “our,” “us” and the “Company” refer to BioSig Technologies, Inc.

Overview

We are a development stage medical device company that is developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Our initial emphasis is on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and catheter ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). Catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue in order to correct heart rhythm disturbances. Our product under development, the PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The PURE EP System is intended to be used in addition to existing electrophysiology recorders. We believe that data provided by the PURE EP System will increase the workload ability and enhance the capabilities of the typical electrophysiology laboratory.

We were formed as BioSig Technologies, Inc., a Nevada corporation, in February 2009. In April 2011, we merged with our wholly-owned subsidiary, BioSig Technologies Inc., a Delaware corporation, with the Delaware corporation continuing as the surviving entity. We have not generated any revenue to date and consequently our operations are subject to all risks inherent in the establishment of a new business enterprise.

Our principal executive offices are located at 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025, telephone number (512) 329-2643. Our website address is www.biosigtech.com. Information accessed through our website is not incorporated into this prospectus and is not a part of this prospectus.
 


The Offering

Common stock offered by the selling stockholders:
 
 
Up to 1,000,000 shares of our common stock to be offered by the selling stockholders upon conversion of shares of our Series E Convertible Preferred Stock (“Series E Preferred Stock”), up to 294,392 shares of our common stock issuable as a make-whole dividend of 7% per annum upon the conversion of the Series E Preferred Stock and up to 683,334 shares of our common stock to be offered by the selling stockholders upon the exercise of outstanding common stock purchase warrants.
 
 
 
Common stock outstanding prior to the offering:
 
36,270,975
 
 
 
Common stock outstanding after this offering:
 
38,248,701 (1)
 
 
 
Use of proceeds:
 
We will not receive any proceeds from the sale of the common stock offered by the selling stockholders. However, we will receive proceeds from the exercise price of the warrants if the warrants are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes.
 
 
 
OTCQB trading symbol: 
 
“BSGM”
 
 
 
Risk factors:
 
 
You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors” section beginning on page 3 of this prospectus before deciding whether or not to invest in shares of our common stock.

(1)
The number of shares of common stock outstanding after the offering is based upon 36,270,975 shares outstanding as of May 16, 2018 and assumes the exercise of all warrants with respect to those shares being registered for resale pursuant to the registration statement of which this prospectus forms a part.

The number of shares of common stock outstanding after this offering excludes:

9,095,319 shares of common stock issuable upon the exercise of currently outstanding options with a weighted average exercise price of $1.95 per share;

1,740 shares of common stock available for future issuance under the BioSig Technologies, Inc. 2012 Equity Incentive Plan;

7,290 shares of common stock issuable for make whole dividends on our Series D Convertible Preferred Stock (“Series D Preferred Stock”);
 
27,000 shares of common stock issuable upon the conversion of our Series D Preferred Stock;

206,409 shares of common stock issuable for accrued dividends on our Series C Convertible Preferred Stock (“Series C Preferred Stock”) as of March 31, 2018;
 
383,338 shares of common stock issuable upon the conversion of our Series C Preferred Stock; and

13,117,223 shares of common stock issuable upon exercise of warrants with a weighted average exercise price of $1.85 per share.
 


RISK FACTORS
 
Investing in our common stock involves a high degree of risk. You should carefully consider the following factors and other information in this prospectus or any accompanying prospectus supplement before making a decision to invest in our common stock. If any of the risks actually occur, our business, financial conditions and operating results may be materially and adversely affected. In that event, the trading price of our common stock may decline, and you could lose all or part of your investment.

Risks Related to Our Business and Industry

Because our condition as a going concern is in doubt, we will be forced to cease our business operations unless we can raise sufficient funds to satisfy our working capital needs.

As shown in the accompanying financial statements during years ended December 31, 2017 and 2016, we incurred net losses attributable to common stockholders of $12,815,620 and $11,697,210, respectively and used $7,470,054 in cash for operating activities for the year ended December 31, 2017. As of May 16, 2018, we had cash on hand of approximately $4,550,000. These factors, among others, raise substantial doubt that we will be able to continue as a going concern for a reasonable period of time.
 
Our existence is dependent upon management’s ability to develop profitable operations. We are devoting substantially all of our efforts to developing product candidates and there can be no assurance that our efforts will be successful. There is no assurance that can be given that our actions will result in profitable operations or the resolution of our liquidity problems.

Because we are an early development stage company with no products near commercialization, we expect to incur significant additional operating losses.

We are an early development stage company and we expect to incur substantial additional operating expenses over the next several years as our research, development, pre-clinical testing, regulatory approval and clinical trial activities increase. The amount of our future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue and do not expect to generate revenues from the commercial sale of our products in the near future, if ever. Our ability to generate revenue and achieve profitability will depend on, among other things, the following:

successful completion of the pre-clinical and clinical development of our products;

obtaining necessary regulatory approvals from the U.S. Food and Drug Administration or other regulatory authorities;

establishing manufacturing, sales, and marketing arrangements, either alone or with third parties; and

raising sufficient funds to finance our activities.

We might not succeed at all, or at any, of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected.

Our product candidates are at an early stage of development and may not be successfully developed or commercialized.

Our main product candidate, the PURE EP System, is in the early stage of development and will require substantial further capital expenditures, development, testing, and regulatory clearances prior to commercialization, especially given that we have not yet completed pre-clinical testing on this product. The development and regulatory approval process takes several years and it is not likely that the PURE EP System, even if successfully developed and approved by the U.S. Food and Drug Administration, may not be commercially available for a number of years. In addition, due to budgetary constraints, we have not been able to devote the level of resources that we desired to our research and development efforts. The continued development of our product candidates is dependent upon our ability to obtain sufficient financing. However, even if we are able to obtain the requisite financing to fund our development program, we cannot assure you that our product candidates will be successfully developed or commercialized. Our failure to develop, manufacture or receive regulatory approval for or successfully commercialize any of our product candidates could result in the failure of our business and a loss of all of your investment in our company.


We expect to derive our revenue from sales of our PURE EP System and other products we may develop. If we fail to generate revenue from these sources, our results of operations and the value of our business will be materially and adversely affected.

We expect our revenue to be generated from sales of our PURE EP System and other products we may develop. Future sales of these products, if any, will be subject to, among other things, the receipt of regulatory approvals and commercial and market uncertainties that may be outside our control. If we fail to generate our intended revenues from these products, our results of operations and the value of our business and securities would be materially and adversely affected.

We may need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may require us to relinquish valuable rights.

Until and unless we receive approval from the U.S. Food and Drug Administration and other regulatory authorities for our products, we will not generate revenues from our products. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand, public or private equity offerings, debt financings, bank credit facilities or corporate collaboration and licensing arrangements. We believe that our existing cash on hand will be sufficient to enable us to fund our projected operating requirements for approximately the next two months. However, we may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate. We also may decide to raise additional funds before we require them if we are presented with favorable terms for raising capital.

If we seek to sell additional equity or debt securities, obtain a bank credit facility or enter into a corporate collaboration or licensing arrangement, we may not obtain favorable terms for us and/or our stockholders or be able to raise any capital at all, all of which could result in a material adverse effect on our business and results of operations. The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that would restrict our operations. Raising additional funds through collaboration or licensing arrangements with third parties may require us to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us or our stockholders. In addition, we could be forced to discontinue product development, reduce or forego sales and marketing efforts and forego attractive business opportunities, all of which could have an adverse impact on our business and results of operations.

We may be unable to develop our existing or future technology.

Our product, the PURE EP System, may not deliver the levels of accuracy and reliability needed to make it a successful product in the marketplace, and the development of such accuracy and reliability may be indefinitely delayed or may never be achieved.  In addition, we may experience delays in the development of our technology for other reasons, including failure to obtain necessary funding and failure to obtain regulatory approvals.  Failure to develop this or other technology could have an adverse material effect on our business, financial condition, results of operations and future prospects.

The results of clinical studies may not support the usefulness of our technology.

Conducting clinical trials is a long, expensive and uncertain process that is subject to delays and failure at any stage. Clinical trials can take months or years. The commencement or completion of any of our clinical trials may be delayed or halted for numerous reasons, including:

the U.S. Food and Drug Administration may not approve a clinical trial protocol or a clinical trial, or may place a clinical trial on hold;

subjects may not enroll in clinical trials at the rate we expect or we may not follow up on subjects at the rate we expect;

subjects may experience events unrelated to our products;

third-party clinical investigators may not perform our clinical trials consistent with our anticipated schedule or the clinical trial protocol and good clinical practices, or other third-party organizations may not perform data collection and analysis in a timely or accurate manner;

interim results of any of our clinical trials may be inconclusive or negative;


regulatory inspections of our clinical trials may require us to undertake corrective action or suspend or terminate the clinical trials if investigators find us not to be in compliance with regulatory requirements; or

governmental regulations or administrative actions may change and impose new requirements, particularly with respect to reimbursement.

Results of pre-clinical studies do not necessarily predict future clinical trial results and previous clinical trial results may not be repeated in subsequent medical trials. We may experience delays, cost overruns and project terminations despite achieving promising results in pre-clinical testing or early clinical testing. In addition, the data obtained from clinical trials may be inadequate to support approval or clearance of a submission. The U.S. Food and Drug Administration may disagree with our interpretation of the data from our clinical trials, or may find the clinical trial design, conduct or results inadequate to demonstrate the safety and effectiveness of the product candidate. The U.S. Food and Drug Administration may also require us to conduct additional pre-clinical studies or clinical trials that could further delay approval of our products. If we are unsuccessful in receiving U.S. Food and Drug Administration approval of a product, we would not be able to commercialize the product in the U.S., which could seriously harm our business. Moreover, we face similar risks in other jurisdictions in which we may sell or propose to sell our products.

The medical device industry is subject to stringent regulation and failure to obtain regulatory approval will prevent commercialization of our products.

Medical devices are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration pursuant to the Federal Food, Drug, and Cosmetic Act, by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Under the Federal Food, Drug, and Cosmetic Act and associated regulations, manufacturers of medical devices must comply with certain regulations that cover the composition, labeling, testing, clinical study, manufacturing, packaging and distribution of medical devices. In addition, medical devices must receive U.S. Food and Drug Administration clearance or approval before they can be commercially marketed in the U.S., and the U.S. Food and Drug Administration may require testing and surveillance programs to monitor the effects of approved products that have been commercialized and can prevent or limit further marketing of a product based on the results of these post-market evaluation programs. The process of obtaining marketing clearance from the U.S. Food and Drug Administration for new products could take a significant period of time, require the expenditure of substantial resources, involve rigorous pre-clinical and clinical testing, require changes to the products and result in limitations on the indicated uses of the product.  In addition, if we seek regulatory approval in non-U.S. markets, we will be subject to further regulatory approvals that may require additional costs and resources.  There is no assurance that we will obtain necessary regulatory approvals in a timely manner, or at all.

Our product, the PURE EP System, will need to receive 510(k) marketing clearance from the U.S. Food and Drug Administration in order permit us to market this product in the U.S. In addition, if we intend to market our product for additional medical uses or indications, we will need to submit additional 510(k) applications to the U.S. Food and Drug Administration that are supported by satisfactory clinical trial results specifically for the additional indication. The results of our initial clinical trials may not provide sufficient evidence to allow the U.S. Food and Drug Administration to grant us such additional marketing clearances and even additional trials requested by the U.S. Food and Drug Administration may not result in our obtaining 510(k) marketing clearance for our product. The failure to obtain U.S. Food and Drug Administration marketing clearance for the PURE EP System, any additional indications for the PURE EP System or any other of our future products would have a material adverse effect on our business.

Even if regulatory approval is obtained, our products will be subject to extensive post-approval regulation.

Once a product is approved by the relevant regulatory body for our targeted commercialization market, numerous post-approval requirements apply, including but not limited to requirements relating to manufacturing, labeling, packaging, advertising and record keeping.  Even if regulatory approval of a product is obtained, the approval may be subject to limitations on the uses for which the product may be marketed, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Any such post-approval requirement could reduce our revenues, increase our expenses and render the approved product candidate not commercially viable.  If we fail to comply with the regulatory requirements of the applicable regulatory authorities, or if previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other negative consequences, including:

restrictions on our products, manufacturers or manufacturing processes;

warning letters and untitled letters;


civil penalties and criminal prosecutions and penalties;

fines;

injunctions;

product seizures or detentions;

import or export bans or restrictions;

voluntary or mandatory product recalls and related publicity requirements;

suspension or withdrawal of regulatory approvals;

total or partial suspension of production; and

refusal to approve pending applications for marketing approval of new products or of supplements to approved applications.

Regulations are constantly changing, and in the future our business may be subject to additional regulations that increase our compliance costs.

We believe we understand the current laws and regulations to which our products will be subject in the future.  However, federal, state and foreign laws and regulations relating to the sale of our products are subject to future changes, as are administrative interpretations of regulatory agencies. If we fail to comply with such federal, state or foreign laws or regulations, we may fail to obtain regulatory approval for our products and, if we have already obtained regulatory approval, we could be subject to enforcement actions, including injunctions preventing us from conducting our business, withdrawal of clearances or approvals and civil and criminal penalties. In the event that federal, state, and foreign laws and regulations change, we may incur additional costs to seek government approvals, in addition to the clearance we intend to seek from the U.S. Food and Drug Administration in order to sell or market our products. If we are slow or unable to adapt to changes in existing regulatory requirements or the promulgation of new regulatory requirements or policies, we or our licensees may, following approval, lose marketing approval for our products which will impact our ability to conduct business in the future.

The market for our technology and revenue generation avenues for our products may be slow to develop, if at all.

The market for our products may be slower to develop or smaller than estimated or it may be more difficult to build the market than anticipated.  The medical community may resist our products or be slower to accept them than we anticipate.  Revenues from our products may be delayed or costs may be higher than anticipated which may result in our need for additional funding.  We anticipate that our principal route to market will be through commercial distribution partners.  These arrangements are generally non-exclusive and have no guaranteed sales volumes or commitments.  The partners may be slower to sell our products than anticipated.  Any financial, operational or regulatory risks that affect our partners could also affect the sales of our products.  In the current economic environment, hospitals and clinical purchasing budgets may exercise greater restraint with respect to purchases, which may result in purchasing decisions being delayed or denied.  If any of these situations were to occur this could have a material adverse effect on our business, financial condition, results of operations and future prospects.

If we seek to market our products in foreign jurisdictions, we may need to obtain regulatory approval in these jurisdictions.

In order to market our products in the European Union and many other foreign jurisdictions, we may need to obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. Approval procedures vary among countries (except with respect to the countries that are part of the European Economic Area) and can involve additional clinical testing. The time required to obtain approval may differ from that required to obtain U.S. Food and Drug Administration approval. Should we decide to market our products abroad, we may fail to obtain foreign regulatory approvals on a timely basis, if at all. Approval by the U.S. Food and Drug Administration does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority, including obtaining CE Mark approval, does not ensure approval by regulatory authorities in other foreign countries or by the U.S. Food and Drug Administration. We may be unable to file for, and may not receive, necessary regulatory approvals to commercialize our products in any foreign market, which could adversely affect our business prospects.

The electrophysiology market is highly competitive.

There are a number of groups and organizations, such as healthcare, medical device and software companies in the electrophysiology market that may develop a competitive offering to our products.  The largest companies in the electrophysiology market are GE, Johnson & Johnson, Boston Scientific, Siemens and Abbott.  All of these companies have significantly greater resources, experience and name recognition than we possess. There is no assurance that they will not attempt to develop similar or superior products, that they will not be successful in developing such products or that any products they may develop will not have a competitive advantage over our products. If we experience delayed regulatory approvals or disputed clinical claims, we may not have a commercial or clinical advantage over competitors’ products that we believe we currently possess.  Should a superior offering come to market, this could have a material adverse effect on our business, financial condition, results of operations and future prospects.

We rely on key officers, consultants and scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.

We are highly dependent on our officers, consultants and scientific and medical advisors because of their expertise and experience in medical device development.  We do not have “key person” life insurance policies for any of our officers.  Moreover, if we are unable to obtain additional funding, we will be unable to meet our current and future compensation obligations to such employees and consultants. In light of the foregoing, we are at risk that one or more of our consultants or employees may leave our company for other opportunities where there is no concern about such employers fulfilling their compensation obligations, or for other reasons.  The loss of the technical knowledge and management and industry expertise of any of our key personnel could result in delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect our results of operations.

We may fail to attract and retain qualified personnel.

We expect to rapidly expand our operations and grow our sales, research and development and administrative operations.  This expansion is expected to place a significant strain on our management and will require hiring a significant number of qualified personnel.  Accordingly, recruiting and retaining such personnel in the future will be critical to our success.  There is intense competition from other companies, research and academic institutions, government entities and other organizations for qualified personnel in the areas of our activities.  Many of these companies, institutions and organizations have greater resources than we do, along with more prestige associated with their names. If we fail to identify, attract, retain and motivate these highly skilled personnel, we may be unable to continue our marketing and development activities, and this could have a material adverse effect on our business, financial condition, results of operations and future prospects.

If we do not effectively manage changes in our business, these changes could place a significant strain on our management and operations.

Our ability to grow successfully requires an effective planning and management process. The expansion and growth of our business could place a significant strain on our management systems, infrastructure and other resources. To manage our growth successfully, we must continue to improve and expand our systems and infrastructure in a timely and efficient manner. Our controls, systems, procedures and resources may not be adequate to support a changing and growing company. If our management fails to respond effectively to changes and growth in our business, including acquisitions, there could be a material adverse effect on our business, financial condition, results of operations and future prospects.

Our strategic business plan may not produce the intended growth in revenue and operating income.

Our strategies ultimately include making significant investments in sales and marketing programs to achieve revenue growth and margin improvement targets. If we do not achieve the expected benefits from these investments or otherwise fail to execute on our strategic initiatives, we may not achieve the growth improvement we are targeting and our results of operations may be adversely affected. We may also fail to secure the capital necessary to make these investments, which will hinder our growth.
 
In addition, as part of our strategy for growth, we may make acquisitions and enter into strategic alliances such as joint ventures and joint development agreements. However, we may not be able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully, and our strategic alliances may not prove to be successful. In this regard, acquisitions involve numerous risks, including difficulties in the integration of the operations, technologies, services and products of the acquired companies and the diversion of management’s attention from other business concerns. Although we will endeavor to evaluate the risks inherent in any particular transaction, there can be no assurance that we will properly ascertain all such risks. In addition, acquisitions could result in the incurrence of substantial additional indebtedness and other expenses or in potentially dilutive issuances of equity securities. There can be no assurance that difficulties encountered with acquisitions will not have a material adverse effect on our business, financial condition and results of operations.

We currently have no sales, marketing or distribution operations and will need to expand our expertise in these areas.

We currently have no sales, marketing or distribution operations and, in connection with the expected commercialization of our planned products, will need to expand our expertise in these areas. To increase internal sales, distribution and marketing expertise and be able to conduct these operations, we would have to invest significant amounts of financial and management resources. In developing these functions ourselves, we could face a number of risks, including:

we may not be able to attract and build an effective marketing or sales force;

the cost of establishing, training and providing regulatory oversight for a marketing or sales force may be substantial; and

there are significant legal and regulatory risks in medical device marketing and sales that we have never faced, and any failure to comply with applicable legal and regulatory requirements for sales, marketing and distribution could result in an enforcement action by the U.S. Food and Drug Administration, European regulators or other authorities that could jeopardize our ability to market our planned products or could subject us to substantial liability.

The liability of our directors and officers is limited.

The applicable provisions of the Delaware General Corporation Law and our Amended and Restated Certificate of Incorporation and By-laws limit the liability of our directors to us and our stockholders for monetary damages for breaches of their fiduciary duties, with certain exceptions, and for other specified acts or omissions of such persons. In addition, the applicable provisions of the Delaware General Corporation Law and of our Amended and Restated Certificate of Incorporation and By-laws provide for indemnification of such persons under certain circumstances. In the event we are required to indemnify any of our directors or any other person, our financial strength may be harmed.

Our product development program depends upon third-party researchers who are outside our control and whose negative performance could materially hinder or delay our pre-clinical testing or clinical trials.

We do not have the ability to conduct all aspects of pre-clinical testing or clinical trials ourselves. We depend upon independent investigators and collaborators, such as commercial third-parties, government, universities and medical institutions, to conduct our pre-clinical and clinical trials under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs.  These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves.  The failure of any of these outside collaborators to perform in an acceptable and timely manner in the future, including in accordance with any applicable regulatory requirements, such as good clinical and laboratory practices, or pre-clinical testing or clinical trial protocols, could cause a delay or otherwise adversely affect our pre-clinical testing or clinical trials, our success in obtaining regulatory approvals and, ultimately, the timely advancement of our development programs. In addition, these collaborators may also have relationships with other commercial entities, some of whom may compete with us.  If our collaborators assist our competitors at our expense, our competitive position would be harmed.

Negative publicity or unfavorable media coverage could damage our reputation and harm our operations.

In the event that the marketplace perceives our products as not offering the benefits which we believe they offer, we may receive negative publicity. This publicity may result in litigation and increased regulation and governmental review. If we were to receive such negative publicity or unfavorable media attention, whether warranted or unwarranted, our ability to market our products would be adversely affected. We may be required to change our products and services and become subject to increased regulatory burdens, and we may be required to pay large judgments or fines and incur significant legal expenses. Any combination of these factors could further increase our cost of doing business and adversely affect our financial position, results of operations and cash flows.

We may face risks associated with future litigation and claims.

We may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract disputes, employment actions, employee benefits, taxes, environmental, health and safety, personal injury and product liability matters. Due to the uncertainties of litigation, we can give no assurance that we will prevail on any claims made against us in any such lawsuit. Also, we can give no assurance that any other lawsuits or claims brought in the future will not have an adverse effect on our financial condition, liquidity or operating results.


Specifically, we believe we will be subject to product liability claims or product recalls, particularly in the event of false positive or false negative reports, because we plan to develop and manufacture medical diagnostic products.  We intend to obtain appropriate insurance coverage once we reach a manufacturing stage. A product recall or a successful product liability claim or claims that exceed our planned insurance coverage could have a material adverse effect on us.  In addition, product liability insurance is expensive. In the future we may not be able to obtain coverage on acceptable terms, if at all.  Moreover, our insurance coverage may not adequately protect us from liability that we incur in connection with clinical trials or sales of our products. In the event of an award against us during a time when we have no available insurance or insufficient insurance, we may sustain significant losses of our operating capital.  In addition, any products liability litigation, regardless of outcome or strength of claims, may divert time and resources away from the day-to-day operation of our business and product development efforts.  Any of these outcomes could adversely impact our business and results of operations, as well as impair our reputation in the medical and investment communities.

We may be subject, directly or indirectly, to U.S. federal and state health care fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such litigation. If we are unable to, or have not fully complied with such laws, we could face substantial penalties.

If we are successful in achieving regulatory approval to market our PURE EP System, our operations will be directly, or indirectly through our customers and health care professionals, subject to various U.S. federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, federal False Claims Act, and federal Foreign Corrupt Practices Act. These laws may impact, among other things, our proposed sales, and marketing and education programs.

The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid programs. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The federal Anti-Kickback Statute is broad and, despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the federal Anti-Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only the Medicare and Medicaid programs.

The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Suits filed under the federal False Claims Act, known as “qui tam” actions, can be brought by any individual on behalf of the government and such individuals, commonly known as “relators” or “whistleblowers,” may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of medical device and health care companies to have to defend a federal False Claim Act action. The federal Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been previously dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims act to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws including qui tam provisions.

The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid starting in 2012 to record any transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosure. Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the U.S., and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states such as Massachusetts and Vermont impose an outright ban on certain gifts to physicians. If we receive U.S. Food and Drug Administration clearance to market our system in the U.S., these laws could affect our promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and gift bans will impose administrative, cost and compliance burdens on us.


We are unable to predict whether we could be subject to actions under any of these laws, or the impact of such actions. If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, or an administrative action of suspension or exclusion from government health care reimbursement programs and the curtailment or restructuring of our operations.

In addition, to the extent we commence commercial operations overseas, we will be subject to the federal Foreign Corrupt Practices Act and other countries’ anti-corruption/anti-bribery regimes, such as the U.K. Bribery Act. The federal Foreign Corrupt Practices Act prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, sales agents or distributors may be ineffective, and violations of the federal Foreign Corrupt Practices Act and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial condition and results of operations.

We have identified a material weakness in our internal control over financial reporting which, if not remediated, could adversely affect our reputation, business or stock price.

As disclosed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2018, as amended by Amendment No. 1 on Form 10-K/A filed with the Securities and Exchange Commission on March 26, 2018, we have identified a material weakness in our internal control over financial reporting related to the segregation of duties in the initiating and recording of transactions.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.  Management has evaluated, and continues to evaluate, avenues for mitigating our internal controls weaknesses, but mitigating controls to completely mitigate internal control weaknesses have been deemed to be impractical and prohibitively costly, due to the size of our organization. While management expects to continue to use reasonable care in following and seeking improvements to effective internal control processes that have been and continue to be in use by us, we cannot assure you that our remedial measures will be sufficient to address the material weakness.  Moreover, we cannot assure you that we will not identify additional material weaknesses in our internal control over financial reporting in the future. If we are unable to remediate the material weakness, our ability to record, process and report financial information accurately, and to prepare financial statements within the time periods specified by the rules and forms of the Securities and Exchange Commission, could be adversely affected. The occurrence of or failure to remediate the material weakness may adversely affect our reputation and business and the market price of our common stock and any other securities we may issue.

Risks Related to Our Intellectual Property

If we do not obtain protection for our intellectual property rights, our competitors may be able to take advantage of our research and development efforts to develop competing products.

We intend to rely on a combination of patents, trade secrets, and nondisclosure and non-competition agreements to protect our proprietary intellectual property.  We have filed a patent application with the U.S. Patent and Trademark Office, and we have filed this patent application under the Patent Cooperation Treaty (PCT) with the U.S. Receiving Office.  We plan to file additional patent applications in the U.S. and in other countries as we deem appropriate for our products.  Our applications have and will include claims intended to provide market exclusivity for certain commercial aspects of the products, including the methods of production, the methods of usage and the commercial packaging of the products. However, we cannot predict:

the degree and range of protection any patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;

if and when such patents will be issued, and, if granted, whether patents will be challenged and held invalid or unenforceable;

whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or

whether we will need to initiate litigation or administrative proceedings which may be costly regardless of outcome.


Our success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors as well as our licensors and contractors.  To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret protection and confidentiality agreements.  To this end, it is our policy to require all of our employees, consultants, advisors and contractors to enter into agreements which prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.  These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information.  If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.

Given the fact that we may pose a competitive threat, competitors, especially large and well-capitalized companies that own or control patents relating to electrophysiology recording systems, may successfully challenge our current and planned patent applications, produce similar products or products that do not infringe our future patents, or produce products in countries where we have not applied for patent protection or that do not respect our patents.

If any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of our intellectual property may be greatly reduced.  Patent protection and other intellectual property protection are important to the success of our business and prospects, and there is a substantial risk that such protections will prove inadequate.

If we infringe upon the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against litigation.

If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial costs and we may be required to:

obtain licenses, which may not be available on commercially reasonable terms, if at all;

abandon an infringing product candidate;

redesign our product candidates or processes to avoid infringement;

cease usage of the subject matter claimed in the patents held by others;

pay damages; and/or

defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of our financial and management resources.

Any of these events could substantially harm our earnings, financial condition and operations.

Risks Related to our Common Stock

The public trading market for our common stock is volatile and may result in higher spreads in stock prices, which may limit the ability of our investors to sell their shares of our common stock at a profit, if at all.

Our common stock trades in the over-the-counter market and is quoted on the OTCQB tier of the OTC Markets Group, Inc. The over-the-counter market for securities has historically experienced extreme price and volume fluctuations during certain periods. These broad market fluctuations may adversely affect the market price of our common stock and result in substantial losses to our investors. In addition, the spreads on stock traded through the over-the-counter market are generally unregulated and higher than on national stock exchanges, which means that the difference between the price at which shares could be purchased by investors in the over-the-counter market compared to the price at which they could be subsequently sold would be greater than on these exchanges. Significant spreads between the bid and asked prices of the stock could continue during any period in which a sufficient volume of trading is unavailable or if the stock is quoted by an insignificant number of market makers. Historically, our trading volume has been insufficient to significantly reduce this spread and we have had a limited number of market makers insufficient to affect this spread. These higher spreads could adversely affect investors who purchase the shares at the higher price at which the shares are sold, but subsequently sell the shares at the lower bid prices quoted by the brokers. Unless the bid price for the stock exceeds the price paid for the shares by the investor, plus brokerage commissions or charges, the investor could lose money on the sale. For higher spreads such as those on over-the-counter stocks, this is likely a much greater percentage of the price of the stock than for exchange listed stocks. There is no assurance that at the time an investor in our common stock wishes to sell the shares, the bid price will have sufficiently increased to create a profit on the sale. 


We do not know whether a market for our common stock will be sustained or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.

Although our common stock now trades on the OTCQB, an active trading market for our shares may not be sustained. It may be difficult for our stockholders to sell their shares without depressing the market price for our shares or at all. As a result of these and other factors, our stockholders may not be able to sell their shares. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration. If an active market for our common stock does not develop or is not sustained, it may be difficult for our stockholders to sell shares of our common stock.

The market price for our common stock may fluctuate significantly, which could result in substantial losses by our investors.

The market price of our common stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:

the outcomes of potential future patent litigation;

our ability to monetize our future patents;

changes in our industry;

announcements of technological innovations, new products or product enhancements by us or others;

announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;

changes in earnings estimates or recommendations by security analysts, if our common stock is covered by analysts;

investors’ general perception of us;

future issuances of common stock;

the addition or departure of key personnel;

general market conditions, including the volatility of market prices for shares of technology companies, generally, and other factors, including factors unrelated to our operating performance; and

the other factors described in this “Risk Factors” section.

These factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock and result in substantial losses by our investors.

Further, the stock market in general, and the market for technology companies in particular, has experienced extreme price and volume fluctuations in the past. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock.

Price volatility of our common stock might be worse if the trading volume of our common stock is low. In the past, following periods of market volatility, stockholders have often instituted securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and divert resources and attention of management from our business, even if we are successful. Future sales of our common stock could also reduce the market price of such stock.

Moreover, the liquidity of our common stock is limited, not only in terms of the number of shares that can be bought and sold at a given price, but by delays in the timing of transactions and reduction in security analysts’ and the media’s coverage of us, if any. These factors may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between the bid and ask prices for our common stock. In addition, without a large float, our common stock is less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate its investment in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will trade in the future.


Our common stock is a “penny stock,” which makes it more difficult for our investors to sell their shares.

Our common stock is subject to the “penny stock” rules adopted under Section 15(g) of the Securities Exchange Act of 1934, as amended. The penny stock rules generally apply to companies whose common stock is not listed on The NASDAQ Stock Market or other national securities exchange and trades at less than $5.00 per share, other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible net worth of at least $5,000,000 ($2,000,000 if the company has been operating for three or more years). These rules require, among other things, that brokers who trade penny stock to persons other than “established customers” complete certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market, if any, for our securities. If our securities are subject to the penny stock rules, investors will find it more difficult to dispose of our securities.

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

If our stockholders sell substantial amounts of our common stock in the public market, it could create a circumstance commonly referred to as an “overhang,” in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

Our stockholders may experience substantial dilution as a result of the conversion of outstanding convertible preferred stock or the exercise of options and warrants to purchase shares of our common stock.

As of May 16, 2018, we have granted options to purchase 9,095,319 shares of common stock and have reserved 1,740 shares of our common stock for further issuances pursuant to our 2012 Equity Incentive Plan. In addition, as of May 16, 2018, we may be required to issue 589,747 shares of our common stock for issuance upon conversion of outstanding convertible Series C preferred stock which includes accrued dividends as of March 31, 2018; 34,290 shares of our common stock for issuance upon conversion of outstanding convertible Series D preferred stock which includes make-whole payment dividends; 1,294,392 shares of our common stock for issuance upon conversion of outstanding convertible Series E preferred stock which includes make-whole payment dividends;  and 13,800,557 shares of our common stock for issuance upon exercise of outstanding warrants.  Should all of these shares be issued, you would experience dilution in ownership of our common stock and the price of our common stock will decrease unless the value of our company increases by a corresponding amount.
 
The interests of our controlling stockholders may not coincide with yours and such controlling stockholders may make decisions with which you may disagree.
 
As of May 16, 2018, two of our stockholders beneficially owned over 22.50% of our common stock. As a result, these stockholders may be able to influence the outcome of matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control of our company and make some future transactions more difficult or impossible without the support of our controlling stockholders. The interests of our controlling stockholders may not coincide with our interests or the interests of other stockholders.
 
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have new research coverage by securities and industry analysts. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.


We are subject to financial reporting and other requirements that place significant demands on our resources.

We are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectiveness of our internal controls over financial reporting. These reporting and other obligations place significant demands on our management, administrative, operational, internal audit and accounting resources. Any failure to maintain effective internal controls could have a material adverse effect on our business, operating results and stock price. Moreover, effective internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed.

We are an “emerging growth company” and we cannot be certain that the reduced disclosure requirements applicable to emerging growth companies will not make our common stock less attractive to investors.

The JOBS Act permits “emerging growth companies” like us to rely on some of the reduced disclosure requirements that are already available to smaller reporting companies. As long as we qualify as an emerging growth company or a smaller reporting company, we would be permitted to omit the auditor’s attestation on internal control over financial reporting that would otherwise be required by the Sarbanes-Oxley Act, as described above, and are also exempt from the requirement to submit “say-on-pay”, “say-on-pay frequency” and “say-on-parachute” votes to our stockholders and may avail ourselves of reduced executive compensation disclosure that is already available to smaller reporting companies.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, as long as we are an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this until we are no longer an emerging growth company or until we affirmatively and irrevocably opt out of this exemption. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will cease to be an emerging growth company upon the earliest to occur of (i) the last day of the fiscal year during which we had total annual gross revenues of $1 billion (as indexed for inflation); (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of common stock under our registration statement on Form S-1 that became effective on June 23, 2014; (iii) the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt; or (iv) the date on which we are deemed to be a “large accelerated filer,” as defined by the Securities and Exchange Commission, which would generally occur upon our attaining a public float of at least $700 million. Once we lose emerging growth company status, we expect the costs and demands placed upon our management to increase, as we would have to comply with additional disclosure and accounting requirements, particularly if we would also not qualify as a smaller reporting company.  In addition, until such time, we cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile and could cause our stock price to decline.

Delaware law and our Amended and Restated Certificate of Incorporation and By-laws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.

Our board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences and other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our common stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely affect the voting or other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences and designations of the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control might benefit our stockholders. In addition, we are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless (i) prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; (ii) the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or (iii) on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.


Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

The terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock. As a result, any return on investment may be limited to the value of our common stock.

The terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock, absent consent from the holders representing a super-majority of the outstanding shares of our Series C Preferred Stock and a certain investor. Because we will likely not pay dividends, our common stock may be less valuable because a return on an investment in our common stock will only occur if our stock price appreciates.

Risks Related to our Series C Preferred Stock

Our Series C Preferred Stock contains covenants that could limit our financing options and liquidity position, which would limit our ability to grow our business.

Covenants in the certificate of designation for our Series C Preferred Stock impose operating and financial restrictions on us. These restrictions prohibit or limit our ability to, among other things:

incur additional indebtedness;

permit liens on assets;

repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;

pay cash dividends to our stockholders; and

engage in transactions with affiliates.

These restrictions may limit our ability to obtain financing, withstand downturns in our business or take advantage of business opportunities. Moreover, debt financing we may seek may contain terms that include more restrictive covenants, may require repayment on an accelerated schedule or may impose other obligations that limit our ability to grow our business, acquire needed assets, or take other actions we might otherwise consider appropriate or desirable.

In addition, the certificate of designation for our Series C Preferred Stock requires us to redeem shares of our Series C Preferred Stock, at each holder’s option and for an amount greater than their stated value, upon the occurrence of certain events, including our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings.

The holders of our Series C Preferred Stock are entitled to receive a dividend, which may be increased if we do not comply with certain covenants.

The holders of the Series C Preferred Stock are entitled to a 9% annual dividend on the $1,000 per share stated value of our Series C Preferred Stock, which is payable in cash or, subject to the satisfaction of certain conditions, in pay-in-kind shares.  The dividend may be increased to a 18% annual dividend if we fail to comply with certain covenants, including our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings.   As a result of the payment of dividends related to our Series C Preferred Stock, we may be obligated to pay significant sums of money or issue a significant number of shares of our common stock, which could negatively affect our operations or result in the dilution of the holders of our common stock, respectively.

Our Series C Preferred Stock and certain of our warrants contain anti-dilution provisions that may result in the reduction of their conversion prices or exercise prices in the future.

Our Series C Preferred Stock and certain of our warrants contain anti-dilution provisions, which provisions require the lowering of the conversion price or exercise price, as applicable, to the purchase price of future offerings. Furthermore, with respect to such warrants, if we complete an offering below the exercise price of such warrants, the number of shares issuable under such warrants will be proportionately increased such that the aggregate exercise price payable after taking into account the decrease in the exercise price, shall be equal to the aggregate exercise price prior to such adjustment. If in the future we issue securities for less than the conversion or exercise price of our Series C Preferred Stock and such warrants, respectively, we will be required to further reduce the relevant conversion or exercise prices, and the number of shares underlying such warrants will be increased.  We may find it more difficult to raise additional equity capital while our Series C Preferred Stock and such warrants are outstanding.


Risks Related to our Series D Preferred Stock

The holders of our Series D Preferred Stock are entitled to receive a dividend.

The holders of the Series D Preferred Stock are entitled to a 9% annual dividend on the $1,500 per share stated value of our Series D Preferred Stock when such holders convert their shares of Series D Preferred Stock into common stock, which is payable in cash or, subject to the satisfaction of certain conditions, in pay-in-kind shares.  As a result of the payment of dividends related to our Series D Preferred Stock, we may be obligated to pay significant sums of money or issue a significant number of shares of our common stock, which could negatively affect our operations or result in the dilution of the holders of our common stock, respectively.

Our Series D Preferred Stock and certain of our warrants contain anti-dilution provisions that may result in the reduction of their conversion prices or exercise prices in the future.

Our Series D Preferred Stock contains anti-dilution provisions, which provisions require the lowering of the conversion price to the purchase price of future offerings. If in the future we issue securities for less than the conversion price of our Series D Preferred Stock and such warrants, respectively, we will be required to further reduce the relevant conversion price.  We may find it more difficult to raise additional equity capital while our Series D Preferred Stock is outstanding.

Risks Related to our Series E Preferred Stock

The holders of our Series E Preferred Stock are entitled to receive a dividend.

The holders of the Series E Preferred Stock are entitled to a 7% annual dividend on the $1,500 per share stated value of our Series E Preferred Stock when such holders convert their shares of Series E Preferred Stock into common stock, which is payable in cash.  As a result of the payment of dividends related to our Series E Preferred Stock, we may be obligated to pay significant sums of money which could negatively affect our operations.

Our Series E Preferred Stock and certain of our warrants contain anti-dilution provisions that may result in the reduction of their conversion prices or exercise prices in the future.

Our Series E Preferred Stock contains anti-dilution provisions, which provisions require the lowering of the conversion price to the purchase price of future offerings. If in the future we issue securities for less than the conversion price of our Series E Preferred Stock and such warrants, respectively, we will be required to further reduce the relevant conversion price.  We may find it more difficult to raise additional equity capital while our Series E Preferred Stock is outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of the occurrence or the expected timing of future performance or results. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.  Important factors that could cause such differences include, but are not limited to:

inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties;

difficulties in obtaining financing on commercially reasonable terms;

changes in the size and nature of our competition;

loss of one or more key executives or scientists; and

difficulties in securing regulatory approval to market our product candidates.

You should review carefully the section entitled “Risk Factors” beginning on page 3 of this prospectus for a discussion of these and other risks that relate to our business and investing in shares of our common stock.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


USE OF PROCEEDS
 
All shares of our common stock offered by this prospectus are being registered for the accounts of the selling stockholders and we will not receive any proceeds from the sale of these shares. However, we will receive proceeds from the exercise price of the warrants if the warrants are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes.

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Market Information

On October 29, 2014, our common stock commenced trading on OTCQB under the symbol “BSGM.” Prior to October 29, 2014, there was no established trading price for our common stock. The following table sets forth, for the periods indicated, the high and low sales prices per share of our common stock as reported by the OTCQB. The quotations reflect inter-dealer prices, without retail markup, markdown or commissions, and may not represent actual transactions.
 
 
 
Fiscal Year 2018
 
 
 
High
   
Low
 
First Quarter
 
$
1.70
   
$
1.29
 
Second Quarter (through May 15, 2018)
 
$
2.36
   
$
1.57
 
 
 
 
Fiscal Year 2017
 
 
 
High
   
Low
 
First Quarter
 
$
2.00
   
$
1.20
 
Second Quarter
 
$
1.76
   
$
1.23
 
Third Quarter
 
$
1.60
   
$
1.25
 
Fourth Quarter
 
$
1.75
   
$
1.29
 
 
 
 
Fiscal Year 2016
 
 
 
High
   
Low
 
First Quarter
 
$
1.59
   
$
0.90
 
Second Quarter
 
$
2.15
   
$
1.33
 
Third Quarter
 
$
1.60
   
$
1.05
 
Fourth Quarter
 
$
1.59
   
$
1.25
 
 
 
 
Fiscal Year 2015
 
 
 
High
   
Low
 
First Quarter
 
$
2.85
   
$
1.31
 
Second Quarter
 
$
4.80
   
$
2.00
 
Third Quarter
 
$
2.30
   
$
1.13
 
Fourth Quarter
 
$
1.90
   
$
1.08
 
 
We have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future, but intend to retain our capital resources for reinvestment in our business.  In addition, the terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock, absent consent from the holders representing a super-majority of the outstanding shares of our Series C Preferred Stock and a certain investor.
 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and the related notes thereto that are included in this prospectus. In addition to historical information, the following discussion and analysis includes forward-looking statements that reflect our plans, estimates and beliefs.  Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the section entitled “Risk Factors.” See “Special Note Regarding Forward-Looking Statements.”

Our Business

We are a development stage medical device company developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Our initial emphasis is on providing intracardiac signal information to electrophysiologists during EP studies and catheter ablation of AF and VT. Our first product is the PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP™ System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiograms and electrograms required during electrophysiology studies and catheter ablation procedures.

We have not generated any revenue to date and consequently our operations are subject to all risks inherent in the establishment of a new business enterprise.

Critical Accounting Policies and Estimates

The following discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of financial statements in accordance with generally accepted accounting principles in the U.S. requires us to make estimates and assumptions that affect the amounts reported in our financial statements. The financial statements include estimates based on currently available information and our judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include allowance for doubtful accounts and accruals for inventory claims. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.

Among the significant judgments made by management in the preparation of our financial statements are the following:

Research and Development.

We account for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.

Stock Based Compensation.

All stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted stock and stock options, which are measured at fair value on the grant date and recognized in the statements of operations as compensation expense over the relevant vesting period. Restricted stock payments and stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable, the measurement date is the date the award is issued.

On October 29, 2014, our common stock commenced trading on OTCQB under the symbol “BSGM.”  Fair value is typically determined by the closing price of our common stock on the date of the award.


Derivative Instrument Liability

We account for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. On December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.

On December 31, 2017 and 2016, we had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions.

Income Taxes.

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. We record an estimated valuation allowance on our deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. We recognize a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Results of Operations

We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development efforts and the timing and outcome of regulatory submissions. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.
 
Three Months Ended March 31, 2018 Compared to Three Months Ended March 31, 2017
 
Revenues and Cost of Goods Sold. We had no revenues or cost of goods sold during the three months ended March 31, 2018 and 2017.
 
Research and Development Expenses. Research and development expenses for the three months ended March 31, 2018 were $862,420, a decrease of $476,184, or 35.6%, from $1,338,604 for the three months ended March 31, 2017. This decrease is primarily due to acquired research and development as we develop our proprietary technology platform in 2017 of $543,927, net with additional personnel and outside design costs Research and development expenses were comprised of the following:

Three months ended:

 
 
March 31,
2018
   
March 31,
2017
 
Salaries and equity compensation
 
$
287,849
   
$
260,722
 
Consulting expenses
   
131,601
     
91,545
 
Clinical studies and design work
   
419,325
     
396,301
 
Acquired research and development
   
-
     
543,927
 
Travel, supplies, other
   
23,645
     
46,109
 
  Total
 
$
862,420
   
$
1,338,604
 

Stock based compensation for research and development personnel was $98,589 and $13,104 for the three months ended March 31, 2018 and 2017, respectively.

General and Administrative Expenses. General and administrative expenses for the three months ended March 31, 2018 were $1,771,796, an increase of $214,455, or 13.8%, from $1,557,341 incurred in the three months ended March 31, 2017. This increase is primarily due to an increase in employees in the current period as compared to the same period in the prior year and additional service provider fees paid.

Payroll related expenses increased to $534,627 in the current period from $279,580 for the three months ended March 31, 2017, an increase of $255,047.  The increase was due to added staff in 2018 for commercialization, support personnel and a full time Chief Financial Officer in 2018.  We incurred $290,121 in stock based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the three months ended March 31, 2018 as compared to $547,642 in stock based compensation for the same period in 2017.

Professional services for the three months ended March 31, 2018 totaled $208,922, an increase of $126,371, or 153.1%, over the $82,551 recognized for the three months ended March 31, 2017. Of professional services, legal fees totaled $161,922 for the three months ended March 31, 2018, an increase of $119,371, or 280.5%, from $42,551 incurred for the three months ended March 31, 2017.  Accounting fees incurred in the three months ended March 31, 2018 amounted to $47,000, an increase of $7,000, or 17.5%, from $40,000 incurred in same period last year.  The increase in legal fees was primarily due registration statements and patent filing and research costs in 2018. 

Consulting, public and investor relations fees for the three months ended March 31, 2018 were $532,050 as compared to $493,666 incurred for the three months ended March 31, 2017. The increase in consulting and investor relations fees during the three months ended March 31, 2018 relate to our continued efforts to develop our recognition throughout the medical industry in an effective manner.
 
Travel, meals and entertainment costs for the three months ended March 31, 2018 were $90,921, an increase of $26,661, or 41.5%, from $64,260 incurred in the three months ended March 31, 2017. Travel, meals and entertainment costs include travel related to business development and financing. Rent for the three months ended March 31, 2018 totaled $34,853, an increase of $3,203 or 10.1%, from $31,650 incurred in three months ended March 31, 2017. 

Depreciation Expense. Depreciation expense for the three months ended March 31, 2018 totaled $2,903 a decrease of $166, or 5.4%, over the expense of $3,069 incurred in the three months ended March 31 2017, as a result of the  aging of office computers and other equipment.

Loss on change in fair values of derivatives.  Beginning in March 2015, we were required to estimate the fair value of the embedded beneficial conversion features of our issued Series C and Series D Preferred Stock and certain warrants with reset (anti-dilution) provisions.  During the three months ended March 31, 2017, we incurred a loss on change in fair values of these derivatives of $373,611. On January 1, 2018, we adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162 and are no longer required to treat certain embedded beneficial conversion features or reset (anti-dilution) provisions as liabilities.

Preferred Stock Dividend. Preferred stock dividend for the three months ended March 31, 2018 totaled $305,046, an increase of $281,301, or 1,184.7% from $23,745 incurred during the three months ended March 31, 2017. Preferred stock dividends are primarily related to the issuance of our Series C, D and E Preferred Stock from 2013 through 2018.  The significant increase in 2018 as compared to 2017 is the result of conversions of the Series D Preferred Stock and the payment, upon conversion, of a required minimum dividend of $270 per share of Series D Preferred Stock for the first three years of issuance.  
 
Net Loss available to common shareholders. As a result of the foregoing, net loss available to common shareholders for the three months ended March 31, 2018 was $2,942,080 compared to a net loss of $3,296,370 for the three months ended March 31, 2017.

Twelve Months Ended December 31, 2017 Compared to Twelve Months Ended December 31, 2016
 
Revenues and Cost of Goods Sold. We had no revenues or cost of goods sold during the twelve months ended December 31, 2017 and 2016.
 
Research and Development Expenses. Research and development expenses for the twelve months ended December 31, 2017 were $4,756,468, an increase of $2,101,967 or 79%, from $2,654,501 for the twelve months ended December 31, 2016. This increase is primarily due to additional personnel and outside design costs as we develop our proprietary technology platform. Research and development expenses were comprised of the following:
 
 
 
2017
   
2016
 
Salaries and equity compensation
 
$
1,481,421
   
$
1,744,780
 
Consulting expenses
   
500,628
     
322,520
 
Clinical studies and design work
   
2,066,028
     
388,447
 
Acquired research and development
   
543,927
     
-
 
Travel, supplies, other
   
164,464
     
198,754
 
  Total
 
$
4,756,468
   
$
2,654,501
 


Stock based compensation for research and development personnel was $432,929 and $760,732 for the year ended December 31, 2017 and 2016, respectively.

On March 15, 2017, we entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby we were granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale.  The agreement expires in ten years from the effective date.  As such, we are obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined.

In consideration, we issued 630,000 warrants to acquire the Company’s common stock at an exercise price of $1.50, expiring on March 15, 2020.  The estimated fair value of $543,927 was charged to operations as acquired research and development.

General and Administrative Expenses. General and administrative expenses for the twelve months ended December 31, 2017 were $8,138,117, a decrease of $361,187, or 4%, from $8,499,304 incurred in the twelve months ended December 31, 2016. This decrease is primarily due to decrease in equity-based compensation, net with increases in professional services, consulting fees and travel, meals and entertainment costs.

Payroll related expenses (including equity compensation) decreased to $5,579,117 in the twelve months ended December 31, 2017 from $6,381,610 for the twelve months ended December 31, 2016, a decrease of $802,493, or 13%. This decrease is due to the value of the stock-based compensation decreasing to $4,316,542 in 2017, as a result of the vesting of stock and stock options issued to board members, officers and employees, as compared to $5,233,818 of stock-based compensation in 2016, net with added additional personnel.

Professional services for the twelve months ended December 31, 2017 totaled $362,663, an increase of $2,968, or 1%, over the $359,695 recognized for the twelve months ended December 31, 2016. Of professional services, legal fees totaled $273,663 for the twelve months ended December 31, 2017, a decrease of $12,532, or 4%, from $286,195 incurred for the twelve months ended December 31, 2016. Accounting fees incurred in the twelve months ended December 31, 2017 amounted to $89,000, an increase of $15,500, or 21%, from $73,500 incurred for the same period in 2016.  The increases in professional fees was primarily related to a increase in legal and audit requirements in 2017 as compared to 2016 as we continue to develop our operations, including legal fees associated with our capital raising transactions and the filing of our registration statements.

Consulting fees totaled $1,453,005 for the twelve months ended December 31, 2017, an increase of $285,585 or 24%, from $1,167,420 for the twelve months ended December 31, 2016.  The increase primarily relates to our fund raising and investor relations to support our increased efforts in market research and potential investor identification.

Travel, meals and entertainment costs for the twelve months ended December 31, 2017 were $379,970, an increase of $105,008, or 38%, from $274,962 incurred during the twelve months ended December 31, 2016. During 2017, additional travel was required than in 2016 due to our marketing and fund-raising efforts.  Rent for the twelve months ended December 31, 2017 totaled $142,975, an increase of $14,419, or 11%, from $128,556 incurred during the same period in 2016.  In 2017, our significant increase was the result of our lease renewal in California along with final settlement with closing our Minneapolis, Minnesota office in late 2017.

Depreciation Expense. Depreciation expense for the twelve months ended 2017 totaled $11,698 as compared to $10,475 incurred during the same period in 2016.  The increase is due primarily to additional equipment purchased in 2017.

Gain (loss) on change in fair values of derivatives.  Beginning in March 2015, we are required to estimate the fair value of the embedded beneficial conversion features of our issued Series C Preferred stock and certain warrants with reset (anti-dilution) provisions, In addition, in November 2017; we issued a Series D Preferred stock and warrants with also contained reset (anti-dilutive) provisions.  During the year ended December 31, 2017, we incurred a gain on change in fair values of these derivatives of $210,465 as compared to a loss of $422,908 for the same period in the year ended December 31, 2016.

Interest Income (expense).  Interest income for the twelve months ended December 31, 2017 totaled $75 as compared to $1 incurred during the twelve months ended December 31, 2016.

Preferred Stock Dividend. Our preferred stock dividend for the twelve months ended December 31, 2017 totaled $119,877, an increase of $9,854, or 9% from $110,023 incurred during the twelve months ended December 31, 2016. The increase in dividends is a result added Series D Preferred Stock issued in 2017, net of conversions of the Series C Preferred Stock to common reducing the number of Series C Preferred shares outstanding. Preferred stock dividends are related to our Series C and D Preferred Stock issued in 2013, 2015 and 2017.



Net Loss Available to Common Stockholders. Net loss available to common stockholders for the twelve months ended December 31, 2017 was $12,815,620, compared to a net loss of $11,697,210 for the twelve months ended December 31, 2016, an increase of $1,118,410 or 10%.  The primary reasons for the increase, as described above, are the increases in research and development expenses, net with a reduction in general and administrative expenses from 2016 to 2017.

Liquidity and Capital Resources

Three Months Ended March 31, 2018 Compared to three Months Ended March 31, 2017

As of March 31, 2018, we had a working capital of $332,764, comprised of cash of $1,035,100 and prepaid expenses of $119,111, which was offset by $338,811 of accounts payable and accrued expenses and accrued dividends on preferred stock issuances of $482,636.  For the three months ended March 31, 2018, we used $2,387,274 of cash in operating activities and $3,644 of cash in investing activities.

Cash provided by financing activities totaled $1,878,439, comprised of proceeds from the sale of our common stock and receipt of common stock subscriptions of $385,470 and the sale of our Series E preferred stock of $1,492,969. In the comparable period in 2017, our aggregate cash provided by financing activities totaled $1,799,692 comprised proceeds from the sale of our common stock. At March 31, 2018, we had cash of $1,035,100 compared to $1,547,579 at December 31, 2017. Our cash is held in bank deposit accounts. At March 31, 2018 and December 31, 2017, we had no convertible debentures or other debt outstanding.

Cash used in operations for the three months ended March 31, 2018 and 2017 was $2,387,274 and $1,609,841, respectively, which represent cash outlays for research and development and general and administrative expenses in such periods. The increase in cash outlays principally resulted from additional in operating costs and general and administrative expenses and a decrease of our outstanding accounts payable by $134,714.

We used $3,644 cash for investing activities for the three months ended March 31, 2018, compared to $1,620 for the three months ended March 31, 2017.  For both periods, we purchased computer and other equipment.
 
Twelve Months Ended December 31, 2017 Compared to Twelve Months Ended December 31, 2016

As of December 31, 2017, we had a working capital deficit (current liabilities in excess of current assets) of $2,300,644, comprised of cash of $1,547,579 and prepaid expenses of $116,938, which was offset by $473,098 of accounts payable and accrued expenses, accrued dividends on preferred stock issuances of $447,901, warrant liability of $2,358,240 and derivative liability of $685,922.  Excluding the derivative and warrant liabilities, our working capital would have been $743,518. For the twelve months ended December 31, 2017, cash provided by financing activities totaled $7,971,174, comprised of proceeds from the sale of our common stock and subscriptions of $6,041,214 and sale of our Series D Preferred stock of $1,929,960.  In the comparable period in 2016, $5,226,368 was raised through the sale of our common stock. At December 31, 2017, we had cash of $1,547,579 compared to $1,055,895 at December 31, 2016. Our cash is held in bank deposit accounts. At December 31, 2017 and 2016, we had no convertible debentures outstanding.

Cash used in operations for the twelve months ended December 31, 2017 and 2016 was $7,470,054 and $5,107,452, respectively, which represent cash outlays for research and development and general and administrative expenses in such periods. Increase in cash outlays principally resulted from increased research and development and general and administrative expenses due to the continued development of our operations.
 
Cash used in investing activities for the twelve months ended December 31, 2017 was $9,436, compared to $16,255 for the twelve months ended December 31, 2016.  During both the twelve months ended December 31, 2017 and the twelve months ended December 31, 2016, we purchased office furniture and computer equipment.
 
October 2015 Private Placement

On October 23, 2015, we entered into a unit purchase agreement with certain accredited investors, pursuant to which we issued and sold, in multiple closings occurring on each of October 23, 2015, October 29, 2015, November 18, 2015, December 18, 2015, December 22, 2015, February 9, 2016, March 9, 2016, April 1, 2016, April 19, 2016 and April 29, 2016, an aggregate of 3,003,016 units, which consisted of, in the aggregate, 3,003,016 shares of our common stock and warrants to purchase up to 1,501,513 shares of our common stock at an exercise price of $1.95, in exchange for aggregate gross proceeds of approximately $4,504,516. As consideration for serving as our placement agent in connection with the private placement, we issued to Laidlaw & Company (UK) Ltd. warrants to purchase an aggregate of 232,960 shares of common stock at an exercise price of $1.50 per share and paid cash fees equal to approximately $257,959.


May 2016 Private Placement

On May 26, 2016, we entered into a unit purchase agreement with certain accredited investors, pursuant to which we issued and sold, in a closing occurring on June 1, 2016, an aggregate of 77,144 units, which consisted of, in the aggregate, 77,144 shares of our common stock and warrants to purchase up to 38,572 shares of our common stock at an exercise price of $2.10, in exchange for aggregate gross proceeds of approximately $135,000.
 
On February 9, 2017, the company entered into an amendment agreement with the investors and the terms of the May 2016 Private Placement Warrants were adjusted. As a result of the amendment, the exercise price applicable to the May 2016 Private Placement Warrants decreased to $1.50 per share from $2.10, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 6,429 shares of common stock may be issued upon exercise of the May 2016 Private Placement Warrants due to the adjustment.

August 2016 Private Placement

On August 30, 2016, we entered into a unit purchase agreement with certain accredited investors, pursuant to which we issued and sold, in two closings occurring on August 30, 2016 and September 19, 2016, an aggregate of 375,026 units, which consisted of, in the aggregate, 375,026 shares of our common stock and warrants to purchase up to 187,513 shares of our common stock at an exercise price of $1.95, in exchange for aggregate gross proceeds of approximately $562,540.

October 2016 Private Placement

On October 28, 2016, we entered into a unit purchase agreement with certain accredited investors, pursuant to which we issued and sold,  in multiple closings occurring on each of October 28, 2016, November 23, 2016, December 16, 2016, December 22, 2016, February 10, 2017 and March 10, 2017 an aggregate of 2,899,974 units, which consisted of, in the aggregate, 2,899,974 shares of our common stock and warrants to purchase 1,449,991 shares of our common stock at an exercise price of $1.50 per share, in exchange for aggregate gross proceeds of $3,972,199, after financing costs of $377,754. As consideration for serving as our placement agent in connection with this private placement, we issued to certain designees of Laidlaw & Company (UK) Ltd., our placement agent in connection with this private placement, warrants to purchase an aggregate of 186,957 shares of common stock at an exercise price of $1.50 per share.
 
April 2017 Private Placement

In April 2017, we entered into securities purchase agreements with certain accredited investors, pursuant to which we issued and sold, in multiple closing occurring on each of April 6, 2017, April 17, 2017, May 5, 2017, June 20, 2017, June 30, 2017, July 13, August 18,  October 11, and November 6, and December 29, 2017 and January 5, 2018 an aggregate of 3,008,607 shares of the Company’s common stock and warrants to purchase 1,504,306 shares of our common stock at $1.50, expiring three years from issuance, for aggregate net cash proceeds of $4,521,901.

Series D Preferred Stock

On November 3, 2017,  we entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which we sold an aggregate of 1,334 shares  of our Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of the Company’s common stock, par value $0.001 per share at an exercise price of $1.75 per share (the “Class A Warrants”), in exchange for aggregate net cash proceeds of $1,929,975, net of expenses of $70,025. Contemporaneously with the entry into the securities purchase Agreement, we and the purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of the common stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price (the “Class B Warrants”). Class A Warrants are exercisable immediately and expire on May 3, 2021 and have an exercise price of $1.75 per share.  The Class B Warrants are exercisable immediately and expire on November 3, 2020 and have an exercise price of $1.50.  The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect.


On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment.

Series E Preferred Stock

On February 16, 2018, we entered into a securities purchase agreement with certain institutional accredited investors (the “Series E Holders”), pursuant to which we sold to the investors an aggregate of 1,000 shares  of our Series E Preferred Stock, par value $0.001 per share, and warrants (the “Series E Warrants”) to purchase an aggregate of 500,000 shares of common stock, par value $0.001 per share, at an exercise price of $1.75 per share, in exchange for aggregate consideration of $1,500,000.

The Series E Warrants were exercisable immediately and expire on August 16, 2021, and had an exercise price of $1.75 per share.  The Series E Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.
On April 30, 2018, the terms of the Series E Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Series E Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 83,334 shares of common stock may be issued upon exercise of the Series E Warrants due to the adjustment.
April 2018 Private Placement

In April 2018, we entered into securities purchase agreements with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued and sold, in two closings occurring on April 30, 2018 and May 11, 2018, pursuant to which we issued 3,333,004 shares of our common stock and 1,666,506 warrants to purchase one share of our common stock, exercisable at a price of $1.75 per share and expiring April 30, 2021 and May 11, 2018, in exchange for aggregate consideration of $4,999,502. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

In their report dated February 27, 2018, our independent registered public accounting firm stated at December 31, 2017, there is substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is an issue raised due to our net losses and negative cash flows from operations since inception and our expectation that these conditions will continue for the foreseeable future. In addition, we will require additional financing to fund future operations. Further, we do not have any commercial products available for sale and have not generated revenues to date, and there is no assurance that, if approval of our products is received, we will be able to generate cash flow to fund operations. In addition, there can be no assurance that our research and development will be successfully completed or that any product will be approved or commercially viable. Our ability to continue as a going concern is subject to our ability to obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, obtaining loans from various financial institutions or being awarded grants from government agencies, where possible. Our continued net operating losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful.

Our Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of December 31, 2017, the aggregate stated value of our Series C Preferred Stock was $985,000. The triggering events include our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation we may not have the ability to meet at the time of such demand.  We will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law.



We expect to incur losses from operations for the near future. We expect to incur increasing research and development expenses, including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as we expand our business development, add infrastructure and incur additional costs related to being a public company, including incremental audit fees, investor relations programs and increased professional services.

Our future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates, the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing and our success in developing markets for our product candidates. We believe our existing cash will not be sufficient to fund our operating expenses and capital equipment requirements. We anticipate we will need approximately $5 million in addition to our current cash on hand to fund our operating expenses and capital equipment requirements for the next 12 months. We will have to raise additional funds to continue our operations and, while we have been successful in doing so in the past, there can be no assurance that we will be able to do so in the future. Our continuation as a going concern is dependent upon our ability to obtain necessary additional funds to continue operations and the attainment of profitable operations.
 
Future financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, existing holders of our securities may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our securities. 

If additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.
 
 
 
 


BUSINESS

History

We were formed as BioSig Technologies, Inc., a Nevada corporation, in February 2009 and in April 2011 we merged with our wholly-owned subsidiary, BioSig Technologies Inc., a Delaware corporation, with the Delaware corporation continuing as the surviving entity. We are principally devoted to improving biomedical signal processing to extract information from physiologic signals.  Our initial focus is on providing intracardiac signal information to electrophysiologists during EP studies and catheter ablation for complex arrhythmias, AF and VT. We have not generated any revenue to date and consequently our operations are subject to all risks inherent in the establishment of a new business enterprise.

Overview

We are a development stage medical device company developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Our initial emphasis is on providing intracardiac signal information to electrophysiologists during EP studies and catheter ablation of AF and VT. Our first product is the PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP™ System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiograms and electrograms required during electrophysiology studies and catheter ablation procedures.

The PURE EP System is designed to assist electrophysiologists in making clinical decisions in real-time by providing information that, we believe, is not always easily obtained, if at all, from any other equipment presently used in electrophysiology labs.  The PURE EP System’s ability to minimize noise and artifacts and acquire high fidelity cardiac signals will potentially increase these signals’ diagnostic value, and therefore offer improved accuracy and efficiency of the EP studies and related procedures.  We are developing signal processing tools within the PURE EP System. We believe that these will assist electrophysiologists in further differentiating true signals from noise and will provide guidance in identifying ablation targets.

Since June 2011, we have collaborated with physicians affiliated with the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas who provided us with data for initial technology validation.  The physicians had provided us with digital recordings obtained with conventional electrophysiology recording systems during different stages of electrophysiology studies.  Using our proprietary signal processing tools that are part of the PURE EP System, we analyzed those recordings and successfully removed baseline wander, noise and artifacts from the data thereby providing better diagnostic quality signals.
 
In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac simulator at our lab, and then by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles.   We believe that our proof of concept unit performed well as compared to the conventional recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals displayed on the conventional recording system.  Subsequently, we analyzed the results of our proof of concept unit to determine the final design of the PURE EP System prototype.

After conducting research of peer-reviewed EP publications (see Initial Analysis in Our Products section below), we contacted Samuel J. Asirvatham. M.D. (who we believed to be an expert in the field of signal-based catheter ablation), at Mayo Clinic in Rochester, Minnesota. Since the end of 2014, we have collaborated with Dr. Asirvatham and other physicians affiliated with Mayo Clinic in Rochester, Minnesota and Jacksonville, Florida. We have performed pre-clinical studies at Mayo Clinic since 2015 to validate technology within the PURE EP System prototype. These studies have been designed to determine clinical effectiveness for features within the PURE EP System that are in development. Since March 2016, we have published seven manuscripts in collaboration with the physicians from Mayo Clinic evidencing our pre-clinical findings. The publications cover a variety of subjects pertaining to the PURE EP System as an enhanced electrophysiology recording system with signal acquisition and differentiation and having specific visualization of different electrophysiology signals.

Our initial focus is on improving intracardiac signal processing and diagnostic information for catheter ablation procedures for the complex arrhythmias, atrial fibrillation, the most common cardiac arrhythmia, and ventricular tachycardia, an arrhythmia evidenced by a fast heart rhythm originating from the lower chambers of the heart, which can be life-threatening. Cardiac catheter ablation is a procedure that corrects conduction of electrical impulses in the heart that cause arrhythmias and is now a preferred treatment for certain arrhythmias.  During this procedure, a catheter is usually inserted using a venous access into a specific area of the heart. Cryo or radiofrequency energy is delivered through the catheter to destroy small areas of the heart muscle that cause the abnormal heart rhythm.  According to a 2014 article in Circulation: Arrhythmia and Electrophysiology, catheter ablation should be considered as the first-line therapy for patients with paroxysmal atrial fibrillation (“Ablation Versus Drugs: What is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation?” (Circ Arrhythm Electrophysiol. 2014; 7:739-746).
 

Catheter ablation for many arrhythmias have high success rates; however, more complex or long-standing examples of the disease often require multiple procedures (each typically lasting from 3-6 hours), evidencing the need for additional research and technology to diagnose and treat these cases. Consequently, ablating AF and VT has been regarded as being extremely difficult. Therefore, access to these procedures has traditionally been limited to being performed by only the most well-trained cardiologists; however, advancements in new technologies and techniques show a strong growth rate for these procedures.

Our overall goal is to establish our proprietary biomedical signal processing technology as a new platform in the electrophysiology market that will have the following advantages over the electrophysiology recording systems currently available on the market:

Precise, uninterrupted, real-time evaluations of electrograms (PURE EP™);

Higher quality cardiac signal acquisition for accurate and more efficient electrophysiology studies and catheter ablation procedures to help reduce costs and length of procedures;

Reliable display of information to better determine precise ablation targets, strategy and end point of procedures with the objective of reducing the need for multiple procedures;

A device that can be fully integrated into existing electrophysiology lab environments.

If we are able to develop our product as designed, we believe that the PURE EP System and its signal processing tools will contribute to an increase in the number of procedures performed in each electrophysiology lab and possibly improved patient outcomes.

Our significant achievements to date include:

Initial system concept validation has been performed in collaboration with physicians at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas in June 2011.  The Texas Cardiac Arrhythmia Institute provided challenging recordings obtained with electrophysiology recording systems presently in use at the institute during various electrophysiology studies. Our technology team successfully imported the data into the PURE EP System software and using proprietary signal processing, the PURE EP System software was able to reduce baseline wander, noise, and artifacts from the data and therefore provide better diagnostic quality signals.

We have established clinical and/or advisory relationships for both technology development and validation studies with physicians and researchers affiliated with the following medical centers: Texas Cardiac Arrhythmia Institute, Austin, TX; Cardiac Arrhythmia Center at the University of California at Los Angeles, Los Angeles, CA; Mount Sinai Medical Center, New York, NY; Beaumont Medical Center, Detroit, MI; University Hospitals Case Medical Center, Cleveland, OH; The Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and Mayo Clinic, Rochester, MN.

The Cardiac Arrhythmia Center at the University of California at Los Angeles and Dr. Kalyanam Shivkumar, a former member of our board of directors, have played a significant role in the initial functional testing of our hardware.  Dr. Shivkumar and his team have enabled us to learn the connectivity of the lab and its devices that pertain to where our PURE EP System will fit in. In June 2013, we commenced our first proof of concept pre-clinical study with the assistance of Dr. Shivkumar in order to further test the components of the PURE EP System hardware, as further explained below.

We are developing signal processing tools within the PURE EP System that will assist electrophysiologists in further differentiating true signals from noise, which may potentially provide guidance in identifying ablation targets.  The signal processing tools are expected to be an integral part of the software of the PURE EP System, which we believe will significantly facilitate the locating of ablation targets.


In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac simulator at our lab, and subsequently by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles.  As part of the testing, we simultaneously recorded electrocardiogram and intracardiac signals on our proof of concept unit and GE’s CardioLab recording system. An identical signal was applied to the input of both systems and the monitor of our proof of concept unit was positioned next to the monitor of GE’s CardioLab recording system to allow for visual comparison. We believe that our proof of concept unit performed well as compared to GE’s CardioLab recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals displayed on GE’s CardioLab recording system.  However, because this was a proof of concept test, without any clearly established protocols, we cannot present this data for publication and we do not have any independent verification or peer review of these findings.

In the third quarter of 2013, we analyzed the results of our proof of concept unit to determine the final design of the PURE EP System prototype, which has since been completed.  

In September 2014, we performed additional tests on the PURE EP System prototype at the University of California at Los Angeles.  

In the fourth quarter of 2014, we appointed Dr. Samuel J. Asirvatham from Mayo Clinic as a member of our Scientific Advisory Board and initiated plans for pre-clinical studies at Mayo Clinic.

In the first quarter of 2015, we appointed Dr. K. L. Venkatachalam from Mayo Clinic, Jacksonville, Florida, as a member of our Scientific Advisory Board.  On March 31, 2015 Drs. Asirvatham and Venkatachalam performed our first pre-clinical study at the Mayo Clinic in Rochester, Minnesota.

On June 10, 2015, Dr. Asirvatham performed our second pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On November 17, 2015, Dr. Asirvatham performed our third pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On February 22, 2016, we signed an agreement to initiate development of its PURE EP System with Minnetronix and are taking steps toward its 510(k) submission.
 
On March 8, 2016, Dr. Ammar Killu from Mayo Clinic presented our preclinical data at the 13th Annual Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy in Tel Aviv, Israel entitled “Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation”.

On March 28, 2016, we announced an Advanced Research Program with Dr. Asirvatham at the Mayo Clinic beginning June 2016.

On June 2, 2016, Dr. Asirvatham performed our fourth pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On June 23 and August 25 and 26, 2016, Dr. Vivek Reddy performed our pre-clinical study on a ventricular scar model at the Mount Sinai Hospital in New York, NY.

On July 27, 2016, Dr. Asirvatham performed our fifth pre-clinical study at Mayo Clinic in Rochester, Minnesota.
 
On August 19, 2016, we presented a poster at the IEEE Engineering in Medicine and Biology Society annual conference (IEEE EMBC 2016) entitled “Enhanced Electrophysiology Recording System.”
  
On September 14, 2016, Dr. Asirvatham performed our sixth pre-clinical study at Mayo Clinic in Rochester, Minnesota.

In December 2016, the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology (Vol.2, No.7, pp.850) published the article entitled, “Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals”, submitted by the Mayo Clinic team.

On December 9, 2016, we filed a provisional patent application entitled “Assessment of Catheter Position by Local Electrogram.”


On December 9, 2016, we filed a provisional patent application entitled “Visualization of Conduction Tissue Signals.”

On February 14, 2017, Dr. Asirvatham performed our seventh pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On March 15, 2017, Dr. Asirvatham performed our eighth pre-clinical study at Mayo Clinic in Rochester, Minnesota.

In April 2017, the PURE EP System was featured in The Journal of Innovations in Cardiac Rhythm Management with the manuscript entitled, “Initial Experience with the BioSig PURE EP™ Signal Recording System: An Animal Laboratory Experience” co-authored by physicians from Mayo Clinic and Harvard Brigham & Women’s Hospital.

On May 2, 2017, Dr. Asirvatham performed our ninth pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On May 11, 2017, the PURE EP System was featured in a poster presentation entitled, “Use of Terminal Unipolar Electrogram Current of Injury as a Novel Marker to Estimate Contact: An Acute Canine Study.”

On May 31, we announced that we have appointed Natasha Russkina as a Managing Director, Europe with the view of establishing European operations of BioSig Technologies, Inc. in Geneva, Switzerland.
 
On July 10, 2017, the PURE EP System was featured in a poster presentation at the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics entitled, “Use of a Novel Electrogram Filtering Algorithm to Visualize Conduction Tissue Signals in the Ventricle in Sinus Rhythm and Arrhythmia: An Acute Canine Study.”

On July 11, 2017, we announced that we have engaged Health Research International (HRI) to compile essential market data and help perform strategic planning for its PURE EP™ platform technology.

On July 12, 2017, the PURE EP System was featured in a poster presentation at the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics entitled, “Assessment of Catheter Position above or below the Aortic Valve by Evaluation of Characteristics of the Local Electro gram: An Acute Canine Study.”

On August 9, 2017, Dr. Asirvatham performed our tenth pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On October 11, 2017, we announced that Mr. Joseph W. Rafferty has joined the Company as Chief Commercialization Officer.

On October 19, 2017, we announced that we have made significant progress towards commercialization of our PURE EP System and recently received the first production units of the PURE EP System from our manufacturing partner, Minnetronix.

On October 24, 2017, we announced that we have engaged Quintain Project Solutions LLC as the manufacturing project management leader for the PURE EP System.
 
On October 26, 2017, we announced that we concluded a key part of the strategic planning project launched earlier this year in collaboration with Health Research International (HRI). HRI conducted a detailed survey of U.S. electrophysiologists primarily based in New York, Texas, Massachusetts, Florida, Pennsylvania, and North Carolina to gather opinions on the main features of the PURE EP System. The inability to record high quality unipolar signals and difficulty detecting small intracardiac signals were consistently reported among the factors interfering with effective ablations. Survey respondents rated all six features listed of the PURE EP System as being ‘Very Helpful’ for their ablations, emphasizing overall noise reduction and improved signal clarity/accuracy as key benefits. Most respondents see signal clarity as paramount to the success of ablations and indicated interest in a technology that reduces ‘noise’.

On November 2, 2017, we announced that we have engaged Sherpa Technology Group as our intellectual property advisor.

On November 10, 2017, we announced that Andrew Filler, Partner and General Counsel of Sherpa Technology Group has joined our board of directors taking the place of Dr. Jerome B. Zeldis.


On November 14, 2017, we announced that we have added the role of Chief Regulatory and Compliance Officer in preparation of our FDA submission.

On January 3, 2018, we announced that Steve Chaussy had been elevated to our full time Chief Financial Officer to facilitate growth trajectory of the Company.

On January 9, 2018, we announced that we have partnered with Charles Austin and JK Advisors in preparation of the commercial launch of our PURE EP System.

On January 10, 2018, Dr. Asirvatham and his team performed our eleventh pre-clinical study at Mayo Clinic in Rochester, Minnesota.

On February 22, 2018, we announced that we have partnered with Focus Marketing to assist our commercial team in preparation of our targeted launch of our PURE EP System.

On March 20, 2018, we announced that we have formed an Advisory Board to advise the leadership of BioSig on a range of subjects, including strategy, marketing, government affairs, partnerships, mergers and acquisitions, intellectual property, and capital markets.

On March 28, 2018, we announced that we have filed our 510(k) application to the U.S. Food and Drug Administration (FDA) for our first product, PURE EP™ System.
 
On May 9, 2018, we filed one “omnibus” hardware and software patent application with multiple claim sets, and a multiple feature-set graphical user interface (“GUI”) design patent, with detailed technical descriptions across multiple BioSig elements of novelty.
 
We have conducted a total of twelve pre-clinical studies to date with the PURE EP™ System prototype. We conducted our first three pre-clinical studies in 2015 at Mayo Clinic in Rochester, Minnesota.  We have continued additional pre-clinical studies as part of an advanced research program since June 2016 at Mayo Clinic in Rochester, Minnesota. We also conducted one pre-clinical study at the Mount Sinai Hospital in New York, NY with emphasis on the VT model.

In the third quarter of 2017 in collaboration with Health Research International, we conducted a detailed survey of U.S. electrophysiologists to gather opinions on the main features of the PURE EP System. 

We intend to continue further pre-clinical studies at Mayo Clinic and we intend to conduct a pre-clinical study at the Cardiac Arrhythmia Center at the University of California at Los Angeles.  We intend to conduct further pre-clinical studies, and research studies. The main objective of these studies is to evaluate various findings and to demonstrate the preclinical potential of the PURE EP System

We have initiated technology development with Minnetronix, a medical technology and innovation company, and engaged Quintain Project Solutions LLC as the manufacturing project management leader for the PURE EP System – implementing steps for obtaining 510(k) clearance from the U.S. Food and Drug Administration for the PURE EP System.

We believe that by the conclusion of 2018, we will have obtained 510(k) marketing clearance from the FDA and will be able to commence marketing and commercialization of the PURE EP System. Our ability to achieve the aforementioned milestones will be principally determined by our ability to obtain necessary financing and regulatory approvals, among other factors.

We have chosen and are working with the National Standards Authority of Ireland (NSAI) as our Notified Body to obtain the CE Mark. CE marking is a mandatory approval for medical devices sold in Europe and Canada.  We plan on submitting for CE Mark in 2019.

Because we are a development stage company, with our initial product under development, we currently do not have any customers. We anticipate that our initial customers will be hospitals and other health care facilities that operate electrophysiology labs.


Our Industry

Electrophysiology is the study of the propagation of electrical impulses throughout the heart. Electrophysiology studies are focused on the diagnosis and treatment of arrhythmias, a medical condition in which conduction of electrical impulses within the heart vary from the normal. Such conditions may be associated with significant health risks to patients. The cardiac electrophysiology study for the evaluation of cardiac conduction disorders has evolved rapidly from a research tool to an established clinical treatment. This technique permits detailed analyses of the mechanism underlying cardiac arrhythmias and determines precise locations of the sites of origin of these arrhythmias, thereby aiding in treatment strategies.

Pharmacological, or medicine-based, therapies have traditionally been used as initial treatments, but they often fail to adequately control the arrhythmia and may have significant side effects. Catheter ablation is now often recommended for an arrhythmia that medicine cannot control. Catheter ablation involves advancing several flexible catheters into the patient’s blood vessels, usually either in the femoral vein, internal jugular vein or subclavian vein. The catheters are then advanced towards the heart. Electrical impulses are then used to induce the arrhythmia and local heating, or freezing is used to ablate (destroy) the abnormal tissue that is causing it. Catheter ablation of most arrhythmias has a high success rate and multiple procedures per patient have been found to be more successful.

Catheter ablation is performed by an electrophysiologist (a specially trained cardiologist) in a catheterization lab or a specialized electrophysiology lab. It is estimated that there are about 3,000 dedicated electrophysiology labs in the U.S. and 1,500 labs outside the U.S., each with an electrophysiology recording system costing an average of $250,000. We believe that the current value of the electrophysiology recording device market in the U.S. is approximately $750 million, based upon the number of electrophysiology labs in U.S. and the average cost of the recording system in each lab. With the potential of 12 million atrial fibrillation patients by the year 2050 (according to the Atrial Fibrillation Fact Sheet, last updated in August 2017 by the Centers for Disease Control and Prevention) and improvements in technology for atrial fibrillation ablation therapy, significant growth is predicted for the number of hospitals building electrophysiology labs. According to the 2016 HRI Global Opportunities in Medical Devices & Diagnostics report, analysts forecast the global market for electrophysiology devices will grow at a 10.3 percent compound annual growth rate, from $3.68 billion in 2015 to $6.015 billion in 2020; in addition, global ablation procedure numbers are predicted to grow from 865,000 to 1,350,000 per year.

Catheter Ablation of Atrial Fibrillation and Ventricular Tachycardia

We believe that the clearer recordings and additional information provided by the PURE EP System may improve outcomes during electrophysiology studies and ablation procedures for a variety of arrhythmias. For patients who are candidates for ablation, an electrophysiology study is necessary to define the targeted sites for the ablation procedure. Two common, yet complex, conditions for which ablation procedures are performed are atrial fibrillation and ventricular tachycardia. We believe that in the near future, the PURE EP System may have a meaningful impact on assisting ablation strategies for these conditions.

Most cardiac arrhythmias are well understood, and ablation simply requires destroying a small area of heart tissue possessing electrical abnormality. In contrast, complex arrhythmias, such as atrial fibrillation and ventricular tachycardia, have complex pathophysiology and, because knowledge of their origins and mechanisms are incomplete, ablation treatments for these arrhythmias are largely empirical.. Furthermore, the length of these procedures, which typically last from 3-6 hours, exposes the physician and staff to extensive radiation, requiring them to wear heavy lead vests. Consequently, ablating atrial fibrillation and ventricular tachycardia has been regarded as being extremely difficult. Therefore, access to these procedures has traditionally been limited to being performed by only especially well-trained cardiologists; however, advancements in new technologies and techniques show a strong growth rate for these procedures.

AF is the most common heart rhythm disorder in the world and increases the risk for stroke 5-fold. In 2010, there was a reported global prevalence of 33.5 million (20.9 million men and 12.6 million women). In 2017, the Centers for Disease Control and Prevention stated that there are an estimated 2.7-6.1 million Americans suffering with AF, more than 750,000 patients hospitalized annually for the condition, and AF contributes to an estimated 130,000 deaths each year. Despite the fact that physicians have been performing radiofrequency ablations since the 1990s, catheter-based treatment is offered to less than 3% of the AF patient population in the U.S. and Europe. An increasing proportion of diagnosed atrial fibrillation cases are now being treated via ablation, as both physician confidence and the devices used in these procedures improve. A growing amount of positive clinical data has demonstrated the efficacy of AF ablation when compared to the traditional first-line treatment of anti-arrhythmic drugs. As a result, AF ablation is becoming the fastest growing procedure type in this market. The American College of Cardiology Foundation/American Heart Association Task Force reported that catheter-directed ablation of atrial fibrillation represents a substantial achievement that promises better therapy for a large number of patients presently resistant to pharmacological or electrical conversion to sinus rhythm (“2014 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2011 Guideline)”). However, rates of success and complications may vary, sometimes considerably.


According to the Heart Rhythm Society, ventricular tachycardia is the most dangerous arrhythmia since it may result in ventricular fibrillation, a rapid chaotic heartbeat in the lower chambers of the heart which can often result in sudden cardiac death. Because the fibrillating muscle cannot contract and pump blood to the brain and vital organs, ventricular fibrillation is the number one cause of sudden cardiac death accounting for more than 350,000 deaths in the U.S. each year. Ventricular tachycardia is typically treated with implantable cardioverter defibrillators, or ICDs, or a combination of ablation along with an ICD. Catheter ablation of VT has historically been used primarily for drug refractory ventricular arrhythmias in patients with ICDs. However, advances in electro-anatomical mapping systems, techniques to identify ablation sites during sinus rhythm, and the use of hemodynamic support devices has broadened the applicability of catheter ablation for ventricular arrhythmias. When performed in centers with high procedural volumes, the rates of complications remain relatively low. However, success rates have historically been quite variable and highly dependent on the specific ablation approach adopted.

According to Dr. Srijoy Mahapatra, the status of ventricular tachycardia ablation is growing at a 14-17% compound annual growth rate due to the fact that ablation of ventricular tachycardia may help patients feel better and live longer, despite the risks, including the occurrence of stroke, and the modest success rates. The success of ventricular tachycardia ablation varies, depending on the patient’s specific heart condition that caused ventricular tachycardia. The procedure is most effective in patients with otherwise normal hearts, in whom the success rate exceeds 90%. In patients with structural heart disease resulting from scar or cardiomyopathy, success rates range between 50% and 75% at six to 12 months. In cases in which a patient experiences a recurrence, two of three patients will still have less ventricular tachycardia than before the initial ablation (Circulation (2010) 122: e389-e391). Therefore, we believe that ablation will continue to become a preferred treatment for ventricular tachycardia, especially considering the challenges presented by ICD therapies; this increase in demand for ablation procedures will likely also increase the demand for technological advances in medical devices essential to ablation procedures, including electrophysiology recorders, in order to better support ablation procedures.

Electrophysiology Lab Environment and Electrophysiology Recording Systems

The electrophysiology lab environment and recording systems create significant amounts of noise and artifacts during electrophysiology procedures.  Current surface and intracardiac recording systems typically consist of large workstations interconnected by a complex set of cables that contribute to significant amounts of noise during signal acquisition. Additional noise and artifacts generated from the electrophysiology lab equipment further hamper recordings of small electrophysiological potentials.  Preserving spaciotemporal (space and time) characteristics of the signal in a very challenging electrophysiology recording environment is a difficult task. To remove noise and artifacts, recorders that are currently on the market offer a family of low pass, high pass and notch filters, but these filters alter signal information context.

The shape and amplitude of electrocardiograms, unipolar and bipolar electrograms, and, consequently, reconstructed endocardial and epicardial maps, are influenced not only by electrophysiological and structural characteristics of the myocardial tissue involved, but with characteristics of the recording system.  Amplitude and morphology of electrocardiogram and intracardiac signals are significantly affected by filters used to remove noise.  Because of the number of amplitude and interval measurements made during an electrophysiology study, it is imperative that the recording system faithfully acquires surface electrocardiogram and intracardiac electrograms.  We believe that the recording systems that are currently available on the market are ineffective in preserving the optimal amount of original information contained in the cardiac signals.

In addition, the electrophysiology lab consists of sophisticated equipment that requires an electrophysiologist to mentally integrate information from a number of sources during procedures. There are numerous monitors in an electrophysiology lab that provide and display this variety of information. An electrophysiologist needs to evaluate the acquired cardiac signals and the patient’s responses to any induced arrhythmias during the procedure.  However, it is difficult for an electrophysiologist to synthesize the disparate information produced by the numerous monitors in the lab and calculate the real-time, three-dimensional orientation of the anatomy and the location of the recording and ablation catheters.  As the number of electrophysiology procedures increase, a variety of diagnostic and therapeutic ablation catheters are becoming more widely available and new highly specialized catheters are being developed.  In addition, remote robotic and magnetic navigation systems are being developed to address limitations of dexterity in controlling the catheter tip, especially during complex arrhythmia ablation procedures. We believe that, considering the improvements being made with respect to other equipment used in the electrophysiology lab and the continual increase of ablation procedures, the electrophysiology recorders currently available on the market are not sufficiently advanced with respect to the quality of their recordings to deliver adequate results.  We believe that the PURE EP System will be able to deliver superior quality of recordings that will allow it to successfully integrate with the other advanced equipment found in the electrophysiology lab.


The requirement for optimal signal integrity is further amplified during ablation treatments of atrial fibrillation and ventricular tachycardia. Presently, one of the main objectives of the atrial fibrillation ablation procedure is to precisely identify, ablate and eliminate pulmonary vein potentials; and one of the main objectives of the ventricular tachycardia procedure is to map the arrhythmia substrate and precisely identify, ablate and eliminate small abnormal potentials. The information provided by recorders is essential for an electrophysiologist to determine ablation strategy during termination of both pulmonary vein potentials and ventricular tachycardia.  Therefore, it is important that the recording system’s noise removal technique does not alter the appearance and fidelity of these potentials. As a result, it is necessary that any new signal processing technology preserves signal fidelity as much as possible during electrophysiology recordings; otherwise, the signals that are needed to guide the ablation procedures will be difficult to distinguish due to noise interference.

Our Products

We intend to bring to the electrophysiology market the PURE EP System, an electrocardiogram/intracardiac recorder that will be coupled with an array of software tools intended for electrophysiology studies and procedures ranging from simple diagnostic tests to ablation for the most complex cases of arrhythmias.  We believe that this system will provide unique recording capabilities because we are developing it to allow precise, uninterrupted, real-time evaluations of electrocardiograms and electrograms, and allow electrophysiologists to obtain data that cannot be acquired from present day recorders.

The PURE EP System uses a combination of analog and digital signal processing to acquire and display cardiac data. Because our technology consists of proprietary hardware, software and algorithms, the original cardiac data is not distorted.  In addition, we are developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in different settings and/or for different arrhythmia treatments. With the software, the PURE EP System can be positioned to provide information that can be used by electrophysiologists to help guide the ablation catheter; shorten procedure times; and can reduce the complexity of maneuvers necessary for identifying ablation targets for various arrhythmias, including atrial fibrillation and ventricular tachycardia.  The PURE EP System is intended to be used in addition to existing electrophysiology recorders.  We believe that the less distorted cardiac data provided by the PURE EP System will increase the workload ability and enhance the capabilities of the typical electrophysiology laboratory.

Initial Analysis

According to S. J. Asirvatham, MD, et. al. (“Signals and Signal Processing for the Electrophysiologist,” Circ Arrhythm Electrophysiol. (2011) 4:965-973), recording environments in a typical electrophysiology laboratory presents challenging situations.  S. J. Asirvatham, MD, et. al., state, “Successful mapping and ablation in the electrophysiology laboratory is critically dependent on acquiring multiple, low-amplitude, intracardiac signals in the presence of numerous sources of electric noise and interference and displaying these signals in an uncomplicated and clinically relevant fashion, with minimal artifacts. This represents a significant engineering challenge and, in real-life electrophysiology laboratory, is not always successful.”

To determine and validate the state of present electrophysiology recording technology in the field, we completed a detailed analysis of the effect of filters used by existing EP recorders to reduce noise on spaciotemporal characteristics of electrocardiograms and intracardiac electrograms. We used a custom-built electrocardiogram/intracardiac simulator with a database of various electrocardiogram signals combined with electrophysiology signals, along with waveforms from publicly available databases. The ability to faithfully reproduce database waveforms generated by an electrocardiogram/intracardiac simulator was tested using the PURE EP System and conventional electrophysiology recorders, the GE CardioLab and St. Jude EP-WorkMate.

We evaluated the signal quality (amplitude, morphology and duration) of the different recorders, along with the ability of the recorders to reduce noise level and remove baseline wander, which are the cardiac signals that have shifted from the isoelectric line (the base line of the signal tracing). The electrocardiogram and intracardiac signals subjected to the PURE EP System’s signal processing showed less baseline wander, noise and artifacts compared to the conventional electrophysiology recorders.  Further, spaciotemporal characteristics of signals were greatly distorted by the conventional electrophysiology system, particularly when a notch filter was used, as compared to the recording of the same spaciotemporal characteristics by the PURE EP System.  A notch filter is used to remove a specific frequency from the signal, especially either 60Hz in the U.S. and 50Hz in Europe, and can be implemented in hardware or software.

During our initial analysis, we did not subject the evaluation of the data produced by our technology to any third-party review, as would be required for the publication of a formal study.  


Proof of Concept Testing

We developed the PURE EP System’s proof of concept unit, which is the version of the product prior to prototype. The proof of concept unit was designed using separate analog and digital boards to allow for easier debugging and to demonstrate single channel electrocardiogram and intracardiac acquisition capabilities. The proof of concept unit was built to (i) verify that the PURE EP System performs in line with our intended design of the product, (ii) validate a portion of the hardware design that we intend to use in the prototype, and (iii) verify the software used by the PURE EP System.  The main objectives of the proof of concept unit were to demonstrate that the system’s hardware and software have the ability to faithfully record small cardiac signals in an electrophysiology laboratory environment and to obtain initial performance results.

In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac simulator at our lab, and subsequently by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles.  As part of the testing, we simultaneously recorded electrocardiogram and intracardiac signals on our proof of concept unit and GE’s CardioLab recording system. An identical signal was applied to the input of both systems and the monitor of our proof of concept unit was positioned next to the monitor of GE’s CardioLab recording system to allow for visual comparison. We believe that our proof of concept unit performed well as compared to GE’s CardioLab recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals displayed on GE’s CardioLab recording system.  However, because this was a proof of concept test, without any clearly established protocols, we cannot present this data for publication and we do not have any independent verification or peer review of these findings.

Subsequently, in the third quarter of 2013, we analyzed the results of our proof of concept unit to determine the final design of the PURE EP System prototype.  Because the proof of concept unit was designed to verify the capabilities of the main components of the PURE EP System, we established a list of tasks necessary to complete the prototype (which we intend to use for end-user preference studies, additional pre-clinical studies and research studies), which has since been completed.  

Proof of Concept Testing at UCLA’s EP Lab
 



Prototype Testing

After conducting research of peer-reviewed EP publications (see Initial Analysis in Our Products section below), we contacted Samuel J. Asirvatham. M.D. (who we believed to be an expert in the field of signal-based catheter ablation), at Mayo Clinic in Rochester, Minnesota. Since the end of 2014, we have collaborated with Dr. Asirvatham and other physicians affiliated with Mayo Clinic in Rochester, Minnesota and Jacksonville, Florida. We have performed pre-clinical studies at Mayo Clinic since 2015 to validate technology within the PURE EP System prototype. These studies have been designed to determine clinical effectiveness for features within the PURE EP System that are in development. Since March 2016, we have published seven manuscripts in collaboration with the physicians from Mayo Clinic evidencing our pre-clinical findings. The publications cover a variety of subjects pertaining to the PURE EP System as an enhanced electrophysiology recording system with signal acquisition and differentiation and having specific visualization of different electrophysiology signals.

The current PURE EP System prototype

Technology and Development Plan

Our technology team consists of six engineers and a consulting firm with expertise in digital signal processing, low power analog and digital circuit design, software development, embedded system development, electromechanical design, testing and system integration, and the regulatory requirements for medical devices. We have also entered into collaboration agreements with advisors and medical institutions in the fields of cardiology and electrophysiology, including Mayo Clinic, Mount Sinai Hospital in New York, NY and the Texas Cardiac Arrhythmia Institute in Austin, TX (see “–Strategic Alliances”).  We envision outsourcing manufacturing of the complete PURE EP System.

We have conducted a total of twelve pre-clinical studies to date with the PURE EP™ System prototype. We conducted our first three pre-clinical studies in 2015 at Mayo Clinic in Rochester, Minnesota.  We have continued additional pre-clinical studies as part of an advanced research program since June 2016 at Mayo Clinic in Rochester, Minnesota. We also conducted one pre-clinical study at the Mount Sinai Hospital in New York, NY with emphasis on the VT model.

In the third quarter of 2017 in collaboration with Health Research International, we conducted a detailed survey of U.S. electrophysiologists to gather opinions on the main features of the PURE EP System. 

We intend to continue further pre-clinical studies at Mayo Clinic and we intend to conduct a pre-clinical study at the Cardiac Arrhythmia Center at the University of California at Los Angeles.  We intend to conduct further pre-clinical studies, and research studies. The main objective of these studies is to evaluate various findings and to demonstrate the preclinical potential of the PURE EP System

We have initiated technology development with Minnetronix, a medical technology and innovation company, and engaged Quintain Project Solutions LLC as the manufacturing project management leader for the PURE EP System – implementing steps for obtaining 510(k) clearance from the U.S. Food and Drug Administration for the PURE EP System.


We believe that by the conclusion of 2018, we will have obtained 510(k) marketing clearance from the FDA and will be able to commence marketing and commercialization of the PURE EP System. Our ability to achieve the aforementioned milestones will be principally determined by our ability to obtain necessary financing and regulatory approvals, among other factors.

We have chosen and are working with the National Standards Authority of Ireland (NSAI) as our Notified Body to obtain the CE Mark. CE marking is a mandatory approval for medical devices sold in Europe and Canada.  We plan on submitting for CE Mark in 2019.

Because we are a development stage company, with our initial product under development, we currently do not have any customers. We anticipate that our initial customers will be hospitals and other health care facilities that operate electrophysiology labs.

Competition

The electrophysiology market is characterized by intense competition and rapid technological advances. There are currently four large companies that share the majority of the electrophysiological recording market share. They produce the following electrophysiology recording systems, each with a unit price of approximately $250,000 per unit:

GE Healthcare’s family of CardioLab Recording Systems were initially developed in the early 1990s by Prucka Engineering, which was acquired by General Electric Company in 1999.
The LabSystem PRO EP Recording System was originally designed in the late 1980s by C.R. Bard. C.R. Bard’s electrophysiology business was acquired by Boston Scientific Corporation in 2013.
Siemens AG developed the Axiom Sensis XP in 2002.
St. Jude Medical, Inc.’s EP-WorkMate Recording System was acquired from EP MedSystems, Inc. in 2008, which had received clearance for the product from the FDA in 2003. In January 2017, Abbott Laboratories acquired St Jude Medical, Inc.

Based upon our analysis of data taken from patent applications filed with the U.S. Patent and Trademark Office (“USPTO”) and 510(k) approval applications filed with the FDA, we believe that the above recording systems are built on relatively old technologies and all use the identical approach in applying digital filters to remove noise and artifacts. We are of the opinion that such an approach sacrifices cardiac signal fidelity and, in the case of ablation; the filters have a direct impact on the ablation strategy of an electrophysiologist. The imprecise method to remove noise and artifacts used by the old recorders could be a contributing factor to the multiple (or repeated) ablation procedures that are frequently required in order to completely cure patients from atrial fibrillation and ventricular tachycardia. We are not currently aware of any other companies that are developing new recording technology for electrophysiology recorders.

Suppliers

The PURE EP System contains proprietary hardware and software modules that are assembled into the system. Hardware boards contain components that are available from different distributors. The parts used to manufacture analog and digital boards are readily available from a number of distributors or manufacturers. We obtained components from various suppliers and have assembled our first prototype in-house. We envision outsourcing manufacturing of the complete PURE EP System.

Research and Development Expenses

Research and development expenses for the fiscal years ended December 31, 2017, 2016 were $4,756,468 and $2,654,501, respectively.

Sales, Marketing and Customer Service

We plan to implement a market development program prior to launch of our PURE EP System. As the product progresses through development and testing, we intend to gather the data produced by the PURE EP System’s processing and presenting electrocardiogram and intracardiac signals and use such data for posters, presentations at cardiology conferences, and, if appropriate, submissions to scientific journals. We believe that as we gather additional data from our existing proof of concept tests and our planned pre-clinical and clinical studies and user preference studies, we will be able to better determine the focus of our marketing efforts. We also plan to leverage our relationships with cardiac research and treatment centers to gain early product evaluation and validation. We believe that through these efforts, we may be able to gain preliminary acceptance of our PURE EP product by experienced professionals and academics in the electrophysiology field.


We also intend to simultaneously develop a branding strategy to introduce and support the PURE EP System. The strategy may include our presence at major relevant cardiology meetings on a national and regional basis to engage and educate physicians concerning the PURE EP System and any of our other products, as well as engaging in a variety of other direct marketing methods. We also intend to develop a small direct sales force together with a distribution network that has existing relationships with hospitals and electrophysiologists. We believe that we may be able to begin targeted commercial sales of the PURE EP System in the second half of 2018.

Intellectual Property

Patents

Our success depends in large part on our ability to establish and maintain the proprietary nature of our technology. Our co-founder and former chief technology officer, Budimir S. Drakulic, Ph.D., conceived of the proprietary elements of the PURE EP System in 2009 and 2010. We filed a patent application with the USPTO in December 2013 directed at systems and methods for the evaluation of electrophysiology systems. In March 2014, the inventors listed on the patent application filed in December 2013 assigned all of their rights to the patent application to us. In December 2014, we filed this patent application under the Patent Cooperation Treaty (PCT) with the U.S. Receiving Office.  Our patent application filed in December 2013 represents a significant portion of our core proprietary intellectual property. Our patent application filed in December 2013 describes a system that can show comparative output of any two cardiac signal systems—such as the PURE EP System as compared to a competitor system, thus showing the value of the PURE EP System.

This patent application describes signal processing evaluators that assess how well a cardiac signal system reading a cardiac signal (such as the PURE EP System or another system) filters out noise, such as non-cardiac signals or other body-generated artifacts. Such noise is filtered by such systems with varying success, thus, an evaluator such as described in the patent application may be used to provide comparison data for a particular system versus another given the same or similar input. The patent application also describes a simulator that can send a simulated signal to a cardiac signal system (the PURE EP System or another system) in order to challenge such cardiac signal system to filter out typical noise. These are adjunct technologies that can be used to show the value of the PURE EP System as compared to other systems existing in the market. The additional patent applications that we intend to file in the U.S. in the future are expected to represent portions of the hardware and software technology associated with our PURE EP System, which technology includes a cardiac signal system that reads cardiac signals and filters such cardiac signals from noise such as non-cardiac signals or other body-generated artifacts. Upon filing of such patent applications, we believe that the novel aspects of our PURE EP System should be subject to pending patent application; however, we cannot be assured that all of the patents related to our patent applications, if any, will be granted.

In November 2017, we engaged 3LP Advisors LLC dba Sherpa Technology Group as our intellectual property advisor.
 
In addition to retaining Sherpa Technology Group, an intellectual property strategy firm based in Silicon Valley, we also retained Sterne Kessler Goldstein & Fox P.L.L.C., a patent firm based in Washington DC, to help develop and execute a strategy for the development of BioSig’s patent portfolio.  As a result of that collaboration, on May 9, 2018 BioSig filed one “omnibus” hardware and software patent application with multiple claim sets, and a multiple feature-set graphical user interface (“GUI”) design patent, with detailed technical descriptions across multiple BioSig elements of novelty.  BioSig plans to expand the patent filings into a robust patent family with multiple domestic and international patents to obtain broad utility claims that cover apparatus, methods and systems in EP and general signal processing areas, and display patents for its key GUI innovations.  BioSig may choose to accelerate the patent prosecution process for key claim sets, e.g., by utilizing the United States Patent and Trademark Office acceleration programs (Track One) to shorten the time to grant domestically, and the Patent Cooperation Treaty and Patent Prosecution Highway to streamline and accelerate foreign filings as applicable.
 
Trademarks

Our trademark for “BIOSIG TECHNOLOGIES”; was registered on April 25, 2017. Our trademark for “PURE EP”; was registered on January 26, 2016.

Government Regulation

Our solutions include software and hardware which will be used for patient diagnosis and, accordingly, are subject to regulation by the U.S. Food and Drug Administration and other regulatory agencies.  U.S. Food and Drug Administration regulations govern, among other things, the following activities that we perform and will continue to perform in connection with:

Product design and development;
Product testing;
Product manufacturing;
Product labeling and packaging;
Product handling, storage, and installation;
Pre-market clearance or approval;
Advertising and promotion; and
Product sales, distribution, and servicing.


U.S. Food and Drug Administration’s Pre-market Clearance and Approval Requirements

The U.S. Food and Drug Administration classifies all medical devices into one of three classes.  Devices deemed to pose lower risks are placed in either Class I or II, which requires the manufacturer to submit to the U.S. Food and Drug Administration a pre-market notification, known as a PMN, and a 510(k) approval, requesting clearance of the device for commercial distribution in the U.S.  Class III devices are devices which must be approved by the pre-market approval process.  These tend to be devices that are permanently implanted into a human body or that may be necessary to sustain life.  For example, an artificial heart meets both these criteria.  Based on analysis of predicate devices, we believe that our products will be classified as Class II. Pursuant to U.S. Food and Drug Administration guidelines, Class II devices include a programmable diagnostic computer, which is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.  Because the PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms, we believe it will be classified as a Class II device.  We must, therefore, first receive a 510(k) clearance from the U.S. Food and Drug Administration for our PURE EP System before we can commercially distribute it in the U.S.  In the event that our PURE EP System is classified as a Class III device, which we believe is unlikely to occur, the U.S. Food and Drug Administration regulatory approval process and the subsequent commercialization of our product will require significantly greater time and resources than if it is classified as a Class II device, which would require us to reassess our strategic business plan of operations.

510(k) Clearance Process

For our PURE EP System, we must submit a pre-market notification to the U.S. Food and Drug Administration demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device, a device that was in commercial distribution before May 28, 1976 for which the U.S. Food and Drug Administration has not yet called for the submission of pre-market approval applications, or is a device that has been reclassified from Class III to either Class II or I.

The U.S. Food and Drug Administration’s 510(k) clearance process usually takes three to six months from the date the application is submitted and filed with the U.S. Food and Drug Administration, but it can take significantly longer. A device that reaches market through the 510(k) process is not considered to be “approved” by the U.S. Food and Drug Administration. They are generally referred to as “cleared” or “510(k) cleared” devices.  Nevertheless, it can be marketed and sold in the U.S.

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new 510(k) clearance or could require a pre-market approval, which requires more data and is generally a significantly longer process than the 510(k) clearance process.  The U.S. Food and Drug Administration requires each manufacturer to make this determination initially, but the U.S. Food and Drug Administration can review any such decision and can disagree with a manufacturer’s determination. If the U.S. Food and Drug Administration disagrees with a manufacturer’s determination, the U.S. Food and Drug Administration can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or a pre-market approval is obtained.

Pervasive and continuing U.S. Food and Drug Administration regulation

After a medical device is placed on the market, numerous U.S. Food and Drug Administration regulatory requirements apply, including, but not limited to the following:

Quality System regulation, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures during the manufacturing process;
Establishment Registration, which requires establishments involved in the production and distribution of medical devices intended for commercial distribution in the U.S. to register with the U.S. Food and Drug Administration;
Medical Device Listing, which requires manufacturers to list the devices they have in commercial distribution with the U.S. Food and Drug Administration;
Labeling regulations, which prohibit “misbranded” devices from entering the market, as well as prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling; and
Medical Device Reporting regulations, which require that manufacturers report to the U.S. Food and Drug Administration if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur.


Failure to comply with applicable regulatory requirements can result in enforcement action by the U.S. Food and Drug Administration, which may include one or more of the following sanctions:

Fines, injunctions, and civil penalties;
Mandatory recall or seizure of our products;
Administrative detention or banning of our products;
Operating restrictions, partial suspension or total shutdown of production;
Refusing our request for 510(k) clearance or pre-market approval of new product versions;
Revocation of 510(k) clearance or pre-market approvals previously granted; and
Criminal penalties.

International Regulation

International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. The time required to obtain approval by a foreign country may be longer or shorter than that required for U.S. Food and Drug Administration approval, and the requirements may differ significantly.

The European Union has adopted legislation, in the form of directives to be implemented in each member state, concerning the regulation of medical devices within the European Union. The directives include, among others, the Medical Device Directive that establishes standards for regulating the design, manufacture, clinical trials, labeling, and vigilance reporting for medical devices. Our PURE EP system may be affected by this legislation. Under the European Union Medical Device Directive, medical devices are classified into four classes, I, IIa, IIb, and III, with class I being the lowest risk and class III being the highest risk. Under the Medical Device Directive, a competent authority is nominated by the government of each member state to monitor and ensure compliance with the Medical Device Directive. The competent authority of each member state then designates a notified body to oversee the conformity assessment procedures set forth in the Medical Device Directive, whereby manufacturers demonstrate that their devices comply with the requirements of the Medical Device Directive and are entitled to bear the CE mark. CE is an abbreviation for Conformité Européenne (or European Conformity) and the CE mark, when placed on a product, indicates compliance with the requirements of the applicable directive. Medical devices properly bearing the CE mark may be commercially distributed throughout the European Union. Failure to obtain the CE mark will preclude us from selling the PURE EP System and related products in the European Union.

Employees

As of May 16, 2018, we had 15 full-time employees. Additionally, we use consultants as needed to perform various specialized services. None of our employees are represented under a collective bargaining agreement.

Properties

Our headquarters is located in Los Angeles, California where we lease an office approximately 2,200 square feet in size. In February 2018, we opened an administrative office located in Austin, Texas.  Because we do not have any manufacturing requirements at this time, we believe our current facilities are sufficient to meet our needs.

Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating result.

There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest.
 

EXECUTIVE OFFICERS AND DIRECTORS
 
The following table sets forth information regarding our executive officers and the members of our board of directors. 
 
Name
 
Age
 
Position with the Company
Kenneth L. Londoner
 
50
 
Chief Executive Officer, Executive Chairman and Director
Steve Chaussy
 
64
 
Chief Financial Officer
Joseph Rafferty
 
60
 
Chief Commercialization Officer
Donald E. Foley
 
66
 
Director
Roy T. Tanaka
 
70
 
Director
Andrew L. Filler
 
51
 
Director
Patrick J. Gallagher
 
53
 
Director
Seth H. Z. Fischer
 
62
 
Director
Jeffrey F. O’Donnell, Sr.
 
58
 
Director
David Weild IV
 
61
 
Director
 
Directors are elected at each annual meeting of our stockholders and hold office until their successors are elected and qualified or until their earlier resignation or removal. Officers are appointed by our board of directors and serve at the discretion of the board of directors.
 
Biographical Information

Kenneth L. Londoner. Mr. Londoner has served as our director since February 2009, as our executive chairman since November 2013 and our chief executive officer since July 2017. He previously served as our chairman and chief executive officer from February 2009 to September 2013. Mr. Londoner has served as the managing partner of Endicott Management Partners, LLC, a firm dedicated to assisting emerging growth companies in their corporate development, since February 2010. From April 2007 to October 2009, he served as executive vice president – corporate business development and senior director of business development and, from November 2009 to December 2010, he served as a consultant to NewCardio, Inc., a medical device designer and developer. Mr. Londoner also served as a director of chatAND Inc. from January 2012 to April 2015. Mr. Londoner is a co-founder and board member of Safe Ports Holdings, Charleston, South Carolina. Mr. Londoner also served as a director of MedClean Technologies, Inc. from November 2008 to September 2010. Mr. Londoner was an investment officer and co-manager of the Seligman Growth Fund, Seligman Capital Fund, and approximately $2 billion of pension assets at J & W Seligman & Co, Inc. in New York from 1991 to 1997. Mr. Londoner graduated from Lafayette College in 1989 with a degree in economics and finance and received his MBA from New York University’s Leonard N. Stern School of Business in 1994.We believe that Mr. Londoner’s extensive experience in financial and venture capital matters, as well as his intimate knowledge of our company as its co-founder make him an asset to our board of directors.

Steve Chaussy. Mr. Chaussy has served as our chief financial officer on a full-time basis since January 2018.  Mr. Chaussy served as our chief financial officer on a part-time basis from May 2011 to January 2018. Since 2005, Mr. Chaussy has been the sole proprietor of Anna & Co., Inc., a consulting company that offers services to small publicly traded companies. Anna & Co., Inc. provides general financial and accounting services, with a special emphasis towards SEC reporting and compliance, to companies that lack sufficient resources to hire full-time employees to provide such services. From 2001 to 2005, Mr. Chaussy provided services as both a chief financial officer and as a consultant to small publicly traded companies. Prior to 2001, Mr. Chaussy served as chief financial officer for a large private distribution and wholesaling company, where he gained international experience. Mr. Chaussy is a graduate of Virginia Polytechnic Institute and State University and is a licensed certified public accountant in Virginia, California and Florida.
 
Joseph Rafferty.  Mr. Rafferty has served as our chief commercialization officer since October 2017.  Mr. Rafferty was the founder, president and chief executive officer of National Medical Sales, LLC June 2009 - 2017. National Medical Sales provided start up medical device companies instant access to a national commercialization platform in the endovascular, interventional oncology, interventional radiology and interventional cardiology markets. He was the vice president of US sales, sales training and physician training at Avinger, Inc. from January 2016 to July 2016. Mr. Rafferty was vice president of global sales at Pathway Medical Technologies from July 2007 to May 2009. He was recruited to lead, design and execute a commercialization plan for the Jetstream Atherectomy device.  He was given the charter to build out a 60-person commercialization organization, including field sales leadership and team, customer service, sales operations, physician training and sales training. Then in 2005 to 2007, Mr. Rafferty was the director of national contracts for Synthes Spine - at that time, he was responsible for a 2-year growth over $80 million in strategically contracted accounts and also functioned as associate EVP, sales operations. Mr. Rafferty was vice president and general manager for Sterilox Technologies from 2001 to 2005.  He had full P&L responsibility for national and international business development and commercialization of medical, dental and food verticals in liquid chemical sterilant/high level disinfectant for the technology startup. Before 2000, Mr. Rafferty was a regional sales manager for ACS/Guidant where he authored the P3 program that leveraged ACS’s breadth of products and became an industry standard practice. He was also a territory manager for the cardiosurgery division at CR Bard and J & J Ethicon Mechanical Products. Mr. Rafferty attended Temple University from 1977 to 1979 and graduated with a BS in communications, public relations/journalism.​



Donald E. Foley. Mr. Foley has served as our director since October 2015. Mr. Foley was chairman of the board and chief executive officer of Wilmington Trust Corporation from 2010-2011. Prior to Wilmington Trust Corporation, Mr. Foley was senior vice president, treasurer and director of tax for ITT Corporation, a supplier of advanced technology products and services. Mr. Foley currently serves on the board of directors of AXA Equitable EQAT Mutual Funds and is an advisory board member of M&T Corporation Trust and Investment Committee. Mr. Foley also served on the boards of directors of M&T Corporation from 2011-2012 and of Wilmington Trust Company and Wilmington Trust Corporation from 2007-2011. In addition, Mr. Foley serves as chairman of the board of trustees of the Burke Rehabilitation Hospital and Burke Medical Research Institute, as well as the W. Burke Foundation since 2009 during which time the Hospital merged with the MonteFiore Hospital System. Mr. Foley holds an M.B.A. from New York University, and a B.A. from Union College where he had served as a trustee, and as a chairman of the President’s Council. He also served as a trustee of the Covent of the Sacred Heart; and currently serves as a trustee at the Sacred Heart Network of schools and a trustee and head finance chair at New Beginning Family Academy, a charter school in Bridgeport, CT. Mr. Foley brings extensive financial, economic, capital markets and executive leadership expertise to our board gained through his successful career on Wall Street and the Fortune 500.

Roy T. Tanaka. Mr. Tanaka has served as our director since July 2012. From 2004 until his retirement in September 2008, Mr. Tanaka served as the worldwide president of Biosense Webster, Inc., a Johnson & Johnson company, a market and technology leader in the field of electrophysiology. He joined Biosense Webster, Inc. as its U.S. president in 1997. Previously he held a variety of senior management positions at Sorin Biomedical, Inc., including president and chief executive officer, and leadership roles at CooperVision Surgical and Shiley, a division of Pfizer, Inc. He currently serves on the boards of directors of Epix Therapeutics Inc., a company developing technology to measure the temperature in a lesion during cardiac ablation procedures, and VytronUS Inc., a company developing ultrasound technology in the diagnosis and treatment of complex cardiac arrythmias. In addition, Mr. Tanaka served as a director of Volcano Corporation until May 2014 and TomoTherapy until its acquisition in June 2011. Mr. Tanaka brings broad experience in executive leadership in the medical device field. His operational expertise and knowledge of the regulatory environment, both in the U.S. and globally, also bring a valuable perspective.

Andrew L. Filler. Mr. Filler has served as our director since November 2017. Mr. Filler brings to BioSig over 20 years of experience in intellectual property for technology and medical device companies. He currently serves as Partner and General Counsel for Sherpa Technology Group since February 2014.  In addition, Mr. Filler had served as General Counsel and Vice President of IP for Nanosys, Inc. from July 2004 until February 2014 and currently consults with Nanosys, Inc. on business and legal matters. Mr. Filler also served as chief intellectual property counsel at Caliper Technologies from January 2002 until June 2004, senior associate attorney at Weil, Gotshal & Manges from January 2000 until January 2002, and director of intellectual property at Corvascular from 1997 until 2000. We believe that Mr. Filler’s extensive experience as an intellectual property lawyer and managing extensive intellectual property portfolios make him a valuable member of our board.

Patrick J. Gallagher. Mr. Gallagher has served as our director since July 2014. Mr. Gallagher, MBA, CFA, is an accomplished capital markets executive, advisor, and investor with a distinguished record of success in both the public and private markets. He has over 20 years of experience on Wall Street and extensive expertise in alternative investments, capital markets, and marketing. Since September 2014, Mr. Gallagher has served as Senior Managing Director and head of healthcare sales at Laidlaw & Co. (UK) Ltd. Mr. Gallagher serves as a strategic consultant for Athenex, Inc., a biopharmaceutical firm focused on next-generation therapies in oncology and immunology and was the vice president of business development and investor relations from September 2012 to October 2013. He also sits on the board of directors of Cingulate Therapeutics since July 2013, a clinical stage biopharmaceutical company focused on innovative new products for ADHD, as well as Evermore Global Advisors, a global money manager since May 2015. In November 2010, he was appointed by broker Concept Capital, a division of Sanders Morris Harris, as a Managing Director and the head of institutional sales. In 2001, Mr. Gallagher co-founded BDR Research Group, LLC, an independent sell-side research firm specializing in healthcare investing, financing and operations, and served as its chief executive officer until November 2010. Prior to 2001, he held various sales positions at investment and research firms Kidder Peabody, PaineWebber and New Vernon Associates. Mr. Gallagher is a CFA charter holder, received his MBA from Pennsylvania State University and holds a B.S. degree in finance from the University of Vermont. We believe that Mr. Gallagher’s experience in capital markets and marketing, with extensive expertise concentrated in the life sciences space, make him a valuable resource on our board.


Seth H. Z. Fischer. Mr. Fischer has served as our director since May 2013. He most recently served as the Chief Executive Officer and as a director of Vivus, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs, with currently marketed products in metabolic disease and sexual health from September 2013 - December 2017.  Prior to Vivus, Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson, a public healthcare company, from 1983 until his retirement in 2012. Mr. Fischer served as Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cardiovascular Devices, Cordis Corporation, from 2008 to 2012, which included responsibility for Cordis and Biosense Webster, and as Company Group Chairman, North America Pharmaceuticals from 2004 to 2007, which included responsibility for Ortho-McNeil Pharmaceuticals, Janssen, McNeil Pediatrics, and Scios. Prior to this position, He served as President of Ortho-McNeil Pharmaceuticals from 2000 to 2004, with his operating responsibilities encompassing the commercialization of products in multiple therapeutic categories including epilepsy, migraine, analgesic, anti-infective, cardiovascular, neurologic, psychiatric and women’s health areas. Mr. Fischer currently serves as a member of the board of directors Agile Therapeutics, Inc., a public pharmaceutical company focused on women’s health. He also serves on the board of directors of Marinus Pharmaceuticals, Inc., a public biopharmaceutical company focused on epilepsy and neuropsychiatric disorders. From April 2013 to September 2013, Mr. Fischer served on the board of directors of Trius Therapeutics, Inc., a public pharmaceutical company, until it was acquired by Cubist Pharmaceuticals, now a wholly owned subsidiary of Merck & Co., Inc. Mr. Fischer holds a Bachelor of General Studies from Ohio University and served as a captain in the U.S. Air Force.  Mr. Fischer brings extensive executive level strategic and operational experience to our Board needed for strategic planning, product development, commercialization and operations.

Jeffrey F. O’Donnell, Sr. Mr. O’Donnell has served as our director since February 2015; he had previously served as a director from October 2011 until February 2014. Mr. O’Donnell has extensive experience in the Healthcare industry, merging a solid, traditional corporate background with emerging growth experience. Jeff brings more than 20 years of Board and Chief Executive experience running emerging medical device firms. Businesses under his direct leadership have achieved over $1.5 Billion in value creation from initial public offering of stock or mergers and acquisitions. Currently, Jeff is the Chief Executive Officer and a Director of Trice Medical. Trice is an emerging growth medical device company developing optical needles used by orthopedic surgeons to diagnose soft tissue damage of joints. In 2008, Jeff started and ran Embrella Cardiovascular, a medical device startup company, which was sold in 2011 to Edwards Lifesciences (NYSE: EW). Prior to Embrella Cardiovascular, Jeff served as President and CEO of PhotoMedex (NASDAQ: PHMD) from 1999 to 2009. Prior to PhotoMedex, Jeff was the President and CEO of Cardiovascular Dynamics. His team took CCVD public on NASDAQ in June of 1996 and purchased Radiance Medical Systems and Endologix (NASDAQ: ELGX). From 1994 to 1995 Jeff held the position of President and CEO of Kensey Nash Corporation (NASDAQ: KNSY). Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and with Johnson & Johnson’s Orthopedic Division. In 2005, Jeff was named LifeSciences CEO of the Year by Price Waterhouse Coopers. In 2011, Jeff was named the Greater Philadelphia Emerging Entrepreneur of the Year by Ernst & Young. In 2017, Jeff assumed the role of Chairman of the Board of Directors for SpectraWave, a cardiology device company. He joined the AdvaMed Accel Board of Directors in 2016 and serves as an observer on the Membership, Ethics and Technology and Regulatory committees of the AdvaMed Board. Previously, Jeff served as Chairman of the Board of Strata Skin Sciences (NASDAQ: SSKN) (2 years) as well as Director on the Board at Cardiac Science (7 yrs.) and Endologix (12 yrs.). Jeff is a graduate of LaSalle University in Philadelphia. Mr. O’Donnell brings his experience in the healthcare industry and cardiovascular space, along with his experience with emerging growth companies, which will make him a valuable member of our board of directors.

David Weild IV. Mr. Weild has served as a director since May 2015. Mr. Weild is founder, chairman and CEO of Weild & Co., Inc., parent company of the investment banking firm Weild Capital, LLC. Prior to Weild & Co., Mr. Weild was vice chairman of NASDAQ, president of PrudentialFinancial.com and head of corporate finance and equity capital markets at Prudential Securities, Inc. Mr. Weild holds an M.B.A. from the Stern School of Business and a B.A. from Wesleyan University. Mr. Weild is currently on the board of PAVmed. From September 2010 to June 2011, Mr. Weild served on the board of Helium.com, until it was acquired by R.R. Donnelly & Sons Co. Since 2003, Mr. Weild was a director and then chairman of the board of the 9-11 charity Tuesday’s Children.   He became chairman emeritus in late 2016 and still serves on the board.  Mr. Weild brings extensive financial, economic, stock exchange, capital markets, and small company expertise to the Company gained throughout his career on Wall Street.  He is a recognized expert in capital markets and has spoken at the White House, Congress, the SEC, OECD and the G-20 on how market structure can be bettered to improve capital formation and economic growth.

Family Relationships

There are no family relationships among any of our officers or executive officers. 


Independent Directors

Our board of directors has determined that each of Roy T. Tanaka, David Weild IV, Patrick J. Gallagher, Donald E. Foley, Seth H. Z. Fischer, Andrew L. Filler, and Jeffrey F. O’Donnell, Sr. is independent within the meaning of Rule 5605(a)(2) of the NASDAQ Listing Rules and the rules and regulations promulgated by the Securities and Exchange Commission.

Committees of the Board of Directors

Our board of directors has established an audit committee, a nominating and corporate governance committee and a compensation committee, each of which has the composition and responsibilities described below.

Audit Committee

Our audit committee is currently comprised of Messrs. Weild, Gallagher and O’Donnell, each of whom our board has determined to be financially literate and qualifies as an independent director under Section 5605(a)(2) and Section 5605(c)(2) of the rules of the NASDAQ Stock Market.  Mr. Weild is the chairman of our audit committee.  In addition, Mr. Weild qualifies as a financial expert, as defined in Item 407(d)(5)(ii) of Regulation S-K.

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee is currently comprised of Messrs. Filler, Foley and Tanaka, each of whom qualifies as an independent director under Section 5605(a)(2) of the rules of the NASDAQ Stock Market. Mr. Filler is the chairman of our nominating and corporate governance committee.

Compensation Committee

Our compensation committee is currently comprised of Messrs. O’Donnell and Gallagher, both of whom qualifies as an independent director under Section 5605(a)(2) of the rules of the NASDAQ Stock Market, an “outside director” for purposes of Section 162(m) of the Internal Revenue Code and a “non-employee director” for purposes of Section 16b-3 under the Securities Exchange Act of 1934, as amended, and does not have a relationship to us which is material to his ability to be independent from management in connection with the duties of a compensation committee member, as described in Section 5605(d)(2) of the rules of the NASDAQ Stock Market.  Mr. O’Donnell is the chairman of our compensation committee.

Code of Ethics

We have adopted a code of business conduct and ethics that applies to our officers, directors and employees, including our principal executive officer, principal financial officer and principal accounting officer. The full text of our Code of Business Conduct and Ethics is published on the Investors section of our website at www.biosigtech.com.  We intend to disclose any future amendments to certain provisions of the Code of Business Conduct and Ethics, or waivers of such provisions granted to executive officers and directors, on this website within four business days following the date of any such amendment or waiver.


EXECUTIVE COMPENSATION
Summary Compensation Table

The following table provides certain summary information concerning compensation, for our last two fiscal years awarded to, earned by or paid to our named executive officers: (i) Kenneth L. Londoner, our chief executive officer, executive chairman and member of our board, (ii) Gregory D. Cash, our former chief executive officer and former member of our board and (iii) Steven Chaussy, our chief financial officer.

Name and principal position
 
Year
 
Salary
($)
   
Bonus
($)
   
Stock Awards
($) (1)
   
Option
Awards ($)
   
Nonequity Incentive Plan Compensation ($)
   
Change in Pension Value and Nonqualified Deferred Compensation Earnings ($)
   
All Other
Compensation
($)
   
Total
($)
 
Kenneth L. Londoner, Chief Executive Officer, Executive Chairman and Director (7)
 
2017
   
435,000
     
-
     
758,500
     
(1
)
   
-
     
-
     
-
     
1,193,500
 
 
2016
   
315,000
     
-
     
538,940
     
(2
)
   
-
     
-
     
-
     
853,940
 
Gregory D. Cash, President, Former Chief Executive Officer and Director
 
2017
   
179,252
             
137,000
     
(3
)
   
-
     
-
     
-
     
316,252
 
 
2016
   
325,000
             
259,221
     
(4
)
   
-
     
-
     
-
     
584,221
 
Steven Chaussy, Chief Financial Officer
 
2017
   
180,833
             
380,000
     
(5
)
   
-
     
-
     
-
     
560,833
 
 
2016
   
110,000
             
386,000
     
(6
)
   
-
     
-
     
-
     
496,000
 
 
(1)
Represents (i) common stock award or 450,000 shares granted November 8, 2017 and (ii) a common stock award of 50,000 shares granted on November 9, 2017
(2)
Represents (i) a common stock award of 250,000 shares granted May 4, 2016 and (ii) a common stock award of 41,500 shares granted December 8, 2016.
(3)
Represents a common stock award of 100,000 shares granted June 6, 2017
(4)
Represents (i) a stock option granted May 18, 2016 for the purchase of 150,000 shares of common stock at $1.84 for ten years, exercisable immediately and (ii) a common stock award of 20,875 shares granted December 8, 2016.
(5)
Represents a common stock award of 250,000 shares granted November 8, 2017
(6)
Represents a common stock award of 200,000 shares granted May 4, 2016.
(7)
Mr. Londoner served as our Executive Chairman and Director through the entirety of our last two fiscal years.  Mr. Londoner has served as our Chief Executive Officer since July 31, 2017.


Agreements with Executive Officers and Change-In-Control Arrangements
 
Kenneth L. Londoner
 
We entered into an employment agreement with Kenneth Londoner on March 1, 2013.  The employment agreement terminated on March 1, 2015, after which Mr. Londoner’s employment became on an at-will basis.  Prior to its termination, Mr. Londoner’s employment agreement required that Mr. Londoner receive an annual base salary of $225,000 and be eligible for annual discretionary bonuses and equity-based incentives, as our board may determine.  Mr. Londoner was also subject to non-competition and non-solicitation obligations, whereby, for a period lasting until one year after the termination of his employment with us, Mr. Londoner was not permitted to, directly or indirectly, (i) in any state in the U.S. or country that we conduct business and for which Mr. Londoner had responsibility, work for, invest in, provide financing to or establish a business that competes with our business, other than an exception that permits limited investment in publicly-traded competitors, (ii) solicit business from or do business with any customer, client, manufacturer or vendor with whom we did business or who we solicited within the preceding two years, and (iii) solicit, engage or hire any person employed by or who served as a consultant to us within the preceding twelve months. In September 2013, Mr. Londoner resigned as our chief executive officer, but remained with us in an executive role.  In November 2013, Mr. Londoner became our executive chairman and on July 31, 2017, Mr. Londoner was again appointed as our chief executive officer.  While Mr. Londoner’s employment agreement expired on March 1, 2015, we intend to continue to compensate Mr. Londoner pursuant to the terms of his former employment agreement for his contributions with respect to corporate finance, investor relations, and business development.
 
Prior to entering into his employment agreement, Mr. Londoner was an at-will employee.
 
Gregory D. Cash
 
On July 15, 2014, we entered into an employment agreement with Gregory Cash. The employment agreement has an initial term of three years that expires on July 15, 2017. Under the employment agreement, Mr. Cash is entitled to an annual base salary of $275,000. On March 31, 2015, upon our closing an equity or equity-linked financing with proceeds of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary automatically increased to $325,000 and he received (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the effective date of the agreement until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the board in consultation with Mr. Cash within 90 days of the effective date.

In accordance with Mr. Cash’s employment agreement, on July 15, 2014, we granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of our common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the effective date of his employment agreement and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of our common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the FDA of our PURE EP technology platform; and (v) 180,824 shares of common stock will vest upon our achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days. 

In connection with the termination of Mr. Cash’s employment with the Company, we entered into a General Release and Severance Agreement (the “Severance Agreement”) with Mr. Cash, pursuant to which Mr. Cash’s employment with the Company was terminated effective as of June 1, 2017.  Pursuant to the Severance Agreement, the Company agreed, among other things, to: (i) make severance payments in an amount equal to Mr. Cash’s base salary, less applicable taxes and other withholdings, through July 14, 2017, payable in equal installments in accordance with the normal payroll policies of the Company, with the first installment being paid on the Company’s first regular pay date on or after the fortieth (40th) day following the Separation Date, which initial payment shall include all installment amounts that would have been paid during the first forty (40) days following the Separation Date had installments commenced immediately following the Separation Date; (ii) provide through December 31, 2017, or until Mr. Cash becomes eligible for comparable employer sponsored health plan benefits, whichever is sooner, all health plan benefits to which Mr. Cash was entitled prior to the Separation Date, pursuant to Mr. Cash’s election of COBRA with the Company and Mr. Cash paying the relative costs therefor in the same proportion as existed while Mr. Cash was an active employee of the Company; (iii) issue 100,000 shares of restricted stock to Mr. Cash, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the Award Agreement (as described below); and (iv) transfer to Mr. Cash title to certain equipment previously issued to him.

In connection with the termination of Mr. Cash’s employment with the Company, on May 31, 2017, the Company also entered into a Restricted Stock Award Agreement (the “Award Agreement”) with Mr. Cash, pursuant to which the Company issued 100,000 shares of restricted stock (the “Severance Shares”) to Mr. Cash, subject to the terms of the Award Agreement.
 
Pursuant to the Award Agreement, the Severance Shares: (i) vested 100% as of the date of grant; (ii) are subject to forfeiture immediately upon any revocation by Mr. Cash of his release of claims against the Company under the Severance Agreement; and (iii) are subject to a one-year lock-up period, during which Mr. Cash will not be permitted to sell, transfer, pledge, hypothecate, margin, assign or otherwise encumber any of the Severance Shares.
 
Outstanding Equity Awards at Fiscal Year End
 
The following table sets forth information regarding equity awards that have been previously awarded to each of the named executive officers and which remained outstanding as of December 31, 2017.

Name
 
Number of Securities underlying Unexercised Options (#) Exercisable
   
Number of Securities underlying Unexercised Options (#) Unexercisable
   
Option Exercise Price ($/Sh)
 
Option Expiration Date
 
Number of Shares or Units of Stock that have not Vested (#)
   
Market Value of Shares of Units That Have Not Vested ($)
   
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#)
   
Equity Incentive Plan Awards: Market of Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)
 
Kenneth
   
250,000
     
-
   
$
2.09
 
1/16/2020
   
-
   
$
-
     
-
   
$
-
 
Londoner
                       
 
                               
 
                       
 
                               
Steven
   
30,000
     
-
   
$
2.09
 
1/16/2020
   
-
   
$
-
     
-
   
$
-
 
Chaussy
   
30,000
     
-
   
$
2.09
 
6/11/2023
   
-
   
$
-
     
-
   
$
-
 
 
BioSig Technologies, Inc. 2012 Equity Incentive Plan

On October 19, 2012, our board of directors adopted the BioSig Technologies, Inc. 2012 Equity Incentive Plan, which provides for the grant of stock options, stock appreciation rights, restricted stock and restricted stock units to employees, directors and consultants, to be granted from time to time as determined by our board of directors or its designees. An aggregate of 15,186,123 shares of common stock are reserved for issuance under the BioSig Technologies, Inc. 2012 Equity Incentive Plan.  As of May 16, 2018, the number of options and restricted stock awards granted under the BioSig Technologies, Inc. 2012 Equity Incentive Plan are 15,184,383.


Equity Compensation Plan Information
As of December 31, 2017

The following table provides certain information as of December 31, 2017, with respect to our equity compensation plans under which our equity securities are authorized for issuance:
 
Plan category
 
Number of securities
to be issued upon
exercise of
outstanding options
(a)
   
Weighted-average
exercise price of
outstanding options
(b)
   
Securities remaining
available for future
issuance under equity
compensation plans
(excluding securities
reflected in column (a))
(c)
 
Equity compensation plans approved by security holders
   
8,510,319
   
$
2.10
     
1,907,509
 
Equity compensation plans not approved by security holders
   
-
     
-
     
-
 
Total
   
8,510,319
     
2.10
     
1,907,509
 

DIRECTOR COMPENSATION
 
The following table sets forth summary information concerning the total compensation paid to our non-employee directors during the fiscal year ended December 31, 2017 for services to our company.
 
Name
 
Fees Earned
or Paid in
Cash ($)
   
Equity
Awards ($)
     
Total ($)
 
Donald E. Foley
 
$
-
   
$
44,700
(1
)
 
$
44,700
 
Roy T. Tanaka
 
$
-
   
$
44,700
(1
)
 
$
44,700
 
Andrew L. Filler
 
$
-
   
$
44,700
(1
)
 
$
44,700
 
Patrick J Gallagher
 
$
-
   
$
42,084
(2
)
 
$
42,084
 
Seth H. Z. Fischer
 
$
     
$
69,537
(3
)
 
$
69,537
 
Jeffrey F O’Donnell, Sr
 
$
-
   
$
378,500
(4
)
 
$
378,500
 
David Weild, IV
 
$
-
   
$
74,500
(5
)
 
$
74,500
 
Jerome B. Zeldis (former member) (6)
 
$
-
   
$
-
     
$
-
 
Total:
 
$
-
   
$
698,721
     
$
698,721
 

(1)
Represents (i) a common stock award of 30,000 shares granted November 9, 2017
(2)
Represents (i) a stock option granted December 22, 2017 for the purchase of 39,926 shares of common stock, vesting immediately, at an exercise price of $1.37 per share and termination date of December 22, 2027.
(3)
Represents (i) 2 stock options granted December 22, 2017 for the purchase of an aggregate of 65,972 shares of common stock, vesting immediately, at an exercise price of $1.37 per share and termination date of December 22, 2027.
(4)
Represents (i) a common stock award of 200,000 shares granted on November 8, 2017 and (ii) a common stock award of 50,000 shares granted November 9, 2017.
(5)
Represents (i) a common stock award of 50,000 shares granted November 9, 2017
(6)
Dr. Zeldis retired as our director on November 9, 2017.
 


SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Common Stock

The following table sets forth information with respect to the beneficial ownership of our common stock as of May 16, 2018:

by each person who is known by us to beneficially own more than 5.0% of our common stock;

by each of our named executive officers and directors; and

by all of our named executive officers and directors as a group.

The percentages of common stock beneficially owned are reported on the basis of regulations of the Securities and Exchange Commission governing the determination of beneficial ownership of securities. Under the rules of the Securities and Exchange Commission, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security.  With respect to the Series C Preferred Stock and warrants held by the beneficial owners listed below, there exist contractual provisions limiting conversion and exercise to the extent such conversion or exercise would cause such beneficial owner, together with its affiliates or members of a “group,” to beneficially own a number of shares of common stock which would exceed from 4.99% to 9.99% of our then outstanding shares of common stock following such conversion or exercise. The shares and percentage ownership of our outstanding shares indicated in the table below do not give effect to these limitations.  Except as indicated in the footnotes to this table, to our knowledge and subject to community property laws where applicable, each beneficial owner named in the table below has sole voting and sole investment power with respect to all shares beneficially owned and each person’s address is c/o BioSig Technologies, Inc., 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025.
 
Name of Beneficial Owner
 
Number of Shares
Beneficially Owned (1)
     
Percentage of Common Stock Owned (1)(2)
 
 
             
5% Owners
             
Lora Mikolaitis
   
3,458,724
(3
)
   
9.45
%
 
                 
David Cherry
   
2,808,639
(4
)
   
7.63
%
 
                 
Ramachandra Malya
   
1,870,000
(5
)
   
5.08
%
 
                 
Officers and Directors
                 
Kenneth L. Londoner
   
4,789,413
(6
)
   
13.06
%
 
                 
Roy T. Tanaka
   
974,802
(7
)
   
2.62
%
 
                 
Seth H. Z. Fischer
   
616,916
(8
)
   
1.67
%
 
                 
Patrick J. Gallagher
   
316,150
(9
)
   
*
 
 
                 
Jeffrey F. O’Donnell, Sr.
   
779,800
(10
)
   
2.13
%
 
                 
Steve Chaussy
   
1,217,323
(11
)
   
3.35
%
 
                 
Andrew L. Filler
   
94,518
(12
)
   
*
 
 
                 
David Weild IV
   
400,000
(13
)
   
1.09
%
 
                 
Donald E. Foley
   
634,166
(14
)
   
1.73
%
 
                 
All directors and executive officers as a group (9 persons)
   
9,823,088
       
26.78
%
 

* Less than 1%
 
(1)
Shares of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assume the exercise of all options and other securities convertible into common stock beneficially owned by such person or entity currently exercisable or exercisable within 60 days of May 16, 2018, except as otherwise noted. Shares issuable pursuant to the exercise of stock options and other securities convertible into common stock exercisable within 60 days are deemed outstanding and held by the holder of such options or other securities for computing the percentage of outstanding common stock beneficially owned by such person, but are not deemed outstanding for computing the percentage of outstanding common stock beneficially owned by any other person.

(2)
These percentages have been calculated based on 36,270,975 shares of common stock outstanding as of May 16, 2018.

(3)
Comprised of (i) 43,750 shares of common stock, (ii) options to purchase 337,500 shares of common stock that are currently exercisable or exercisable within 60 days of May 16, 2018, and (iii) 3,077,474 shares of common stock held by Miko Consulting Group, Inc. Lora Mikolaitis has sole voting and dispositive power over the securities held for the account of Miko Consulting Group, Inc.

(4)
Comprised of (i) 10,000 shares of common stock and warrants to purchase 5,000 shares of common stock, (ii) 316,642 shares of common stock and warrants to purchase 158,321 shares of common stock held by Thomas David Cherry as Trustee of Cherry Family Trust, a trust for which David Cherry is deemed the beneficial owner, and (iii) 1,545,784 shares of common stock and warrants to purchase 772,892 shares of common stock held by Cherry Pipes Ltd., David Cherry has sole voting and dispositive power over the securities held for the account of Cherry Pipes Ltd.

(5)
Comprised of (i) 1,330,000 shares of common stock and (ii) warrants to purchase 540,000 shares of common stock.

(6)
Comprised of (i) 1,422,985 shares of common stock directly held by Mr. Londoner, (ii) 2,953,307 shares of common stock held by Endicott Management Partners, LLC, an entity for which Mr. Londoner is deemed the beneficial owner, (iii) warrants to purchase 163,121 shares of common stock, and (v) options to purchase 250,000 shares of common stock that are currently exercisable.

(7)
Comprised of (i) 80,875 shares of common stock and (ii) options to purchase 893,927 shares of common stock that are currently exercisable.

(8)
Comprised of (i) 25,000 shares of common stock and (ii) options to purchase 591,916 shares of common stock that are currently exercisable or exercisable within 60 days of May 16, 2018.

(9)
Comprised of (i) 53,000 shares of common stock directly held by Mr. Gallagher, (ii) 6,000 shares of common stock held by Amy E Gallagher Educational Trust for which Mr. Gallagher is deemed the beneficial owner, (iii) 6,000 shares of common stock held by Hans Gallagher Educational Trust for which Mr. Gallagher is deemed the beneficial owner, (iv) options to purchase 239,926 shares of common stock that are currently exercisable or exercisable within 60 days of May 16, 2018, and (v) warrants to purchase 11,224 shares of common stock.

(10)
Comprised of (i) 409,000 shares of common stock and (ii) options to purchase 370,800 shares of common stock that are currently exercisable.

(11)
Comprised of (i) 1,157,323 shares of common stock and (ii) options to purchase 60,000 shares of common stock that are currently exercisable.

(12)
Comprised of (i) 44,518 shares of common stock and (ii) options to purchase 50,000 shares of common stock that are currently exercisable.

(13)
Comprised of (i) 50,000 shares of common stock and (ii) options to purchase 350,000 shares of common stock that is currently exercisable.

(14)
Comprised of (i) 255,000 shares of common stock, (ii) options to purchase 279,166 shares of common stock that are currently exercisable or exercisable within 60 days of May 16, 2018 and (iii) warrants to purchase 100,000 shares of common stock.

SELLING STOCKHOLDERS
 
Up to 1,977,726 shares of our common stock are currently being offered by the selling stockholders under this prospectus. This reflects the sum of the number of shares of our common stock (i) into which the Series E Preferred Stock are currently exercisable, at a price of $1.50 per share per $1,500 principal amount of Series E Preferred Stock, (ii) issuable upon payment of the make-good dividend of 7% per annum payable upon conversion of the Series E Preferred Stock (iii) into which the Series E Warrants are exercisable at $1.50 per share, and (iv) into which the Consent Warrants (as defined below) are exercisable at $1.50 per share. All of the shares of Series E Preferred Stock and the Series E Warrants were purchased by the Series E Holders pursuant to the Securities Purchase Agreement dated as of February 16, 2018 (the “Series E Purchase Agreement”), by and among the Company and the Series E Holders (the “Private Placement”). The Series E Holders paid $1,500 for a unit consisting of one share of Series E Preferred Stock and a Series E Warrant to purchase up to an aggregate of 500,000 shares of our common stock at an exercise price of $1.75 per share.  On April 30, 2018, the terms of the Series E Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Series E Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 83,334 shares of common stock may be issued upon exercise of the Series E Warrants due to the adjustment.

In connection with the Private Placement, on February 14, 2018, we entered into a consent agreement (the “Consent”) with the holders of our Series D Convertible Preferred Stock (the “Series D Holders”).  In consideration for their entry into the Consent, we issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of common stock (the “Consent Warrants”).  The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that we issue any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. 

We are registering the shares of common stock in order to permit the selling stockholders to offer the shares for resale from time to time pursuant to this prospectus. The selling stockholders may also sell, transfer or otherwise dispose of all or a portion of their shares in transactions exempt from the registration requirements of the Securities Act of 1933, as amended, or pursuant to another effective registration statement covering those shares. Except for the ownership of the shares of common stock and the warrants issued pursuant to the Series E Purchase Agreement, the Series E Holders have not had any material relationship with us within the past three years.  Except for the ownership of the Consent Warrants and the purchase of shares of our Series D Preferred Stock and the Series D Warrants, the Series D Holders have not had any material relationship with us within the past three years.
 
The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of the Series E Preferred Stock, the Series E Warrants and/or the Consent Warrants, as of May 16, 2018, assuming exercise of all warrants held by the selling stockholder on that date, without regard to any limitations on exercise.
 
The third column lists the shares of common stock being offered by this prospectus by the selling stockholders and does not take in account any limitations on (i) conversion of the Series E Preferred Stock or issuance of common stock or (ii) exercise of the Series E Warrants or the Consent Warrants.
 
In accordance with the terms of a registration rights agreement with the Series E Holders (the “Registration Rights Agreement”), this prospectus generally covers the resale of at least the sum of (i) the number of shares of common stock issued upon conversion of the Series E Preferred Stock issued pursuant to the Series E Purchase Agreement as of the trading day immediately preceding the date the registration statement is initially filed with the SEC, (ii) the number of shares of common stock issuable as a make-whole dividend of 7% per annum upon the conversion of our Series E Preferred Stock and (ii) the maximum number of shares of common stock issued and issuable upon exercise of the Series E Warrants as of the trading day immediately preceding the date the registration statement is initially filed with the SEC. The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus.


Under the terms of the Series E Preferred Stock, a selling stockholder may not convert the Series E Preferred Stock to the extent such exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed 4.99% of our then outstanding shares of common stock following such exercise. Under the terms of the Series E Warrants and the Consent Warrants, a selling stockholder may not exercise the Series E Warrants or the Consent Warrants to the extent such exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed 4.99% of our then outstanding shares of common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second column does not reflect these limitations. The selling stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.” 
 
 
 
Ownership Before Offering
     
Ownership After Offering
 
Selling Stockholder
 
Number of shares
of common stock
beneficially owned (1)
     
Number of
shares offered
     
Number of shares
of common stock
beneficially owned (1)
     
Percentage of
common stock
beneficially owned (1)
 
Cavalry Fund I LP (2)
   
1,053,863
(3
)
   
938,863
(4
)
   
115,000
       
*
 
L1 Capital Global Opportunities Master Fund (5)
   
1,053,863
(6
)
   
938,863
(7
)
   
115,000
       
*
 
Alpha Capital Anstalt (8)
   
1,792,095
(9
)
   
87,500
(9
)
   
1,704,595
(9
)
   
4.48
%
Brio Capital Master Fund Ltd (10)
   
336,734
(11
)
   
12,500
(12
)
   
324,234
(13
)
   
*
 
 
* Less than 1%

(1)
In computing the percentage of our common stock beneficially owned by each selling stockholder after the offering, we have assumed the exercise by such selling stockholder of all warrants with respect to those shares being offered by such selling stockholder, and therefore the calculation is based on a number of shares of common stock outstanding comprised of (i) 36,270,975 shares of common stock outstanding as of May 16, 2018 plus (ii) the number of shares offered by the selling stockholder in this offering underlying warrants held by such selling stockholder.  The shares offered by one selling stockholder underlying warrants held by such selling stockholder are not deemed outstanding for the purpose of computing the percentage ownership of any other selling stockholder.

(2)
Thomas Walsh has sole voting and dispositive power over the securities held for the account of this selling stockholder.

(3)
Includes (i) 115,000 shares of common stock (ii) 500,000 shares of common stock issuable upon conversion of Series E Preferred Stock, (iii) 147,196 shares of common stock as a make-good dividend issuable upon the conversion of Series E Preferred Stock, and (iv) 291,667 of common stock issuable upon the exercise of warrants.

(4)
Includes (i) 500,000 shares of common stock issuable upon conversion of Series E Preferred Stock, (ii) 147,196 shares of common stock as a make-good dividend issuable upon the conversion of Series E Preferred Stock, and (iii) 291,667 of common stock issuable upon the exercise of warrants.

(5)
David Feldman has sole voting and dispositive power over the securities held for the account of this selling stockholder.

(6)
Includes (i) 115,000 shares of common stock (ii) 500,000 shares of common stock issuable upon conversion of Series E Preferred Stock, (iii) 147,196 shares of common stock as a make-good dividend issuable upon the conversion of Series E Preferred Stock, and (iv) 291,667 of common stock issuable upon the exercise of warrants.

(7)
Includes (i) 500,000 shares of common stock issuable upon conversion of Series E Preferred Stock, (ii) 147,196 shares of common stock as a make-good dividend issuable upon the conversion of Series E Preferred Stock, and (iii) 291,667 of common stock issuable upon the exercise of warrants.

(8)
Konrad Ackerman has sole voting and dispositive power over the securities held for the account of this selling stockholder.

(9)
Includes shares of common stock issuable upon the exercise of warrants.

(10)
Shaye Hirsch has sole voting and dispositive power over the securities held for the account of this selling stockholder.

(11)
Includes (i) 27,000 shares of common stock issuable upon conversion of Series D Preferred Stock, (ii) 7,290 shares of common stock as a make-whole dividend issuable upon the conversion of Series D Preferred Stock, and (iii) 302,444 of common stock issuable upon the exercise of warrants.

(12)
Includes shares of common stock issuable upon the exercise of warrants.

(13)
Includes (i) 27,000 shares of common stock issuable upon conversion of Series D Preferred Stock, (ii) 7,290 shares of common stock as a make-whole dividend issuable upon the conversion of Series D Preferred Stock, and (iii) 289,944 of common stock issuable upon the exercise of warrants.







CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Accrued expenses related primarily to travel reimbursements due related parties as of December 31, 2017 and 2016 was $27,375 and $15,755, respectively.

On April 1, 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from Mr. Londoner.

On June 16, 2017 Mr. Cash was granted 100,000 shares of common stock at a cost basis of $1.37 per share in connection with his severance settlement. The granted shares vested immediately.

On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors,  the Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company’s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned.  Mr. Filler is the general counsel and partner of Sherpa. 

On February 15, 2018, the Company granted our board member, Andrew L. Filler, 50,000 options to purchase common stock in connection with his appointment as chairman of our Nominating and Corporate Governance Committee at the exercise price of $1.42 per share for a term of ten years, vesting immediately.

DESCRIPTION OF SECURITIES 
 
We have authorized 201,000,000 shares of capital stock, par value $0.001 per share, of which 200,000,000 are shares of common stock and 1,000,000 are shares of “blank check” preferred stock, of which 200 are authorized as Series A Preferred Stock, 600 are authorized as Series B Preferred Stock, 4,200 are authorized as Series C Preferred Stock, 1,400 are authorized as Series D Preferred Stock, and 1,000 are authorized as Series E Preferred Stock. On May 16, 2018, there were 36,270,975 shares of common stock issued and outstanding, 575 shares of Series C Preferred Stock issued and outstanding, 27 shares of Series D Preferred Stock issued and outstanding, 1,000 shares of Series E Preferred Stock issued and outstanding, and no shares of Series A Preferred Stock or Series B Preferred Stock issued and outstanding.
 
Holders of Capital Stock
 
As of May 16, 2018, there were approximately 309 holders of our common stock, as determined by counting our record holders and the number of participants reflected in a security position listing provided to us by the Depository Trust Company. Because the “DTC participants” are brokers and other institutions holding shares of our common stock on behalf of their customers, we do not know the actual number of unique shareholders represented by these record holders.  As of May 16, 2018, there were: no holders of our Series A Preferred Stock or Series B Preferred Stock; 9 holders of our Series C Preferred Stock; 1 holder of our Series D Preferred Stock; and 2 holders of our Series E Preferred Stock.
 
Common Stock

The holders of common stock are entitled to one vote per share on all matters to be voted upon by stockholders.  Holders of our common stock are entitled to receive ratably dividends as may be declared by the board of directors out of funds legally available for that purpose. The rights of the holders of our Series C Preferred Stock, as described below, prohibit us from paying cash dividends to our holders of common stock absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, which holders must include Alpha Capital Anstalt, so long as Alpha Capital Anstalt holds not less than $100,000 of the Series C Preferred Stock. We have not paid any dividends since our inception, and, subject to our obligations to pay dividends to the holders of the Series C Preferred Stock, as described below, we presently anticipate that all earnings, if any, will be retained for development of our business. Even if we are permitted to pay cash dividends in the future, any future disposition of dividends will be at the discretion of our board of directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.


Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of stockholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the stockholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of our common stock have no preemptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Subject to the rights of the holders of our preferred stock, upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities. There are no provisions in our Amended and Restated Certificate of Incorporation or our By-laws that would prevent or delay a change in our control.

Preferred Stock

There are presently no issued and outstanding shares of Series A Preferred Stock or Series B Preferred Stock.

Series C Preferred Stock

Each share of the Series C Preferred Stock is entitled to a nine percent (9%) annual dividend on the $1,000 per share stated value. Unless the Series C Preferred Stock is converted into shares of common stock, the dividends shall accrue and be payable in cash or, subject to the satisfaction of certain conditions, in pay-in-kind shares. Such cumulative dividends are payable quarterly, commencing on September 30, 2013 and on each conversion date.  The terms of the Series C Preferred Stock were amended on March 27, 2014 and August 15, 2014.  The description herein reflects such amended terms.

In the event that

(i)
we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,
(ii)
we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,
(iii)
we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,
(iv)
we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,
(v)
we are party to a change of control transaction,
(vi)
we file for bankruptcy or a similar arrangement or are adjudicated insolvent,
(vii)
we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,

the holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.

In the event of our liquidation or winding up of affairs, the holders of the Series C Preferred Stock will be entitled to a liquidation preference of the stated value plus any accrued but unpaid dividends or any other fees due the holder. The shares of the Series C Preferred Stock rank senior to the rights of the common stock and all other securities exercisable or convertible into shares of common stock.

Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share, subject to the beneficial ownership limitation described below. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.


In the event we issue any equity or equity-linked securities with terms more favorable than those of the Series C Preferred Stock, any holder of the Series C Preferred Stock may request to amend the terms of such holder’s Series C Preferred Stock to be equivalent to the terms of such issued equity or equity-linked securities, subject to certain exempted issuances.

The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, which holders must include Alpha Capital Anstalt, so long as Alpha Capital Anstalt holds not less than $100,000 of Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:

incur additional indebtedness;

permit liens on assets;

repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;

pay cash dividends to our stockholders; and

engage in transactions with affiliates.

Series D Preferred Stock

Each share of our Series D Preferred Stock is entitled to receive cumulative dividends at the rate per share (as a percentage of the stated value per share of Series D Preferred Stock) of 9% per annum, with respect to the Series D Preferred Stock on each date that such holder converts Series D Preferred Stock into common stock (with respect only to Series D Preferred Stock being converted).  We may pay such dividends, at its option, in cash, common stock or a combination thereof.  Payment of dividends in shares of common stock is subject to the satisfaction of certain equity conditions set forth in the Certificate of Designations.  Upon the conversion of Series D Preferred Stock prior to November 3, 2020, we shall also pay to the holders of the Series D Preferred Stock so converted cash, or at our option, common stock or a combination thereof, with respect to the Series D Preferred Stock so converted in an amount equal to $270 per $1,000 of stated value of the Series D Preferred Stock being converted, less the amount of all prior dividends paid on such converted Series D Preferred Stock before the relevant date of conversion.  Any dividends, whether paid in cash or shares of common stock, that are not paid within seven trading days following a dividend payment date shall continue to accrue and shall entail a late fee, which must be paid in cash, at the rate of 18% per annum or the lesser rate permitted by applicable law which shall accrue daily from the dividend payment date through and including the date of actual payment in full.

In the event of our liquidation or winding up of its affairs, the holders of Series D Preferred Stock will be entitled to a liquidation preference of the stated value per share of $1,500 plus any accrued but unpaid dividends or any other fees due the holder. A total of 1,400 shares were designated as Series D Preferred Stock.

Each share of Series D Preferred Stock may, at any time, be converted into shares of common stock determined by dividing the stated value of the Series D Preferred Stock being converted by the conversion price of $1.50 per share.  The conversion price is subject to “full ratchet” anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the conversion price as well as other customary anti-dilution protection.


Series E Preferred Stock

Each share of our Series E Preferred Stock is entitled to receive cumulative dividends at the rate per share (as a percentage of the stated value per share of Series E Preferred Stock) of 7% per annum, with respect to the Series E Preferred Stock on each date that such holder converts shares of Series E Preferred Stock into common stock (with respect only to shares of Series E Preferred Stock being converted).  Upon the conversion of shares of Series E Preferred Stock prior to February 16, 2021, we shall also pay to the holders of the Series E Preferred Stock so converted cash, or at our option, common stock or a combination thereof, with respect to the Series E Preferred Stock so converted in an amount equal to $210 per $1,000 of stated value of the Series E Preferred Stock being converted, less the amount of all prior dividends paid on such converted Series E Preferred Stock before the relevant date of conversion.

In the event of our liquidation or winding up of its affairs, the holders of Series E Preferred Stock will be entitled to a liquidation preference of the stated value per share of $1,500 plus any accrued but unpaid dividends or any other fees due the holder. A total of 1,000 shares were designated as Series E Preferred Stock.

Each share of Series E Preferred Stock may, at any time, be converted into shares of common stock determined by dividing the stated value of the Series E Preferred Stock being converted by the conversion price of $1.50 per share.  The conversion price is subject to “full ratchet” anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the conversion price as well as other customary anti-dilution protection.

Warrants

Five-Year Warrants

In connection with the private placement of our Series C Preferred Stock, on February through July 2013, we issued to the holders of our Series C Preferred Stock five-year warrants to purchase up to an aggregate of 1,330,629 shares of common stock at an exercise price of $2.61 per share. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.  As a result of the full-ratchet anti-dilution protection provision of the warrants, the exercise price of the warrants was subsequently decreased from $2.61 per share to $1.50 per share and the aggregate number of shares issuable under the warrants was increased to 2,315,301.
 
Five-Year Amendment Warrants

As consideration for (i) extending the termination date of the securities purchase agreement and (ii) extending the filing and effectiveness dates for the filing of the registration statement pursuant to the registration rights agreement related to our Series C Preferred Stock, on July 15, 2013, we issued to the holders of our Series C Preferred Stock that purchased shares of our Series C Preferred Stock prior to the July 15, 2013 closing, five-year warrants to purchase up to an aggregate of 289,730 shares of common stock. The terms of these warrants are identical to the Five-Year Warrants described above.  As a result of the full-ratchet anti-dilution protection provision of the warrants, the exercise price of the warrants subsequently decreased from $2.61 per share to $1.50 per share and the aggregate number of shares issuable under the warrants was increased to 504,130.

October 2013 Five-Year Amendment Warrants

As consideration for amending the terms of the securities purchase agreement to permit our private placement of our common stock and warrants in December 2013, on October 14, 2013, we issued to the holders of our Series C Preferred Stock five-year warrants to purchase up to an aggregate of 332,684 shares of common stock. The terms of these warrants are identical to the Five-Year Warrants described above.  As a result of the full-ratchet anti-dilution protection provision of the warrants, the exercise price of the warrants was subsequently decreased from $2.61 per share to $1.50 per share and the aggregate number of shares issuable under the warrants was increased to 578,870.

December 2013 Five-Year Warrants

In connection with the private placement of our common stock in December 2013 and January 2014, we issued to the investors participating in the private placement five-year warrants to purchase up to an aggregate of 177,947 shares of common stock at an exercise price of $3.67 per share. The warrants contain customary anti-dilution protections. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.

April 2014 Five-Year Warrants

In connection with the private placement of our common stock in April 2014, we issued to the investors participating in the private placement five-year warrants to purchase up to an aggregate of 114,880 shares of common stock at an exercise price of $3.75 per share. The warrants contain customary anti-dilution protections. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.

August 2014 Five-Year Warrants

In connection with the private placement of our common stock in August and September 2014, we issued to the investors participating in the private placement five-year warrants to purchase up to an aggregate of 190,600 shares of common stock at an exercise price of $2.75 per share. The warrants contain customary anti-dilution protections. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.

December 2014 Warrants

In connection with the private placement of our common stock in December 2014 and January, February and March 2015, we issued to the investors participating in the private placement five-year warrants to purchase up to an aggregate of 801,800 shares of common stock. The warrants are exercisable at $3.75 per share and expire March 31, 2020. The warrants contain customary anti-dilution protections. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.

October 2015 Three-Year Warrants

In connection with the private placement of our common stock in October, November and December 2015 and February, March and April 2016, we issued to the investors participating in the private placement three-year warrants to purchase up to an aggregate of 1,501,513 shares of common stock at an exercise price of $1.95 per share. The warrants contain customary anti-dilution protections and are exercisable for cash.

May 2016 Warrants

In connection with the private placement of our common stock in June 2016, we issued to the investors participating in the private placement three-year warrants to purchase up to an aggregate of 38,572 shares of common stock at an exercise price of $2.10 per share. The warrants contain customary anti-dilution protections and are exercisable for cash. In February 2017, we exchanged these warrants for warrants to purchase up to an aggregate of 45,001 shares of common stock at an exercise price of $1.50, with all other terms and conditions the same.

August 2016 Warrants

In connection with the private placement of our common stock in August and September 2016, we issued to the investors participating in the private placement three-year warrants to purchase up to an aggregate of 187,513 shares of common stock at an exercise price of $1.95 per share. The warrants contain customary anti-dilution protections and are exercisable for cash.

October 2016 Warrants

In connection with the private placement of our common stock in October, November and December 2016 and February and March 2017, we issued to the investors participating in the private placement three-year warrants to purchase up to an aggregate of 1,449,991 shares of common stock at an exercise price of $1.50 per share. The warrants contain customary anti-dilution protections and are exercisable for cash.


April 2017 Warrants

In connection with the private placement of our common stock in April, May, June, July, August, September, October, November and December 2017 and January 2018, we issued to the investors participating in the private placement three-year warrants to purchase up to an aggregate of 1,504,306 shares of common stock at an exercise price of $1.50 per share. The warrants contain customary anti-dilution protections and are exercisable for cash.

Series D – Class A Warrants and Class B Warrants

On November 3, 2017, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which we issued Class A Warrants to purchase an aggregate of 667,000 shares of common stock at an exercise price of $1.75 per share. Contemporaneously with the entry into the Purchase Agreement, we and the Investors agreed to exchange outstanding warrants to purchase 780,506 shares of common stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price.

On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment.

Class A Warrants are exercisable immediately and expire on May 3, 2021.  The Class B Warrants are exercisable immediately and expire on November 3, 2020 and have an exercise price of $1.50.  The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that we issue any common stock at a per share price lower than the applicable exercise price then in effect, and the ability to be exercised via a cashless exercise.

Series E Warrants

On February 16, 2018, we entered into a Securities Purchase Agreement with certain institutional accredited investors pursuant to which we issued Series E Warrants to purchase an aggregate of 500,000 shares of common stock, par value $0.001 per share, at an exercise price of $1.75 per share. The Series E Warrants are exercisable immediately and expire on August 16, 2021. The Series E Warrants include a “full ratchet” anti-dilution adjustment in the event that we issue any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.

On April 30, 2018, the terms of the Series E Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Series E Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 83,334 shares of common stock may be issued upon exercise of the Series E Warrants due to the adjustment.

Consent Warrants

On February 14, 2018, in connection with our entry into the Series E Purchase Agreement, we entered into the Consent with the Series D Holders.  Pursuant to the Consent, the Series D Holders consented to the Private Placement and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Private Placement.  In consideration for their entry into the Consent, we issued to the Series D Holders the Consent Warrants.  The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that we issue any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. 

April 2018 Warrants

In connection with the private placement of our common stock on April 30 and May 11, 2018, we issued to the investors participating in the private placement three-year warrants to purchase up to an aggregate of 1,666,506 shares of common stock at an exercise price of $1.75 per share. The warrants contain customary anti-dilution protections and are exercisable for cash.

Mayo Warrant

In March 2017, we issued to Mayo Clinic Ventures three-year warrants to purchase up to an aggregate of 630,000 shares of common stock at an exercise price of $1.50 per share in connection with a know-how licensing agreement with Mayo Foundation for Medical Education and Research. The warrants contain customary anti-dilution protections and are exercisable for cash.

Series A Placement Agent Warrant

As consideration for serving as our placement agent in connection with the private placement of Series A Preferred Stock, on January 18, 2013, we issued to Laidlaw & Company (UK) Ltd. a seven-year warrant to purchase up to 35,076 shares of common stock at an exercise price of $1.84 per share. The terms of this warrant are otherwise identical to the Five-Year Warrants described above.

Series B Placement Agent Warrant

As consideration for serving as our placement agent in connection with the private placement of Series B Preferred Stock, on January 18, 2013, we issued to Laidlaw & Company (UK) Ltd. a seven-year warrant to purchase up to 30,755 shares of common stock at an exercise price of $2.02 per share. The terms of this warrant are otherwise identical to the Five-Year Warrants described above.

Series C Placement Agent Warrant

As consideration for serving as our placement agent in connection with the private placement of Series C Preferred Stock, on July 15, 2013, we issued to Laidlaw & Company (UK) Ltd. a warrant to purchase up to 177,057 shares of common stock. The terms of this warrant are identical to the Five-Year Warrants described above. As a result of the full-ratchet anti-dilution protection provision of the warrants, the exercise price of the warrants subsequently decreased from $2.61 per share to $1.50 per share and the aggregate number of shares issuable under the warrants was increased to 308,079.

Par Value Warrant

As consideration for providing general financial advisory services, on January 7, 2013, we issued to Jamess Capital Group LLC a seven-year warrant to purchase up to 383,320 shares of common stock at an exercise price of $0.001 per share. The terms of this warrant are otherwise identical to the Five-Year Warrants described above.

Consultant Warrant

As consideration for providing general financial advisory services, on August 17, 2015, we issued Alere Financial Partners, LLC a three-year warrant to purchase up to 100,000 shares of common stock each at an exercise price of $2.00 per share and a three-year warrant to purchase up to 100,000 shares of common stock each at an exercise price of $2.50 per share. The warrants contain customary anti-dilution protections and are exercisable for cash or may be exercised by means of a “cashless exercise”.

Common Stock Placement Agent Warrants

As consideration for serving as our placement agent in connection with a private placement of our common stock, on December 31, 2013 and January 31, 2014, we issued to Laidlaw & Company (UK) Ltd. warrants to purchase an aggregate of up to 40,327 shares of common stock. The terms of this warrant are identical to the December 2013 Five-Year Warrants described above.

As consideration for serving as our placement agent in connection with a private placement of our common stock, on April 4 and April 30, 2014, we issued to Laidlaw & Company (UK) Ltd. warrants to purchase an aggregate of up to 22,976 shares of common stock. The terms of this warrant are identical to the April 2014 Five-Year Warrants described above.
 
As consideration for serving as our placement agent in connection with a private placement of our common stock, on August 15 and September 12, 2014, we issued to Laidlaw & Company (UK) Ltd. warrants to purchase an aggregate of up to 38,120 shares of common stock. The terms of this warrant are identical to the August 2014 Five-Year Warrants described above.
 
As consideration for serving as our placement agent in connection with a private placement of our common stock, between December 2014 and March 2015, we issued to Laidlaw & Company (UK) Ltd. warrants to purchase an aggregate of up to 400,900 shares of common stock. The terms of this warrant are identical to the December 2014 Warrants described above.


As consideration for serving as our placement agent in connection with a private placement of our common stock, between October 2015 and April 2016, we issued to Laidlaw & Company (UK) Ltd. and certain designated employees of Laidlaw & Company (UK) Ltd., three-year warrants to purchase up to an aggregate of 232,960 shares of common stock at an exercise price of $1.50 per share. The warrants contain customary anti-dilution protections and are exercisable for cash or may be exercised by means of a “cashless exercise”.

As consideration for serving as our placement agent in connection with a private placement of our common stock, between October 2016 and March 2017, we issued to certain designated employees of Laidlaw & Company (UK) Ltd., three-year warrants to purchase up to an aggregate of 186,957 shares of common stock at an exercise price of $1.50 per share. The warrants contain customary anti-dilution protections and are exercisable for cash or may be exercised by means of a “cashless exercise”.

Registration Rights

2013 Series C Private Placement

On February 6, 2013, in connection with our private placement of our Series C Preferred Stock and warrants, we entered into a registration rights agreement with the purchasers pursuant to which we agreed to provide certain registration rights with respect to the common stock issuable upon conversion of our Series C Preferred Stock and exercise of the warrants issued to holders of our Series C Preferred Stock. Specifically, we agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after we are notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after we are notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then we are subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, we shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreement, we must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the our right to suspend or defer the use of the registration statement in certain events.

We filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014. We (i) filed a post-effective amendment to the registration statement on June 30, 2015, which was declared effective on July 13, 2015, to update the registration statement to include audited financial statements for the 2014 fiscal year, (ii) filed a post-effective amendment to the registration statement on May 27, 2016, which was declared effective on June 13, 2016, to update the registration statement to include audited financial statements for the 2015 fiscal year, and (iii) filed a post-effective amendment to the registration statement on May 26, 2017, which was declared effective on June 5, 2017, to update the registration statement to incorporate by reference audited financials for the 2016 fiscal year, to satisfy the requirements under the registration rights agreement with the purchasers of our Series C Preferred Stock and warrants.  We intend to file additional post-effective amendments to such registration statement as may be required by law, rule or regulation.


2014 Private Placement

On each of December 31, 2013, April 4, 2014, August 15, 2014, and December 19, 2014, in connection with private placements of our common stock and warrants, we entered into registration rights agreements with the purchasers in such private placements pursuant to which we agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued to such investors. Specifically, we agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placements and issuable upon the exercise of the warrants within 45 days of the termination date of such private placements and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 30 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, and within 180 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 30 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 180 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then we are subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that we will not be required to make any payments if any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that we will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that we are unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreements dated December 31, 2013, April 4, 2014 and August 15, 2014 shall be 3% of the aggregate purchase price paid by the purchasers, (ii) the maximum aggregate liquidated damages due under the registration rights agreement dated December 19, 2014 shall be 6% of the aggregate purchase price paid by the purchasers and (iii) if any partial amount of liquidated damages remains unpaid for more than seven days, we shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreements, we must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions and without the requirement to be in compliance with the current public information requirement under Rule 144, subject to the our right to suspend or defer the use of the registration statement in certain events.

We filed a registration statement on May 20, 2015, which was originally declared effective on June 12, 2015. We filed a post-effective amendment to the registration statement on June 17, 2016, which was declared effective on July 1, 2016, to update the registration statement to include audited financial statements for the 2015 fiscal year, to satisfy the requirements under the registration rights agreement with the purchasers of our common stock and warrants. We filed a post-effective amendment to the registration statement on May 26, 2017, which was declared effective on June 5, 2017, to update the registration statement to incorporate by reference audited financial statements for the 2016 fiscal year, to satisfy the requirements under the registration rights agreement with the purchasers of our common stock and warrants.  We intend to file additional post-effective amendments to such registration statement as may be required by law, rule or regulation.


2015 Private Placement

On October 23, 2015, in connection with concurrent and related private placements of our common stock and warrants, we entered into registration rights agreements with the purchasers in such private placements pursuant to which we agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued such investors. Specifically, we agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the final termination date of such private placements and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 10 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, and within 120 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 10 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 120 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then we are subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that we will not be required to make any payments if any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that we will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that we are unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement dated October 23, 2015 shall be 6% of the aggregate purchase price paid by the purchasers and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, we shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreements, we must maintain the effectiveness of the registration statement from the effective date until the first to occur of (i) the date that is one year from the date the registration statement is declared effective by the Securities and Exchange Commission and (ii) the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions and without the requirement to be in compliance with the current public information requirement under Rule 144, subject to the our right to suspend or defer the use of the registration statement in certain events.

We filed a registration statement on August 2, 2016, which was originally declared effective on August 9, 2016. We filed a post-effective amendment to the registration statement on May 22, 2017, which was declared effective on May 31, 2017, to update the registration statement to incorporate by reference audited financial statements for the 2016 fiscal year, to satisfy the requirements under the registration rights agreement with the purchasers of our common stock and warrants.  We intend to file additional post-effective amendments to such registration statement as may be required by law, rule or regulation.

2016 Private Placement

On October 28, 2016 in connection with concurrent and related private placements of our common stock and warrants, we entered into registration rights agreements with the purchasers in such private placements pursuant to which we agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued to such investors. Specifically, we agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the final termination date of such private placements and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 10 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, and within 120 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.


If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 10 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 120 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then we are subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that we will not be required to make any payments if any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that we will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that we are unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement dated October 28, 2016 shall be 6% of the aggregate purchase price paid by the purchasers and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, we shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreements, we must maintain the effectiveness of the registration statement from the effective date until the first to occur of (i) the date that is one year from the date the registration statement is declared effective by the Securities and Exchange Commission and (ii) the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions and without the requirement to be in compliance with the current public information requirement under Rule 144, subject to the our right to suspend or defer the use of the registration statement in certain events.

We filed a registration statement on June 8, 2017, which was declared effective on September 21, 2017.  We intend to file additional post-effective amendments to such registration statement as may be required by law, rule or regulation.

2017 Private Placement

On April 6, 2017, in connection with concurrent and related private placements of our common stock and warrants, we entered into registration rights agreements with the purchasers in such private placements pursuant to which we agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued to such investors. Specifically, we agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the final termination date of such private placements and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 10 calendar days after we are notified that the registration statement is not being reviewed by the Securities and Exchange Commission, and within 120 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 10 calendar days after we are notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 120 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then we are subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that we will not be required to make any payments if any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that we will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that we are unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement dated April 6, 2017 shall be 6% of the aggregate purchase price paid by the purchasers and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, we shall pay interest of 18% per annum, accruing daily, on such unpaid amount.


Pursuant to the registration rights agreements, we must maintain the effectiveness of the registration statement from the effective date until the first to occur of (i) the date that is one year from the date the registration statement is declared effective by the Securities and Exchange Commission and (ii) the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions and without the requirement to be in compliance with the current public information requirement under Rule 144, subject to the our right to suspend or defer the use of the registration statement in certain events.

We filed a registration statement on February 28, 2018, and Amendment No. 1 to the registration statement on March 22, 2018, which was declared effective on March 26, 2018.  We intend to file additional post-effective amendments to such registration statement as may be required by law, rule or regulation.

November 2017 Private Placement - Series D Preferred Stock

On November 3, 2017, in connection with a private placement of our Series D Preferred Stock and warrants, we entered into a registration rights agreement with the purchasers in such private placement whereby we agreed to file a registration statement with the Securities and Exchange Commission within 45 days of the closing of the private placement covering the resale of (a) all shares of common stock issuable upon conversion of the Series D Preferred Stock issued in the private placement, (b) all shares of common stock issuable upon exercise of the Class A Warrants and Class B Warrants (the “ Nov. 2017 Warrants”), (c) any additional shares of common stock issuable in connection with any anti-dilution provisions in the Nov. 2017 Warrants, and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (collectively, “November Registrable Securities”), not then registered.  We agreed to use our reasonable best efforts to cause such registration statement to be declared effective by the Securities and Exchange Commission (such date, the “Effectiveness Date”) within 90 days of the initial filing date of the registration statement.

If (i) the registration statement is not filed on or within to 45 days of the closing of the private placement , (ii) we fail to file with the Securities and Exchange Commission a request for acceleration of a registration statement within 5 calendar days of the date that we are notified by the Securities and Exchange Commission that such registration statement will not be reviewed or will not be subject to further review, (iii) prior to the effective date of a registration statement, we fail to file a pre-effective amendment and otherwise respond in writing to comments made by the Securities and Exchange Commission in respect of such registration statement within 30 days after the receipt of comments by or notice from the Securities and Exchange Commission that such amendment is required in order for such registration statement to be declared effective, (iv) the registration statement is not declared effective by the Effectiveness Date or (v) certain other events described in the registration rights agreement (each, an “Event”), then we shall pay liquidated damages to the Investors in an amount equal to 1% of the aggregate purchase price paid by the Investors on the day of delinquency and each 30th day of delinquency thereafter.  Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 10% of the aggregate purchase price paid by the Investors.

We filed a registration statement on December 18, 2017, which was originally declared effective on December 29, 2017. We filed a post-effective amendment to the registration statement on January 18, 2018, which was declared effective on January 23, 2018, to update the registration statement.  We intend to file additional post-effective amendments to such registration statement as may be required by law, rule or regulation.

February 2018 Private Placement - Series E Preferred Stock

On February 16, 2018, in connection with a private placement of our Series E Preferred Stock and warrants, we entered into a registration rights agreement with the purchasers in such private placement  whereby we agreed to file a registration statement with the Securities and Exchange Commission within 90 days of the closing of the private placement covering the resale of (a) all shares of common stock issuable upon conversion of the Series E Preferred Stock issued in the private placement, (b) all shares of common stock issuable upon exercise of the warrants issued in the private placement, (c) all other shares of common stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the purchasers in the private placement (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (collectively, the “ Registrable Securities”), not then registered.  We agreed to use our reasonable best efforts to keep the registration statement effective pursuant to Rule 415 under the Securities Act of 1933, as amended, until the earlier of (i) the date on which the purchasers in the private placement shall have sold all the December Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.


Delaware Anti-Takeover Law and Provisions of our Amended and Restated Certificate of Incorporation and By-laws

Section 203 of the Delaware General Corporation Law, in general, prohibits a business combination between a corporation and an interested stockholder within three years of the time such stockholder became an interested stockholder, unless:

prior to such time the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
 
upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, exclusive of shares owned by directors who are also officers and by certain employee stock plans; or

at or subsequent to such time, the business combination is approved by the board of directors and authorized by the affirmative vote at a stockholders’ meeting of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

The term “business combination” is defined to include, among other transactions between an interested stockholder and a corporation or any direct or indirect majority owned subsidiary thereof: a merger or consolidation; a sale, lease, exchange, mortgage, pledge, transfer or other disposition (including as part of a dissolution) of assets having an aggregate market value equal to 10% or more of either the aggregate market value of all assets of the corporation on a consolidated basis or the aggregate market value of all the outstanding stock of the corporation; certain transactions that would result in the issuance or transfer by the corporation of any of its stock to the interested stockholder; certain transactions that would increase the interested stockholder’s proportionate share ownership of the stock of any class or series of the corporation or such subsidiary; and any receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or any such subsidiary.

In general, Section 203 defines an “interested stockholder” as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term “owner” is broadly defined to include any person that individually, with or through that person’s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.

The restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject to Section 203 of the Delaware General Corporation Law or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders. Our Amended and Restated Certificate of Incorporation and By-laws do not opt out of Section 203.

Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

Provisions of our Amended and Restated Certificate of Incorporation and By-laws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests.  Therefore, these provisions could adversely affect the price of our common stock.  Among other things, our Amended and Restated Certificate of Incorporation and By-laws:

do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);

provide that special meetings of our stockholders may be called only by our board of directors, chairman, chief executive officer, president or secretary; and

provide advance notice provisions with which a stockholder who wishes to nominate a director or propose other business to be considered at a stockholder meeting must comply.


Indemnification of Directors and Officers

Pursuant to Section 145 of the Delaware General Corporation Law, a corporation has the power to indemnify its directors and officers against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with a third-party action, other than a derivative action, and against expenses actually and reasonably incurred in the defense or settlement of a derivative action, provided that there is a determination that the individual acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe the individual’s conduct was unlawful. Such determination will be made, in the case of an individual who is a director or officer at the time of such determination:

by a majority of the disinterested directors, even though less than a quorum;

by a committee of such directors designated by a majority vote of such directors, even though less than a quorum;

if there are no disinterested directors, or if such directors so direct, by independent legal counsel; or

by a majority vote of the stockholders, at a meeting at which a quorum is present.

Without court approval, however, no indemnification may be made in respect of any derivative action in which such individual is adjudged liable to the corporation.

The Delaware General Corporation Law requires indemnification of directors and officers for expenses relating to a successful defense on the merits or otherwise of a derivative or third-party action.

The Delaware General Corporation Law permits a corporation to advance expenses relating to the defense of any proceeding to directors and officers contingent upon such individuals’ commitment to repay any advances unless it is determined ultimately that such individuals are entitled to be indemnified.

Under the Delaware General Corporation Law, the rights to indemnification and advancement of expenses provided in the law are non-exclusive, in that, subject to public policy issues, indemnification and advancement of expenses beyond that provided by statute may be provided by law, agreement, vote of stockholders, disinterested directors or otherwise.

Limitation of Personal Liability of Directors

The Delaware General Corporation Law provides that a corporation’s certificate of incorporation may include a provision limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. However, no such provision can eliminate or limit the liability of a director for:

Our Amended and Restated Certificate of Incorporation provides that our directors will not be personally liable to us or any of our stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the Delaware General Corporation Law.

Disclosure of Commission Position on Indemnification for Securities Act Liabilities

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to our directors, officers and persons controlling us, we have been advised that it is the Securities and Exchange Commission’s opinion that such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable.

PLAN OF DISTRIBUTION
 
Each selling stockholder (the “Selling Stockholders”) of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the OTCQB or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately negotiated transactions;

settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;

In transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;

through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

a combination of any such methods of sale; or

any other method permitted pursuant to applicable law.

The Selling Stockholders may also sell securities under Rule 144 under the Securities Act of 1933, as amended, if available, rather than under this prospectus.

Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker- dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. In no event shall any broker- dealer receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).

We are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
 

Because Selling Stockholders may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. The Selling Stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities by the Selling Stockholders.

We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for us to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) the date on which all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

LEGAL MATTERS

Haynes and Boone, LLP, New York, New York, will pass upon the validity of the shares of our common stock offered by the selling stockholders under this prospectus.

MATERIAL CHANGES

There have been no material changes to us since December 31, 2017 that have not been described in a Form 10-Q, a Current Report on Form 8-K or in this prospectus that should be included.

EXPERTS

Our financial statements as of December 31, 2017 and 2016 and for the years then ended included in this prospectus have been audited by Liggett & Webb, P.A., an independent registered public accounting firm, as stated in its report appearing in the registration statement, and are included in reliance upon the report of such firm given upon its authority as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the Securities and Exchange Commission a registration statement on Form S-1, together with any amendments and related exhibits, under the Securities Act of 1933, as amended, with respect to our shares of common stock offered by this prospectus. The registration statement contains additional information about us and our shares of common stock that the selling stockholders are offering in this prospectus.

We are required to file annual, quarterly and current reports and other information with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Our Securities and Exchange Commission filings are available to the public over the Internet at the Securities and Exchange Commission’s website at http://www.sec.gov. You may also read and copy any document we file at the Securities and Exchange Commission’s public reference room located at 100 F Street, N.E., Washington, D.C. 20549. Please call the Securities and Exchange Commission at 1-800-SEC-0330 for further information on the public reference rooms and their copy charges. Access to those electronic filings is available as soon as practicable after filing with the Securities and Exchange Commission. You may also request a copy of those filings, excluding exhibits, from us at no cost. Any such request should be addressed to us at: 12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025, Attention: Kenneth L. Londoner, Chief Executive Officer.

 
BIOSIG TECHNOLOGIES, INC.

FINANCIAL STATEMENTS

TABLE OF CONTENTS

F-1
   
F-2
F-3
F-4
F-6
F-7

F-35
F-36
F-37
F-38
F-39
   
 

 

 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
To the Board of Directors and Stockholders of
BioSig Technologies, Inc.
 
Opinion on the Financial Statements
 
We have audited the accompanying balance sheets of BioSig Technologies. Inc. (“Company”) as of December 31, 2017 and 2016, and the related statements of operations, stockholders’ deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

The Company’s Ability to Continue as a Going Concern
 
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred losses from operations since inception and has a net stockholders’ deficiency. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  Management’s plans in regard to these matters are described in Note 2 to the financial statements. The financial statements do not include any adjustments that may result from the outcome of this uncertainty.
 
Basis for Opinion
 
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
/s/ Liggett & Webb, P.A.
 
We have served as the Company’s auditor since 2013.
 
New York, New York 
February 27, 2018


BIOSIG TECHNOLOGIES, INC.
 
BALANCE SHEETS
 
DECEMBER 31, 2017 AND 2016
 
             
   
2017
   
2016
 
ASSETS
           
Current assets:
           
Cash
 
$
1,547,579
   
$
1,055,895
 
Prepaid expenses
   
116,938
     
134,263
 
  Total current assets
   
1,664,517
     
1,190,158
 
                 
Property and equipment, net
   
18,716
     
24,188
 
                 
Other assets:
               
Deposits
   
17,084
     
27,612
 
                 
  Total assets
 
$
1,700,317
   
$
1,241,958
 
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
               
Current liabilities:
               
Accounts payable and accrued expenses, including $27,375 and $15,755 to related parties as of December 31, 2017 and 2016, respectively
 
$
473,098
   
$
373,103
 
Dividends payable
   
447,901
     
359,891
 
Warrant liability
   
2,358,240
     
1,937,234
 
Derivative liability
   
685,922
     
288,934
 
  Total current  liabilities
   
3,965,161
     
2,959,162
 
                 
Series C Preferred Stock, 985 and 1,070 shares issued and outstanding; liquidation preference of $985,000 and $1,070,000 as of December 31, 2017 and 2016, respectively
   
985,000
     
1,070,000
 
                 
Stockholders’ deficit
               
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C and 1,400 shares of Series D Preferred Stock
               
Series D Preferred Stock, $0.001 par value, 1,334 and 0 shares issued and outstanding; liquidation preference of $2,001,000 and $0 as of December 31, 2017 and 2016, respectively
   
1
     
-
 
Common stock, $0.001 par value, authorized 200,000,000 shares, 29,321,204 and 22,588,184 issued and outstanding as of December 31, 2017 and 2016, respectively
   
29,321
     
22,588
 
Additional paid in capital
   
53,215,635
     
41,019,251
 
Common stock subscription
   
29,985
     
-
 
Accumulated deficit
   
(56,524,786
)
   
(43,829,043
)
  Total stockholders’ deficit
   
(3,249,844
)
   
(2,787,204
)
                 
Total liabilities and stockholders’ deficit
 
$
1,700,317
   
$
1,241,958
 

See the accompanying notes to the financial statements


BIOSIG TECHNOLOGIES, INC.
 
STATEMENTS OF OPERATIONS
 
             
   
Year ended December 31,
 
   
2017
   
2016
 
Operating expenses:
           
Research and development
 
$
4,756,468
   
$
2,654,501
 
General and administrative
   
8,138,117
     
8,499,304
 
Depreciation
   
11,698
     
10,475
 
  Total operating expenses
   
12,906,283
     
11,164,280
 
                 
Loss from operations
   
(12,906,283
)
   
(11,164,280
)
                 
Other income (expense):
               
Gain (loss) on change in fair value of derivatives
   
210,465
     
(422,908
)
Interest income
   
75
     
1
 
                 
Loss before income taxes
   
(12,695,743
)
   
(11,587,187
)
                 
Income taxes (benefit)
   
-
     
-
 
                 
Net loss
   
(12,695,743
)
   
(11,587,187
)
                 
Preferred stock dividend
   
(119,877
)
   
(110,023
)
                 
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
 
$
(12,815,620
)
 
$
(11,697,210
)
                 
Net loss per common share, basic and diluted
 
$
(0.50
)
 
$
(0.60
)
                 
Weighted average number of common shares outstanding, basic and diluted
   
25,550,686
     
19,490,767
 

See the accompanying notes to the financial statements

BIOSIG TECHNOLOGIES, INC.
 
CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT
 
TWO YEARS ENDED DECEMBER 31, 2017
 
                                                 
                           
Additional
    Common              
   
Series D Preferred stock
   
Common stock
   
Paid in
   
stock
   
Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Subscription
   
Deficit
   
Total
 
Balance, January 1, 2016
   
-
   
$
-
     
16,825,703
   
$
16,826
   
$
29,314,399
   
$
-
   
$
(32,241,856
)
 
$
(2,910,631
)
Sale of common stock
   
-
     
-
     
3,798,417
     
3,798
     
5,222,570
     
-
     
-
     
5,226,368
 
Common stock issued for services
   
-
     
-
     
1,335,000
     
1,335
     
2,469,715
     
-
     
-
     
2,471,050
 
Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share
   
-
     
-
     
267,334
     
267
     
400,733
     
-
     
-
     
401,000
 
Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.55 per share
   
-
     
-
     
58,185
     
58
     
90,365
     
-
     
-
     
90,423
 
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares
   
-
     
-
     
-
     
-
     
103,096
     
-
     
-
     
103,096
 
Stock based compensation
   
-
     
-
     
303,545
     
304
     
3,528,396
     
-
     
-
     
3,528,700
 
Preferred Stock dividend
   
-
     
-
     
-
     
-
     
(110,023
)
   
-
     
-
     
(110,023
)
Net loss
   
-
     
-
     
-
     
-
     
-
     
-
     
(11,587,187
)
   
(11,587,187
)
  Balance, December 31, 2016
   
-
   
$
-
     
22,588,184
   
$
22,588
   
$
41,019,251
   
$
-
   
$
(43,829,043
)
 
$
(2,787,204
)




BIOSIG TECHNOLOGIES, INC.
 
CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT
 
TWO YEARS ENDED DECEMBER 31, 2017
 
                                                 
                           
Additional
    Common              
   
Series D Preferred stock
   
Common stock
   
Paid in
   
stock
   
Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Subscription
   
Deficit
   
Total
 
Balance, December 31, 2016
   
-
   
$
-
     
22,588,184
   
$
22,588
   
$
41,019,251
   
$
-
   
$
(43,829,043
)
 
$
(2,787,204
)
Sale of common stock
   
-
     
-
     
4,131,536
     
4,131
     
6,007,098
     
-
     
-
     
6,011,229
 
Sale of Series D preferred stock
   
1,334
     
1
     
-
     
-
     
1,929,959
     
-
     
-
     
1,929,960
 
Common stock issued for services
   
-
     
-
     
2,271,788
     
2,272
     
3,384,345
     
-
     
-
     
3,386,617
 
Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share
   
-
     
-
     
56,669
     
57
     
84,943
     
-
     
-
     
85,000
 
Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.37 per share
   
-
     
-
     
24,021
     
24
     
31,844
     
-
     
-
     
31,868
 
Common stock received and canceled in connection with short term swing profit reimbursement
   
-
     
-
     
(10,744
)
   
(11
)
   
11
     
-
     
-
     
-
 
Common stock subscription received
   
-
     
-
     
-
     
-
     
-
     
29,985
     
-
     
29,985
 
Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance
   
-
     
-
     
-
     
-
     
(1,049,216
)
   
-
     
-
     
(1,049,216
)
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares
   
-
     
-
     
-
     
-
     
20,757
     
-
     
-
     
20,757
 
Fair value of warrant issued to acquire research and development
   
-
     
-
     
-
     
-
     
543,927
     
-
     
-
     
543,927
 
Stock based compensation
   
-
     
-
     
259,750
     
260
     
1,362,593
     
-
     
-
     
1,362,853
 
Preferred stock dividend
   
-
     
-
     
-
     
-
     
(119,877
)
   
-
     
-
     
(119,877
)
Net loss
   
-
     
-
     
-
     
-
     
-
     
-
     
(12,695,743
)
   
(12,695,743
)
  Balance, December 31, 2017
   
1,334
   
$
1
     
29,321,204
   
$
29,321
   
$
53,215,635
   
$
29,985
   
$
(56,524,786
)
 
$
(3,249,844
)
 
See the accompanying notes to the financial statements


BIOSIG TECHNOLOGIES, INC.
 
STATEMENTS OF CASH FLOWS
 
   
   
Year ended December 31,
 
   
2017
   
2016
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
 
$
(12,695,743
)
 
$
(11,587,187
)
Adjustments to reconcile net loss to cash used in operating activities:
               
Depreciation
   
11,698
     
10,475
 
Equipment distribution as officer compensation
   
3,210
     
-
 
Change in derivative liabilities
   
(210,465
)
   
422,908
 
Equity based compensation
   
4,749,470
     
5,999,750
 
Fair value of issued warrant to acquire research and development
   
543,927
     
-
 
Changes in operating assets and liabilities:
               
Prepaid expenses
   
17,325
     
(102,955
)
Security deposit
   
10,528
     
-
 
Accounts payable
   
102,338
     
149,661
 
Deferred rent payable
   
(2,342
)
   
(104
)
  Net cash used in operating activities
   
(7,470,054
)
   
(5,107,452
)
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchase of property and equipment
   
(9,436
)
   
(16,255
)
  Net cash used in investing activity
   
(9,436
)
   
(16,255
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from sale of common stock
   
6,011,229
     
5,226,368
 
Proceeds from sale of Series D preferred stock
   
1,929,960
     
-
 
Proceeds from common stock subscription
   
29,985
     
-
 
  Net cash provided by financing activities
   
7,971,174
     
5,226,368
 
                 
Net increase in cash and cash equivalents
   
491,684
     
102,661
 
                 
Cash and cash equivalents, beginning of the period
   
1,055,895
     
953,234
 
Cash and cash equivalents, end of the period
 
$
1,547,579
   
$
1,055,895
 
                 
Supplemental disclosures of cash flow information:
               
Cash paid during the period for interest
 
$
-
   
$
-
 
Cash paid during the period for income taxes
 
$
-
   
$
-
 
                 
Non cash investing and financing activities:
               
Common stock issued upon conversion of Series C Preferred Stock and accrued dividends
 
$
116,868
   
$
491,423
 
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock
 
$
1,049,216
   
$
-
 
Reclassify fair value of derivative liability to equity
 
$
20,757
   
$
103,096
 

See the accompanying notes to the financial statements

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.

Business and organization
 
BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
 
Revenue Recognition
 
The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

Use of estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Concentrations of Credit Risk
 
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.  At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively.
 
Prepaid Expenses
 
Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments.

Property and Equipment
 
Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Long-Lived Assets
 
The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.  Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

Fair Value of Financial Instruments
 
Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
 
The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
 
Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.
 
At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).
 
Research and development costs
 
The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468 and $2,654,501 for the year ended December 31, 2017 and 2016, respectively.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Income Taxes
 
The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as non-current.

Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
 
The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
 
 
 
2017
 
 
2016
 
Series C convertible preferred stock
 
 
656,667
 
 
 
713,333
 
Series D convertible preferred stock
   
1,334,000
     
-
 
Options to purchase common stock
 
 
8,510,319
 
 
 
8,245,190
 
Warrants to purchase common stock
 
 
12,789,086
 
 
 
9,128,189
 
Totals
 
 
23,290,072
 
 
 
18,086,712
 
 
Stock based compensation
 
The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash.

As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Registration Rights

The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  

Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on March 31, 2017. On June 8, 2017, the Company filed the required registration statement and on September 19, 2017 was declared effective. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

On November 3, 2017, in connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Recent Accounting Pronouncements
 
There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As of December 31, 2017, the Company had cash of $1,547,579 and working capital deficit (current liabilities in excess of current assets) of $2,300,644 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised $6,041,214 through the sale of common stock and warrants (See Note 8) and $1,929,960 through the sale of Series D preferred stock and warrants (Note 6) in 2017. Subsequent to December 31, 2017, the Company raised $1,500,000 from the sale of Series E preferred stock and warrants and $270,000 from the sale of common stock (Note 13). As of December 31, 2017, excluding the derivative and warrant liabilities, the Company’s working capital would have been $743,518. During the year ended December 31, 2017, the Company used net cash in operating activities of $7,470,054.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months.

The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at December 31, 2017 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.
 
Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 – RELATED PARTY TRANSACTIONS
 
The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009.  No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. As of December 31, 2017 and 2016, all advances had been repaid.

Accrued expenses related primarily to travel reimbursements due related parties as of December 31, 2017 and 2016 was $27,375 and $15,755, respectively.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

On May 4, 2016, Mr. Londoner and Mr. Chaussy were granted 250,000 and 200,000 shares of common stock at a cost basis of $1.93 per share for their 2016 performance, respectively. The granted shares vested immediately.

On December 8, 2016, Mr. Londoner and Mr. O’Donnell each were granted 41,500 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017.

On December 8, 2016 Mr. Cash and Mr. Tanaka each were granted 20,875 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017.

On December 22, 2016 Mr. Zeldis and Mr. Weild each were granted options to purchase 50,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term.

On December 22, 2016 Mr. Gallagher and Mr. Foley each were granted options to purchase 25,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term.

On April 1, 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from Mr. Londoner.

On June 16, 2017 Mr. Cash was granted 100,000 shares of common stock at a cost basis of $1.37 per share in connection with his severance settlement. The granted shares vested immediately.

On November 8, 2017, Mr. Londoner, Mr. Chaussy and Mr. O’Donnell were granted 450,000, 250,000 and 200,000 shares of common stock at a cost basis of $1.52 per share for their 2017 performance, respectively. The granted shares vested immediately.

On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors,  the Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company’s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned.  Mr. Filler is the general counsel and partner of Sherpa. 

On November 9, 2017, Mr. Londoner, Mr. O’Donnell and Mr. Weild, as members of the board of directors, were granted each 50,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board and committee service. The granted shares vested immediately.

On November 9, 2017, Mr. Tanaka, Mr. Filler and Mr. Foley, as members of the board of directors, were granted each 30,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board service. The granted shares vested immediately.

On December 22, 2017 Mr. Gallagher and Mr. Fischer were granted options to purchase 39,926 and 65,972 shares of common stock at a cost basis of $1.37 per share for their 2017 board service. The granted options vested as of December 22, 2017 and are exercisable for a ten year term.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

NOTE 4 – PROPERTY AND EQUIPMENT
 
Property and equipment as of December 31, 2017 and 2016 is summarized as follows:
 
 
 
2017
   
2016
 
Computer equipment
 
$
87,059
   
$
84,704
 
Furniture and fixtures
   
12,975
     
10,117
 
Subtotal
   
100,034
     
94,821
 
Less accumulated depreciation
   
(81,318
)
   
(70,633
)
Property and equipment, net
 
$
18,716
   
$
24,188
 

During the year ended December 31, 2017, the Company distributed equipment with a book value of $3,210 to a prior employee in connection with a settlement agreement.

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
 
Depreciation expense was $11,698 and $10,475 for the years ended December 31, 2017 and 2016, respectively.

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 
Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following:
 
 
 
2017
   
2016
 
Accrued accounting and legal
 
$
93,595
   
$
120,464
 
Accrued reimbursements
   
2,600
     
43,116
 
Accrued consulting
   
109,059
     
1,192
 
Accrued research and development expenses
   
246,030
     
181,884
 
Accrued office and other
   
7,912
     
10,202
 
Deferred rent
   
569
     
2,912
 
Accrued settlement related to arbitration
   
13,333
     
13,333
 
 
 
$
473,098
   
$
373,103
 

NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK

Series C 9% Convertible Preferred Stock

On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:

 ●
incur additional indebtedness;
permit liens on assets;
repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;
pay cash dividends to our stockholders; and
engage in transactions with affiliates.

Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.

In the event that:
  (i)  
we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,
(ii)  
we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,
(iii)  
we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,
 (iv)  
we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,
(v)  
we are party to a change of control transaction,
(vi)  
we file for bankruptcy or a similar arrangement or are adjudicated insolvent,
(vii)  
we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,

The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. 

As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.

In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense.

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There was no established market for the Company’s common stock.  As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.

Issuances:

During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock.

During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910.

On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000.  

2017 and 2016 conversions: 

In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.
 
In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

In June 2017, the Company issued an aggregate of 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends.

In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

For the year ended December 31, 2017, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $20,757 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.74% to 1.06%, a dividend yield of 0%, and volatility of 151% to 166%.

Series C Preferred Stock issued and outstanding totaled 985 and 1,070 as of December 31, 2017 and 2016, respectively.  As of December 31, 2017 and 2016, the Company has accrued $419,283 and $359,891 dividends payable on the Series C Preferred Stock.

Registration Rights Agreement

In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.

Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.
 
The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.  At December 31, 2017 and 2016, the Company estimated the liability at $-0-.


BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES

Series C 9% Convertible Preferred Stock and related warrants

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.

The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%.

Series D Convertible Preferred Stock and related warrants

At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively.

The Company valued the reset provisions of the Series D Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%.

At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The Company recorded a gain from change in fair value of derivatives of $210,465 for year ended December 31, 2017. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%

NOTE 8 – STOCKHOLDER EQUITY

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2017 and 2016, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock and (in 2017) 1,400 shares of Series D Preferred Stock. As of December 31, 2017 and 2016, there were no outstanding shares of Series A and Series B preferred stock.

Series C Preferred Stock

In February 2016, the Company issued 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2017, the Company issued 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends.

In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

Cumulatively from January 1, 2017 to December 31, 2017, the Company exchanged 85 shares of the Company’s Series C Preferred Stock and dividends with a recorded value of $116,868 for 80,690 shares of common stock.

As of December 31, 2017 and 2016, the Company has 985 and 1,070 Series C Preferred Stock issued and outstanding.

Series D Preferred Stock

On November 3, 2017, the Board of Directors authorized the issuance of up to 1,400 shares of Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and accordingly, the Company filed the Certificate of Designations for the Series D Preferred Stock with the Secretary of State of the State of Delaware.  Pursuant to such Certificate of Designations, in the event of the Company’s liquidation or winding up of its affairs, the holders of Preferred Shares will be entitled to a liquidation preference of the stated value per Preferred Share of $1,500 (the “Stated Value”) plus any accrued but unpaid dividends or any other fees due the holder.

A holder of Preferred Shares is entitled at any time to convert any whole or partial number of shares of Preferred Shares into shares of Common Stock determined by dividing the Stated Value of the Preferred Shares being converted by the conversion price of $1.50 per share (the “Conversion Price”).  The Conversion Price is subject to “full ratchet” anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the Conversion Price as well as other customary anti-dilution protection.

A holder of the Preferred Shares shall be entitled to receive cumulative dividends at the rate per Preferred Share (as a percentage of the Stated Value per Preferred Share) of 9% per annum, with respect to the Series D Preferred Stock on each date that such Holder converts Preferred Shares into Common Stock (with respect only to Preferred Shares being converted).  The Company may pay such dividends, at its option, in cash, Common Stock or a combination thereof.  Payment of dividends in shares of Common Stock is subject to the satisfaction of certain equity conditions set forth in the Certificate of Designations.  Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

On November 3, 2017,  the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold an aggregate of 1,334 shares (the “Preferred Shares”) of its Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of the Company’s common stock, par value $0.001 per share at an exercise price of $1.75 per share (the “Class A Warrants”), in exchange for aggregate net cash proceeds of $1,929,960, net of expenses of $70,040. Contemporaneously with the entry into the Purchase Agreement, the Company and the Purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of the Common Stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price (the “Class B Warrants”). Class A Warrants are exercisable immediately and expire on May 3, 2021, and have an exercise price of $1.75 per share.  The Class B Warrants are exercisable immediately and expire on November 3, 2020, and have an exercise price of $1.50.  The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect.

On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment.

In connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

As of December 31, 2017, the Company has 1,334 Series D Preferred Stock issued and outstanding and has accrued $28,618 dividends payable on the Series D Preferred Stock.

Common stock

On November 18, 2016 at the Special Meeting, the stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 200,000,000 shares (the “Certificate Amendment”). The Certificate Amendment had been previously approved by the Company’s Board on September 7, 2016, subject to stockholder approval. Immediately following the Special Meeting on November 18, 2016, the Company filed the Certificate Amendment with the Secretary of State of the State of Delaware.

As of December 31, 2017 and 2016, the Company had 29,321,204 and 22,588,184 shares issued and outstanding, respectively.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

During the year ended December 31, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share).

During the year ended December 31, 2016, the Company issued an aggregate of 545,000 shares of common stock for services rendered totaling $1,051,850 ($1.93 average per share).

During the year ended December 31, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 3,798,417 shares of common stock and 2,040,504 warrants for aggregate proceeds of $5,226,368, net of $490,543 in expenses.

During the year ended December 31, 2016, the Company issued 220,000 shares of common stock as vested previously issued restricted stock units

During the year ended December 31, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

During the year ended December 31, 2017, the Company issued an aggregate of 1,825,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $2,705,250 ($1.48 average per share).

During the year ended December 31, 2017, the Company issued an aggregate of 446,788 shares of its common stock for services totaling $681,367 ($1.53 per share).

During the year ended December 31, 2017, the Company issued an aggregate of 135,000 and 124,750 shares of its common stock for vested restricted stock units and stock based compensation previously accrued in 2016.

During the year ended December 31, 2017, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 4,131,536 shares of common stock and 2,246,300 warrants for aggregate proceeds of $6,011,229, net of $186,075 in expenses.

In April 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from an officer and member of the Company’s Board of Directors.

In connection with the securities purchase agreements described above, the Company entered into registration rights agreements with the purchasers in such private placements pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued such investors. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the termination date of such private placement and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and within 180 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 180 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that the Company will not be required to make any payments any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that the Company will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that the Company is unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended.

Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreements shall be 3% to 6% of the aggregate purchase price paid by the purchasers and (iii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreements, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.

The Company filed registration statements, which was declared effective to satisfy the requirements under the registration rights agreements with the purchasers of its common stock and warrants prior to April 6, 2017. The final closing under the April 6, 2017 Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

Options

On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan.

During the year ended December 31, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers, directors and key consultants.

During the year ended December 31, 2016, the Company granted an aggregate of 723,545 stock grants to officers, employees and key consultants under the plan. See Note 8.

During the year ended December 31, 2017, the Company granted an aggregate of 1,680,898 options to officers, directors and key consultants.

During the year ended December 31, 2017, the Company granted an aggregate of 2,009,750 stock grants to officers, employees and key consultants under the plan. See Note 8.

The following table presents information related to stock options at December 31, 2017:

Options Outstanding
   
Options Exercisable
 
           
Weighted
       
           
Average
   
Exercisable
 
Exercise
   
Number of
   
Remaining Life
   
Number of
 
Price
   
Options
   
In Years
   
Options
 
$
1.01-2.00
   
 
3,825,540
   
 
6.8
   
$
2,662,707
 
 
2.01-3.00
     
4,384,779
     
3.7
     
4,384,779
 
 
3.01-4.00
     
300,000
     
7.3
     
300,000
 
         
8,510,319
     
5.2
     
7,347,486
 

A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at January 1, 2016
   
7,780,190
   
$
2.30
     
6.4
   
$
-
 
Grants
   
905,000
     
1.71
     
10.0
   
$
-
 
Exercised
   
-
             
-
     
-
 
Canceled
   
(440,000
)
   
2.24
             
-
 
Outstanding at December 31, 2016
   
8,245,190
   
$
2.24
     
5.7
   
$
-
 
Grants
   
1,680,898
     
1.50
     
10.0
   
$
-
 
Exercised
   
-
                         
Canceled
   
(1,415,769
)
 
$
2.17
                 
Outstanding at December 31, 2017
   
8,510,319
   
$
2.11
     
5.2
   
$
27,045
 
Exercisable at December 31, 2017
   
7,347,486
   
$
2.19
     
4.8
   
$
25,394
 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.44 as of December 31, 2017, which would have been received by the option holders had those option holders exercised their options as of that date.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the years ended December 31, 2017 and 2016 was estimated using the Black-Scholes pricing model.
 
On May 18, 2016, the Company granted an aggregate of 685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent.

On December 22, 2016, the Company granted an aggregate of 150,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.36 per share for a term of ten years with vesting immediately.

On December 29, 2016, the Company granted 5,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.35 per share for a term of ten years with vesting immediately.

The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016:

         
Risk-free interest rate
 
 
1.08% - 2.04
%
Dividend yield
 
 
0
%
Stock price volatility
 
 
109.3% to 122.82
%
Expected life
5 – 10 years
 
Weighted average grant date fair value
 
$
1.47
 

On February 8, 2017, the Company granted an aggregate of 130,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.55 per share for a term of ten years with vesting immediately.

On November 8, 2017, the Company granted 200,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020.

On November 8, 2017, the Company granted 475,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 237,500 vesting immediately and 237,500 at one year anniversary.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

On November 24, 2017, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years, vesting immediately.

On November 24, 2017, the Company granted 420,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years with 120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent.

On November 24, 2017, the Company granted 300,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.50 per share for a term of ten years with 150,000 vesting immediately and 150,000 performance contingent.

On December 22, 2017, the Company granted 105,898 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.37 per share for a term of ten years, vesting immediately.

The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2017:

         
Risk-free interest rate
 
 
2.01% - 2.34
%
Dividend yield
 
 
0
%
Stock price volatility
 
 
95.72% to 107.17
%
Expected life
5 – 10 years
 
Weighted average grant date fair value
 
$
1.17
 

The fair value of all options vesting during the year ended December 31, 2017 and 2016 of $1,269,591 and $2,801,948, respectively, was charged to current period operations.  Unrecognized compensation expense of $979,812 and $310,817 at December 31, 2017 and 2016, respectively, will be expensed in future periods.

Restricted Stock

The following table summarizes the restricted stock activity for the two years ended December 31, 2017:
 
Restricted shares issued as of January 1, 2016
 
 
175,000
 
Granted
 
 
180,000
 
Vested
   
(220,000
)
Total restricted shares issued as of December 31, 2016
 
 
135,000
 
Granted
 
 
-
 
Vested
 
 
(135,000
)
Vested restricted shares as of December 31, 2017
 
 
-
 
Unvested restricted shares as of December 31, 2017
 
 
-
 

On September 7, 2016, the Company granted 180,000 restricted stock units (“RSU”) to a consultant vesting monthly over one year beginning October 7, 2016.

Stock based compensation expense related to restricted stock grants was $93,261 and $213,174 for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017, the stock-based compensation relating to restricted stock of $-0- remains unamortized. 

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017: 

Exercise
   
Number
 
Expiration
Price
   
Outstanding
 
Date
$
0.001
     
383,320
 
January 2020
$
1.50
     
8,667,440
 
February 2018 to May 2021
$
1.84
     
35,076
 
January 2020
$
1.95
     
1,689,026
 
October 2018 to September 2019
$
2.00
     
100,000
 
August 2018
$
2.02
     
30,755
 
January 2020
$
2.50
     
100,000
 
August 2018
$
2.75
     
228,720
 
August 2019 to September 2019
$
3.67
     
214,193
 
December 2018 to January 2019
$
3.75
     
1,340,556
 
April 2019 to March 2020
         
12,789,086
 
 

On February 9, 2016, the Company issued 25,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services.

On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services.

On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 18,040 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services.

On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 17,996 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services.

On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company’s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services.

On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company’s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company’s common stock.

On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company’s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company’s common stock.

On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company’s common stock.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

On October 28, 2016, the Company issued an aggregate of 173,284 warrants to purchase the Company’s common stock at $1.50 per share, expiring on October 28, 2019, in connection with the sale of the Company’s common stock.

On November 23, 2016, the Company issued an aggregate of 50,002 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 23, 2019, in connection with the sale of the Company’s common stock

On December 16, 2016, the Company issued an aggregate of 456,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 16, 2019, in connection with the sale of the Company’s common stock

On December 22, 2016, the Company issued an aggregate of 115,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 22, 2019, in connection with the sale of the Company’s common stock

On February 9, 2017, the Company exchanged 38,572 warrants with an exercise price of $2.10 with 45,001 warrants with an exercise price of $1.50, all other terms and conditions the same, to 2016 investors to adjust offered terms in connection with the Company’s equity raise with other investors.

On February 10, 2017, the Company issued an aggregate of 300,628 warrants to purchase the Company’s common stock at $1.50 per share, expiring on February 10, 2020, in connection with the sale of the Company’s common stock.

On March 10, 2017, the Company issued an aggregate of 197,159 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 10, 2020, in connection with the sale of the Company’s common stock.

On March 15, 2017, the Company issued 630,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 15, 2020, to Mayo Foundation in connection with a know-how licensing agreement (See Note 10). The fair value of the of the issued warrants of $543,927, determined using the Black-Scholes option model with an estimated volatility of 105.22%, risk free rate of 1.599%, dividend yield of -0- and fair value of the Company’s common stock of $1.37, was charged to current period operations as acquired research and development.

On March 31, 2017, the Company issued an aggregate of 157,250 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 31, 2020, in connection with the sale of the Company’s common stock.

On April 6, 2017, the Company issued an aggregate of 288,300 warrants to purchase the Company’s common stock at $1.50 per share, expiring on April 6, 2020, in connection with the sale of the Company’s common stock.

On May 5, 2017, the Company issued an aggregate of 6,667 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 5, 2020, in connection with the sale of the Company’s common stock.

On May 17, 2017, the Company issued an aggregate of 186,957 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 17, 2020, for placement agent services in connection with the sale of the Company’s common stock.

On June 20, 2017, the Company issued 10,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 20, 2020, in connection with the sale of the Company’s common stock.

On June 30, 2017, the Company issued an aggregate of 108,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 30, 2020, in connection with the sale of the Company’s common stock.

On July 13, 2017, the Company issued an aggregate of 133,501 warrants to purchase the Company’s common stock at $1.50 per share, expiring on July 13, 2020, in connection with the sale of the Company’s common stock.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

On August 18, 2017, the Company issued an aggregate of 175,500 warrants to purchase the Company’s common stock at $1.50 per share, expiring on August 18, 2020, in connection with the sale of the Company’s common stock.

On September 18, 2017, the Company issued an aggregate of 51,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on September 18, 2020, in connection with the sale of the Company’s common stock.

On October 11, 2017, the Company issued an aggregate of 193,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on October 11, 2020, in connection with the sale of the Company’s common stock.

On November 3, 2017, the Company issued an aggregate of 667,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 3, 2021, in connection with the sale of the Company’s Series D preferred stock.  The warrants contain certain anti-dilutive provisions (see Note 8).

On November 3, 2017, the Company issued an aggregate of 780,506 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 3, 2020 in exchange for the return and cancellation of previous issued 780,505 warrants.  The transaction was in connection with the sale of the Series D preferred stock.  Both the issued and canceled warrants contain certain anti-dilutive provisions (see Note 8).

On November 6, 2017, the Company issued an aggregate of 206,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 6, 2020, in connection with the sale of the Company’s common stock.

On November 6, 2017, due to certain anti-dilutive provisions embedded in the November 3, 2017 warrants issued in connection with the sale of Series D preferred stock (see above), exercise price of the previously issued 667,000 warrants were reset to $1.50 and an additional 111,167 warrants were issued with an exercise price of $1.50 per share, expiring May 3, 2021.

On December 29, 2017, the Company issued an aggregate of 230,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 29, 2020, in connection with the sale of the Company’s common stock.

Stock based compensation related to warrants issued for services was $0 and $56,931 for the years ended December 31, 2017 and 2016, respectively.

A summary of the warrant activity for the years ended December 31, 2017 and 2016 is as follows:

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at January 1, 2016
   
7,078,685
   
$
2.02
     
3.0
     
497,933
 
Grants
   
2,049,504
   
$
1.74
     
2.5
     
-
 
Exercised
   
-
           
$
-
     
-
 
Canceled
   
-
           
$
-
     
-
 
Outstanding at December 31, 2016
   
9,128,189
   
$
1.96
     
2.1
   
$
494,099
 
Grants
   
4,479,974
     
1.50
     
3.0
     
-
 
Exercised
   
-
                         
Canceled
   
(819,077
)
 
$
1.50
                 
Outstanding at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
 
                               
Vested and expected to vest at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
Exercisable at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.44 as of December 31, 2017, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

NOTE 10 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
 
All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of December 31, 2017 and 2016, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company.

As of December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.

The derivative and warrant liability as of December 31, 2017, in the amount of $685,922 and $2,358,240, respectively, has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2017:

 
 
Warrant
Liability
   
Derivative
 
Balance, December 31, 2015
 
$
1,621,199
   
$
285,157
 
Total (gains) losses
               
Transfers out due to conversion of Series C Preferred Stock
   
-
     
(103,096
)
Mark to market to December 31, 2016
   
316,035
     
106,873
 
Balance, December 31, 2016
   
1,937,234
     
288,934
 
Initial fair value of derivative at date of issuance of Series D Preferred Stock
   
-
     
397,162
 
Initial fair value of warrant liability at date of issuance
   
652,054
     
-
 
Transfers out due to conversion of Series C Preferred Stock
   
-
     
(20,757
)
Mark to market to December 31, 2017
   
(231,048
)
   
20,583
 
Balance, December 31, 2017
   
2,358,240
     
685,922
 
Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016
 
$
231,048
   
$
(20,583
)

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

NOTE 11 – COMMITMENTS AND CONTINGENCIES

Operating leases
 
On February 8, 2017, the Company entered into a lease amendment agreement, whereby the Company agreed to extend the lease for office space in Los Angeles, California, commencing September 1, 2017 and expiring on August 31, 2019.  In connection with the lease, the Company is obligated to lease parking spaces at an aggregate approximate cost of $978 per month.  In addition, the Company entered into a lease for storage space with the Los Angeles, California building commencing on December 1, 2017 and expiring on August 31, 2019.

Future minimum lease payments under these three agreements are as follows:
 
Year Ending December 31,
     
2018
 
$
112,994
 
2019
   
76,995
 
 
 
$
189,989
 

Licensing agreements

On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale.  The agreement expires in ten years from the effective date.

The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined.

In consideration, the Company issued 630,000 warrants to acquire the Company’s common stock at an exercise price of $1.50, expiring on March 15, 2020.

Employment agreements

On July 14, 2014, the Company’s Board of Directors (the “Board”) increased the size of the Board to eight members and appointed Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer.

In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.

Effective July 15, 2017, the Company elected not to continue under the above described agreement and accordingly terminated employment with Mr. Cash.

As of December 31, 2017, there are no outstanding employment agreements.

Litigation

The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business.  Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.  There was no outstanding litigation as of December 31, 2017.

NOTE 12 – INCOME TAXES
 
At December 31, 2017, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $24,000,000, expiring in the year 2036, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.  During the year ended December 31, 2017, the Company has increased the valuation allowance from $5,500,000 to $8,200,000.We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns.  ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.  

Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement.  The Company had no tax positions relating to open income tax returns that were considered to be uncertain.

The Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2013.
The effective rate differs from the statutory rate of 34% for due to the following:

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

 
 
2017
 
 
2016
 
Statutory rate on pre-tax book loss
 
 
(34.00
)%
 
 
(34.00
)%
(Gain) loss on change in fair value of derivatives
 
 
(0.56
)%
 
 
1.24
%
Stock based compensation
 
 
12.72
%
 
 
17.6
%
Fair value of warrant to acquire research and development
   
1.46
%
   
0.00
%
Other
 
 
0.09
%
 
 
0.09
%
Valuation allowance
 
 
20.29
%
 
 
15.07
%
 
 
 
0.00
%
 
 
0.00
%
 
The Company’s deferred taxes as of December 31, 2017 and 2016 consist of the following:
 
 
 
2017
   
2016
 
Non-Current deferred tax asset:
           
 Net operating loss carry-forwards
 
$
8,200,000
   
$
5,500,000
 
 Valuation allowance
   
(8,200,000
)
   
(5,500,000
)
 Net non-current deferred tax asset
 
$
-
   
$
-
 
 
NOTE 13 – SUBSEQUENT EVENTS

Adoption of Accounting Standards

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.

When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018.  As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Series E Preferred Stock Issuance

On February 16, 2018, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the “Preferred Shares”) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.75 per share (the “Warrants”), in exchange for aggregate consideration of $1,500,000 (the “Transaction”). The sale of the Preferred Shares and Warrants were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”) provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.

The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type.  The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the “ROFR”) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement))  Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering.

In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.

The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.  The Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.

In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the “Consent”) with the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Holders”).  Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction.  In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the “Consent Warrants”).  The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.  The issuance of the Consent Warrants to the Series D Holders was in reliance on the exemption from registration under the Securities Act provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.

BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2017

Common Stock Issuance

On January 5, 2018, the Company entered into a unit purchase agreements with certain accredited investors pursuant to which the Company issued 200,000 shares of our common stock and 100,000 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring January 5, 2021, in exchange for aggregate consideration of $299,985, net of expenses of $15 (of which $29,985 were received as common stock subscriptions as of December 31, 2017).

In January and February 2018, the Company issued an aggregate of 367,343 shares of common stock in exchange for 280 shares of our Series D 9% Convertible Preferred Stock and accrued dividends.

On February 14, 2018, the Company issued an aggregate of 9,919 shares of common stock in exchange for 10 shares of our Series C 9% Convertible Preferred Stock and accrued dividends.

On February 1, 2018, the Company granted 200,000 restricted stock units to consultants for services rendered, of which 100,000 vest upon date of grant and 100,000 shares vest at the one-year anniversary of the date of grant provided the consultants are providing services through the vesting date.

Options

On February 15, 2018, the Company granted our board member, Andrew L. Filler 50,000 options to purchase common stock in connection with his appointment as chairman of our Nominating and Corporate Governance Committee at the exercise price of $1.42 per share for a term of ten years, vesting immediately.
 
BIOSIG TECHNOLOGIES, INC.
 
CONDENSED BALANCE SHEETS
 
   
   
March 31,
   
December 31,
 
   
2018
   
2017
 
   
(unaudited)
       
ASSETS
           
Current assets:
           
Cash
 
$
1,035,100
   
$
1,547,579
 
Prepaid expenses
   
119,111
     
116,938
 
  Total current assets
   
1,154,211
     
1,664,517
 
                 
Property and equipment, net
   
19,457
     
18,716
 
                 
Other assets:
               
Deposits
   
22,477
     
17,084
 
                 
  Total assets
 
$
1,196,145
   
$
1,700,317
 
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
               
Current liabilities:
               
Accounts payable and accrued expenses, including $7,236 and $27,375 to related parties as of March 31, 2018 and December 31, 2017, respectively
 
$
338,811
   
$
473,098
 
Dividends payable
   
482,636
     
447,901
 
Warrant liability
   
-
     
2,358,240
 
Derivative liability
   
-
     
685,922
 
  Total current  liabilities
   
821,447
     
3,965,161
 
                 
Series C Preferred Stock, 965 and 985 shares issued and outstanding; liquidation preference of $965,000 and $985,000 as of March 31, 2018 and December 31, 2017, respectively
   
965,000
     
985,000
 
                 
Stockholders’ deficit
               
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E Preferred Stock
               
Series D Preferred Stock, $0.001 par value, 687 and 1,334 shares issued and outstanding; liquidation preference of $1,030,500 and $2,001,000 as of March 31, 2018 and December 31, 2017, respectively
   
1
     
1
 
Series E Preferred Stock, $0.001 par value, 1,000 and 0 shares issued and outstanding; liquidation preference of $1,500,000 and $0 as of March 31, 2018 and December 31, 2017, respectively
   
1
     
-
 
Common stock, $0.001 par value, authorized 200,000,000 shares, 30,497,707 and 29,321,204 issued and outstanding as of March 31, 2018 and December 31, 2017, respectively
   
30,498
     
29,321
 
Additional paid in capital
   
55,381,386
     
53,215,635
 
Common stock subscription
   
115,470
     
29,985
 
Accumulated deficit
   
(56,117,658
)
   
(56,524,786
)
  Total stockholders’ deficit
   
(590,302
)
   
(3,249,844
)
                 
Total liabilities and stockholders’ deficit
 
$
1,196,145
   
$
1,700,317
 
                 
See the accompanying notes to the unaudited condensed financial statements
 
 
 
BIOSIG TECHNOLOGIES, INC.
 
CONDENSED STATEMENTS OF OPERATIONS
 
(unaudited)
 
             
   
Three months ended March 31,
 
   
2018
   
2017
 
Operating expenses:
           
Research and development
 
$
862,420
   
$
1,338,604
 
General and administrative
   
1,771,796
     
1,557,341
 
Depreciation
   
2,903
     
3,069
 
  Total operating expenses
   
2,637,119
     
2,899,014
 
                 
Loss from operations
   
(2,637,119
)
   
(2,899,014
)
                 
Other income (expense):
               
Loss on change in fair value of derivatives
   
-
     
(373,611
)
Interest income
   
85
     
-
 
                 
Loss before income taxes
   
(2,637,034
)
   
(3,272,625
)
                 
Income taxes (benefit)
   
-
     
-
 
                 
Net loss
   
(2,637,034
)
   
(3,272,625
)
                 
Preferred stock dividend
   
(305,046
)
   
(23,745
)
                 
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
 
$
(2,942,080
)
 
$
(3,296,370
)
                 
Net loss per common share, basic and diluted
 
$
(0.09
)
 
$
(0.14
)
                 
Weighted average number of common shares outstanding, basic and diluted
   
29,944,445
     
23,051,872
 
                 
See the accompanying notes to the unaudited condensed financial statements
 

 
BIOSIG TECHNOLOGIES, INC.
 
CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT
 
THREE MONTHS ENDED MARCH 31, 2018
 
                                                             
                                       
Additional
                   
   
Series D Preferred stock
   
Series E Preferred stock
   
Common stock
   
Paid in
   
Common stock
   
Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Subscription
   
Deficit
   
Total
 
Balance, December 31, 2017
   
1,334
   
$
1
     
-
   
$
-
     
29,321,204
   
$
29,321
   
$
53,215,635
   
$
29,985
   
$
(56,524,786
)
 
$
(3,249,844
)
Reclassify fair value of derivative and warrant liabilities to equity upon adoption of ASU 2017-11
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
-
     
3,044,162
     
3,044,162
 
Common stock issued for services
   
-
     
-
     
-
     
-
     
100,000
     
100
     
141,900
     
-
     
-
     
142,000
 
Sale of common stock
   
-
     
-
     
-
     
-
     
200,000
     
200
     
299,785
     
(29,985
)
   
-
     
270,000
 
Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share
   
-
     
-
     
-
     
-
     
13,334
     
13
     
19,987
     
-
     
-
     
20,000
 
Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.25 per share
   
-
     
-
     
-
     
-
     
6,595
     
7
     
8,269
     
-
     
-
     
8,276
 
Common stock issued upon conversion of Series D Preferred Stock at $1.50 per share
   
(647
)
   
-
     
-
     
-
     
647,000
     
647
     
(647
)
   
-
     
-
     
-
 
Common stock issued settlement of Series D Preferred Stock accrued dividends at $1.25 per share
   
-
     
-
     
-
     
-
     
209,574
     
210
     
261,825
     
-
     
-
     
262,035
 
Sale of Series E Preferred stock
   
-
     
-
     
1,000
     
1
     
-
     
-
     
1,492,968
     
-
     
-
     
1,492,969
 
Common stock subscription received
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
115,470
     
-
     
115,470
 
Stock based compensation
   
-
     
-
     
-
     
-
     
-
     
-
     
246,710
     
-
     
-
     
246,710
 
Preferred stock dividend
   
-
     
-
     
-
     
-
     
-
     
-
     
(305,046
)
   
-
     
-
     
(305,046
)
Net loss
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(2,637,034
)
   
(2,637,034
)
  Balance, March 31, 2018 (unaudited)
   
687
   
$
1
     
1,000
   
$
1
     
30,497,707
   
$
30,498
   
$
55,381,386
   
$
115,470
   
$
(56,117,658
)
 
$
(590,302
)
                                                                                 
See the accompanying notes to the unaudited condensed financial statements
 
 
BIOSIG TECHNOLOGIES, INC.
 
CONDENSED STATEMENTS OF CASH FLOWS
 
(unaudited)
 
   
   
Three months ended March 31,
 
   
2018
   
2017
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
 
$
(2,637,034
)
 
$
(3,272,625
)
Adjustments to reconcile net loss to cash used in operating activities:
               
Depreciation
   
2,903
     
3,069
 
Change in derivative liabilities
   
-
     
373,611
 
Equity based compensation
   
388,710
     
560,746
 
Fair value of issued warrant to acquire research and development
   
-
     
543,927
 
Changes in operating assets and liabilities:
               
Prepaid expenses
   
(2,173
)
   
(27,514
)
Security deposit
   
(5,393
)
   
-
 
Accounts payable
   
(134,714
)
   
209,466
 
Deferred rent payable
   
427
     
(521
)
  Net cash used in operating activities
   
(2,387,274
)
   
(1,609,841
)
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchase of property and equipment
   
(3,644
)
   
(1,620
)
  Net cash used in investing activity
   
(3,644
)
   
(1,620
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from sale of common stock
   
270,000
     
1,799,692
 
Proceeds from sale of Series E preferred stock
   
1,492,969
     
-
 
Proceeds from common stock subscription
   
115,470
     
-
 
  Net cash provided by financing activities
   
1,878,439
     
1,799,692
 
                 
Net (decrease) increase in cash and cash equivalents
   
(512,479
)
   
188,231
 
                 
Cash and cash equivalents, beginning of the period
   
1,547,579
     
1,055,895
 
Cash and cash equivalents, end of the period
 
$
1,035,100
   
$
1,244,126
 
                 
Supplemental disclosures of cash flow information:
               
Cash paid during the period for interest
 
$
-
   
$
-
 
Cash paid during the period for income taxes
 
$
-
   
$
-
 
                 
Non cash investing and financing activities:
               
Common stock issued upon conversion of Series C Preferred Stock and accrued dividends
 
$
28,276
   
$
-
 
Common stock issued upon conversion of Series D Preferred Stock and accrued dividends
 
$
262,035
   
$
-
 
Reclassify fair value of derivative and warrant liabilities to equity upon adoption of ASU 2017-11
 
$
3,044,162
   
$
-
 
Accrual of dividend payable charged to additional paid in capital
 
$
305,046
   
$
23,745
 
                 
See the accompanying notes to the unaudited condensed financial statements
 
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)
 
NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
 
The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
 
The condensed balance sheet as of December 31, 2017 has been derived from audited financial statements.
 
Operating results for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2017 filed with the Company’s Form 10-K/A with the Securities and Exchange Commission on March 26, 2018.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As of March 31, 2018, the Company had cash of $1,035,100 and working capital of $332,764. The Company raised approximately $1,500,000 through the sale of Series E preferred stock and warrants and $385,000 through the sale of common stock and warrants during the three months ended March 31, 2018 and approximately $4,675,000 subsequent to March 31, 2018 (See Note 11). During the three months ended March 31, 2018, the Company used net cash in operating activities of $2,387,274.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months.

The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at March 31, 2018 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.

Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
 
The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
 
Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.

At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).

Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420 and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively.

Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
 
The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
 
 
 
March 31,
2018
   
March 31,
2017
 
Series C convertible preferred stock
   
643,333
     
713,333
 
Series D convertible preferred stock
   
687,000
     
-
 
Series E convertible preferred stock
   
1,000,000
     
-
 
Options to purchase common stock
   
8,230,319
     
8,245,190
 
Warrants to purchase common stock
   
12,237,628
     
10,419,655
 
Totals
   
22,798,280
     
19,378,178
 

Stock Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested.

As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as non-current.

Registration Rights

On February 16, 2018, in connection with the Company’s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

Adoption of Accounting Standards

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.

When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.

NOTE 4 – PROPERTY AND EQUIPMENT
 
Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows:
 
 
 
March 31,
2018
   
December 31,
2017
 
Computer equipment
 
$
90,703
   
$
87,059
 
Furniture and fixtures
   
12,975
     
12,975
 
Subtotal
   
103,678
     
100,034
 
Less accumulated depreciation
   
(84,221
)
   
(81,318
)
Property and equipment, net
 
$
19,457
   
$
18,716
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
 
Depreciation expense was $2,903 and $3,069 for the three months ended March 31, 2018 and 2017, respectively.

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 
Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following:
 
 
 
March 31,
2018
   
December 31,
2017
 
Accrued accounting and legal
 
$
151,745
   
$
93,595
 
Accrued reimbursements
   
10,510
     
2,600
 
Accrued consulting
   
12,650
     
109,059
 
Accrued research and development expenses
   
148,932
     
246,030
 
Accrued office and other
   
644
     
7,912
 
Deferred rent
   
997
     
569
 
Accrued settlement related to arbitration
   
13,333
     
13,333
 
 
 
$
338,811
   
$
473,098
 

NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK
 
On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. 

As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.

In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

Series C Preferred Stock issued and outstanding totaled 965 and 985 as of March 31, 2018 and December 31, 2017, respectively.  As of March 31, 2018 and December 31, 2017, the Company has accrued $432,660 and $419,283 dividends payable on the Series C Preferred Stock.

NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES

Series C 9% Convertible Preferred Stock and related warrants

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.

The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%.

Series D Convertible Preferred Stock and related warrants

At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively.

The Company valued the reset provisions of the Series D Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%.

At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

NOTE 8 – STOCKHOLDER EQUITY

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2018 and December 31, 2017, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock and (2018) 1,000 shares of Series E Preferred Stock. As of March 31, 2018 and December 31, 2017, there were no outstanding shares of Series A and Series B preferred stock.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

Series C Preferred Stock

In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

Series D Preferred Stock

In January 2018, the Company issued an aggregate of 235,911 shares of its common stock in exchange for 180 shares of the Company’s Series D Preferred Stock and accrued dividends.

In February 2018, the Company issued an aggregate of 131,432 shares of its common stock in exchange for 100 shares of the Company’s Series D Preferred Stock and accrued dividends.

In March 2018, the Company issued an aggregate of 489,231 shares of its common stock in exchange for 367 shares of the Company’s Series D Preferred Stock and accrued dividends.

Series E Preferred Stock

On February 16, 2018, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the “Preferred Shares”) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.75 per share (the “Warrants”), in exchange for aggregate consideration of $1,492,969, net of transaction expenses of $7,031 (the “Transaction”).

The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type.  The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the “ROFR”) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement))  Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering.

In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.

The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.  The Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the “Consent”) with the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Holders”).  Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction.  In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the “Consent Warrants”).  The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. 

Common stock

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2018 and December 31, 2017, the Company had 30,497,707 and 29,321,204 shares issued and outstanding, respectively.

During the three months ended March 31, 2018, the Company issued 100,000 shares of its common stock for services totaling $142,000 ($1.42 per share).

During the three months ended March 31, 2018, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 180,000 shares of common stock and 90,000 warrants for aggregate proceeds of $270,000.

During the three months ended March 31, 2018, the Company issued 20,000 shares of common stock and 10,000 warrants for a previously received common stock subscription of $29,985.

NOTE 9 – OPTIONS AND WARRANTS

Options

On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years.

The following table presents information related to stock options at March 31, 2018:

Options Outstanding
   
Options Exercisable
 
           
Weighted
       
           
Average
   
Exercisable
 
Exercise
   
Number of
   
Remaining Life
   
Number of
 
Price
   
Options
   
In Years
   
Options
 
$
1.01-2.00
     
3,545,540
     
7.2
     
2,483,540
 
 
2.01-3.00
     
4,384,779
     
3.4
     
4,384,779
 
 
3.01-4.00
     
300,000
     
7.0
     
300,000
 
         
8,230,319
     
5.2
     
7,168,319
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at December 31, 2017
   
8,510,319
   
$
2.11
     
5.2
   
$
27,045
 
Grants
   
50,000
   
$
1.42
     
10.0
   
$
-
 
Exercised
   
-
                         
Canceled
   
(330,000
)
   
1.66
                 
Outstanding at March 31, 2018
   
8,230,319
   
$
2.12
     
5.2
   
$
158,930
 
Exercisable at March 31, 2018
   
7,168,319
   
$
2.20
     
4.7
   
$
104,305
 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.57 as of March 31, 2018, which would have been received by the option holders had those option holders exercised their options as of that date.

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the three months ended March 31, 2018 and 2017 was estimated using the Black-Scholes pricing model.

On February 15, 2018, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.42 per share for a term of ten years with vesting immediately.

The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018:

Risk-free interest rate
   
2.65
%
Dividend yield
   
0
%
Stock price volatility
   
94.10
%
Expected life
 
5 years
 
Weighted average grant date fair value
 
$
1.01
 

The fair value of all options vesting during the three months ended March 31, 2018 and 2017 of $246,710 and $42,984, respectively, was charged to current period operations.  Unrecognized compensation expense of $783,894 and $979,812 at March 31, 2018 and December 31, 2017, respectively, will be expensed in future periods.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018: 

Exercise
   
Number
 
Expiration
Price
   
Outstanding
 
Date
$
0.001
     
383,320
 
January 2020
$
1.50
     
7,615,982
 
February 2018 to May 2021
$
1.75
     
500,000
 
August 2021
$
1.84
     
35,076
 
January 2020
$
1.95
     
1,689,026
 
October 2018 to September 2019
$
2.00
     
100,000
 
August 2018
$
2.02
     
30,755
 
January 2020
$
2.50
     
100,000
 
August 2018
$
2.75
     
228,720
 
August 2019 to September 2019
$
3.67
     
214,193
 
December 2018 to January 2019
$
3.75
     
1,340,556
 
April 2019 to March 2020
         
12,237,628
 
 

On January 5, 2018, the Company issued 100,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on January 5, 2021, in connection with the sale of the Company’s common stock.

On February 14, 2018, the Company entered into a consent agreement with the holders of the Company’s Series D Convertible Preferred Stock.  Pursuant to the consent, the Series D Holders consented to the Series E Preferred Stock transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the transaction.  In consideration for their entry into the consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of common stock.  The consent warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share. The warrants contain certain anti-dilutive provisions (see Note 8).

On February 16, 2018, the Company issued an aggregate of 500,000 warrants to purchase the Company’s common stock at $1.75 per share, expiring on August 16, 2021, in connection with the sale of the Company’s Series E preferred stock.  The warrants contain certain anti-dilutive provisions (see Note 8).

A summary of the warrant activity for the three months ended March 31, 2018 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
Grants
   
700,000
   
$
1.68
     
3.0
     
-
 
Exercised
   
-
                         
Expired
   
(1,251,458
)
 
$
1.50
     
-
     
-
 
Outstanding at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
 
                               
Vested and expected to vest at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
Exercisable at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

NOTE 10 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of March 31, 2018 and December 31, 2017, the Company did not have any items that would be classified as level 1 or 2 disclosures.

As of March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.

The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of March 31, 2018:

 
 
Warrant
Liability
   
Derivative
 
Balance, December 31, 2017
 
$
2,358,240
   
$
685,922
 
Total (gains) losses
               
Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018
   
(2,358,240
)
   
(685,922
)
Balance, March 31, 2018
 
$
-
   
$
-
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2018
(unaudited)

NOTE 11 – SUBSEQUENT EVENTS

In April 2018, the Company issued an aggregate of 577,339 shares of its common stock in exchange for 454 shares of the Company’s Series D Preferred Stock and accrued dividends.

In April 2018, the Company issued an aggregate of 351,021 shares of its common stock in exchange for 370 shares of the Company’s Series C Preferred Stock and accrued dividends.

On April 30, 2018 the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 3,193,004 shares of  the Company’s common stock  and warrants to purchase an aggregate of 1,596,506 shares of the Company’s common stock, at an exercise price of $1.75 per share, in exchange for aggregate consideration of $4,789,502, net of transaction expenses of approximately $1,000 (the “April 2018 private placement”), of which $115,470 was received as common stock subscriptions as of March 31, 2018.

In connection with the April 2018 private placement, the Company issued additional warrants to purchase an aggregate of 83,334 shares of the Company’s common stock, at an exercise price of $1.50 per share to the Series E holders. In addition, 500,000 warrants to purchase the Company’s common stock at an exercise price of $1.75 per share previously issued to the Series E holders were reset to an exercise price of $1.50 per share.



 




 


BioSig Technologies, Inc.

Up to 1,294,392 Shares of Common Stock Underlying Series E Convertible Preferred Stock and up to 683,334 Shares of Common Stock Underlying Warrants


PROSPECTUS

           , 2018 


 

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13.                                Other Expenses of Issuance and Distribution.

We are paying all of the selling stockholders’ expenses related to this offering, except that the selling stockholders will pay any applicable underwriting discounts and commissions. The fees and expenses payable by us in connection with this Registration Statement are estimated as follows:
 
Securities and Exchange Commission Registration Fee
 
$
453.06
 
Accounting Fees and Expenses
 
$
3,500.00
 
Legal Fees and Expenses
 
$
15,000.00
 
Printing Expenses
 
$
None
 
Miscellaneous Fees and Expenses
 
$
None
 
Total
 
$
18,953.06
 
 
Item 14.                                Indemnification of Directors and Officers.
 
Section 145 of the General Corporation Law of the State of Delaware provides, in general, that a corporation incorporated under the laws of the State of Delaware, as we are, may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful.  In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or any other court in which such action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses.

We are also permitted to apply for, and currently maintain, insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether or not the General Corporation Law of the State of Delaware would permit indemnification.

Item 15.                                Recent Sales of Unregistered Securities.

On April 4, 2014 and April 30, 2014, in two separate closings, we entered into a securities purchase agreement with twenty-eight accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 229,760 shares of our common stock and five-year warrants to purchase 114,880 shares of our common stock for aggregate cash proceeds of $574,400. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On April 30, 2014, in connection with the above described private placement, we issued a five-year warrant to purchase up to 22,976 shares of common stock upon the same terms as the warrants in the above described private placement to Laidlaw & Company (UK) Ltd., our placement agent in the private placement. The warrant was not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and was offered and sold in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving a public offering. Laidlaw & Company (UK) Ltd. was an accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended) at the time of the private placement.


On August 15, 2014 and September 12, 2014, in two separate closing, we entered into a securities purchase agreement with 23 accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 381,200 shares of our common stock and five-year warrants to purchase 190,600 shares of our common stock for aggregate cash proceeds of $953,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On August 15, 2014 and September 12, 2014, in connection with the above described private placement, we issued a warrant to purchase up to an aggregate of 38,120 shares of common stock upon the same terms as the warrants in the above described private placement to Laidlaw & Company (UK) Ltd., our placement agent in the private placement. The warrant was not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and was offered and sold in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving a public offering. Laidlaw & Company (UK) Ltd. was an accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended) at the time of the private placement.
 
On December 19, 2014, December 30, 2014, January 23, 2015, February 10, 2015, February 27, 2015 and March 31, 2015, in six separate closing, we entered into a securities purchase agreement with 102 accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 1,603,600 shares of our common stock, “A” warrants expiring July 31, 2015 to purchase 1,603,600 shares of our common stock and “B” warrants expiring March 21, 2020 to purchase 801,800 shares of our common stock for aggregate cash proceeds of $4,009,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On March 31, 2015, in connection with the above described private placement, we issued a warrant to purchase up to 400,900 shares of common stock upon the same terms as the “B” warrants in the above described private placement to Laidlaw & Company (UK) Ltd., our placement agent in the private placement. The warrant was not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and was offered and sold in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving a public offering. Laidlaw & Company (UK) Ltd. was an accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended) at the time of the private placement.
 
On May 11, 2015, we entered into a securities purchase agreement with Alpha Capital Anstalt and a securities purchase agreement with Brio Capital Master Fund Ltd., pursuant to which we issued 450 shares of our Series C Preferred Stock and five-year warrants to purchase 374,641 shares of our common stock for aggregate cash proceeds of $450,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On August 17, 2015, as consideration for providing general financial advisory services, we issued Alere Financial Partners, LLC a three-year warrant to purchase up to 100,000 shares of common stock each at an exercise price of $2.00 and a three-year warrant to purchase up to 100,000 shares of common stock each at an exercise price of $2.50 per share. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On October 23, 2015, October 29, 2015, November 18, 2015, December 18, 2015, December 22, 2015, February 9, 2016, March 9, 2016, April 1, 2016, April 19, 2016 and April 29, 2016, in ten separate closings, we entered into a securities purchase agreement with 49 accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 3,003,016 shares of our common stock and three-year warrants to purchase an aggregate of up to 1,501,513 shares of our common stock for aggregate cash proceeds of approximately $4,504,516. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 

On October 23, 2015, October 29, 2015, November 18, 2015, December 18, 2015, December 22, 2015, February 9, 2016, March 9, 2016, April 1, 2016, April 19, 2016 and April 29, 2016, in connection with the above described private placement, we issued warrants to purchase an aggregate of up to 232,960 shares of common stock exercisable for cash or by means of a cashless exercise at a price of $1.50 per share, and the same other terms as the warrants in the above described private placement to Laidlaw & Company (UK) Ltd. (“Laidlaw”), our placement agent in the private placement, and certain of its designated employees pursuant to the terms of the Company’s engagement letter with Laidlaw. However, prior to their issuance, Laidlaw assigned its rights to the Employee Warrants to certain designated employees.  Rather than issue such Employee Warrants first to Laidlaw, and then immediately process an assignment to the designated Laidlaw employees, for administrative convenience, we issued the Employee Warrants directly to Laidlaw’s designated employees.  The warrant was not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and was offered and sold in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving a public offering. Laidlaw & Company (UK) Ltd. was an accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended) at the time of the private placement.

On June 1, 2016, we entered into a securities purchase agreement with 3 accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 77,144 shares of our common stock and three-year warrants to purchase up to 38,572 shares of our common stock, exercisable at $2.10 per share and expiring June 1, 2019, in exchange for aggregate cash proceeds of approximately $135,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On September 1, 2016, we entered into a securities purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 305,026 shares of our common stock and 152,513 warrants to purchase one share of our common stock, exercisable at a price of $1.95 per share and expiring August 30, 2019, in exchange for aggregate consideration of $431,549, net of $25,990 in expenses. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On September 19, 2016, we entered into a securities purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 70,000 shares of our common stock and 35,000 warrants to purchase one share of our common stock, exercisable at a price of $1.95 per share and expiring September 19, 2019, in exchange for aggregate consideration of $98,533, net of $6,467 in expenses. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On October 28, 2016, November 23, 2016, December 16, 2016, December 22, 2016, February 10, 2017, March 10, 2017 and March 31, 2017, in seven separate closings, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued an aggregate of 2,899,974 units, which consisted of, in the aggregate, 2,899,974 shares of our common stock and warrants to purchase 1,449,991 shares of our common stock at an exercise price of $1.50 per share, in exchange for aggregate gross proceeds of $3,972,199, after financing costs of $377,754. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On October 28, 2016, November 23, 2016, December 16, 2016, December 22, 2016, February 10, 2017, March 10, 2017 and March 31, 2017, in connection with the above described private placement, we issued warrants to purchase an aggregate of up to 186,957 shares of common stock exercisable for cash or by means of a cashless exercise at a price of $1.50 per share expiring January 13, 2020, and the same other terms as the warrants in the above described private placement to certain designated employees of Laidlaw, our placement agent in the private placement, pursuant to the terms of the Company’s engagement letter with Laidlaw. However, prior to their issuance, Laidlaw assigned its rights to the Employee Warrants to certain designated employees.  Rather than issue such Employee Warrants first to Laidlaw, and then immediately process an assignment to the designated Laidlaw employees, for administrative convenience, we issued the Employee Warrants directly to Laidlaw’s designated employees. The warrant was not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and was offered and sold in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving a public offering. Laidlaw was an accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended) at the time of the private placement.
 

In March 2017, we issued to Mayo Clinic Ventures three-year warrants to purchase up to an aggregate of 630,000 shares of common stock at an exercise price of $1.50 per share in connection with a know-how licensing agreement with Mayo Foundation for Medical Education and Research. The securities were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On April 6, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 426,667 shares of our common stock and 213,334 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring April 6, 2020, in exchange for aggregate consideration of $640,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On April 17, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 149,932 shares of our common stock and 74,966 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring April 17, 2020, in exchange for aggregate consideration of $224,898. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On May 5, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 13,334 shares of our common stock and 6,667 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring May 5, 2020, in exchange for aggregate consideration of $20,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On June 20, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 20,000 shares of our common stock and 10,000 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring June 20, 2020, in exchange for aggregate consideration of $30,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On June 30, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 216,667 shares of our common stock and 108,334 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring June 30, 2020, in exchange for aggregate consideration of $325,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On July 13, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 267,002 shares of our common stock and 133,501 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring July 13, 2020, in exchange for aggregate consideration of $400,500. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On August 18, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 351,000 shares of our common stock and 175,500 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring August 18, 2020, in exchange for aggregate consideration of $526,500. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.


On September 18, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 103,334 shares of our common stock and 51,668 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring September 18, 2020, in exchange for aggregate consideration of $155,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On October 11, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 386,667 shares of our common stock and 193,334 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring October 11, 2020, in exchange for aggregate consideration of $580,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On November 3, 2017,  we entered into a securities purchase agreement with certain institutional accredited investors pursuant to which we sold to the investors an aggregate of 1,334 shares of our Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of common stock, par value $0.001 per share at an exercise price of $1.75 per share, in exchange for aggregate net cash proceeds of $1,929,975, net of expenses of $70,025. Contemporaneously with the entry into the securities purchase agreement, we and the purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of common stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price. On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment.  The Class A Warrants are exercisable immediately and expire on May 3, 2021 and have an exercise price of $1.50 per share.  The Class B Warrants are exercisable immediately and expire on November 3, 2020 and have an exercise price of $1.50.  The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.
 
On November 6, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 413,336 shares of our common stock and 206,668 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring November 6, 2020, in exchange for aggregate consideration of $620,002. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On December 29, 2017, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 460,668 shares of our common stock and 230,334 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring December 29, 2020, in exchange for aggregate consideration of $691,001. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On January 5, 2018, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 200,000 shares of our common stock and 100,000 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring January 5, 2021, in exchange for aggregate consideration of $300,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.


On February 16, 2018, we entered into a securities purchase agreement  with certain institutional accredited investors pursuant to which we sold to the investors an aggregate of 1,000 shares of Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an initial aggregate of 500,000 shares of common stock, par value $0.001 per share, at an initial exercise price of $1.75 per share, in exchange for aggregate consideration of $1,500,000. The sale of the securities sold in this offering were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended  provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended. The warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.  The warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.  In connection with the entry into the purchase agreement, on February 14, 2018, we entered into a consent agreement (the “Consent”) with the holders of our Series D Convertible Preferred Stock (the “Series D Holders”).  Pursuant to the Consent, the Series D Holders consented to the February 16, 2018 transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the transaction.  In consideration for their entry into the Consent, we issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of common stock (the “Consent Warrants”).  The Consent Warrants are exercisable immediately and expire on February 14, 2021 and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.  The issuance of the Consent Warrants to the Series D Holders was in reliance on the exemption from registration under the Securities Act provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.

On April 30, 2018, the terms of the Series E Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Series E Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 83,334 shares of common stock may be issued upon exercise of the Series E Warrants due to the adjustment.

On April 30, 2018, we entered into a unit purchase agreement with certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 3,193,004 shares of our common stock and 1,596,506 warrants to purchase one share of our common stock, exercisable at a price of $1.75 per share and expiring April 30, 2021, in exchange for aggregate consideration of $4,789,502. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On May 11, 2018, we entered into a unit purchase agreement with a certain accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 140,000 shares of our common stock and 70,000 warrants to purchase one share of our common stock, exercisable at a price of $1.75 per share and expiring May 11, 2021, in exchange for aggregate consideration of $210,000. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.




Item 16.                                Exhibits and Financial Statement Schedules.

Exhibit No.
 
Description
3.1
 
3.2
 
3.3
 
3.4
 
3.5
 
3.6
 
3.7
 
3.8
 
3.9
 
3.10
 
5.1
 
10.1
 
10.2
 
10.3
 
10.4
 
10.5
 
10.6
 
10.7
 
10.8
 
10.9
 
10.10
 
10.11
 
10.12
 
10.13
 
10.14
 


10.15
 
10.16
 
10.17
 
10.18
 
10.19
 
10.20
 
10.21
 
10.22
 
10.23
 
10.24
 
10.25
 
10.26
 
10.27
 
10.28
 
10.29
 
10.30
 
10.31
 
10.32
 
10.33
 
10.34
 
10.35
 
10.36
 
10.37
 
10.38
 
10.39
 
10.40
 
 


10.41
 
 10.42
 
10.43
 
10.44
 
10.45
 
10.46
 
10.47
 
10.48
 
10.49
 
10.50
 
10.51
 
10.52
 
10.53
 
10.54
 
10.55
 
10.56
 
10.57
 
10.58
 
10.59
 
23.1
 
23.2
 
24.1
 


Item 17.                                Undertakings.

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

provided, however, that subparagraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement;

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (§230.430A of this chapter), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5) That, for the purpose of determining liability of the undersigned registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and


(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(6) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
 
 


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on May 16, 2018.

 
BIOSIG TECHNOLOGIES, INC.
 
 
 
 
By:
/s/ Kenneth L. Londoner
 
 
Name: Kenneth L. Londoner
 
 
Title: Chief Executive Officer and Chairman
 
POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that we, the undersigned officers and directors of BioSig Technologies, Inc., a Delaware corporation, do hereby constitute and appoint Kenneth L. Londoner as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement and any subsequent registration statement filed by the registrant pursuant to Rule 462(b) of the Securities Act of 1933, as amended, which relates to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature
 
Title
 
Date
 
 
 
 
 
/s/ Kenneth L. Londoner
 
Chief Executive Officer, Chairman and Director (principal executive officer)
 
May 16, 2018
Kenneth L. Londoner
 
 
 
 
 
 
 
 
 
/s/ Steve Chaussy
 
Chief Financial Officer (principal financial and accounting officer)
 
May 16, 2018
Steve Chaussy
 
 
 
 
 
 
 
 
 
/s/ Donald E. Foley
 
Director
 
May 16, 2018
Donald E. Foley
 
 
 
 
 
 
 
 
 
/s/ Roy T. Tanaka
 
Director
 
May 16, 2018
Roy T. Tanaka
 
 
 
 
 
 
 
 
 
/s/ Patrick J. Gallagher
 
Director
 
May 16, 2018
Patrick J. Gallagher
 
 
 
 
 
 
 
 
 
/s/ Seth H.Z. Fischer
 
Director
 
May 16, 2018
Seth H. Z. Fischer
 
 
 
 
 
 
 
 
 
/s/ Jeffrey F. O’Donnell, Sr.
 
Director
 
May 16, 2018
Jeffrey F. O’Donnell, Sr.
 
 
 
 
 
 
 
 
 
/s/ Andrew L. Filler
 
Director
 
May 16, 2018
Andrew L. Filler
 
 
 
 
 
 
 
 
 
/s/ David Weild IV
 
Director
 
May 16, 2018
David Weild IV
 
 
 
 
 
 
 
 
 


II-12

EX-5.1 2 ex5-1.htm EX-5.1

Exhibit 5.1
 
May 16, 2018



BioSig Technologies, Inc.
12424 Wilshire Boulevard, Suite 745
Los Angeles, California 90025

Re:          BioSig Technologies, Inc. – Registration Statement on Form S-1

Ladies and Gentlemen:

We have acted as counsel to BioSig Technologies, Inc., a Delaware corporation (the “Company”), in connection with the proposed registration of 1,977,726 shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), comprised of (i) up to 1,000,000 shares of Common Stock (the “Shares”) issuable upon the conversion of 1,000 shares of  the Company’s Series E Convertible Preferred Stock (the “Series E Stock”), (ii) up to 294,392, shares of Common Stock issuable as a make-whole dividend upon conversion of the Series E Stock (the “Dividend Shares” and together with the Shares the “Conversion Shares”) and (iii) up to 683,334 shares of Common Stock (the “Warrant Shares”) issuable upon the exercise of warrants (the “Warrants”), pursuant to the registration statement on Form S-1 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Securities Act”), filed with the Securities and Exchange Commission (the “Commission”) on May 16, 2018.

The opinions expressed herein are limited exclusively to the General Corporation Law of the State of Delaware (the “DGCL”) and applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the DGCL and such provisions of the Delaware Constitution and we have not considered, and express no opinion on, any other laws or the laws of any other jurisdiction.

In rendering the opinions expressed herein, we have examined and relied upon the originals, or copies certified to our satisfaction, of (i) the Registration Statement, including the prospectus, and all exhibits thereto; (ii) the Company’s Certificate of Incorporation and any amendments to date certified by the Secretary of State of the State of Delaware; (iii) the Company’s By-laws and any amendments to date certified by the Executive Chairman of the Company; (iv) the minutes and records of the corporate proceedings of the Company with respect to the authorization of the issuance of the Conversion Shares and the Warrant Shares covered by the Registration Statement and related matters thereto; (v) the Warrants; (vi) a specimen of the Company’s Common Stock certificate; and (vii) such other records, documents and instruments as we have deemed necessary for the expression of the opinions stated herein.
 

BioSig Technologies, Inc.
May 16, 2018
Page 2
In making the foregoing examinations, we have assumed the genuineness of all signatures (other than those of the Company), the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies thereof and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions, where such facts have not been independently established, we have relied, to the extent we have deemed reasonably appropriate, upon representations or certificates of officers of the Company or governmental officials.
 
Based upon the foregoing and subject to the assumptions and qualifications stated herein, we are of the opinion that:

The Conversion Shares have been duly authorized for issuance by all necessary corporate action of the Company and, when issued and paid for in accordance with the terms and conditions of the Series E Stock, the Conversion Shares will be validly issued, fully paid and non-assessable.

The Warrant Shares have been duly authorized for issuance by all necessary corporate action of the Company and, when issued and paid for in accordance with the terms and conditions of the Warrants, the Warrant Shares will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement and to the reference to our firm under the caption “Legal Matters” in the prospectus constituting part of such Registration Statement.  In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.  

Very truly yours,

/s/ Haynes and Boone, LLP

Haynes and Boone, LLP

EX-23.1 3 ex23-1.htm EX-23.1

 
 
Exhibit 23.1

 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 
We hereby consent to use in this Form S-1 Registration Statement of our report dated February 27, 2018, relating to the financial statements of BioSig Technologies. Inc. which appear in this Registration Statement.  Our report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern

We also consent to the references to us under the heading "Experts" in such Registration Statement.


/s/Liggett & Webb, P.A.                                                                                                            
                                                                                                           
New York, New York
May 16, 2018


 
 
 
 
 
 
EX-101.INS 4 bios-20180331.xml XBRL INSTANCE DOCUMENT 0001530766 2017-12-31 0001530766 2016-12-31 0001530766 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2016-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2017-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2018-03-31 0001530766 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2018-03-31 0001530766 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2017-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2016-12-31 0001530766 2017-01-01 2017-12-31 0001530766 2016-01-01 2016-12-31 0001530766 2018-01-01 2018-03-31 0001530766 2017-01-01 2017-03-31 0001530766 us-gaap:CommonStockMember 2015-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001530766 us-gaap:RetainedEarningsMember 2015-12-31 0001530766 2015-12-31 0001530766 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-12-31 0001530766 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001530766 us-gaap:CommonStockMember 2016-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001530766 us-gaap:RetainedEarningsMember 2016-12-31 0001530766 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-12-31 0001530766 bios:CommonStockSubscriptionMember 2017-01-01 2017-12-31 0001530766 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2017-12-31 0001530766 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2017-12-31 0001530766 us-gaap:CommonStockMember 2017-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001530766 bios:CommonStockSubscriptionMember 2017-12-31 0001530766 us-gaap:RetainedEarningsMember 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001530766 bios:CommonStockSubscriptionMember 2018-01-01 2018-03-31 0001530766 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember bios:CommonStockSubscriptionMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember bios:CommonStockSubscriptionMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember bios:CommonStockSubscriptionMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember bios:CommonStockSubscriptionMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2018-03-31 0001530766 us-gaap:CommonStockMember 2018-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001530766 bios:CommonStockSubscriptionMember 2018-03-31 0001530766 us-gaap:RetainedEarningsMember 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2016-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2017-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2017-12-31 0001530766 bios:SettlementOfPreferredStockMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember 2016-01-01 2016-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2016-01-01 2016-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2017-01-01 2017-03-31 0001530766 2017-03-31 0001530766 us-gaap:SeriesDPreferredStockMember 2017-01-01 2017-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2016-01-01 2016-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-01-01 2018-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-01-01 2017-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-03-31 0001530766 2018-05-04 0001530766 srt:MinimumMember 2017-01-01 2017-12-31 0001530766 srt:MaximumMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001530766 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001530766 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001530766 us-gaap:SubsequentEventMember 2017-01-01 2017-12-31 0001530766 bios:WorkingCapitalExcludingDerivativeAndWarrantLiabilitiesMember 2017-12-31 0001530766 us-gaap:ChiefExecutiveOfficerMember 2016-05-04 2016-05-04 0001530766 us-gaap:ChiefFinancialOfficerMember 2016-05-04 2016-05-04 0001530766 us-gaap:ChiefExecutiveOfficerMember 2016-05-04 0001530766 us-gaap:ChiefFinancialOfficerMember 2016-05-04 0001530766 us-gaap:ChiefExecutiveOfficerMember 2016-12-08 2016-12-08 0001530766 us-gaap:DirectorMember 2016-12-08 2016-12-08 0001530766 us-gaap:ChiefExecutiveOfficerMember 2016-12-08 0001530766 us-gaap:DirectorMember 2016-12-08 0001530766 bios:FormerChiefExecutiveOfficerAndPresidentMember 2016-12-08 2016-12-08 0001530766 bios:Director2Member 2016-12-08 2016-12-08 0001530766 bios:FormerChiefExecutiveOfficerAndPresidentMember 2016-12-08 0001530766 bios:Director2Member 2016-12-08 0001530766 bios:FormerDirectorMember 2016-12-22 2016-12-22 0001530766 us-gaap:DirectorMember 2016-12-22 2016-12-22 0001530766 2016-12-22 2016-12-22 0001530766 bios:Director3Member 2016-12-22 2016-12-22 0001530766 bios:Director2Member 2016-12-22 2016-12-22 0001530766 2017-04-01 2017-04-01 0001530766 2017-06-16 2017-06-16 0001530766 2017-06-16 0001530766 us-gaap:ChiefExecutiveOfficerMember 2017-11-08 2017-11-08 0001530766 us-gaap:ChiefFinancialOfficerMember 2017-11-08 2017-11-08 0001530766 us-gaap:DirectorMember 2017-11-08 2017-11-08 0001530766 2017-11-08 0001530766 srt:AffiliatedEntityMember 2017-11-01 2017-11-01 0001530766 us-gaap:ChiefExecutiveOfficerMember 2017-11-09 2017-11-09 0001530766 us-gaap:DirectorMember 2017-11-09 2017-11-09 0001530766 2017-11-09 0001530766 bios:Director3Member 2017-11-09 2017-11-09 0001530766 bios:Director4Member 2017-11-09 2017-11-09 0001530766 bios:Director5Member 2017-11-09 2017-11-09 0001530766 us-gaap:DirectorMember 2017-12-22 2017-12-22 0001530766 bios:Director2Member 2017-12-22 2017-12-22 0001530766 2017-12-22 0001530766 2017-12-22 2017-12-22 0001530766 us-gaap:ComputerEquipmentMember 2017-12-31 0001530766 us-gaap:ComputerEquipmentMember 2016-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2013-01-09 0001530766 us-gaap:SeriesCPreferredStockMember 2013-01-09 2013-01-09 0001530766 2013-01-09 0001530766 bios:WarrantsAt261Member 2013-01-09 2013-01-09 0001530766 bios:WarrantsAt261Member 2013-01-09 0001530766 2013-01-09 2013-01-09 0001530766 bios:FullRatchetAntiDilutionProtectionProvisionMember 2013-01-09 0001530766 us-gaap:OptionMember us-gaap:SeriesCPreferredStockMember 2013-01-01 2013-12-31 0001530766 us-gaap:WarrantMember us-gaap:SeriesCPreferredStockMember 2013-01-01 2013-12-31 0001530766 us-gaap:OptionMember us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 us-gaap:WarrantMember us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 bios:IssuanceCostsMember us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 us-gaap:WarrantMember 2013-12-31 0001530766 us-gaap:BridgeLoanMember us-gaap:SeriesCPreferredStockMember 2013-02-01 2013-02-28 0001530766 us-gaap:SeriesCPreferredStockMember 2013-02-01 2013-07-31 0001530766 us-gaap:SeriesCPreferredStockMember 2013-05-11 2013-05-11 0001530766 us-gaap:SeriesCPreferredStockMember 2016-02-01 2016-02-28 0001530766 us-gaap:SeriesCPreferredStockMember 2016-05-01 2016-05-31 0001530766 us-gaap:SeriesCPreferredStockMember 2016-06-01 2016-06-30 0001530766 us-gaap:SeriesCPreferredStockMember 2016-12-01 2016-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2017-06-01 2017-06-30 0001530766 us-gaap:SeriesCPreferredStockMember 2017-07-01 2017-07-31 0001530766 srt:MinimumMember us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-12-31 0001530766 srt:MaximumMember us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-12-31 0001530766 2015-03-31 0001530766 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-03-31 2015-03-31 0001530766 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-03-31 2015-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-03-31 2015-03-31 0001530766 2017-11-03 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-11-03 2017-11-03 0001530766 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-01-01 2017-12-31 0001530766 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-01-01 2017-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2017-11-03 0001530766 us-gaap:SeriesDPreferredStockMember 2017-11-03 2017-11-03 0001530766 bios:SaleOfClassAWarrantsMember us-gaap:SeriesDPreferredStockMember 2017-11-03 2017-11-03 0001530766 bios:SaleOfClassAWarrantsMember us-gaap:SeriesDPreferredStockMember 2017-11-03 0001530766 bios:ExchangeOfOutstandingWarrantsForClassBWarrantsMember us-gaap:SeriesDPreferredStockMember 2017-11-03 2017-11-03 0001530766 bios:ExchangeOfOutstandingWarrantsForClassBWarrantsMember us-gaap:SeriesDPreferredStockMember 2017-11-03 0001530766 bios:ClassAWarrantAdjustmentMember 2017-11-06 0001530766 bios:ClassAWarrantAdjustmentMember 2017-11-06 2017-11-06 0001530766 2017-11-17 0001530766 2017-11-18 0001530766 bios:EquityIncentive2012PlanMember 2016-01-01 2016-12-31 0001530766 bios:EquityIncentive2012PlanMember 2016-12-31 0001530766 bios:ServicesProvidedMember 2016-01-01 2016-12-31 0001530766 bios:ServicesProvidedMember 2016-12-31 0001530766 us-gaap:PrivatePlacementMember 2016-01-01 2016-12-31 0001530766 us-gaap:PhantomShareUnitsPSUsMember 2016-01-01 2016-12-31 0001530766 bios:ExerciseOfOptionsMember 2016-01-01 2016-12-31 0001530766 bios:ExerciseOfOptionsMember 2016-12-31 0001530766 bios:EquityIncentive2012PlanMember 2017-01-01 2017-12-31 0001530766 bios:EquityIncentive2012PlanMember 2017-12-31 0001530766 bios:CommonStockIssuedForServicesMember 2017-01-01 2017-12-31 0001530766 bios:CommonStockIssuedForServicesMember 2017-12-31 0001530766 us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2012-10-19 0001530766 2012-10-19 2012-10-19 0001530766 bios:EquityIncentive2012PlanMember bios:OfficersDirectorsAndKeyConsultantsMember 2016-01-01 2016-12-31 0001530766 bios:EquityIncentive2012PlanMember bios:OfficersDirectorsAndKeyConsultantsMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2017-12-31 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2016-05-18 2016-05-18 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2016-08-24 2016-08-24 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-08-24 2016-08-24 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-08-24 2016-08-24 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2016-08-24 2016-08-24 0001530766 2016-12-29 2016-12-29 0001530766 2017-02-08 2017-02-08 0001530766 bios:ServicesProvidedMember 2017-11-08 2017-11-08 0001530766 2017-11-08 2017-11-08 0001530766 bios:ServicesProvidedMember 2017-11-24 2017-11-24 0001530766 bios:ServicesProvided2Member 2017-11-24 2017-11-24 0001530766 2017-11-24 2017-11-24 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2016-01-01 2016-12-31 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2016-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2016-09-07 2016-09-07 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0001530766 bios:WarrantsAt1.95Member 2016-02-09 2016-02-09 0001530766 bios:WarrantsAt1.95Member 2016-02-09 0001530766 bios:WarrantsAt1.50Member 2016-02-09 2016-02-09 0001530766 bios:WarrantsAt1.50Member 2016-02-09 0001530766 bios:WarrantsAt1.95Member 2016-03-09 2016-03-09 0001530766 bios:WarrantsAt1.95Member 2016-03-09 0001530766 bios:WarrantsAt1.50Member 2016-03-09 2016-03-09 0001530766 bios:WarrantsAt1.50Member 2016-03-09 0001530766 bios:WarrantsAt1.95Member 2016-04-01 2016-04-01 0001530766 bios:WarrantsAt1.95Member 2016-04-01 0001530766 bios:WarrantsAt1.50Member 2016-04-01 2016-04-01 0001530766 bios:WarrantsAt1.50Member 2016-04-01 0001530766 bios:WarrantsAt1.95Member 2016-04-19 2016-04-19 0001530766 bios:WarrantsAt1.95Member 2016-04-19 0001530766 bios:WarrantsAt1.50Member 2016-04-19 2016-04-19 0001530766 bios:WarrantsAt1.50Member 2016-04-19 0001530766 bios:WarrantsAt1.95Member 2016-04-29 2016-04-29 0001530766 bios:WarrantsAt1.95Member 2016-04-29 0001530766 bios:WarrantsAt1.50Member 2016-04-29 2016-04-29 0001530766 bios:WarrantsAt1.50Member 2016-04-29 0001530766 bios:WarrantsAt1.50Member srt:MinimumMember 2016-04-29 2016-04-29 0001530766 bios:WarrantsAt1.50Member srt:MaximumMember 2016-04-29 2016-04-29 0001530766 bios:WarrantsAt210Member 2016-06-01 2016-06-01 0001530766 bios:WarrantsAt210Member 2016-06-01 0001530766 bios:WarrantsAt1.95Member 2016-08-30 2016-08-30 0001530766 bios:WarrantsAt1.95Member 2016-08-30 0001530766 bios:WarrantsAt1.95Member 2016-09-19 2016-09-19 0001530766 bios:WarrantsAt1.95Member 2016-09-19 0001530766 bios:WarrantsAt1.50Member 2016-10-28 2016-10-28 0001530766 bios:WarrantsAt1.50Member 2016-10-28 0001530766 bios:WarrantsAt1.50Member 2016-11-23 2016-11-23 0001530766 bios:WarrantsAt1.50Member 2016-11-23 0001530766 bios:WarrantsAt1.50Member 2016-12-16 2016-12-16 0001530766 bios:WarrantsAt1.50Member 2016-12-16 0001530766 bios:WarrantsAt1.50Member 2016-12-22 2016-12-22 0001530766 bios:WarrantsAt1.50Member 2016-12-22 0001530766 bios:WarrantsAt210Member 2017-02-09 2017-02-09 0001530766 bios:WarrantsAt210Member 2017-02-09 0001530766 bios:WarrantsAt1.50Member 2017-02-09 2017-02-09 0001530766 bios:WarrantsAt1.50Member 2017-02-09 0001530766 bios:WarrantsAt1.50Member 2017-02-10 2017-02-10 0001530766 bios:WarrantsAt1.50Member 2017-02-10 0001530766 bios:WarrantsAt1.50Member 2017-03-10 2017-03-10 0001530766 bios:WarrantsAt1.50Member 2017-03-10 0001530766 bios:WarrantsAt1.50Member 2017-03-15 2017-03-15 0001530766 bios:WarrantsAt1.50Member 2017-03-15 0001530766 2017-03-15 2017-03-15 0001530766 2017-03-15 0001530766 bios:WarrantsAt1.50Member 2017-03-31 2017-03-31 0001530766 bios:WarrantsAt1.50Member 2017-03-31 0001530766 bios:WarrantsAt1.50Member 2017-04-06 2017-04-06 0001530766 bios:WarrantsAt1.50Member 2017-04-06 0001530766 bios:WarrantsAt1.50Member 2017-05-05 2017-05-05 0001530766 bios:WarrantsAt1.50Member 2017-05-05 0001530766 bios:WarrantsAt1.50Member 2017-05-17 2017-05-17 0001530766 bios:WarrantsAt1.50Member 2017-05-17 0001530766 bios:WarrantsAt1.50Member 2017-06-20 2017-06-20 0001530766 bios:WarrantsAt1.50Member 2017-06-20 0001530766 bios:WarrantsAt1.50Member 2017-06-30 2017-06-30 0001530766 bios:WarrantsAt1.50Member 2017-06-30 0001530766 bios:WarrantsAt1.50Member 2017-07-13 2017-07-13 0001530766 bios:WarrantsAt1.50Member 2017-07-13 0001530766 bios:WarrantsAt1.50Member 2017-08-18 2017-08-18 0001530766 bios:WarrantsAt1.50Member 2017-08-18 0001530766 bios:WarrantsAt1.50Member 2017-09-18 2017-09-18 0001530766 bios:WarrantsAt1.50Member 2017-09-18 0001530766 bios:WarrantsAt1.50Member 2017-10-11 2017-10-11 0001530766 bios:WarrantsAt1.50Member 2017-10-11 0001530766 bios:WarrantsAt1.50Member us-gaap:SeriesDPreferredStockMember 2017-11-03 2017-11-03 0001530766 bios:WarrantsAt1.50Member us-gaap:SeriesDPreferredStockMember 2017-11-03 0001530766 bios:WarrantsAt1.50Member 2017-11-03 2017-11-03 0001530766 bios:WarrantsAt1.50Member 2017-11-03 0001530766 bios:WarrantsAt1.50Member 2017-11-06 2017-11-06 0001530766 bios:WarrantsAt1.50Member 2017-11-06 0001530766 bios:WarrantsAt1.50Member us-gaap:SeriesDPreferredStockMember 2017-11-06 2017-11-06 0001530766 bios:WarrantsAt1.50Member us-gaap:SeriesDPreferredStockMember 2017-11-06 0001530766 bios:WarrantsAt1.50Member 2017-12-29 2017-12-29 0001530766 bios:WarrantsAt1.50Member 2017-12-29 0001530766 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001530766 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001530766 srt:MinimumMember bios:OptionsAt1.01To2.00Member 2017-01-01 2017-12-31 0001530766 srt:MaximumMember bios:OptionsAt1.01To2.00Member 2017-01-01 2017-12-31 0001530766 bios:OptionsAt1.01To2.00Member 2017-12-31 0001530766 bios:OptionsAt1.01To2.00Member 2017-01-01 2017-12-31 0001530766 srt:MinimumMember bios:OptionsAt2.01To3.00Member 2017-01-01 2017-12-31 0001530766 srt:MaximumMember bios:OptionsAt2.01To3.00Member 2017-01-01 2017-12-31 0001530766 bios:OptionsAt2.01To3.00Member 2017-12-31 0001530766 bios:OptionsAt2.01To3.00Member 2017-01-01 2017-12-31 0001530766 srt:MinimumMember bios:OptionsAt3.01To4.00Member 2017-01-01 2017-12-31 0001530766 srt:MaximumMember bios:OptionsAt3.01To4.00Member 2017-01-01 2017-12-31 0001530766 bios:OptionsAt3.01To4.00Member 2017-12-31 0001530766 bios:OptionsAt3.01To4.00Member 2017-01-01 2017-12-31 0001530766 2014-12-31 0001530766 2015-01-01 2015-12-31 0001530766 srt:MinimumMember 2016-01-01 2016-12-31 0001530766 srt:MaximumMember 2016-01-01 2016-12-31 0001530766 bios:WarrantsAt0.001Member 2017-12-31 0001530766 bios:WarrantsAt0.001Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt1.50Member 2017-12-31 0001530766 bios:WarrantsAt1.50Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt1.84Member 2017-12-31 0001530766 bios:WarrantsAt1.84Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt1.95Member 2017-12-31 0001530766 bios:WarrantsAt1.95Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt2_00Member 2017-12-31 0001530766 bios:WarrantsAt2_00Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt2.02Member 2017-12-31 0001530766 bios:WarrantsAt2.02Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt2.50Member 2017-12-31 0001530766 bios:WarrantsAt2.50Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt2.75Member 2017-12-31 0001530766 bios:WarrantsAt2.75Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt3.67Member 2017-12-31 0001530766 bios:WarrantsAt3.67Member 2017-01-01 2017-12-31 0001530766 bios:WarrantsAt3.75Member 2017-12-31 0001530766 bios:WarrantsAt3.75Member 2017-01-01 2017-12-31 0001530766 us-gaap:WarrantMember 2015-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-12-31 0001530766 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001530766 us-gaap:WarrantMember 2016-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2016-12-31 0001530766 us-gaap:WarrantMember us-gaap:SeriesDPreferredStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesDPreferredStockMember 2017-01-01 2017-12-31 0001530766 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001530766 us-gaap:WarrantMember 2017-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-12-31 0001530766 bios:ParkingSpaceLeasesMember 2017-01-01 2017-12-31 0001530766 srt:MinimumMember 2017-03-15 2017-03-15 0001530766 srt:MaximumMember 2017-03-15 2017-03-15 0001530766 2017-07-14 2017-07-14 0001530766 us-gaap:ChiefExecutiveOfficerMember 2014-07-15 2014-07-15 0001530766 srt:MinimumMember bios:AnnualSalaryMember bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember 2014-07-15 0001530766 2014-07-15 0001530766 bios:SigningBonusMember bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember 2014-07-15 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-07-15 0001530766 bios:OptionsVestingInElevenEqualInstallmentsMember bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-07-15 0001530766 bios:FinalInstallmentOfVestedOptionsMember bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember bios:SharebasedCompensationAwardTrancheFourMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember bios:SharebasedCompensationAwardTrancheFiveMember 2014-07-15 0001530766 bios:EmployeeAgreementMember us-gaap:ChiefExecutiveOfficerMember bios:SharebasedCompensationAwardTrancheFiveMember 2014-07-15 2014-07-15 0001530766 us-gaap:SubsequentEventMember 2018-01-01 2018-01-31 0001530766 us-gaap:SeriesEPreferredStockMember us-gaap:SubsequentEventMember 2018-02-16 2018-02-16 0001530766 us-gaap:SeriesEPreferredStockMember us-gaap:SubsequentEventMember 2018-02-16 0001530766 bios:ConsentAgreementSeriesDHoldersMember us-gaap:SubsequentEventMember 2018-02-16 2018-02-16 0001530766 bios:ConsentAgreementSeriesDHoldersMember us-gaap:SubsequentEventMember 2018-02-16 0001530766 bios:UnitPurchaseAgreementsMember us-gaap:SubsequentEventMember 2018-01-05 2018-01-05 0001530766 bios:UnitPurchaseAgreementsMember us-gaap:SubsequentEventMember 2018-01-05 0001530766 bios:UnitPurchaseAgreementsMember 2017-12-31 0001530766 us-gaap:SubsequentEventMember 2018-01-01 2018-02-27 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:SubsequentEventMember 2018-01-01 2018-02-27 0001530766 us-gaap:SubsequentEventMember 2018-02-14 2018-02-14 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2018-02-14 2018-02-14 0001530766 us-gaap:SubsequentEventMember 2018-02-01 2018-02-01 0001530766 us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-02-01 2018-02-01 0001530766 us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-02-01 2018-02-01 0001530766 us-gaap:SubsequentEventMember 2018-02-15 2018-02-15 0001530766 bios:CommonStockAndWarrantMember 2018-01-01 2018-03-31 0001530766 bios:SeriesCAndDPreferredStockMember us-gaap:SubsequentEventMember 2018-04-01 2018-05-03 0001530766 2018-01-01 2018-01-01 0001530766 us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001530766 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001530766 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001530766 srt:MinimumMember 2018-01-01 2018-03-31 0001530766 srt:MaximumMember 2018-01-01 2018-03-31 0001530766 us-gaap:ComputerEquipmentMember 2018-03-31 0001530766 us-gaap:FurnitureAndFixturesMember 2018-03-31 0001530766 bios:FullRatchetAntiDilutionProtectionProvisionMember us-gaap:SeriesCPreferredStockMember 2013-01-09 0001530766 2018-02-01 2018-02-28 0001530766 us-gaap:SeriesCPreferredStockMember 2018-02-01 2018-02-28 0001530766 2018-03-01 2018-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2018-03-01 2018-03-31 0001530766 srt:MinimumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-01-01 2015-03-31 0001530766 srt:MaximumMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-01-01 2015-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-01-01 2015-03-31 0001530766 us-gaap:SeriesDPreferredStockMember 2018-01-01 2018-01-31 0001530766 us-gaap:SeriesDPreferredStockMember 2018-02-01 2018-02-28 0001530766 us-gaap:SeriesDPreferredStockMember 2018-03-01 2018-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2018-02-16 2018-02-16 0001530766 us-gaap:SeriesEPreferredStockMember 2018-02-16 0001530766 bios:SaleOfWarrantsInConnectionWithSeriesEPreferredStockMember 2018-02-16 2018-02-16 0001530766 bios:SaleOfWarrantsInConnectionWithSeriesEPreferredStockMember 2018-02-16 0001530766 bios:ConsentAgreementSeriesDHoldersMember 2018-02-16 2018-02-16 0001530766 bios:ConsentAgreementSeriesDHoldersMember 2018-02-16 0001530766 bios:ServicesProvidedMember 2018-01-01 2018-03-31 0001530766 bios:ServicesProvidedMember 2018-03-31 0001530766 bios:SecuritiesPurchaseAgreementsMember 2018-01-01 2018-03-31 0001530766 bios:CommonStockSubscriptionMember 2018-01-01 2018-03-31 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2012-10-19 2012-10-19 0001530766 srt:MaximumMember us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2012-10-19 2012-10-19 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2018-03-31 0001530766 bios:OptionsAt142Member 2018-02-15 2018-02-15 0001530766 bios:OptionsAt142Member 2018-02-15 0001530766 2018-02-15 2018-02-15 0001530766 us-gaap:EmployeeStockOptionMember bios:EquityIncentive2012PlanMember 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt1.50Member 2018-01-05 2018-01-05 0001530766 bios:WarrantsAt1.50Member 2018-01-05 0001530766 bios:ConsentAgreementSeriesDHoldersMember 2018-02-14 2018-02-14 0001530766 bios:ConsentAgreementSeriesDHoldersMember 2018-02-14 0001530766 bios:WarrantsAt175Member us-gaap:SeriesEPreferredStockMember 2018-02-16 2018-02-16 0001530766 bios:WarrantsAt175Member us-gaap:SeriesEPreferredStockMember 2018-02-16 0001530766 bios:OptionsAt1.01To2.00Member 2018-01-01 2018-03-31 0001530766 bios:OptionsAt1.01To2.00Member 2018-03-31 0001530766 bios:OptionsAt2.01To3.00Member 2018-01-01 2018-03-31 0001530766 bios:OptionsAt2.01To3.00Member 2018-03-31 0001530766 bios:OptionsAt3.01To4.00Member 2018-01-01 2018-03-31 0001530766 bios:OptionsAt3.01To4.00Member 2018-03-31 0001530766 bios:WarrantsAt0.001Member 2018-03-31 0001530766 bios:WarrantsAt0.001Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt1.50Member 2018-03-31 0001530766 bios:WarrantsAt1.50Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt175Member 2018-03-31 0001530766 bios:WarrantsAt175Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt1.84Member 2018-03-31 0001530766 bios:WarrantsAt1.84Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt1.95Member 2018-03-31 0001530766 bios:WarrantsAt1.95Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt2_00Member 2018-03-31 0001530766 bios:WarrantsAt2_00Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt2.02Member 2018-03-31 0001530766 bios:WarrantsAt2.02Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt2.50Member 2018-03-31 0001530766 bios:WarrantsAt2.50Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt2.75Member 2018-03-31 0001530766 bios:WarrantsAt2.75Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt3.67Member 2018-03-31 0001530766 bios:WarrantsAt3.67Member 2018-01-01 2018-03-31 0001530766 bios:WarrantsAt3.75Member 2018-03-31 0001530766 bios:WarrantsAt3.75Member 2018-01-01 2018-03-31 0001530766 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001530766 us-gaap:WarrantMember 2018-03-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-03-31 0001530766 us-gaap:SeriesDPreferredStockMember us-gaap:SubsequentEventMember 2018-04-01 2018-04-30 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2018-04-01 2018-04-30 0001530766 bios:April2018PrivatePlacementMember us-gaap:SubsequentEventMember 2018-04-30 2018-04-30 0001530766 bios:April2018PrivatePlacementMember us-gaap:SubsequentEventMember 2018-04-30 0001530766 bios:April2018PrivatePlacementMember 2018-03-31 0001530766 bios:April2018PrivatePlacementMember us-gaap:SeriesEPreferredStockMember us-gaap:SubsequentEventMember 2018-04-01 2018-04-30 0001530766 bios:April2018PrivatePlacementMember us-gaap:SeriesEPreferredStockMember us-gaap:SubsequentEventMember 2018-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 1547579 1055895 1035100 116938 134263 119111 1664517 1190158 1154211 18716 24188 19457 17084 27612 22477 1700317 1241958 1196145 473098 373103 338811 447901 359891 482636 2358240 1937234 0 685922 288934 0 3965161 2959162 821447 985000 1070000 965000 1 0 1 1 29321 22588 30498 53215635 41019251 55381386 29985 0 115470 -56524786 -43829043 -56117658 -3249844 -2787204 -590302 1700317 1241958 1196145 27375 15755 7236 985 1070 965 985 1070 965 985000 1070000 965000 0.001 0.001 0.001 1000000 1000000 1000000 200 200 200 600 600 600 4200 4200 4200 1400 1400 1400 1000 1000 1000 0.001 0.001 0.001 1334 0 687 1334 0 687 2001000 0 1030500 0.001 1000 1000 1500000 0.001 0.001 0.001 200000000 200000000 200000000 29321204 22588184 30497707 29321204 22588184 30497707 4756468 2654501 862420 1338604 8138117 8499304 1771796 1557341 11698 10475 2903 3069 12906283 11164280 2637119 2899014 -12906283 -11164280 -2637119 -2899014 210465 -422908 0 -373611 75 1 85 0 -12695743 -11587187 -2637034 -3272625 0 0 0 0 -12695743 -11587187 -2637034 -3272625 119877 110023 305046 23745 -12815620 -11697210 -2942080 -3296370 -0.50 -0.60 -0.09 -0.14 25550686 19490767 29944445 23051872 16825703 16826 29314399 32241856 -2910631 3798417 3798 5222570 5226368 1335000 1335 2469715 2471050 267334 267 400733 401000 58185 58 90365 90423 103096 103096 303545 304 3528396 3528700 110023 -11587187 22588184 22588 41019251 -43829043 4131536 4131 6007098 6011229 1334 1 1929959 1929960 2271788 2272 3384345 3386617 56669 57 84943 85000 24021 24 31844 31868 10744 -11 11 29985 29985 -1049216 1049216 20757 20757 543927 543927 259750 260 1362593 1362853 119877 -12695743 1334 1 0 29321204 29321 53215635 29985 -56524786 0 0 0 0 0 3044162 3044162 0 0 0 0 100000 100 141900 0 0 142000 0 0 0 0 200000 200 299785 29985 0 270000 0 0 0 13334 13 19987 0 0 20000 0 0 0 0 6595 7 8269 0 0 8276 -647 647000 647 -647 0 0 209574 210 261825 0 0 262035 0 0 1000 1 0 0 1492968 0 0 1492969 0 0 0 0 115470 0 115470 0 0 0 246710 0 0 246710 0 0 0 305046 0 0 0 0 0 0 0 -2637034 687 1 1000 1 30497707 30498 55381386 115470 -56117658 1.50 1.55 1.50 1.37 1.50 1.25 1.25 3210 0 0 0 4749470 5999750 388710 560746 543927 0 0 543927 -17325 102955 2173 27514 -10528 0 5393 0 102338 149661 -134714 209466 2342 104 -427 521 -7470054 -5107452 -2387274 -1609841 9436 16255 3644 1620 -9436 -16255 -3644 -1620 6011229 5226368 270000 1799692 1929960 0 1929960 0 0 0 0 29985 0 115470 0 7971174 5226368 1878439 1799692 491684 102661 -512479 188231 1055895 953234 1547579 1035100 1244126 0 0 0 0 0 0 0 0 116868 491423 28276 0 0 262035 0 0 0 3044162 0 0 0 0 0 0 305046 23745 20757 103096 0 0 BIOSIG TECHNOLOGIES, INC. S-1 --12-31 34619071 false 0001530766 Yes No Smaller Reporting Company No 2018 Q1 2018-03-31 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 1&#xa0;&#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Business and organization</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">BioSig Technologies Inc. (the &#x201c;Company&#x201d;) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Revenue Recognition</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (&#x201c;ASC 605-10&#x201d;) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#x2019;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Use of estimates</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company&#x2019;s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Concentrations of Credit Risk</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.&#xa0;&#xa0;At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Prepaid Expenses</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Property and Equipment</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Long-Lived Assets</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company follows Accounting Standards Codification 360-10-15-3, &#x201c;Impairment or Disposal of Long-lived Assets,&#x201d; which established a &#x201c;primary asset&#x201d; approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.&#xa0;&#xa0;Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#xa0;&#xa0;The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.&#xa0;&#xa0;Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Fair Value of Financial Instruments</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#x201c;ASC 820-10&#x201d;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;), which permits entities to choose to measure many financial instruments and certain other items at fair value.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Derivative Instrument Liability</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Research and development costs</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468&#xa0;and $2,654,501 for the year ended December 31, 2017 and 2016, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Income Taxes</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Deferred taxes are classified as non-current.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Net Income (loss) Per Common Share</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.&#xa0;&#xa0;Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or &#x201c;if converted&#x201d; methods as applicable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:</div><br/><table id="z013ab63acb2b446a93ae65af1d9a112f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">656,667</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">713,333</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Series D convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1,334,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">9,128,189</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">23,290,072</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">18,086,712</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Stock based compensation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Registration Rights</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (&#x201c;ASC 825-20&#x201d;). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists,&#xa0;to record or adjust the liability to current period operations.&#xa0;&#xa0;</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors&#xa0;pursuant to which the Company sold to the investors units, which each unit&#xa0;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#xa0;&#xa0;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#xa0;&#xa0;The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on March 31, 2017. On June 8, 2017, the Company filed the required registration statement and on September 19, 2017 was declared effective. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On November 3, 2017, in connection with the Company&#x2019;s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors&#xa0;pursuant to which the Company sold to the investors units, which each unit&#xa0;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#xa0;&#xa0;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#xa0;&#xa0;The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Recent Accounting Pronouncements</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Subsequent Events</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.&#xa0; Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.</div><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Business and organization</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">BioSig Technologies Inc. (the &#x201c;Company&#x201d;) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Revenue Recognition</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (&#x201c;ASC 605-10&#x201d;) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#x2019;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Use of estimates</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company&#x2019;s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Concentrations of Credit Risk</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.&#xa0;&#xa0;At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively.</div></div> 1297579 805895 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Prepaid Expenses</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments.</div></div> 100000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Property and Equipment</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.</div></div> 3 5 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Long-Lived Assets</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company follows Accounting Standards Codification 360-10-15-3, &#x201c;Impairment or Disposal of Long-lived Assets,&#x201d; which established a &#x201c;primary asset&#x201d; approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.&#xa0;&#xa0;Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#xa0;&#xa0;The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.&#xa0;&#xa0;Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Fair Value of Financial Instruments</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#x201c;ASC 820-10&#x201d;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;), which permits entities to choose to measure many financial instruments and certain other items at fair value.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Derivative Instrument Liability</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Research and development costs</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468&#xa0;and $2,654,501 for the year ended December 31, 2017 and 2016, respectively.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Income Taxes</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Deferred taxes are classified as non-current.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Net Income (loss) Per Common Share</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.&#xa0;&#xa0;Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or &#x201c;if converted&#x201d; methods as applicable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:</div><br/><table id="z013ab63acb2b446a93ae65af1d9a112f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">656,667</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">713,333</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Series D convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1,334,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">9,128,189</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">23,290,072</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">18,086,712</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Stock based compensation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.</div></div> 8510319 7347486 8245190 7028639 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Registration Rights</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (&#x201c;ASC 825-20&#x201d;). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists,&#xa0;to record or adjust the liability to current period operations.&#xa0;&#xa0;</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors&#xa0;pursuant to which the Company sold to the investors units, which each unit&#xa0;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#xa0;&#xa0;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#xa0;&#xa0;The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on March 31, 2017. On June 8, 2017, the Company filed the required registration statement and on September 19, 2017 was declared effective. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On November 3, 2017, in connection with the Company&#x2019;s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors&#xa0;pursuant to which the Company sold to the investors units, which each unit&#xa0;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#xa0;&#xa0;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#xa0;&#xa0;The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Recent Accounting Pronouncements</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Subsequent Events</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.&#xa0; Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:<br /><br /><table id="z013ab63acb2b446a93ae65af1d9a112f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">656,667</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">713,333</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Series D convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1,334,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">9,128,189</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">23,290,072</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">18,086,712</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table></div> 656667 713333 1334000 0 8510319 8245190 12789086 9128189 23290072 18086712 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 2 &#x2013; GOING CONCERN AND MANAGEMENT&#x2019;S LIQUIDITY PLANS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017, the Company had cash of $1,547,579&#xa0;and working capital deficit (current liabilities in excess of current assets) of $2,300,644 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised $6,041,214 through the sale of common stock and warrants (See Note 8) and $1,929,960 through the sale of Series D preferred stock and warrants (Note 6) in 2017. Subsequent to December 31, 2017, the Company raised $1,500,000 from the sale of Series E preferred stock and warrants and $270,000 from the sale of common stock (Note 13). As of December 31, 2017, excluding the derivative and warrant liabilities, the Company&#x2019;s working capital would have been $743,518.&#xa0;During the year ended December 31, 2017, the Company used net cash in operating activities of $7,470,054.&#xa0; These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company&#x2019;s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders&#x2019; deficiencies at December 31, 2017 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company&#x2019;s research and development will be successfully completed or that any product will be approved or commercially viable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.</div><br/></div> -2300644 6041214 1929960 1500000 270000 -743518 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 3 &#x2013; RELATED PARTY TRANSACTIONS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company&#x2019;s President and shareholders have advanced funds to the Company for working capital purposes since the Company&#x2019;s inception in February 2009.&#xa0;&#xa0;No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. As of December 31, 2017 and 2016, all advances had been repaid.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Accrued expenses related primarily to travel reimbursements due related parties as of December 31, 2017 and 2016 was $27,375 and $15,755, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On May 4, 2016, Mr. Londoner and Mr. Chaussy were granted 250,000 and 200,000 shares of common stock at a cost basis of $1.93 per share for their 2016 performance, respectively. The granted shares vested immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 8, 2016, Mr. Londoner and Mr. O&#x2019;Donnell each were granted 41,500 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 8, 2016 Mr. Cash and Mr. Tanaka each were granted 20,875 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 22, 2016 Mr. Zeldis and Mr. Weild each were granted options to purchase 50,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 22, 2016 Mr. Gallagher and Mr. Foley each were granted options to purchase 25,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On April 1, 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from Mr. Londoner.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 16, 2017 Mr. Cash was granted 100,000 shares of common stock at a cost basis of $1.37 per share in connection with his severance settlement. The granted shares vested immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 8, 2017, Mr. Londoner, Mr. Chaussy and Mr. O&#x2019;Donnell were granted 450,000, 250,000 and 200,000 shares of common stock at a cost basis of $1.52 per share for their 2017 performance, respectively. The granted shares vested immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 1, 2017, in connection with Mr. Filler joining the Company&#x2019;s Board of Directors,&#xa0; the Company entered into a Master Services Agreement (the &#x201c;Agreement&#x201d;) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (&#x201c;Sherpa&#x201d;) and an initial statement of work (the &#x201c;SOW&#x201d;), pursuant to which Sherpa will develop, execute and expand the Company&#x2019;s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing.&#xa0;In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company&#x2019;s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned.&#xa0; Mr. Filler is the general counsel and partner of Sherpa.&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 9, 2017, Mr. Londoner, Mr. O&#x2019;Donnell and Mr. Weild, as members of the board of directors, were granted each 50,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board and committee service. The granted shares vested immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 9, 2017, Mr. Tanaka, Mr. Filler and Mr. Foley, as members of the board of directors, were granted each 30,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board service. The granted shares vested immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 22, 2017 Mr. Gallagher and Mr. Fischer were granted options to purchase 39,926 and 65,972 shares of common stock at a cost basis of $1.37 per share for their 2017 board service. The granted options vested as of December 22, 2017 and are exercisable for a ten year term.</div><br/></div> 27375 15755 250000 200000 1.93 1.93 41500 41500 1.36 1.36 20875 20875 1.36 1.36 50000 50000 1.36 P10Y 25000 25000 1.36 1.36 P10Y P10Y 10744 100000 1.37 450000 250000 200000 1.52 Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company&#x2019;s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned 50000 50000 1.49 30000 30000 30000 39926 65972 1.37 P10Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">NOTE&#xa0;4 &#x2013; PROPERTY AND EQUIPMENT</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Property and equipment as of December 31, 2017 and 2016 is summarized as follows:</div><br/><table id="zd43b192a819d494093b71701d462c998" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Computer equipment</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">87,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">84,704</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Furniture and fixtures</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,975</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10,117</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Subtotal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,034</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">94,821</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Less accumulated depreciation</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(81,318</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(70,633</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Property and equipment, net</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,716</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">24,188</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company distributed equipment with a book value of $3,210 to a prior employee in connection with a settlement agreement.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Depreciation expense was $11,698 and $10,475 for the years ended December 31, 2017 and 2016, respectively.</div><br/></div> 3210 P3Y P5Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Property and equipment as of December 31, 2017 and 2016 is summarized as follows:<br /><br /><table id="zd43b192a819d494093b71701d462c998" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Computer equipment</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">87,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">84,704</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Furniture and fixtures</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,975</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10,117</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Subtotal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,034</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">94,821</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Less accumulated depreciation</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(81,318</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(70,633</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Property and equipment, net</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,716</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">24,188</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 87059 84704 12975 10117 100034 94821 81318 70633 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">NOTE&#xa0;5&#xa0;&#x2013; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following:</div><br/><table id="z3d314bd9e79e47fb8eff2925d2fe6315" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued accounting and legal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">93,595</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">120,464</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued reimbursements</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,600</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">43,116</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued consulting</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">109,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,192</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued research and development expenses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">246,030</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">181,884</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued office and other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,912</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10,202</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Deferred rent</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">569</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,912</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued settlement related to arbitration</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">473,098</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">373,103</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following:<br /><br /><table id="z3d314bd9e79e47fb8eff2925d2fe6315" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued accounting and legal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">93,595</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">120,464</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued reimbursements</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,600</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">43,116</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued consulting</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">109,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,192</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued research and development expenses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">246,030</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">181,884</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued office and other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,912</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10,202</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Deferred rent</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">569</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,912</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued settlement related to arbitration</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">473,098</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">373,103</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 93595 120464 2600 43116 109059 1192 246030 181884 7912 10202 569 2912 13333 13333 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE&#xa0;6&#xa0;&#x2013; SERIES C 9% CONVERTIBLE PREFERRED STOCK</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Series C 9% Convertible Preferred Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On January 9,&#xa0;2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the &#x201c;Series C Preferred Stock&#x201d;).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.&#xa0;&#xa0;The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.&#xa0;&#xa0;The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.&#xa0;&#xa0;The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:</div><br/><table id="z03bfa63f07cc4b78874136f80e6db64f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#xa0;&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">incur additional indebtedness;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">permit liens on assets;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">pay cash dividends to our stockholders; and</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">engage in transactions with affiliates.</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share.&#xa0;The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In the event that:</div><br/><table id="za6ff285a82e14cf6a036432178527498" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;&#xa0;(i)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(ii)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(iii)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;(iv)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(v)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we are party to a change of control transaction,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(vi)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we file for bankruptcy or a similar arrangement or are adjudicated insolvent,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(vii)&#xa0;&#xa0;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.&#xa0;&#xa0;&#xa0;The Company determined that certain of the defined triggering events were outside the Company&#x2019;s control and therefore classified the Series C Preferred Stock outside of equity.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company&#x2019;s common stock at $2.61 per share expiring five years from the initial exercise date.&#xa0;&#xa0;The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a &#x201c;cashless exercise&#x201d;.&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the&#xa0;intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.&#xa0;&#xa0;The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671),&#xa0;the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the &#x201c;readily convertible to cash&#x201d; as described in Accounting Standards Codification 815 and therefore bifurcation is not required.&#xa0;&#xa0;There was no established market for the Company&#x2019;s common stock.&#xa0;&#xa0;As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company&#x2019;s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Issuances:</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company&#x2019;s Series C Preferred Stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company&#x2019;s Series C Preferred Stock for net proceeds of $1,814,910.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000.&#xa0;&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">2017 and 2016 conversions:&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In June 2017, the Company issued an aggregate of 60,846 shares of its common stock in exchange for 65 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">For the year ended December 31, 2017, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $20,757 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.74% to 1.06%, a dividend yield of 0%, and volatility of 151% to 166%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Series C Preferred Stock issued and outstanding totaled 985 and 1,070 as of December 31, 2017 and 2016, respectively.&#xa0;&#xa0;As of December 31, 2017 and 2016, the Company has accrued $419,283 and $359,891 dividends payable on the Series C Preferred Stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Registration Rights Agreement</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the Company&#x2019;s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.&#xa0;&#xa0;At December 31, 2017 and 2016, the Company estimated the liability at $-0-.</div><br/></div> 4200 0.09 1000 1000 payable quarterly The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.&#xa0;&#xa0;The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:&#xa0;&#x25cf;incur additional indebtedness;&#x25cf;permit liens on assets;&#x25cf;repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;&#x25cf;pay cash dividends to our stockholders; and&#x25cf;engage in transactions with affiliates Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share.&#xa0;The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:&#xa0;&#xa0;(i)&#xa0;&#xa0;we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii)&#xa0;&#xa0;we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii)&#xa0;&#xa0;we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,&#xa0;(iv)&#xa0;&#xa0;we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v)&#xa0;&#xa0;we are party to a change of control transaction,(vi)&#xa0;&#xa0;we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii)&#xa0;&#xa0;we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18% 1.50 1330627 2.61 P5Y after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a &#x201c;cashless exercise&#x201d;. 1.50 2315301 1303671 1064739 1303671 1064739 412590 2781000 1242590 4097444 600 2181 1814910 450 450000 54859 75 197713 236 54759 70 18188 20 60846 65 19844 20 P2Y 0.0074 0.0106 0.00 1.51 1.66 419283 359891 In connection with the Company&#x2019;s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE&#xa0;7&#xa0;&#x2013; WARRANT AND DERIVATIVE LIABILITIES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Series C 9% Convertible Preferred Stock and related warrants</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the &#x201c;readily convertible to cash&#x201d; as described in Accounting Standards Codification 815 and therefore bifurcation was not required.&#xa0;&#xa0;There was no established market for the Company&#x2019;s common stock.&#xa0;&#xa0;&#xa0;As of March 31, 2015, the Company determined a market had been established for the Company&#x2019;s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company valued the reset provisions of the Series C Preferred Stock&#xa0;and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Series D Convertible Preferred Stock and related warrants</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company valued the reset provisions of the Series D Preferred Stock&#xa0;and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The Company recorded a gain from change in fair value of derivatives of $210,465 for year ended December 31, 2017. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%</div><br/></div> 1242590 4097444 0.0056 0.0089 0.00 1.41 397162 652054 0.0174 0.00 1.30 P1Y156D P3Y131D 0.0139 0.0189 0.00 1.31 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 8&#xa0;&#x2013; STOCKHOLDER EQUITY</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Preferred stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company is authorized to issue 1,000,000 shares of&#xa0;$0.001 par value preferred stock. As of December 31, 2017 and 2016,&#xa0;the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock and (in 2017) 1,400 shares of Series D Preferred Stock. As of December 31, 2017 and 2016, there were no outstanding shares of Series A and Series B preferred stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Series C Preferred Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In February 2016, the Company issued 54,859&#xa0;shares of its common stock in exchange for 75 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In June 2017, the Company issued 60,846&#xa0;shares of its common stock in exchange for 65 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Cumulatively from January 1, 2017 to December 31, 2017, the Company exchanged 85 shares of the Company&#x2019;s Series C Preferred Stock and dividends with a recorded value of $116,868 for 80,690 shares of common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017 and 2016, the Company has 985 and 1,070 Series C Preferred Stock issued and outstanding.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Series D Preferred Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 3,&#xa0;2017, the Board of Directors authorized the issuance of up to 1,400 shares of Series D Convertible Preferred Stock (the &#x201c;Series D Preferred Stock&#x201d;) and accordingly<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, the Company filed the Certificate of Designations for the Series D Preferred Stock with the Secretary of State of the State of Delaware.&#xa0; Pursuant to such Certificate of Designations, in the event of the Company&#x2019;s liquidation or winding up of its affairs, the holders of Preferred Shares will be entitled to a liquidation preference of the stated value per Preferred Share of $1,500 (the &#x201c;Stated Value&#x201d;) plus any accrued but unpaid dividends or any other fees due the holder.</font></div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">A holder of Preferred Shares is entitled at any time to convert any whole or partial number of shares of Preferred Shares into shares of Common Stock determined by dividing the Stated Value of the Preferred Shares being converted by the conversion price of $1.50 per share (the &#x201c;Conversion Price&#x201d;).&#xa0; The Conversion Price is subject to &#x201c;full ratchet&#x201d; anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the Conversion Price as well as other customary anti-dilution protection.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">A holder of the Preferred Shares shall be entitled to receive cumulative dividends at the rate per Preferred Share (as a percentage of the Stated Value per Preferred Share) of 9% per annum, with respect to the Series D Preferred Stock on each date that such Holder converts Preferred Shares into Common Stock (with respect only to Preferred Shares being converted).&#xa0; The Company may pay such dividends, at its option, in cash, Common Stock or a combination thereof.&#xa0; Payment of dividends in shares of Common Stock is subject to the satisfaction of certain equity conditions set forth in the Certificate of Designations.&#xa0; Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company&#x2019;s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 3, 2017,&#xa0; the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional accredited investors (the &#x201c;Investors&#x201d;), pursuant to which the Company sold an aggregate of 1,334 shares (the &#x201c;Preferred Shares&#x201d;) of its Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of the Company&#x2019;s common stock, par value $0.001 per share at an exercise price of $1.75 per share (the &#x201c;Class A Warrants&#x201d;), in exchange for aggregate net cash proceeds of $1,929,960, net of expenses of $70,040. Contemporaneously with the entry into the Purchase Agreement, the Company and the Purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of the Common Stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price (the &#x201c;Class B Warrants&#x201d;). Class A Warrants are exercisable immediately and expire on May 3, 2021, and have an exercise price of $1.75 per share.&#xa0; The Class B Warrants are exercisable immediately and expire on November 3, 2020, and have an exercise price of $1.50.&#xa0; The Class A Warrants and Class B Warrants otherwise have similar terms, including, a &#x201c;full ratchet&#x201d; anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In connection with the Company&#x2019;s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017, the Company has 1,334 Series D Preferred Stock issued and outstanding and has accrued $28,618 dividends payable on the Series D Preferred Stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Common stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 18, 2016 at the Special Meeting, the stockholders approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 200,000,000 shares (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Certificate Amendment</font>&#x201d;). The Certificate Amendment had been previously approved by the Company&#x2019;s Board on September 7, 2016, subject to stockholder approval. Immediately following the Special Meeting on November 18, 2016, the Company filed the Certificate Amendment with the Secretary of State of the State of Delaware.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017 and 2016, the Company had 29,321,204 and 22,588,184 shares issued and outstanding, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company issued an aggregate of 545,000 shares of common stock&#xa0;for services rendered totaling $1,051,850 ($1.93 average per share).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 3,798,417 shares of common stock and 2,040,504 warrants for aggregate proceeds of $5,226,368, net of $490,543 in expenses.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company issued 220,000 shares of common stock as vested previously issued restricted stock units</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.&#xa0; The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:&#xa0; dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company&#x2019;s common stock: $1.84.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company issued an aggregate of 1,825,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $2,705,250 ($1.48 average per share).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company issued an aggregate of 446,788 shares of its common stock for services totaling $681,367 ($1.53 per share).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company issued an aggregate of 135,000 and 124,750 shares of its common stock for vested restricted stock units and stock based compensation previously accrued in 2016.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 4,131,536 shares of common stock and 2,246,300 warrants for aggregate proceeds of $6,011,229, net of $186,075 in expenses.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In April 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from an officer and member of the Company&#x2019;s Board of Directors.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the securities purchase agreements described above, the Company entered into registration rights agreements with the purchasers in such private placements pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued such investors. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the termination date of such private placement and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and within 180 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 180 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that the Company will not be required to make any payments any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that the Company will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that the Company is unable to register due to limits imposed by the Securities and Exchange Commission&#x2019;s interpretation of Rule 415 under the Securities Act of 1933, as amended.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreements shall be 3% to 6% of the aggregate purchase price paid by the purchasers and (iii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Pursuant to the registration rights agreements, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company filed registration statements, which was declared effective to satisfy the requirements under the registration rights agreements with the purchasers of its common stock and warrants prior to April 6, 2017. The final closing under the April 6, 2017 Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.</div><br/></div> 0 0 85 116868 80690 1400 1500 1.50 0.09 Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company&#x2019;s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion 1334 0.001 667000 1.75 1929960 70040 780506 1.50 1.50 111167 28618 50000000 200000000 790000 1419200 1.80 545000 1051850 1.93 3798417 2040504 5226368 490543 220000 83545 100000 0.00 1.2282 0.0108 P5Y 1.84 1825000 2705250 1.48 446788 681367 1.53 135000 124750 4131536 2246300 6011229 186075 10744 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 9&#xa0;&#x2013; OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Options</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On October 19, 2012, the Company&#x2019;s Board of Directors approved the 2012 Equity Incentive Plan (&#x201c;the &#x201c;Plan) and terminated the Long-Term Incentive Plan (the &#x201c;2011 Plan&#x201d;). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended)&#xa0;shares of the Company&#x2019;s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers,&#xa0;directors and key consultants.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2016, the Company granted an aggregate of 723,545 stock grants to officers, employees and key consultants under the plan. See Note 8.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company granted an aggregate of 1,680,898 options to officers,&#xa0;directors and key consultants.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the year ended December 31, 2017, the Company granted an aggregate of 2,009,750 stock grants to officers, employees and key consultants under the plan. See Note 8.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The following table presents information related to stock options at December 31, 2017:</div><br/><table id="z112a025c1ef549308c0a4822215937ea" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Remaining Life</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">In Years</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr style="HEIGHT: 13px"> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.01-2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3,825,540</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.8</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,662,707</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.01-3.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.01-4.00</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.3</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,347,486</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">A summary of the stock option&#xa0;activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows:</div><br/><table id="ze697ed993c954aa481aebeac21081793" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,780,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.30</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.4</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">905,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.71</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(440,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.24</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.24</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,680,898</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,415,769</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.17</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.11</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">27,045</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercisable at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,347,486</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.19</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.8</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">25,394</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company&#x2019;s stock price of $1.44 as of December 31, 2017, which would have been received by the option holders had those option holders exercised their options as of that date.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company&#x2019;s own historical stock prices.&#xa0;Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">For employees, the Company accounts for the expected life of options in accordance with the &#x201c;simplified&#x201d; method, which is used for &#x201c;plain-vanilla&#x201d; options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.&#xa0; The fair value of stock-based payment awards during the years ended December 31, 2017 and 2016 was estimated using the Black-Scholes pricing model.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On May 18, 2016, the Company granted an aggregate of&#xa0;685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.&#xa0; The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:&#xa0; dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company&#x2019;s common stock: $1.84.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 22, 2016, the Company granted an aggregate of 150,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.36 per share for a term of ten years with vesting immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 29, 2016, the Company granted 5,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.35 per share for a term of ten years with vesting immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016:</div><br/><table id="z0ecdfce9282046cbbd42fa5092d7802f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.08% - 2.04</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">109.3% to 122.82</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">5 &#x2013; 10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.47</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 8, 2017, the Company granted an aggregate of 130,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.55 per share for a term of ten years with vesting immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 8, 2017, the Company granted 200,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 8, 2017, the Company granted 475,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 237,500 vesting immediately and 237,500 at one year anniversary.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 24, 2017, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years, vesting immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 24, 2017, the Company granted 420,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years with 120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 24, 2017, the Company granted 300,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.50 per share for a term of ten years with 150,000 vesting immediately and 150,000 performance contingent.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 22, 2017, the Company granted 105,898 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.37 per share for a term of ten years, vesting immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2017:</div><br/><table id="zc59a64c476fb450b8205e8a109b6b3dd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">2.01% - 2.34</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">95.72% to 107.17</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">5 &#x2013; 10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.17</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The fair value of all options vesting during the year ended December 31, 2017 and 2016 of $1,269,591 and $2,801,948, respectively, was charged to current period operations.&#xa0;&#xa0;Unrecognized compensation expense of $979,812 and $310,817 at December 31, 2017 and 2016, respectively, will be expensed in future periods.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Restricted Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The following table summarizes the restricted stock activity for the two years ended December 31, 2017:</div><br/><table id="z81fa81ea80a14d9fbdc0d51830fe553a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Restricted shares issued as of January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">175,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Granted</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(220,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Total restricted shares issued as of December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">135,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Granted</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(135,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested restricted shares as of December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Unvested restricted shares as of December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On September 7, 2016, the Company granted 180,000 restricted stock units (&#x201c;RSU&#x201d;) to a consultant vesting monthly over one year beginning October 7, 2016.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Stock based compensation expense related to restricted stock grants was $93,261 and $213,174 for the years ended December 31, 2017 and 2016,&#xa0;respectively.&#xa0;As of December 31, 2017, the stock-based compensation relating to restricted stock of $-0- remains unamortized.&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Warrants</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017:&#xa0;</div><br/><table id="zd27e3f44c8384edaa4ad447f0bdb6877" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Expiration</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 48%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Date</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.001</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">383,320</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,667,440</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">February 2018 to May 2021</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.84</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">35,076</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.95</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,689,026</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">October 2018 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">30,755</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">228,720</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">August 2019 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.67</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">214,193</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">December 2018 to January 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.75</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,340,556</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">April 2019 to March 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On February 9, 2016, the Company issued 25,000 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 6,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 12,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 18,040 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 17,996 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company&#x2019;s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On October 28, 2016, the Company issued an aggregate of 173,284 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on October 28, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 23, 2016, the Company issued an aggregate of 50,002 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on November 23, 2019, in connection with the sale of the Company&#x2019;s common stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 16, 2016, the Company issued an aggregate of 456,668 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on December 16, 2019, in connection with the sale of the Company&#x2019;s common stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 22, 2016, the Company issued an aggregate of 115,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on December 22, 2019, in connection with the sale of the Company&#x2019;s common stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 9, 2017, the Company exchanged 38,572 warrants with an exercise price of $2.10 with 45,001 warrants with an exercise price of $1.50, all other terms and conditions the same, to 2016 investors to adjust offered terms in connection with the Company&#x2019;s equity raise with other investors.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 10, 2017, the Company issued an aggregate of 300,628 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on February 10, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On March 10, 2017, the Company issued an aggregate of 197,159 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on March 10, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On March 15, 2017, the Company issued 630,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on March 15, 2020, to Mayo Foundation in connection with a know-how licensing agreement (See Note 10). The fair value of the of the issued warrants of $543,927, determined using the Black-Scholes option model with an estimated volatility of 105.22%, risk free rate of 1.599%, dividend yield of -0- and fair value of the Company&#x2019;s common stock of $1.37, was charged to current period operations as acquired research and development.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On March 31, 2017, the Company issued an aggregate of 157,250 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on March 31, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On April 6, 2017, the Company issued an aggregate of 288,300 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on April 6, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On May 5, 2017, the Company issued an aggregate of 6,667 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on May 5, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On May 17, 2017, the Company issued an aggregate of 186,957 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on May 17, 2020, for placement agent services in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 20, 2017, the Company issued 10,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on June 20, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 30, 2017, the Company issued an aggregate of 108,334 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on June 30, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On July 13, 2017, the Company issued an aggregate of 133,501 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on July 13, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 18, 2017, the Company issued an aggregate of 175,500 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on August 18, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On September 18, 2017, the Company issued an aggregate of 51,668 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on September 18, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On October 11, 2017, the Company issued an aggregate of 193,334 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on October 11, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 3, 2017, the Company issued an aggregate of 667,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on May 3, 2021, in connection with the sale of the Company&#x2019;s Series D preferred stock.&#xa0; The warrants contain certain anti-dilutive provisions (see Note 8).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 3, 2017, the Company issued an aggregate of 780,506 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on November 3, 2020 in exchange for the return and cancellation of previous issued 780,505 warrants.&#xa0; The transaction was in connection with the sale of the Series D preferred stock.&#xa0; Both the issued and canceled warrants contain certain anti-dilutive provisions (see Note 8).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 6, 2017, the Company issued an aggregate of 206,668 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on November 6, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 6, 2017, due to certain anti-dilutive provisions embedded in the November 3, 2017 warrants issued in connection with the sale of Series D preferred stock (see above), exercise price of the previously issued 667,000 warrants were reset to $1.50 and an additional 111,167 warrants were issued with an exercise price of $1.50 per share, expiring May 3, 2021.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On December 29, 2017, the Company issued an aggregate of 230,334 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on December 29, 2020, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Stock based compensation related to warrants issued for services was $0 and $56,931 for the years ended December 31, 2017 and 2016, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">A summary of the warrant&#xa0;activity for the years ended December 31, 2017 and 2016 is as follows:</div><br/><table id="z246812a68d7747e1b09a0507edcf9149" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,078,685</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">497,933</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,049,504</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.74</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.5</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9,128,189</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.96</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.1</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">494,099</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,479,974</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(819,077</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested and expected to vest at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercisable at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company&#x2019;s stock price of $1.44 as of December 31, 2017, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.</div><br/></div> 15186123 the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder 227388 750000 100000 723545 1680898 2009750 1.44 685000 1.84 P10Y 83545 100000 0.00 1.2282 0.0108 P5Y 1.84 65000 1.33 P10Y 12500 37500 15000 150000 5000 1.35 P10Y 130000 1.55 P10Y 200000 1.57 P10Y 50000 50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020 475000 1.57 P10Y 237500 237,500 vesting immediately and 237,500 at one year anniversary 50000 1.45 P10Y 420000 1.45 P10Y 120000 120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent 300000 1.50 P10Y 150000 150,000 vesting immediately and 150,000 performance contingent 105898 1.37 1269591 2801948 979812 310817 180000 P1Y 93261 213174 25000 1.95 6000 1.50 2019-02-09 100000 1.95 12000 1.50 2019-03-09 100327 1.95 18040 1.50 2019-04-01 84980 1.95 17996 1.50 2019-04-19 567866 1.95 96256 1.50 2018-10-23 2019-04-29 38572 2.10 2019-06-01 152513 1.95 2019-08-30 35000 1.95 2019-09-19 173284 1.50 2019-10-28 50002 1.50 2019-11-23 456668 1.50 2019-12-16 115000 1.50 2019-12-22 38572 2.10 45001 1.50 300628 1.50 2020-02-10 197159 1.50 2020-03-10 630000 1.50 543927 1.0522 0.01599 0.00 1.37 157250 1.50 2020-03-31 288300 1.50 2020-04-06 6667 1.50 2020-05-05 186957 1.50 2020-05-17 10000 1.50 2020-06-20 108334 1.50 2020-06-30 133501 1.50 2020-07-13 175500 1.50 2020-08-18 51668 1.50 2020-09-18 193334 1.50 2020-10-11 667000 1.50 2021-05-03 780506 1.50 2020-11-03 780505 206668 1.50 111167 1.50 2021-05-03 230334 1.50 2020-12-29 0 56931 1.44 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table presents information related to stock options at December 31, 2017:<br /><br /><table id="z112a025c1ef549308c0a4822215937ea" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Remaining Life</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">In Years</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr style="HEIGHT: 13px"> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.01-2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3,825,540</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.8</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,662,707</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.01-3.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.01-4.00</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.3</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,347,486</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 1.01 2.00 3825540 P6Y292D 2662707 2.01 3.00 4384779 P3Y255D 4384779 3.01 4.00 300000 P7Y109D 300000 P5Y73D 7347486 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows:<br /><br /><table id="ze697ed993c954aa481aebeac21081793" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,780,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.30</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.4</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">905,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.71</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(440,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.24</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.24</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,680,898</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,415,769</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.17</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.11</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">27,045</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercisable at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,347,486</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.19</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.8</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">25,394</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 7780190 2.30 P6Y146D 0 905000 1.71 P10Y 0 0 0 440000 2.24 2.24 P5Y255D 0 1680898 1.50 P10Y 0 0 0 1415769 2.17 2.11 27045 2.19 P4Y292D 25394 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016:<br /><br /><table id="z0ecdfce9282046cbbd42fa5092d7802f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.08% - 2.04</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">109.3% to 122.82</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">5 &#x2013; 10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.47</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table><table id="zc59a64c476fb450b8205e8a109b6b3dd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">2.01% - 2.34</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">95.72% to 107.17</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">5 &#x2013; 10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 57%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 15%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.17</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table></div> 0.00 1.093 1.2282 P5Y P10Y 1.47 0.00 0.9572 1.0717 P5Y P10Y 1.17 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table summarizes the restricted stock activity for the two years ended December 31, 2017:<br /><br /><table id="z81fa81ea80a14d9fbdc0d51830fe553a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Restricted shares issued as of January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">175,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Granted</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(220,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Total restricted shares issued as of December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">135,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Granted</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(135,000</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested restricted shares as of December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Unvested restricted shares as of December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">-</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table></div> 175000 180000 220000 135000 0 135000 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017:<br /><br /><table id="zd27e3f44c8384edaa4ad447f0bdb6877" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Expiration</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 48%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Date</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.001</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">383,320</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,667,440</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">February 2018 to May 2021</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.84</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">35,076</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.95</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,689,026</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">October 2018 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">30,755</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">228,720</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">August 2019 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.67</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">214,193</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">December 2018 to January 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.75</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,340,556</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 48%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">April 2019 to March 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 48%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> </table></div> 0.001 383320 January 2020 1.50 8667440 February 2018 to May 2021 1.84 35076 January 2020 1.95 1689026 October 2018 to September 2019 2.00 100000 August 2018 2.02 30755 January 2020 2.50 100000 August 2018 2.75 228720 August 2019 to September 2019 3.67 214193 December 2018 to January 2019 3.75 1340556 April 2019 to March 2020 12789086 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> A summary of the warrant activity for the years ended December 31, 2017 and 2016 is as follows:<br /><br /><table id="z246812a68d7747e1b09a0507edcf9149" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,078,685</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">497,933</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,049,504</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.74</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.5</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9,128,189</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.96</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.1</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">494,099</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,479,974</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(819,077</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Vested and expected to vest at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exercisable at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 7078685 2.02 P3Y 497933 2049504 1.74 P2Y6M 0 0 9128189 1.96 P2Y36D 494099 4479974 1.50 P3Y 0 -819077 1.50 1.82 P1Y255D 551636 12789086 1.82 P1Y255D 551636 12789086 1.82 P1Y255D 551636 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE&#xa0;10&#xa0;&#x2013; FAIR VALUE MEASUREMENT</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Level 2 &#x2013; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Level 3 &#x2013; Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The carrying value of the Company&#x2019;s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017 and 2016, the Company did not have any items that would be classified as level 1 or 2 disclosures.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The derivative and warrant liability as of December 31, 2017, in the amount of $685,922 and $2,358,240, respectively, has a level 3 classification.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The following table provides a summary of changes in fair value of the Company&#x2019;s level 3 financial liabilities as of December 31, 2017:</div><br/><table id="z741d5830b3bc46dca7600adf14a5e470" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Warrant</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Liability</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Derivative</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Balance, December 31, 2015</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,621,199</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">285,157</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Total (gains) losses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Transfers out due to conversion of Series C Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(103,096</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Mark to market to December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">316,035</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">106,873</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Balance, December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,937,234</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">288,934</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Initial fair value of derivative at date of issuance of Series D Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">397,162</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Initial fair value of warrant liability at date of issuance</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">652,054</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Transfers out due to conversion of Series C Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(20,757</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Mark to market to December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(231,048</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">20,583</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Balance, December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,358,240</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">685,922</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">231,048</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(20,583</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Fluctuations in the Company&#x2019;s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company&#x2019;s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company&#x2019;s derivative instruments.</div><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table provides a summary of changes in fair value of the Company&#x2019;s level 3 financial liabilities as of December 31, 2017:<br /><br /><table id="z741d5830b3bc46dca7600adf14a5e470" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Warrant</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Liability</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Derivative</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Balance, December 31, 2015</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,621,199</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">285,157</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Total (gains) losses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Transfers out due to conversion of Series C Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(103,096</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Mark to market to December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">316,035</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">106,873</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Balance, December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,937,234</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">288,934</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Initial fair value of derivative at date of issuance of Series D Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">397,162</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Initial fair value of warrant liability at date of issuance</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">652,054</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Transfers out due to conversion of Series C Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(20,757</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Mark to market to December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(231,048</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">20,583</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Balance, December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,358,240</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">685,922</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 72%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">231,048</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(20,583</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> </table></div> 1621199 285157 0 103096 316035 106873 1937234 288934 0 397162 652054 0 0 20757 -231048 20583 2358240 685922 231048 -20583 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 11&#xa0;&#x2013; COMMITMENTS AND CONTINGENCIES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Operating leases</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 8, 2017, the Company entered into a lease amendment agreement, whereby the Company agreed to extend the lease for office space in Los Angeles, California, commencing September 1, 2017 and expiring on August 31, 2019.&#xa0;&#xa0;In connection with the lease, the Company is obligated to lease parking spaces at an aggregate approximate cost of $978 per month.&#xa0; In addition, the Company entered into a lease for storage space with the Los Angeles, California building commencing on December 1, 2017 and expiring on August 31, 2019.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Future minimum lease payments under these three agreements are as follows:</div><br/><table id="zd932bfd5f24c4ea9bb3698e8a365bb76" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 61%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Year Ending December 31,</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">112,994</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2019</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">76,995</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">189,989</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Licensing agreements</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale.&#xa0; The agreement expires in ten years from the effective date.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In consideration, the Company issued 630,000 warrants to acquire the Company&#x2019;s common stock at an exercise price of $1.50, expiring on March 15, 2020.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Employment agreements</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On July 14, 2014, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) increased the size of the Board to eight members and appointed&#xa0;Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company&#x2019;s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company&#x2019;s president and chief executive officer.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the appointment of Mr. Cash, on July 15, 2014 (the &#x201c;Effective Date&#x201d;), the Company entered into an employment agreement with Mr. Cash (the &#x201c;Employment Agreement&#x201d;). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a &#x201c;Qualified Financing&#x201d;), Mr. Cash&#x2019;s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash&#x2019;s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company&#x2019;s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company&#x2019;s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company&#x2019;s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company&#x2019;s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Effective July 15, 2017, the Company elected not to continue under the above described agreement and accordingly terminated employment with Mr. Cash.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December 31, 2017, there are no outstanding employment agreements.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="text-decoration:underline">Litigation</font></div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business.&#xa0;&#xa0;Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.&#xa0;&#xa0;There was no outstanding litigation as of December 31, 2017.</div><br/></div> 978 P10Y 0.01 0.02 8 P3Y 275000 3500000 30000 1265769 2.21 P10Y 542473 45206 45207 180824 180824 180824 180824 150000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Future minimum lease payments under these three agreements are as follows:<br /><br /><table id="zd932bfd5f24c4ea9bb3698e8a365bb76" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 61%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Year Ending December 31,</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">112,994</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2019</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">76,995</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">189,989</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 112994 76995 189989 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 12&#xa0;&#x2013; INCOME TAXES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">At December 31, 2017, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $24,000,000, expiring in the year 2036, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company&#x2019;s ownership, the future use of its existing net operating losses may be limited.&#xa0;All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.&#xa0;&#xa0;During the year ended December 31, 2017, the Company has increased the valuation allowance from $5,500,000 to $8,200,000.We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns.&#xa0;&#xa0;ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.&#xa0;&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement.&#xa0;&#xa0;The Company had no tax positions relating to open income tax returns that were considered to be uncertain.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2013.</div><br/><table id="z1362e6da18d942dd95b6dd251c2a64ca" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Statutory rate on pre-tax book&#xa0;loss</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(34.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(34.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Gain) loss on change in fair value of derivatives</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(0.56</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.24</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock based compensation</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">12.72</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">17.6</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Fair value of warrant to acquire research and development</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.46</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.09</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.09</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Valuation allowance</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">20.29</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">15.07</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company&#x2019;s deferred taxes as of December 31, 2017 and 2016 consist of the following:</div><br/><table id="z6ff7f0f4e0b240e885ac9b95efc5d954" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Non-Current deferred tax asset:</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;Net operating loss carry-forwards</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,200,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5,500,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;Valuation allowance</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(8,200,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(5,500,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;Net non-current deferred tax asset</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/></div> 24000000 P2036Y 5500000 8200000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2013.<br /><br /><table id="z1362e6da18d942dd95b6dd251c2a64ca" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Statutory rate on pre-tax book&#xa0;loss</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(34.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(34.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Gain) loss on change in fair value of derivatives</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(0.56</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">)%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.24</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock based compensation</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">12.72</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">17.6</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Fair value of warrant to acquire research and development</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.46</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.09</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.09</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Valuation allowance</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">20.29</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">15.07</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; WIDTH: 11%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ccecff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">%</div> </td> </tr> </table></div> 0.3400 0.3400 -0.0056 0.0124 0.1272 0.176 0.0146 0.0000 0.0009 0.0009 0.2029 0.1507 0.0000 0.0000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The Company&#x2019;s deferred taxes as of December 31, 2017 and 2016 consist of the following:<br /><br /><table id="z6ff7f0f4e0b240e885ac9b95efc5d954" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Non-Current deferred tax asset:</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;Net operating loss carry-forwards</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,200,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5,500,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;Valuation allowance</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(8,200,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(5,500,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#xa0;Net non-current deferred tax asset</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 8200000 5500000 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOTE 13 &#x2013; SUBSEQUENT EVENTS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify">Adoption of Accounting Standards</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In July 2017, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#x2014;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018.&#xa0; As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify">Series E Preferred Stock Issuance</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 16, 2018, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional accredited investors (the &#x201c;Investors&#x201d;), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the &#x201c;Preferred Shares&#x201d;) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), at an exercise price of $1.75 per share (the &#x201c;Warrants&#x201d;), in exchange for aggregate consideration of $1,500,000 (the &#x201c;Transaction&#x201d;). The sale of the Preferred Shares and Warrants were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type.&#xa0; The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the &#x201c;ROFR&#x201d;) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement))&#xa0; Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the &#x201c;Filing Date&#x201d;) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (&#x201c;Registrable Securities&#x201d;), not then registered.&#xa0; The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.&#xa0; The Warrants include a &#x201c;full ratchet&#x201d; anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the &#x201c;Consent&#x201d;) with the holders of the Company&#x2019;s Series D Convertible Preferred Stock (the &#x201c;Series D Holders&#x201d;).&#xa0; Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction.&#xa0; In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the &#x201c;Consent Warrants&#x201d;).&#xa0; The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.&#xa0; The Consent Warrants include a &#x201c;full ratchet&#x201d; anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.&#xa0; The issuance of the Consent Warrants to the Series D Holders was in reliance on the exemption from registration under the Securities Act provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify">Common Stock Issuance</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On January 5, 2018, the Company entered into a unit purchase agreements with certain accredited investors pursuant to which the Company issued 200,000 shares of our common stock and 100,000 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring January 5, 2021, in exchange for aggregate consideration of $299,985, net of expenses of $15 (of which $29,985 were received as common stock subscriptions as of December 31, 2017).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In January and February 2018, the Company issued an aggregate of 367,343 shares of common stock in exchange for 280 shares of our Series D 9% Convertible Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 14, 2018, the Company issued an aggregate of 9,919 shares of common stock in exchange for 10 shares of our Series C 9% Convertible Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 1, 2018, the Company granted 200,000 restricted stock units to consultants for services rendered, of which 100,000 vest upon date of grant and 100,000 shares vest at the one-year anniversary of the date of grant provided the consultants are providing services through the vesting date.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify">Options</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 15, 2018, the Company granted our board member, Andrew L. Filler 50,000 options to purchase common stock in connection with his appointment as chairman of our Nominating and Corporate Governance Committee at the exercise price of $1.42 per share for a term of ten years, vesting immediately.</div><br/></div> 3044162 1000 0.001 500000 0.001 1.75 1500000 100000 1.50 200000 100000 1.50 299985 15 29985 367343 280 9919 10 200000 100000 100000 50000 1.42 P10Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">NOTE 1 &#x2013;&#xa0;NATURE OF OPERATIONS AND BASIS OF PRESENTATION</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">BioSig Technologies Inc. (the &#x201c;Company&#x201d;) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The condensed balance sheet as of December 31, 2017 has been derived from audited financial statements.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Operating results for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2017 filed with the Company&#x2019;s Form 10-K/A with the Securities and Exchange Commission on March 26, 2018.</div><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE 2 &#x2013; GOING CONCERN AND MANAGEMENT&#x2019;S LIQUIDITY PLANS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of March 31, 2018, the Company had cash of $1,035,100&#xa0;and working capital of $332,764. The Company raised approximately $1,500,000 through the sale of Series E preferred stock and warrants and $385,000 through the sale of common stock and warrants during the three months ended March 31, 2018 and approximately $4,675,000 subsequent to March 31, 2018 (See Note 11). During the three months ended March 31, 2018, the Company used net cash in operating activities of $2,387,274.&#xa0; These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company&#x2019;s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders&#x2019; deficiencies at March 31, 2018 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company&#x2019;s research and development will be successfully completed or that any product will be approved or commercially viable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.</div><br/></div> -332764 1500000 385000 4675000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">NOTE&#xa0;3 &#x2013;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Use of estimates</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company&#x2019;s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Fair Value of Financial Instruments</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#x201c;ASC 820-10&#x201d;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;), which permits entities to choose to measure many financial instruments and certain other items at fair value.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Derivative Instrument Liability</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Research and development costs</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420&#xa0;and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Net Income (loss) Per Common Share</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.&#xa0;&#xa0;Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or &#x201c;if converted&#x201d; methods as applicable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:</div><br/><table id="zef6cc174627647d9be3aba49b31a3d51" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31, </div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31, </div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">643,333</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">713,333</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series D convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">687,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series E convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,000,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10,419,655</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">22,798,280</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">19,378,178</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Stock Based Compensation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Income Taxes</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Deferred taxes are classified as non-current.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Registration Rights</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On February 16, 2018, in connection with the Company&#x2019;s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the &#x201c;Filing Date&#x201d;) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (&#x201c;Registrable Securities&#x201d;), not then registered.&#xa0; The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Adoption of Accounting Standards</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In July 2017, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#x2014;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Recent Accounting Pronouncements</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Subsequent Events</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.&#xa0; Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.</div><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Use of estimates</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company&#x2019;s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Fair Value of Financial Instruments</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#x201c;ASC 820-10&#x201d;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;), which permits entities to choose to measure many financial instruments and certain other items at fair value.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Derivative Instrument Liability</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Research and development costs</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420&#xa0;and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Net Income (loss) Per Common Share</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.&#xa0;&#xa0;Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or &#x201c;if converted&#x201d; methods as applicable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:</div><br/><table id="zef6cc174627647d9be3aba49b31a3d51" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31, </div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31, </div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">643,333</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">713,333</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series D convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">687,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series E convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,000,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10,419,655</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">22,798,280</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">19,378,178</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Stock Based Compensation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested.</div></div> 8230319 7168319 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Income Taxes</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Deferred taxes are classified as non-current.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Registration Rights</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On February 16, 2018, in connection with the Company&#x2019;s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the &#x201c;Filing Date&#x201d;) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (&#x201c;Registrable Securities&#x201d;), not then registered.&#xa0; The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018.</div></div> 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Adoption of Accounting Standards</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In July 2017, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#x2014;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Recent Accounting Pronouncements</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</div></div> 3044162 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Subsequent Events</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.&#xa0; Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:<br /><br /><table id="zef6cc174627647d9be3aba49b31a3d51" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31, </div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31, </div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">643,333</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">713,333</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series D convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">687,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Series E convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,000,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,245,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10,419,655</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">22,798,280</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">19,378,178</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 643333 713333 687000 0 1000000 0 8230319 8245190 12237628 10419655 22798280 19378178 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">NOTE&#xa0;4 &#x2013; PROPERTY AND EQUIPMENT</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows:</div><br/><table id="ze24872f09a554925b4651d1fa627bf33" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Computer equipment</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">90,703</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">87,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Furniture and fixtures</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,975</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,975</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Subtotal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">103,678</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">100,034</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Less accumulated depreciation</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(84,221</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(81,318</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Property and equipment, net</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">19,457</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">18,716</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Depreciation expense was $2,903 and $3,069 for the three months ended March 31, 2018 and 2017, respectively.</div><br/></div> P3Y P5Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows<br /><br /><table id="ze24872f09a554925b4651d1fa627bf33" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Computer equipment</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">90,703</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">87,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Furniture and fixtures</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,975</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,975</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Subtotal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">103,678</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">100,034</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Less accumulated depreciation</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(84,221</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(81,318</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Property and equipment, net</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">19,457</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">18,716</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 90703 12975 103678 84221 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">NOTE&#xa0;5&#xa0;&#x2013; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following:</div><br/><table id="zd92901d1b8c64081b3686d320b0fd89b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued accounting and legal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">151,745</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">93,595</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued reimbursements</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10,510</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2,600</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued consulting</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,650</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">109,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued research and development expenses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">148,932</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">246,030</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued office and other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">644</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,912</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Deferred rent</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">997</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">569</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued settlement related to arbitration</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">338,811</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">473,098</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following:<br /><br /><table id="zd92901d1b8c64081b3686d320b0fd89b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">March 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2018</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">2017</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued accounting and legal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">151,745</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">93,595</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued reimbursements</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10,510</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2,600</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued consulting</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,650</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">109,059</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued research and development expenses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">148,932</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">246,030</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued office and other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">644</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,912</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Deferred rent</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">997</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">569</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Accrued settlement related to arbitration</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">338,811</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">473,098</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 151745 10510 12650 148932 644 997 13333 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE&#xa0;6&#xa0;&#x2013; SERIES C 9% CONVERTIBLE PREFERRED STOCK</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On January 9,&#xa0;2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the &#x201c;Series C Preferred Stock&#x201d;).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.&#xa0;&#xa0;The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.&#xa0;&#xa0;The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.&#xa0;&#xa0;The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company&#x2019;s common stock at $2.61 per share expiring five years from the initial exercise date.&#xa0;&#xa0;The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a &#x201c;cashless exercise&#x201d;.&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Series C Preferred Stock issued and outstanding totaled 965 and 985 as of March 31, 2018 and December 31, 2017, respectively.&#xa0;&#xa0;As of March 31, 2018 and December 31, 2017, the Company has accrued $432,660 and $419,283 dividends payable on the Series C Preferred Stock.</div><br/></div> The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. 1.50 2315301 9919 10 10010 10 432660 419283 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE&#xa0;7&#xa0;&#x2013; WARRANT AND DERIVATIVE LIABILITIES</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Series C 9% Convertible Preferred Stock and related warrants</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the &#x201c;readily convertible to cash&#x201d; as described in Accounting Standards Codification 815 and therefore bifurcation was not required.&#xa0;&#xa0;There was no established market for the Company&#x2019;s common stock.&#xa0;&#xa0;&#xa0;As of March 31, 2015, the Company determined a market had been established for the Company&#x2019;s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company valued the reset provisions of the Series C Preferred Stock&#xa0;and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Series D Convertible Preferred Stock and related warrants</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company valued the reset provisions of the Series D Preferred Stock&#xa0;and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.</div><br/></div> 0.0056 0.0089 0.00 1.41 P0Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE 8&#xa0;&#x2013; STOCKHOLDER EQUITY</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Preferred stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company is authorized to issue 1,000,000 shares of&#xa0;$0.001 par value preferred stock. As of March 31, 2018 and December 31, 2017,&#xa0;the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock and (2018) 1,000 shares of Series E Preferred Stock. As of March 31, 2018 and December 31, 2017, there were no outstanding shares of Series A and Series B preferred stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Series C Preferred Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Series D Preferred Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In January 2018, the Company issued an aggregate of 235,911 shares of its common stock in exchange for 180 shares of the Company&#x2019;s Series D Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In February 2018, the Company issued an aggregate of 131,432 shares of its common stock in exchange for 100 shares of the Company&#x2019;s Series D Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In March 2018, the Company issued an aggregate of 489,231 shares of its common stock in exchange for 367 shares of the Company&#x2019;s Series D Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Series E Preferred Stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On February 16, 2018, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional accredited investors (the &#x201c;Investors&#x201d;), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the &#x201c;Preferred Shares&#x201d;) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), at an exercise price of $1.75 per share (the &#x201c;Warrants&#x201d;), in exchange for aggregate consideration of $1,492,969, net of transaction expenses of $7,031 (the &#x201c;Transaction&#x201d;).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type.&#xa0; The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the &#x201c;ROFR&#x201d;) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement))&#xa0; Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the &#x201c;Filing Date&#x201d;) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (&#x201c;Registrable Securities&#x201d;), not then registered.&#xa0; The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.&#xa0; The Warrants include a &#x201c;full ratchet&#x201d; anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the &#x201c;Consent&#x201d;) with the holders of the Company&#x2019;s Series D Convertible Preferred Stock (the &#x201c;Series D Holders&#x201d;).&#xa0; Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction.&#xa0; In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the &#x201c;Consent Warrants&#x201d;).&#xa0; The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.&#xa0; The Consent Warrants include a &#x201c;full ratchet&#x201d; anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.&#xa0;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Common stock</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2018 and December 31, 2017, the Company had 30,497,707 and 29,321,204 shares issued and outstanding, respectively.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">During the three months ended March 31, 2018, the Company issued 100,000 shares of its common stock for services totaling $142,000 ($1.42 per share).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">During the three months ended March 31, 2018, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 180,000 shares of common stock and 90,000 warrants for aggregate proceeds of $270,000.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">During the three months ended March 31, 2018, the Company issued 20,000 shares of common stock and 10,000 warrants for a previously received common stock subscription of $29,985.</div><br/></div> 9919 10010 235911 180 131432 100 489231 367 1000 0.001 500000 0.001 1.75 1492969 7031 100000 1.50 100000 142000 1.42 180000 90000 270000 20000 10000 29985 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE 9&#xa0;&#x2013; OPTIONS AND WARRANTS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Options</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On October 19, 2012, the Company&#x2019;s Board of Directors approved the 2012 Equity Incentive Plan (&#x201c;the &#x201c;Plan) and terminated the Long-Term Incentive Plan (the &#x201c;2011 Plan&#x201d;). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended)&#xa0;shares of the Company&#x2019;s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The following table presents information related to stock options at March 31, 2018:</div><br/><table id="z458314c5f2fb4628a2781322e90dff22" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Remaining Life</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">In Years</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.01-2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3,545,540</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2,483,540</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.01-3.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.4</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.01-4.00</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7.0</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,168,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">A summary of the stock option&#xa0;activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows:</div><br/><table id="zc01a00933aab4ce4b1bcc301f3f022cb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.11</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">27,045</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">50,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.42</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(330,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.66</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.12</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">158,930</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercisable at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,168,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.20</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">4.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">104,305</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company&#x2019;s stock price of $1.57 as of March 31, 2018, which would have been received by the option holders had those option holders exercised their options as of that date.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company&#x2019;s own historical stock prices.&#xa0;Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">For employees, the Company accounts for the expected life of options in accordance with the &#x201c;simplified&#x201d; method, which is used for &#x201c;plain-vanilla&#x201d; options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.&#xa0; The fair value of stock-based payment awards during the three months ended March 31, 2018 and 2017 was estimated using the Black-Scholes pricing model.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On February 15, 2018, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.42 per share for a term of ten years with vesting immediately.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018:</div><br/><table id="z9affad0ab9844b5e888d8233847a77e5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.65</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">94.10</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt">5 years</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.01</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The fair value of all options vesting during the three months ended March 31, 2018 and 2017 of $246,710 and $42,984, respectively, was charged to current period operations.&#xa0;&#xa0;Unrecognized compensation expense of $783,894 and $979,812 at March 31, 2018 and December 31, 2017, respectively, will be expensed in future periods.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Warrants</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018:&#xa0;</div><br/><table id="zef9e4d34509749818843d5d6f0992c1b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 50%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Number</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Expiration</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 23%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Date</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">0.001</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">383,320</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,615,982</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">February 2018 to May 2021</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">500,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2021</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.84</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">35,076</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.95</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,689,026</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">October 2018 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">30,755</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">228,720</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2019 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.67</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">214,193</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">December 2018 to January 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,340,556</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">April 2019 to March 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> </tr> </table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On January 5, 2018, the Company issued 100,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring on January 5, 2021, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On February 14, 2018, the Company entered into a consent agreement with the holders of the Company&#x2019;s Series D Convertible Preferred Stock.&#xa0; Pursuant to the consent, the Series D Holders consented to the Series E Preferred Stock transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the transaction.&#xa0; In consideration for their entry into the consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of common stock.&#xa0; The consent warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.&#xa0;The warrants contain certain anti-dilutive provisions (see Note 8).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On February 16, 2018, the Company issued an aggregate of 500,000 warrants to purchase the Company&#x2019;s common stock at $1.75 per share, expiring on August 16, 2021, in connection with the sale of the Company&#x2019;s Series E preferred stock.&#xa0; The warrants contain certain anti-dilutive provisions (see Note 8).</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">A summary of the warrant&#xa0;activity for the three months ended March 31, 2018 is as follows:</div><br/><table id="z08b8928ab7b44450bee245c87187441d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">700,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.68</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Expired</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(1,251,458</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.85</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,134,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Vested and expected to vest at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.85</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,134,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercisable at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.85</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,134,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/></div> the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. P10Y 1.57 50000 1.42 vesting immediately 246710 42984 783894 100000 1.50 2021-01-05 100000 1.50 500000 1.75 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table presents information related to stock options at March 31, 2018:<br /><br /><table id="z458314c5f2fb4628a2781322e90dff22" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Remaining Life</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">In Years</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.01-2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3,545,540</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2,483,540</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.01-3.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.4</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">4,384,779</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.01-4.00</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7.0</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 16%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 16%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,168,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 1.01 2.00 3545540 P7Y73D 2483540 2.01 3.00 4384779 P3Y146D 4384779 3.01 4.00 300000 P7Y 300000 P5Y73D 7168319 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows:<br /><br /><table id="zc01a00933aab4ce4b1bcc301f3f022cb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,510,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.11</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">27,045</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">50,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.42</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(330,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.66</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">8,230,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.12</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">5.2</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">158,930</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercisable at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,168,319</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.20</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">4.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">104,305</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 50000 1.42 P10Y 0 330000 1.66 2.12 158930 2.20 P4Y255D 104305 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018:<br /><br /><table id="z9affad0ab9844b5e888d8233847a77e5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.65</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">94.10</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt">5 years</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.01</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 0.0265 0.00 0.9410 P5Y 1.01 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018:<br /><br /><table id="zef9e4d34509749818843d5d6f0992c1b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 50%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Number</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Expiration</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 23%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Date</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">0.001</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">383,320</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">7,615,982</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">February 2018 to May 2021</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">500,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2021</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.84</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">35,076</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.95</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,689,026</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">October 2018 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">30,755</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">228,720</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">August 2019 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.67</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">214,193</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">December 2018 to January 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,340,556</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 23%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">April 2019 to March 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 23%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> </tr> </table></div> 0.001 383320 January 2020 1.50 7615982 February 2018 to May 2021 1.75 500000 August 2021 1.84 35076 January 2020 1.95 1689026 October 2018 to September 2019 2.00 100000 August 2018 2.02 30755 January 2020 2.50 100000 August 2018 2.75 228720 August 2019 to September 2019 3.67 214193 December 2018 to January 2019 3.75 1340556 April 2019 to March 2020 12237628 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> A summary of the warrant activity for the three months ended March 31, 2018 is as follows:<br /><br /><table id="z08b8928ab7b44450bee245c87187441d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,789,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.82</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">551,636</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">700,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.68</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Expired</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(1,251,458</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Outstanding at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.85</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,134,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Vested and expected to vest at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.85</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,134,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Exercisable at March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">12,237,628</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.85</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1.7</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">1,134,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 700000 1.68 P3Y 0 1251458 1.50 1.85 P1Y255D 1134548 12237628 1.85 P1Y255D 1134548 12237628 1.85 P1Y255D 1134548 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE&#xa0;10&#xa0;&#x2013; FAIR VALUE MEASUREMENT</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Level 2 &#x2013; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Level 3 &#x2013; Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The carrying value of the Company&#x2019;s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of March 31, 2018 and December 31, 2017, the Company did not have any items that would be classified as level 1 or 2 disclosures.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">As of March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">The following table provides a summary of changes in fair value of the Company&#x2019;s level 3 financial liabilities as of March 31, 2018:</div><br/><table id="z363bcf2ff5734eaa9d755ecbc13e019f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Warrant</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Liability</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Derivative</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Balance, December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2,358,240</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">685,922</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Total (gains) losses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(2,358,240</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(685,922</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Balance, March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table><br/></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> The following table provides a summary of changes in fair value of the Company&#x2019;s level 3 financial liabilities as of March 31, 2018:<br /><br /><table id="z363bcf2ff5734eaa9d755ecbc13e019f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#xa0;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Warrant</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Liability</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Derivative</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Balance, December 31, 2017</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">2,358,240</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">685,922</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Total (gains) losses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(2,358,240</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">(685,922</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Balance, March 31, 2018</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#xa0;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 11.4pt">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#xa0;</td> </tr> </table></div> 2358240 685922 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">NOTE 11 &#x2013; SUBSEQUENT EVENTS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In April 2018, the Company issued an aggregate of 577,339 shares of its common stock in exchange for 454 shares of the Company&#x2019;s Series D Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In April 2018, the Company issued an aggregate of 351,021 shares of its common stock in exchange for 370 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">On April 30, 2018 the Company entered into a Unit Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;), pursuant to which the Company sold to the Investors an aggregate of 3,193,004 shares of&#xa0; the Company&#x2019;s common stock&#xa0; and warrants to purchase an aggregate of 1,596,506 shares of the Company&#x2019;s common stock, at an exercise price of $1.75 per share, in exchange for aggregate consideration of $4,789,502, net of transaction expenses of approximately $1,000 (the &#x201c;April 2018 private placement&#x201d;), of which $115,470 was received as common stock subscriptions as of March 31, 2018.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">In connection with the April 2018 private placement, the Company issued additional warrants to purchase an aggregate of 83,334 shares of the Company&#x2019;s common stock, at an exercise price of $1.50 per share to the Series E holders. In addition, 500,000 warrants to purchase the Company&#x2019;s common stock at an exercise price of $1.75 per share previously issued to the Series E holders were reset to an exercise price of $1.50 per share.</div><br/></div> 577339 454 351021 370 3193004 1596506 1.75 4789502 1000 115470 83334 1.50 EX-101.SCH 5 bios-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - SERIES C 9% CONVERTIBLE PREFERRED STOCK link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - WARRANT AND DERIVATIVE LIABILITIES link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - STOCKHOLDER EQUITY link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - FAIR VALUE MEASUREMENT link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - FAIR VALUE MEASUREMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - WARRANT AND DERIVATIVE LIABILITIES (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - STOCKHOLDER EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Compensation, Stock Options, Activity link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - FAIR VALUE MEASUREMENT (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - INCOME TAXES (Details) link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity link:presentationLink link:definitionLink link:calculationLink 060 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions link:presentationLink link:definitionLink link:calculationLink 061 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 062 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights link:presentationLink link:definitionLink link:calculationLink 063 - Disclosure - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation link:presentationLink link:definitionLink link:calculationLink 064 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 bios-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 bios-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 bios-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 bios-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 image5.jpg begin 644 image5.jpg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ࡺ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
E5KZV+(T@'-38:-'09N#S6Z\@(XZUPNGRS)+CE1 MFNVMVA%JK2. <5#0-EB 90D]:C+LC'TJI)?KO\N$[L^E/_LZ^D =48@U+6@$ MP>W#[I,5*VI68.U&%-@\/W$V/-RN>QK5MO"42X9W'YU*3*,QM1CC7(-94VJP M23[2PS]:[O\ L"S>/8=N<5R^L^"'=FEMB?;!IMC2,*^%C( 9-I/:F:=J4UC< M!@Q$(IBZ-/92?Z7DCMFMRTBMKE!%Y8^M<\YV'J=!IVK66HQ;693)VYK02QE7 ME!\IKA+[3Y+"826S'CL*N:?XIOH1MGB;'O6/M'NBCL6MX0.@\RDEA'V1RP[& ML:+7DO&V@;6-274[K;L3+QCI4N?-H-'&ZBT/VEA)C&:>D"-:;K?KCC%9]\?M MMPR1#+9[5T'06MCY]\M-2MLCRW7=]:T/,:4[B:\0L;FX-P/]+*UU<;:DUO^ZN';CJ*& M@9WUQ=V\ _>,OYU5MM;MS<;4L6 MSR746].13#YBL1S7-V6J7=K'A8F(%6O^$HE8[3:$'U_R:BPTS:&&.#UJ3RPH MYK*@U=YF'^CD9[UKQ$RQ\KUIE#6!0%-N?6DR;ZE70K>. MVM?,( 85B>*I;J^(6$DX]*T_$L_]EH8HVQD=JYG2KMY69G;=4,3(M%TB^CNU MDO%;R>^X5WUM/:6\7[G:,>E.#3_" M_AZYU2\W7<;,G4;A4N@>$Y!,))E+ '/->C6[06,($2@,!VIIV$S9TVWATFP$ M" * *QM7UI;92 ^,^]9FHZXR%B6_"N&US6FNCA#3W%<-;U$73N V23ZU@@A0 M0W>I8\L=S"GRHA0MD=*I 9TAAARS8%49[M&!P1BFWV7;:&[U"MNH3).?:F Z M&7+<'BMB$!E&.M9,2*&':M2)^ %% Q[( ?>E7'>I%R>JT&41_P &ZDV*PT#G MGI2'&?:G>:6Z)^%,*2-SL(HN GR'I1^[[8S1M*]5Q2[EZ;:D%848J09[]*1, M8Z4_(I@*,?A3MWITIH(':@D'MBF(4E3TIFX ^])G)Z8I<#TH&!?UI-U+M]LT MNWVI6$,S^5)T^[4VP8I"N.U,8S=&XVGK0&BB7!Q21J%DR1Q3IC&QP #3!%K3 M(H;B;#@$5U<.A6K0[MBX^E<5%(;5@RUV.CZCYUNJ%N34,.I8BTFU4\(OY5:C MT^%3\JC\JG6(J0>U7(WCQT K-E$$=K&H^Z,_2IPJ#J!3BZXXJ/S O;-(KH2% M\#VJN[DGBG-+Q]VHC/C^"J"Q'-]VLTN)MR?=Q6U99C2>Z,9]:L&X$&0>,UGAV^T;UK5$-DVH:; M"MJR[1DBN\M5%"1[?\*5 ME/TJ+%B(0#\M39!'O4*]>E3(?]FCU 525/-.FD^3DTI (JE=2%5]:%H!7F8% MZ9&GS# J$,7E_I6G!$#C/%&J ==JOV'@M>D7Z;;(\=J\TUH_Z M7C&:::N)HS9CO7':JQA..G%:HB38#3'\L#%4)7,C[.6<8%:D$2Q*#BEC6/=U M JU(JL@ H;*0T.A'O28!'-(#L&-F?>D#EF QC-(9FWB'/%4QY@Z9Q7H>F^%U MU",,6ZTMSX*B23'G ?C0(\^ =NF:M6:;90<$UL MXRZ\@=Z5[;$O4Y%E5YUWUW/AVWA7:2!TKBKU##=JH&>:[+PTC94L>,4[C2.E ME*CA>E56\S?E>E6IYX(5Z@GTK(N=4._;&F?I2N4T:;1F50!UJU;Q%4VFN=6> M\?G8R@]ZM0VE[.P/FLH-*Y-CH!" .:A:!(VWMC%5TT>Y"Y:\)JG-'+&Q4S%L M4KF]-,9K$RK;LT/W@.U<(]U?SR$,7P*]$LX/,8"1-P]*74[6VAV[+8+FHDSK MC5Y&<"A1!F?\]BMK<] ,UHQR6ZV'FD!<"L&>\@NR0'!Q6;YW8 >IJKI%N;9%RW:K6JE!;%@O/K57.)RY7H7O^$C#8,C\_6ID\0VVF)-M"OX"LB;X?W90B. _]\UMI M>WD#[-[''>IO[>ND.TEOK3N$*-CB9? .HQ9+P-_WS61<>%;^%CF)\#VKU>W\ M5-!]^'S\^U74\2V,QS+8J,^O_P"NFF@E3U/#9=(NH3DHPQ[5 7GBX^;BO?C/ MHMZ/FMXTS59_#NAW73RUS]:0*+1X>/[^7IZDM(]AB\4"4XE<;?.IX@&9Q\RPY/TK-G\+Z&Y+01Q^V!7'0>((I/O,%J]'KB=% MF&*UC4L'+J:DOA=#_J(Q[8%5F\*:F?N1MCZ4Z#5LGY;FM*+69H^1,6KHCB4B MFD8[>&M5B&6C? ]JJR6%Y">5;\JZZ+Q)(/O1EZM+XB@;A].!_#_Z];+%I$-' M"89!R#NIGGL#@YKT$WFFSC+6B)FH6L-)NOXT3-;+&HBUSBEG@Q^\(I/,@8X7 M%=;/X,L)_FCOU^@/_P!:J\7A6.TDW+()<=JWCC$+E.<\J5AF,''TJO+NC^\# M7HUN5MH"O]F[SC_/>LN?$\I$NF^6N>I__75?6DQ6.(\R)E_VJ@9BO6O5=/TG M19(P9_+C/?.:L77A/0+M<1WT2GZG_"LIUXCLSQ>Y>%E^;%46*=$Z5Z7K/P\L MH5,L6H*X] ?_ *UW8 =S7(YZEE#C^+K2"3!YZ4LV\M@)0%51EJ7,@L.)0KN-(LP' MRJ?EINU2<@Y'I3691P!BES%$\F(QNB^][4J2O*NTD[C5=-P.3R*5I IRI^:E M<$3_ #6WWN,UK:!HTNH7RET)0GTJ/0]!NM);'1M(5 B^7(=< ]*Y?5M02WC)#8/UJ M_?7(CC9B<5Y]K6I&Y)1?6M%892U*[$]R7SFN>U:+[2!WK76/,?S#\:SKJ*4L M/+0M]*JX(Y=[62%\X.*>C$]:Z*6QF>WYA.:R)K&>,D^411NEM]UC0H; MP&2R0%C_ '17*36D]E-LF4C'J*Z&SU:6UQ@%EK;CO-/U*'9/&JR-W-.Q-]3@ MI/*M $@5Y!^[^[3-SVQRN0: M9',<\':/2K:W$3## 4BDABSO,O.7'-7H9;<=@*2XN(L'"@TD)F5(H6 MDCR3[4DC;FX%3P1DX_E5$LM0@#I5Y.!D565".U6U<;,8KJHF4O,7(QSUIOUI MXPW:D*;?>NI;D; ,=Z7Y/:F9/I29;^Y56#<]D>,@?-5:0XZ5J7* +QS65)P> M:\.QU7(=S'OBH)*?(=W3BH6;C!J0*LQZUBW[,&'?Z5LW'W#625RV3S0A$1B_ M<;B0/K69=P%T8J01CM5K5[E4M"%;!K.TVX#0-N.36D1G/3PLDC8&.:K; M<5GW^Q8CM()I6N,?I6HSQ3*\CY .>M>IZ%XTM618G&"!C)KQ6W+F4<'&:ZFU MCRBX;::E@CV^&6._B\R%UYZP-8$^M/!%Y*L7QQD5E_:);J8,V1SWIQH6#F-R M'4K:WF+Q0MN/?%3RW^K7@Q;DJIZ9!J&T,2J-X%7'\0P64958LX]*W5,39!;: M!JEX_P#I,Z@>Y_\ KU=N/"S6T.]KF(\?WA_C6)-XMFN3MABK:'[A #@5 M6FTMY)MV:L'3Y @%-"9EW$!N+5H6Y8CK7+2>#)C+E<'->B1:<2E6[?3MIR<& MFF(XFR^&TVU96(_2NQT[PV;2W"MC [5T$";$ JPD)*T([,!>,"K0A.W.*40NRG I7 R+V6*W3+$#\:YN[U^!)"BGGUS6[ MK>DW-S'A5(KE3X0O7ER5/UH$-?4_-D&YLCZUV6BZC;Q1JSJ>E-AE8Y]JD7PP9F#,A!]Q7:>59V1W JV/2J]QJT+ A%Q2MJ M!CP^'%MU!9EQZ<592VMK8[CCBJUQ>G).ZL^2ZSU>G8#H&UR.*,I%\M8TNK3J MY;S 0?>LN><-T:JA8YY-58DFU*^DGC8[N:Y*2[:)_G.:W;GYHR,U@3P9;KFG ML,G74]Z;0#4$MU,3M4X!IT<04=*&Y=PW5LVWA[:!G!K6B*N@Q5B'Y6ZYJ6QV,HZ+CCBG1Z'% M_$ :TI&R_6GKG'-1S#L9J:5;H_W:LMI]N(\[.:D)PV:D5@W%-,5CE=4C2(_= M-9",K/CM74:W;$@$"N::+8WO3N)DNW^Z>*3:1T-(JD]34RQD\=*M ,"L?K2A M&'6K*1<8IWEX]Z!%?RSBE$1_"K B]Z7:!WH3 C">G%)LYXZU)P?:F&EJ TH> MYYJ-MWC7$ MK@'S.E# V([D3KE2*;-&2O%-L]--JN'<5=,:.,;A4,#/52..]#2M"PR:N-"% M'!JG- 6/6@9O:9?O\O-7[C4YDZ X^EE7K;Q39W!"3D1D^M5$ MGJ7)=5>48)Q]:R9299"5.#ZUJ7$6GW@!ANTSZ"JDFF7&W]VI8>HK51)ZE+]X MG!8'Z4UR[# JY'I]T@^:,TDD+1C)6K40*D<3DY8\5950M1AVSC::<>>6XI65 MQHEW*>A J<3,L./UK,E*GA7%:$3#[%@^G6F)F5>!Y#G.:J)=&%L,>E6F8 M@ MYK'NF :0<\UT04Q+SQ3>PEN3E3U'6FDC^+ MFH?MD9.W=S3LANAS4W90$C/6IH^G6JYB[[J>@7&"XS0!-(?E^4UF7#,>A%79 M2J+RU9S@.WWJ &0X\T CFMB->E9L,.&%:<;^7VS0%PU.0BR/TK@KRR^U7&X$ M#GO7=ZFVZS.!SCI7$3A_M0[XCFT[S-PR1TH''4\]U=-MZ"/6M[19I7 5 1Q M7/:Q*#?#GO74^&G#%1M[5)1I?V9//)O=ACWI_P!DB@8!AEO45H2DGY1Q51EP M_)S0"9*!)M&2-M7+:9EPN,BJ3990%YJW#.MM%ND[4BXQ&:GJBVH /RY]:RA> M"0[P#SWHU,0:S(N)E3;ZU8>VM[33P%D5F [47[FR5A$U40CCK6=J.M22#D_2 ML>^O+E)?W4#.OJ*+9+B_/,3+]:5KF\.7J4;S4M2?(1CM_&M+1KF_:/8[$YJ? M4K,:?8&9EY JAH>NPM<*C#'S8HLQU))+0TM4\+W>IP@HV#UYJ/3]#N-)4"20 M96N_9[=;!9!(!D5PNOZH59T3)'J*M');F9/?7-O/"4G96X]:K>'M*L&NV< > MO:N6BDEN'(W&NJ\,64JSDENHI:G1[)6N4O%&L/:2O:0JVSIQFL30UGEF+9(! M/>N\U3P\+J0N0,FL^VT9;%N6 S29DJ\J20YYK$OM&N8)-T8/7M0BIR26B.ZT*Q5;5=C#/L:Z%;:=8SDYKG?#,$L.GI M),2,#O740:I:LI7S!FF<J*)+DRQ2AN>@K;\/-,8MK0D\TQ2I'4P^*KU3\Y M/Y&KB^)K648N4R3UJA):#R]Q7;6'+M-WY6>IHV,'"S.IDN?#EU_K+?)_S[54 MD\/^&[GD0@9^G^%9QJW/@/3KCFU**/0D5 MF3?#*63_ %,L8_$5>@N)G7?'(2!Z5876;J,XV-2YB>=MG+S_ QU-,[)5/Y? MXUDW7@+5(#\P+?1:].@\1-P'1JN)XB@Z/#GWI-FB3/$G\-7L).^"0X_V:J2Z M?>1' BD _P!TU[^E]I=YP50'Z5'-H>DW0)\Z($]JF[!JQX'']MBY7:YR]^',W.P@T[LS[&JL/M?^63A?JU:4&M2<&.=!_P "KRH1R)SYF*!J$T)P M'/%7&;1+1["GB&]5A_I"$?6KO]OK(K9O^6@%5[9E6.HN;"XN8 M\03*H]S62?!MS)+YQGCW_4?XTEOK<$G G JVNI(3Q/0ZUQV-/3H]0TE2KRJV M?2LS7O[0OX74<@^@JPFIJO\ %NJW%JL?>//M4\PCRZZTG4H7/[F0CV4UF3VM MV>#:S?\ ?!KVO^U+5OOV_P"E!GTZ;AH57\*3F!XI''+$GS6LN?\ =-(8Y).1 M;2D_[IKVM[/2IDP?+7\*A%KI=OP/+;Z"ES >-"WOII.0KG0>&]".I2B>1>A[ MBO0TM4LHP(\"H=,T]+"$+D#BK,Z^:0$;-9O40BH[MDG/TK8T^S+8;&/K46F: M>V]2W2MYE6!...*12"67[+$-AYK#O)#)F5F&?K5BXNP<@US6J7N-P#4K#,G7 M=2<+L!SGTKETB+R%F/6K]W*TC< M4$<#$YZ56Y5M!#'QM%4+EYK<_N@>?:M& M0B%=Q/2J!U2W,H64A>>]%QHLV(O+D@;3S[5=GTJ1N'')]JZ/2#8?9DD61"<5 M3U>]B\X!*8.*.0O?#;GYLBN7U/39+)&?TKT=IMR?/Q7/W]DNHEH@P&:=R% \ MW>X=R0#4:[D.2:VM6\.SV,OR+N'7BL=E;.UAC%*Y:C8D^TR,NP4S:(SE^:T; M2R+Q @9J&]LW3M3N4XBK>;D"1\8JQ%,O<_/]:R 2#@#FID^3YRW/I1S&;5CJ M].UJYLN"_P IK9,VD:U'Y31@3MU8UPD=\).#Q6A"PCQ(DG-%Q&GJ'@6;!DMI M$*]<#%N*]!T35',>U\L*K>+6@%F&11N- SSP[TXS2J[=S3 MRF\[J>D((R3B@0(O/%7K91N&:J*N3BKUM&20*!.YKP6GFKP,_2DELV3.5./I M6[H%MD'/-;UQH\IYR^Y&XX%.5RW?'UKH[S03G<"*Q;K39(SZ M5HJQ/*5>AI=[58MK(NX5CBM(:.F/]8M:*N'*>MO$".!6/>H%8\%GQUK&2+3+L@S"36:"-K8%7?-W MQX[U$MN3G<*R*.(U>6625D5&//84[2K:8+\T;_E7:0V%KYVZ51^5;4=I8_9S ML1>G]VM$Q,\_OH@L8)'-,@NWA08/%;^IZ3YI;RZYFXMS 2K9XJKZ")Y;ZYD. M8W J 7^H \R<5ESW+1-A,TS[?.!RM&X7.B747DB\N0Y8UGSPRYRG&:HVUV[3 M@L#C-=1!"EU'\HI 844M[;MN\S('85J1Z_<^5L(;'T-1/92Q3DH,^QK1MK?= MCS8U!]A0Y,$9CSR79Z$?6E:SBV9?!-:5]"D2C8 /PK)PTC;23BE=C(2L,;85 M>:N03F+F0$K[57:$1MQS4IF;;@*/RI#V+0O%W;E8*/0FM.VU=!%MY)]JYDVZ M32;F=E]A4WF"UXC^8^]4H! D2@FM>^N["6$_9EQ+7-Q6JC[AJY8V6R<.6)]J MAI(7,R5+V[6,Q.QP:A739YVW1N!ZUJ3VTM7 MX["!%P5YID5VKG:,;JE>8Q\M0%Q)+(J,]JRI88S/L?I5NXUE-NUW$W MF"G<:9N:?86JR*$C))/I7I?AS1HHAO,)&1_=KE?!VGFYG5I%'RFO7HFC@ME5 M448'I3N!YWXB\!6VIW33;!D^PKGU^&$1/W1^0KU2X?S'/I5=B(CQ1SB/-'^& MZ6@\S:,#V%:VF6*:?"5 QBNOO+@/;D5S\T98$BIYQ&9>78'"C'-/M;DC!-9F MISF+L.M+IUT)F5#24K@:\FJ(D@!%6QJ$@M3ENEQS1<#>;5W5<@U)%XB=!UYKFS)[;&T5I>47;.!4"L= M2OBU[G@Y%,^UFX;(ZFL&.W?&0!Q1#J;PS[".!1<318U+59[&7()XJ@?$%U?< M;SQ4NJ,+N OCM6%8,(F:J$:$US*J[I'R/K5,ZBO:FWA9E.#6:%YYI,:+CWV_ M@ U7:0L>](..HIV]:8#,'^*CMSTH9_2J\\IB7- B*ZG ! Z5EDEFXI\LS22U M*D)858#5P1CO32@SR*[M-ERPP>M>NK8^=$VX#@5Y_KEIY-R_'>M$R&<^L*CJ*<(\=JE7..!2CK5J MY(S&/I2]J4TE/H W=SP*:<'MS3Z:V>PXH ;@#K3&(%.&>U(02:.H$>X=J3S! MZ4_RSGFE:+UHZA88&!Z"D;'<E.P#E55Y?D4[;&W04V7<5^6FQ M*^>:$,JD^#^M*P[$T7A.X<@[3CZ5J6 MW@Y?^6RYKJ;/4&:W 6-<8]*>6ED/0"H92,>+PE:1 -M!_*M&WL[>V7:L?'TJ MVH ZDYI^?:HN@93E>"$9$>#]*JO?"0;5%7;J(R)R!67CRWQ@4[AZE&[C:1LF MH$C"'YC6NZ&1> *SI8"IS6;86(V*XXZ5"8R_W3CZU8"QXY)W4QX@W4D?2DF! MD7H=5(^]]*YN>WB>7+POGUQ7:+&@?U^M4]2#>6VV),8ZXK6+$SG8LP];(DZB+QO*!B;)]>M3+XNL+@ MX:)L^_\ ^JN6:TFC_P!8HJ)HQW&/I57 [RWNK*[&8V52?4U7OXP%)5U;CL:X MD>QJQ'J%S&,;BP]S4W'H71*XF((/6MJ.9OL7MBN>34'E."HK62XQ9 M^^*+B($)9FQ6=J \M"V*T+24.QW"JVMC%HQQ5+4EDWAV56()]:ZF[96@)]!7 M%^&BV..F:ZR7>T14=ZH2.).I.-6,>?ES7;:6!-;[JY5]!?[<9_?-=-IK-!#L M-(HN$*20.*QM1N3:,S^E;#*P^;UK&U:W:>)E ZBF@.>N/$;R\!NGO53^WY > M34#:1-'(=HSFFOI$V,XJ1F_INN-*ZJ3UKKK:3S%! -<#I>GS).IQWKOK0.B# M:,.' M!8YI-XQGF@.&Z9I =OHMV/(",XZ>M5]3T9+Z8OO3!]Q7)I>R0_<8_G4PU>X M^\V?K0)HZ.Q\+0QG=O3\Q6E GGFNN\,D*5SZ5Q4UQ))K@)1>0*Q]0NI=S*@%)HZ8HFT_0)) MRS*P-3368@)21@<=JE\.:D;9'$O>JTTOVO46*D\FBQ;9=M$MPF&C)'TI\DMM M;G]S&1^%30CR8L,HJ,QB8\ 4TC&?,WH5;VT_M>V,..M8T?@U+)_,.,@Y[5U" M++;C=M&!52]N9I.]1:?9Q6URS M!%'X4K&SJW1N0R1O #*/FQ7.Z\"<&'MZ5L38?O@>U9ESYB&X!DVC!KF+W2[F"Z'E=,U#1W4Y\BLC6 ML?#AN)=PY[UT'V**RBPRX([U1T*\FL<&X QBKNLS&]MF,/4U)$I-LS[F]B3. MT@_0UE-K(WX>-F ]!4*6%T)/GZ9]:U8;.U11O )^E!<>5+4SKCQ).;.TB8#&M6^D2*=B3A?:L>>]D:3$9X^M-%0I.6Q-X<\/W%L6< ML"!Z5T+>+X=//V>0$E>*Y^VUF\L$8!00:Q)[G[;>%G'S$TKDO#M;G='Q);7Z M'"GFL#5(%G4F)&S]*DTK369 _85N*;9$VN!G'I5(7PGG4%W'I^HC[4C%0:]1 M\.7]C>V>ZWB(Q7)WVAVE_>%W("9[5I6EW;^'K8QVYW#'>K1A*M8ZX1&X8J_W M:QY],A6_S@9S6#;^-GDN"@]:W[&=;UUG8G-.R,^?F&ZKITDL'[LXXKSEM#O' MU0B-N3$=W'%:=S M(ZW#,$6N7UO4V$WEL,9]*AHZXTU8997Z&Y*@X.>YKHH;>691(CC\ZYO2]'-] M*&4XSSUKOM,T@6T*H['-!,Z9F?:+^U((:%(Y7!7-U/$S#[ZG'TJ?^W+*X'S1USE]Y\#7L>1Y+Y'?;7J$7B&>/[Z@FKJ>)3*-LEM%CUVC_"I MN)IGAD_AF^A)!AD_[YJHVD74?WHW_*OH,7NFW _?0H,]?E%1R:9H%R. !_P& MFAH^?-EU > P_"IDO+U!G>:]KNO ^D77,3=?;_Z]9%S\-[?X=7:G[BXK*N?!%]%G]VN*=Q6(4\7@CYU8_G M5A/%MK_&C5ER^&[^'@1+BJ,FCW:_\LQ4MB.I3Q3I[\%6Q]:M1^(]+(^Z?SKA MO[+NMW*D4-IUR&& *K2:,Q0QL93T(KF(]%U&YPH7C M\:Z[PUX'F$\<\ZC .30(ATC0;_6IM\P;:#QD5ZMI6FPV%HB;1O JS:6D=M$J MP1J..>*D8*#G)W>E(5B&8,[X'2M'3M.9CG%,M+9IY02*Z6"W,"<@4#&QJL"= M.15&\NAG!I]S=X8K6/>W&$8^U [(J:A=)&I.:Y*_N7ED.W.*L7EV\TA52>M+ M"B;I18,1(SZ$T7'%EJS\'"!@DCZFTGEB9< M+_GUJ9-*DMX@S.:V1I,Z69E=5*@52DS*3['#-#(O16_*GQS21GYLX%=5:01W?[HJ^<3B;CK+W84IC9HNM M(Q;M2J3WKI9D*8UJ#TIHM .A-9-%DZ-&YYJW&55<+TJFD 0YS4A<+WH6@B8X;(%9UU MI$-SG@[CWJTCY;DU9_AXJ@ZG.GPK!GYQDU*GA6U_C&16WM8T[!'0T%-(R$\, MV*'.T_G5Z+3K> 8B&/K4Y )Y/-.$2GJ302RL;&$G('S59BTZ)A]TYJ:*W3=E MCQ5IKJV@3&>E)B1AZEI VYS7'7<$EO*<,,"N[N+E+KA6-9[,,[[?J:-!F# M?2QV]P5'./2H8YXY)!DTZXM8TE_>LJLU_*_%;\'A6YEP"AQ]#6A%X&=NJG\C2NA-'&P> M>)-ZFK++=S,,D;?I7<0^"-N.#GZ&KT7@X 88<_2DV@Y3@%TM) , [N]6(;;R ML)L.?7%>AVW@U8FW/TJ#4=+L[2)CD;@/2H3&B?P7%Y:L6(SVKJI+EHB=[ K[ M5Q7A]IGW^1SBG:EK-QIX)GX'O5@=/)J0+\*:KSW#R8VL!]:X5_'*9PN"?PJO M-XMN)A\HQ]*=KC.[N+R)(<-(N[ZU3^TI) Q4@\=J\WFU2^GD^8L%)]:[CPVB MS:1(SL2<=ZFR),FX@DO[CRT(ZUNVW@V\L[9;IF&W&:Y2XU;^QM1,A/R[N]=O M!\0+'4-*6W20>;MZ<4T@0R+PWOPDB_I_C7+:E\0=0T:Y$-N M@*D_Y[5T'ASQ]->29OB$4CU%-I@64^']ZK;GE4_E_C5U/!I098;L>E7Y/&6F M!]OG_J*?_P )I911-Y;AL^N*D:L8&IK::/;EI!]VKF@W=GJ42E!U-<7XGU4Z MN\B*QP3V-2>&+Z/3-B%SN!Z9I-#31ZG-:P6D!(&"17C_ (MM;Z]GE1#\A/I7 MH%[K?VJ-1NK%N6C=22 3]*6J+5F>4Q^&9E!W@DFC_A'9%.2K?E7IT5JDG.T? ME4DEG;HN2H_*AN1<5$\GDT"8GY4;\JL67AN[9P3D#/<5Z8L5GG! S]*E\F ? M= 'X4^9@VD8&F:*UL 2><5L)M4[3UITA;&.@J-4RV3TI&3)99Q",$CFJ#+&S M^9D<^]5=:D6-E".?SJ..(O;A@QSCUID79J;/-MR%88K*^QF,DYQ1'8Y!-59#9ZDG.VFK"V?FS4XA4]!3NA$:1^W-3HLO8U M8C6-4^;K3UA>4XA&:5T!7-M*>2$JU!92,<.,+VK3BLPG4<5FY7*2L9\5BQY;K5Z.S7' MSU=6)0.*"H_AJ;W*1$MHH^[5B.)QT(%(OR_6G_,W7BD42^4,9[T+M!^84Z-E M'#&DE (^7I0T36\@ZUUUI&>:S/$-J#:,>]-;DL\QB5DR& M-/X/2I+J,1R$9J$ =S6B8@/'7K333B5[GBFG;_":8K#0&SS00?PI0P/2@LH^ MM,!O^[Q4>2#[TKR+W.*12#]* 8A>*:D?<5.(U MZYYH*XHN(9\V,4Y2?QI=H/7B@*!TH <=QX:HSOMF#Q'G-2_2ADR*3!'9>&]0 M,D2+(PR:Z]E^4%.]>2Z=>M;7BC)J&DW:WD0R>E0RTRRD?S?-3W49XJ1L9 MVBD"\5FQW&&+K,\6&Y MZU!MQUX%59 9\D)1LT)AA@U?DB#H<5GLGD&E8"O+"ZDLM9]Z\@A;)%;D3+*< M=ZRM7M@J,?:J@2SD)0TA:JVFKLU'@\YJX",MFJ=I_P A#CUK7H3H=G'"L\?[ MSDX[5 VEHQJS9 F*I^]1=@9,NF83Y:HR:9*<[:Z0]*9A>XI59-MF0^P( MK830[B9#]F9OP)KE-=TC4+8.9F?:/4FM%(DM>$(@5*L1G-=JUCM4?.O/O7EV MEWLUF,Q9+"M1O%5YTFROI5.0CNSIAD'$B?G49TB9#D2*?H:XQ/%$V/OMCZU8 MC\62K_$3]32Y@.K:WG488Y'M52>UE?/( ]ZQE\8R]@#4,WBEY0I-$W8UV7_"+V_EY*FN7\/75K;ZL\DKX M4FO1EUS1WA"F;'Y55A',/X6B+?*#2/X37;U%=.FIZ/CB?]?_ *]*;O2F^[.? MS_\ KTAHY0>$7QPPQ3&\)L/NL!7:1BSDY24_G1+;0?\ /3]:&4<._A20CY6& M:KGPK.&QN%=YY$3<;_UIWV%",J&V*EP20/K2;'!&)=3&.+J*PPDT]X# MN&PFNIN=#DGRB9)%8%]9/IV>3O%%SLC:Q=>W2%1@]:GM((U<.%.:S]%\[4&/ MFYP*Z=+>.-=IIHSJ.VQ6E!<8!%/M+9N3D4DENS2C9]VKL-L$7@FF91EW(+IM MD9W$8K(:YB#<]*NZ@G!^8U1AL(9D)=CF@M.Y86XLG& ,-]:C%G%+,&5OUJC- M8!#\K&I[:&2+#;CM'O0/D5S9%N\5NQ'85@QW$SW+*I'!K<34HQ;LA/45@!XT MN&=#G)I,OE[%R;41#$4;EZRMUQ=R97( ]14X6&2Y#RMCFIKZ]MX4"V^,GTI7 M#E9;%[%;VH64@D#M53-K>'*KS5"WT^XNYO,DSY9J^]NMFOR]J&[EIM%>\TV8 MJ"&&VG &"W >0DKE>IJM=>&$E!EQS]*+G1";2,RUC2_3 (! MK1L?"\?V@.X.*K6^GFUDX)%=;;7,2VH!/.*5BI5+F5=H-/\ DC("USFKZO%! M'E3EO8UL:[OEW&,G&*\]OXIO,;.3S5)'%5D2C6M0N)ML&=OT-.F74Y_E;//M M3=%ODMKM5E1>O<5Z!9I::A&'55S["J.>S>YQVC^'+LS^8^>>:[6WCDMK?REX M>M2QMUA;]XH"]N*IWMU&EUA.10;121S&MW%W"1YSC!JKI$4%W=+YC+R?6KOB M&SEU!04'2N=TG2M0CU !=W!]32L:>T26A[%I$26=MMC(*U:E*R*=G!]ZR]"C MEBMPEP3NJ_=%84SG%:=##F;EARGAK7+BUO-K(=OTKUK39?MEF)RZKQT)KD_#]AH MM]<-L8;OI5?Q)JESHSO%:9\M>G-",JC:ZG>,5:!\.IP/6L73U62]<-CK7$:# MXMNKB0QS$\G'6NXTV**7,FX@D9K2R.:[YAFNZ?;RV[J9%!(]17':?X/%Q<%H MYTX/]X5:\7/<1-((G?;]:Y?P]JMW!V$R2_NR,9J&[WJLLG>N\T[18;*!&A'N1]:ZM(XV?;)UK+URT MA0KL/6BQSR:3,N/4;J,_(PJPFO7,;#>RTD=F$AW'TKA=?UJ2UO6B'"YH-(:H M](7Q'N&&*GZ4?VM;R?ZQ>*X?PW=+?9RQ-=4VEEDRF2: DB]]ITF3[\9I5L]# MN#Q&0?K_ /6K"EM)83\P(I8'.[&2*9B[F^/#NCR'('ZBI%\+:,3DKD_45A^9 M-OP&;;]:F%U/%]UB?QIC.BB\.Z;%RB_RJZEHL*;8UX^EHI6&S=1)1]U#^5/BLWED^XP/KBJ]MXNM?^6H4?@*UH/%>FR8 *@_A1U( M>Y?L;5;=WA484BF?VI;3QGRV!JA+(K G.:311#<3J%+N:Y;5=08R;8 MR-M6=8U%(XV4-S]:YA'2\1J<"N5T' M=O0HHKO8U>2(;^.*+ 8\T$ CVD0Y;BN9U_0-[F1&. * M8[G/FQB"Y5UY]ZRM0T.[EC)1Q@U+(!#-M:1L ^M=):W>CBU433G=CG_.:FPM MCS.32+FW?+'I3O.GC !4G'M7?7<.DW39@DS6;/IT2#*J"/I2:'=]##@UP"'R M-C!SWQ6#K-EJ%U\ZNH6NR&D0%O,8 ?A3VTJ"X&U2:+!=GE<*F*;8L3O+W(&: MZ_2M!U34(E,I"6YZAA@UT\&C:3H+&ZN,$G^\*S-5\9)\T-DJA.@Q@4K"+4>@ M:)HZ[WY?V85DZCXJ#JUI N$' R*P)[R\NV)=FQ]:C5$8XEX]ZI7"QSGB O-, M7)!^E<_$"SX85U.K6JE_W3;A6$\31GYEQ6B CQM/!XJ14W]Q4)*,V,G-&Q@X MVDTV!I6MJH;(K3MU*R 5GV1"8\PX%;,"QSX"'K4-@=9H+Q(I\QUS]:U9-V1FLN\MXP,D"M9 0..:IWD.Y364D4F<]*B \" MJ[)^%6+B#9(3DU \F>#63B5ACN1M*X[6-*+4MQXP:O?:25^=,@UR&DM(+M$)R"PZUZ;)ID+:?&X W8%#>@S M AT2#4)PS+C)Z5N)X/M8P"$JA8F:+44B4<9KNE3:B[_2HN"1S7_",VSC:8ZM MV_A:Q0E64'_ "P4U.MO:KR(%IZEOK3]PZ < MTN8JP!85&1$!1O4]% I1D]12X%*]A[.7.T]J[7Q-,PM< 5Y[)*C38)^?-6@:.P\)RB.3:$SD\UK>- M-,CN=-#"+!-8OAJZ%JV^0#CIFMS6?$*W=MY3JH4?2FB&>3M91P3;3%GGK6G; M6\17_5"M&<))-D*,>N*=A(T.P"J%X![5RZ@M>]3UZ5 MU=@A%J1[4#N<+XL4R/@+_%4^BVBPVR2"/YL5T,VF1WLQ$H&,^E7HK&"TB & M![4UV"YR.HJ)9@7AR155UFV@0H1]*[1[>WG<;E'Y5I6>EV,?S *3[BFP.'L] M/GD0.Y;-67T^=L89@*["X%O&V%51]!3H%@:%RP'Y4GV_VQWK(LKA MS?+D\9J76[A_M\B$X3-9]NTAF'E#(]:0'I-M(LD0Q@U-Y8SD]*R="2;;^\K9 MN&_=X7K4E)D+-M^[Q49=GX-.BVX)<\T.Q/&.*!J5@2%.IILAV<#FF'=V-.#% M4/>@.8@:5@>1FB>4+;%AP<4@=I6(P*HWDBG,(/S'M3(;,X1M?R9)/%79[E+2 MUV\<"GV$4=HCM.<9Z5R&LWTUS=/%&3LSQ@T(1LQR"ZDW UL6Q55P3FN:T6&5 M(L-G!]:T9Y6MV!0DTQC])>Q"&3!S5#4M'123 M&H_ 4^@,Y6.W0]>#4OE[1A15C^S;KS,%2%K3M=-(0;Q2;L)&/%"[-@@UJ06& M,'&:U(=.3^%1^57H;;RCP :3D-:E.VTB.0!F%:<.GP0]%%3( >.A]JG2VRJKNJ1@ M47=@4KA:Q"6.>!BGH<]J%E#G! S4WE.!D@8JEJ S ]*7?M[9IF6W[0*L"(H, MN!BJ4;";( K%L_I5T;4AW,.E4[O5+&SA+;QO';BN*U/QM<&1HX "O:J$=3>: M[':=-HKE-8\3O<1,BX_"N>N;RYU YF8K]#4"J(^Y;ZT:!Z@9WE;+"E)P*4AW MY5!BFENPZTT2+G*YQ49)["I1G'-(2 <8H$,4$^U*2.AIY( S49!8Y[50"%!] M:-H S3A_L\TA&?K0%QN:.M+L]>M(5(ZTPN+NXZ4!O6EYQSTI,9Z4A"9P?6EQ MGFG;<=*7;^=,! 13@2W&*3;ZT^,L#TI- 5W&QMV.?6NH\,:FT9*DYKG9$9^H MXIUK+)9R@Q<\\U+12/8+;]Y&)".M3L WM6+H.M"Y@2%L;L5O-'R#4-:%7*V. M>E/V[AC%2LHQ35+ ].*@91N+48)QFLN2/:QS73'#+C%9EU;#DKUJN@&1QFJ] MU!Y@XJQ*FQ^>M"Y(Y%2!E1#RI:BU1A);-QVJ]<6S ^E7$3.*E78S M52M3MO,^]:%R2&;:,U0M@/M>>^:UZ$G9Z,<5H,F1TJKI$8,&>]7"S$X(X MK-WZ"17=3TI%7CGFI9,^G%1AF' %3J4B-B4Y S3HLNP/2I!ST&:0-MDZM^^4- MSWKT+4/!&GW$:E8P/I7GWP_SOZDV4S$Q,0#Z52D%CS(^3%U0/FE'D'DPK75WW@&ZM 6M M5,G^]FN>N=,U"U)WPXQ[5::)MJ5O)@;GRP*/LD#_ ,(%-.X?ZP$&F-(HZ,:T M4D!+_9D+>U,EL!$/EY%$W!5SOQTJA%-[&8G*3,*(X)P<>JWRW+@4]I=0'_+TYJLEZV,=ZD%UCEZ )#/?H,_:7--75=21\>>^*0:A$>$Y M;WIPN1G)5<_2I8QMQJE^TB_O&KT/PJ[7ZQQ,?F(KSYK@R, $7\JZG0+V[TZ1 M)[= S#M3N4F>F/X8<@8+P_PK:M_'L15.P1Q&0S&NHN7^T0 ME9$4+ZXK N=ML2(CQ0S2+&R1'J#FL>_O)8 P!X%:EK*[.>]5M12WEW+)PQJ3 M>)@P:H9"=QJ1K\9XQ4;:1" S*YK.>!R^U"3@U+1M$VHRTZY'>M2PM8$R9B&/ M;-9-A-)'&(RHS3=0>XC964D?0U!HDK'7VAS-M5?DJ/6(PL;$#M7/VGB"]AA" MB-3CO5:^\1WLAVM&,&FK&H+*W4H<<56F\SS2J$_G6B1SRD[F9KDSHY"=*R],@6ZG(E6M^2!6.)NM5 M+F)+1=\?'TIBW(I?#,+2^8@KHM&T_P"RQ=.!6-'K#I;X0;F]ZEB\1WRQF/RE M -,GE-O5KLF#;$.1Z5SBW:QS9FQG/>I(M1E1V=QG/8URFMRWMU>,85P#Z4R6 MS5U_7UA51#C\*I>']=>34%R!UK)CT/4+MAYJDC\:Z_0?"<=NZ2R9!H2(N=WI MTXG56(I-8?"<C^*]0CE$3R%@3CFO2-6TMK MFR,4T8SWXK'L/!=FJ&=OO+R.*I&,X]3:TX?:H%DD&216?XLAF&EN(B>G05I: M<[C,:J-J<57UK6+6VMV$N"1U!H)BG<\DM&U*/4% 9P-WI7M'AR65+=#<.<;1 MUKF=*O=%O9U9P@;/H*U?%VI+8Z4K6?'':@TY;(ZM[JV>7:K#=67JR[&4DYS7 MD5CXIU#^T5)9SSW->BVNI2:DJ^?QBB]CG:U-U&C%H"P'2N,U6'3[B^*R*F2: MZS4H6CTX&#).*\=U_P"WC4F8,X.>Q-+YKT4W-JJ_O& ;O0.6Q6N#&\9S$,XZUBQV@,Y/O6^\T,L3>4 M0:SK>*7SV)7BJ1@V*;!#%P>:KFP*\EC6BR@/P3GTH//WJJP(R6A0?\L\U RK MT$0K<*#'*BF;%/\ "/RI6*,%K<'MBHWMGB&Y&.:WFMD;I4+6B+R#D^E(C0S[ M#5)X)0K,<5NRZN3%P<5SMW"!+N'!'I43RR;<&EJ417]VT\K#/>F6_P BII^_P"3=_%2 O*/,'7%/3*-\M9:7H!<"']*H6FJVMO&#/&NT=25%6QX MJ\-GY7* _P"Z* W*7_"=7S2X)Q5T:]=7L!S,1D5#*/"UT/-2X 8]AC_&J9N- M#MY B7)_/_Z]-"U*CQ3&8LTA.35^"6-% = ?K4\S64D8,4@/XUF2K/(2L0!] M.:!V9MPBWD^8.$QVJ]]MBC7&U7Q7GUY8ZX'W0@[?8FH4OM>M>L6[Z_\ ZJ+! M8] %U'--M("J:Z#3[*RV%C* ?K7DBZMJ4K8D3:?:KT-S> 9,\@_X$:0'4>+$ MAFC,8<$"O.;D)&QC5!]:T]0N;IUPS,1ZYK+:547=+^=,&-M\Q9)^:F7,ZNI MP#5*ZUVUMQA&R:PY]6>X<^4>M"L@&:G=207 PV14]EM02H\0^4[<>E4!H76EA9BZ$E:J%-DH7-6M.U3=BWF^[TR:MSV$4S;X3FDV ML-L&0$FMC3+8+,O-8T*NAPV<"M&TFFBD#1C)%0]0._MSY<8&VHYH8I,[X@:R M[3794 %TJKZ5I)JEM*.HYJ7H-&=8K0XIM=U&S.UBS >HIO_"87?_/']*ZJ6UMY>#&N?I4']DVW_/)/ M^^:?,-':D#@CYJS8C*N M[/>IP*PYK"52>IKL"H/TIKP1LIP!63V!,X)P\3A<5>.:3@'K2%\#!HV[A[5)8K8]YIP04[9#WQ38B+8I.0?PIQ M '3BHY9H(^A&?K6;<:I&@Y9@6K$T'4UN]26+=D9] M:](B@5%& ,8I-EV,V/181C=@U4\2:-"FE,R8SBMYE)(V55U*XK1I&>5".E*Q2&A4;MFC"+T%*-H/%.'EYYQFE8LCP6 MZ<4[;Q[U/\F.U,&-WM0 Q1V)IVWWS2G;GBE_W:0AF/?\*E<.T?[]L>M:(R9#)$ ^0:9+]WTJ63"GWJK._K56(*48 MQM7H) HY/%-BN2W'WCS4MK@1-EL\52GG&[KQ203CD MTK@)NN*"DB"*,0G*C'O5Q+A3P_-,#(QQQBHI8NZ_96T;-O7>.U<7J?C2:9ML6<>U<5T6E^');S;(\9(/M0!EK:S7; 0@GZ M5TVB^%))'5IS\I]:Z33-$@L%R4 _"M62=%CVQXS[5#8SF]4\/PVT#&/' [5Y M](I2Z=?0UZS<@R6K[N3@UYGJ5N8;EV88&35Q,V52#MZTJ1!ESG-("&7VH#;5 MP*8#< '&U2Q+L.2*H8Y\,>#^%,Q@#2%*0;L\U?09E7=B>6%8TK-$V*[-D5XL&L2]T\,0Q#=NE:XL2K<+S]*KZE9L+9B5YQZ5<26>.E"&S2L).,9K)\8Q_\2IVW M5>MSL/%5O%>UM&;UQ6D5J0S \!R8N0N>_2O8)5)B4].*\7\%$)J*C_:KVN1Q MY"9]*517U!;C$? P:<2C#K48VL.>E.,8QQ6!=AOEX.0V:=YC)4>[8:=YB'KU MIIM +]I+### J&2WM)OOVX-2%X1]_&>U)N!^[TI\XBC+H&F3]847-9%YX&L9 MAF*11]#71-$6.3]V@>6GW::J"/.;SP!<(289"WL#6%>>%]1M%8LK8%>S&Y<# M]V>:;=>7-82&X +;3UJX5&V%CYZ+/%,5=2"#5V.1RH[#UK5U:V@_M!@0,%ZZ M>'PB;K25DBBSE>PK;G)Z'$;S_P ]3@?6J >/&&^]28M_\ EI^%.X'0C1+.YCQ! M.H;U%0/X9NT/R9<50L;>]DE_T$/^%=_H5MK$:(;D/M[YI@<-)H6H^:H6)Q7H M?AO16MXHY+@YXY!K;D>(*.!FI(6\PA>U 7L7#:V4RXV+FFPZ+:J^[Y5S3D\F M,C=C-7%6.4 #%#'XR.M;MS)9K\Y*YH'KPR+< "0UMQM$&W@C-96ICS+@-U HN4HV)='A8-ESVHU"*,SG('UJS8S1@ M,1TJMK,B"!V7TI7-%H8U_)'#$51@216%I\$\ETQR2":=$[7#-DYQ5[2K@13D M9I%*5B^852+.?WGI4,44LQ(F!'IFM58%E<35?CBAEC)8#BE8KG.7ELI8CN . MVF+;&;^#-6[O42UPULIX!QBK%FKKCWHL/F*,>FLK9VYJR]I*D>50GVK3N9#% M&".M.MYFD44,7/8QEM+EU)$9%4Y/M$+?O$(%=[:E1"=V,UB:TT97YL=: ]M8 MQ;=R^"!6@L4CC[QJM;*N 5Z5IQ*Q'%%A>U*AAF3G>2/2H#(T;[F&<5J$-G!I M)((C$68#-%C-U+C;2\652/N8I!*GGG)_&JT42L3LJ%HW60YSBJ1F]2MJMTRW M:A#D5/M\V 9&>*S;TXN%)K0M[Z%4 )%#9I%613@*VU]F1/DSTK3>..\E5HE" MKWQ1<"TGM]PV[JDT^2*"$@D TKBD375C$;=0" :HBTA1.<%JMKEN7NC\I)%2Y'1&G8AU$37198LC/I6?;^'I MI)0\[$\]ZV8I'@^9JT[6]BFP&(J;A*))ID4.GJ##:"1\=JV%U>_7[MDRCTI; M2:VML.N,FM6WU%)F R.:I&,D93:A<7 _>VY7ZTQ;NX4'RT*UHZQ(05V=_2G6 M,6Y:]AM)8Y;1'XW$#-!; MDCDH?"]JET'\E1S5Z\@6V*"),?2N@F5!&7'6L*YN-\H!-!C?4LWNH&VTQ2\? M&*X&76;*750LT2X)Y)KN]6C^TZ6JGD8KSRX\.^=>Y"=30=4&^4]$TR>P%FQM M N[':O*_$>I:K'JDFQW";J]&\-:,UE$V5(R/2HM2TBWNIV#("2?2DC.1S7A7 M4[Z2,>8S-S7H5O*SQCL<5GZ7HUO9VYP@!^E6;>;$Q7L*M&#+>/FY//K01COF ME(SSVI,^E-#09]\TE'%)D=*!ASZT ;S@G%(2!UI 0.:5NI+W,^_C"-US63*V M.G-:6H/E_:LR3_9J;#(E4$Y)I).#35<;\=ZD;:>O6EL%R+&[MFGKQP4II;R^ M:77,WE@\<BZ+?/=D-7H]M!4\S-.1'+ MR76K0@>7;3HW/"C\JJR:1$!G:/RHYA6.UA\4V-R0-JJ3WK1CN+: M0;A,*\JFL)(FW1@\>E$=Y?1<*STR6>FW6LV5H,.5>H?M.EZC#GSD0GM7F[?: M+H_O-QJQ%!Y2]P:+H#K9O"=A>'*WBC\?_K56;P8D7,5P#]#6''/&D'Y MTT!R)M[A&_U1#5HV%Q/"P64$<]ZZ2+5-(D;=*4\RGROI5SRNPGM0P+FE:=!J MBXWA3BL;6K=M)O&"29"UI6-Q'IS%U( KGM?U6.ZN&RV<^]%@)K?6XYSME('U MK3CEBP'2X'TK@&VELK4L5U+$>&/'O2<;@>A1ZI+$?E8D5=AUMV^^N*X>RU=5 M'[UN?36/ LC#(C)%=2FEB:3#D%:MR6EI:6[+\H./6L)&B1R:0O*=H7F MGW=O+9VYE*D@=JNVDZQWAXXS6Y?Q)?6!11R166MRM#RG4/%#6[E1%61)XCN; MDX52E2>+]/DM+_ -8T#LH&[FM4B78N27=U(.9&JC-)..LA-7QETXJG<0MZXJ MN5#1?\)7;P:PC'GFO>;-?M5HLN_;QTKYWTV0VMVKJ>0*V]L#%0>"7,>J-AP#GN:&M"4]3V".QMTP8[<#Z5( MPQQMQ3[1I7A!W \=:9/.J/M?D^U1:5LYXCX]:9M+#('%.%UL7RRP M% M0VCUIWEKC[U1"2%.7E0?C2_:+0<^?&/\ @0I$W8I4#G-*)!Z5!)J%@A^: MYA_[[%0-K^E0_?FC/T<4#7F:2MGM5>XE*-]W-9LGC31X!RRGZ-6=<>*K:^;- MKPOUH*V-\3QMU(I%G5),ALCTKF3>.>0U-&I['P6Y^M");.LN[E)K=AMV\5Q% MPA6=B#WK4.H^=&1NK)F)#DGFK1DR%\XR5S[U3?YSTK18DPG%9;[MW%63H2PH M2^!5P9BXJ"U1MP-33YSR:!H<\S$<#%,R9!MZ4S>6XS4H3:NXD8H6HS-N0\4G M'-3VDS.<&BY#,?EZ5':*_F="*!$]PI!)!IEMN8^E: M&D7)I8K/8YMXTP6&1[U5;4(EZ,,?6I&F7)%]!41##W]JJ?VJAZ,/SI@ MU1-W7FFD4I%\*3_!2&.0]4(]ZKQZF-XK2-ZKQCI0@O!K6 M&/[P^N:@;PS;Q'&\&MZ]NY$C.UJYN6\G=_E:D:1CW%E\+P[=RS#/I6;<:6MM MD;MU:R2S%>33)(FE;YCDT[$R.<\@RMM";?>I!I,^-R@M720:62IJ:#R96V[QGTKO;NU@NK9@% .*\XU+39M/G:2$]^U38: M;.EMK=44,#GVK0C)88"XKC+75;F.,;]W'?!K0AUR0G&\?G2LAW.AD#+SMIT/ MSCD5GPZB^ TS I2W&O6D<96/AL<ZI>9$4AVY[5SQM[ACB96SW.*?*B7)DUSJMWJ#%C.P'I578PY9?QI6C6W M'(YJ(33W+>7'3M8:8K,5Y#?A5FTL9]1;"*2!6SH_A:6ZVRSC*GKQ7&8X2KS("?0UU/R0+LB3;CTI6<8^05&-Q//6I;8[(D0/)]Y MB*D8+MQC!]:CW%?ON:XGQ-:"%"X&:=+F.X,?O3S&2,YJDR6A@ ]*-OM2C@\T_:Q''2 MK)(]OMFEVT_:1WI=OIUIB&A1BC;Z\4_:>_6EQGKS0,9CV_&C&.V:?@_A2TA$ M>"/>G=NE*<]J!GO3 :![8HQNXQBG]J0 YYH&AP&%P!^-(N%ZC-/YQUXIH&>E M KC&7G/;TH@EDBND9<@ ]*DPG>']3%]&D1X( KH)$VC&/QKR MGPUJ;VEX-[<&O4X[@7-FKJ0@C EN.:8>#]W-3J-J\U$^XG(Z5+N4AA^E&<"C?G@ M=:,$_6D@:0(QW#C%&OQ^?I#+C''6F@E6&>:GU(F33B/:K5R3C/#F;35T3&U.6P+&/ M-8(IV)\JPY%,9E4XV?C31DZB3EF'YT_9W!,G:0AL9_"C"MU.*JC5+ '#,N[ZU.L]M<_ZMU_.I<"E8,L#A M5S[T^3<]LP9>U-*S1#5^++<03JXXR]>B>%YV_L2'G M/R]*XCQTJ (0/XJZGPK.O]CPKG!VUO;W3(VY_+D;YD%0M8V$@_>6RFGS2+U) M%4GO,'&'=+G!VPHA/>LO_A$+*-]V5>M=F+KN!J#S&4\9JAD]K!9 MV*!8X%R.XJ1[AG^ZV!Z565PW7K4BJA[TE"1Z 4UDC$;&IAH]\H^ZPKJ/[>6,8\IA]14T&H_;#@.H M^IJEJ"./72+HR9>5OI6DF@R2P$%STK8N)K:W?,LT8/NPJ2WO;>4?NKJ'_OL4 MVBCC#X=DLYBY;;D]:6Y\/7%W;,R7)&176ZC937\6%N8SCT85CK+/IK^3*X9! MUQ4,#BD\'76\[KIB/K_]:K:_#V&=YS6JQW<+,MO(S*.A%5K.6Y$9\\DM[UT=CX?U2 M2,'S588Z?Y-9.M:1J=I-GD >U0;**92;5KFP;=Y!<59;Q%!>695T"R$?=K$O M+B^:/8I)/L*H6^E7SW GEC?;GKMJ+E.EV+T1/V@<;5)KJ8+.V6)7XW$5R.J- M*@7R3@BG:7>7LS;))UP!W-*XI4[:'7^:EN=P?('\-5Y]5:Y(6)-GKBN6NK^> M&\V%MRY[5K6FI0*,O$P^HJDS&5.1NQ:9%)&)./,-(8IH'&%)%+IVN6#RB/(4 M^YK<,]G*N!<19/\ M"JMF$,JKMS[TS4M(EG7>*GE3;;D;@KG]8NC=NJH>E-(SE4 MGT)-/CCFF#O\P/\ #71KI5M-"61 AQ69H^G_ "H[5T!>.&/:6'YU2BB>>;,! MXC8R$D>8,]*T+:[CE0#8(VIP:%G/F$$?6L^YVI-N0@)4[;%69JM9F4;C/FH5 M::W;Y27]J;87UNXVEAGZU9=E',; ?C0I7!Q8UKB5TR8#FBWO6C.)4X]ZL13- MM^9@:;+Y3_>7/TJE%,Q?,B=A:7D>$18W/\58M]))8/Y8=&TF1P*5BE>Q/H1616)/6H=5TR&X+!HPV:SM(N7BF= <8K;ED=DR.M-! M8H:9X9LU/F>6H(.<5T: J@C$>T#O6$M[/$V.:TH-19A^]Z55DQ6N6[F9%M64 M]<=:P((P\A.=U:MW/;/"?7'K61;'$G[KBI)Y44/%$]Y;V7[I6Q[5YS#K%^FI M L[=?NU[1>6C7EJ$0YP!@46NQ6SMR:+I<-@$"FVX96SF@18DW% MLC@>E-R<34K%(ADG M%9[7\3RE%(S]:EA8AO0-VHTVC M1\/7/V>_5G/?I7<72-J$'F1RXP/NBN"TA$FO%#]:Z]YC90?NCVK-IEQDS+BN M7LYF6:SW#/4U;BDM+EOF*IGM4-EK$=U*R7?/I5NYT>UGB\RV=0YZH6W#YP/8TKLKEB5#;.@_>0X M^M0O%;G^ UL#5H9^)UR3UI)%T^3[J9*<]:LR6DSH.*JZ,K26XR-%";SS5VV!<@J M<54\ITBVFK=DK <56@[V-/>PCP?FXKG]0=3*1LK>+'9Z5@7QS.?6GH5&UM2D M![8HIS _6E"$CK2#0CP?2GJY7H:=M91UIH7=181(+R=/NN:7^TKK^^U0'@T4 M ?30(['-)MRT&VLK5ODR=IKRO 6^D"\8)ZU2,Y%P808JK<@M[4_?B3!&?>G3!2O)JQ M)F>F4D!/K7J?A?5HXM.12^*\Q@B>XN!&%)&>PKN=*TU;>V5I2 !U!J)&L&S> MU.9KR11$^ZNGT#2"(TD89.*YJRUO0].!\Y 6^O\ ]:G2_$ZTMV*6MO(<=, _ MX5%BV3>.+,@-M&/E->=>'0\6K-N;:,UOZMXRGUE#=E8E+4]JT[5+6'2P&G7CWE\R2M(/)/49KKWT2. M.,+"-IQS6)J1ZYXJATRVS'\Y]!7"W/CNYFE+1V\AKLU\)ILWO^JM)OTJ#?X@N?E^S3+GWKVF#3].MA^ZAQ^%2$0KR M$'Y5=UV"S/$T\.Z]HJW"1 MCY>#5(EHL'[N,U4=!GGBK0P3@\FF31].,U5R&A00D>:IW%R.<$SFN72YF'K2SZL8H\;6S2L7%=R_J6J!002:Q4O\ M>W>L^XNGO9L!6_*M"QTQ^KT&JT+RZE\F-IJU:S>:P(HATM6(W=*TX+&*!/E6 MFB)6+UIMC )/:I'9&?((JG'^\;:!BI<1H<$9/K2=R":5PL#<]JXV\G$DS!AQ MFMS5+P11$ \D5Q[W9CF9I5+J3VI,1>58I_W*XR:AN/#MS#^\09'M4<5W&'$L M<#@CVHOO$FIE-D 91]#1816.IK$?(D;:1QS44EM]I/FI*#CM7.W*SR3F:=6R M3DG%.CU@68VAOUJK ;PO'MOE:(D=,U8WV]PF7PF?6L:VUI;D[6C9OH#5N./S M9,R1MY9[8I@%QIMO.^%F7FM#2/#$44OF>:K59M5TB)E(8[;D>M(J;6SG\*D'(^7BD4'?R*D!0='@>E4A'C^J6IBOSGUJ->F,YKH?$MD8KAG(XKG$P3Q6B(8NS!S3 MA3\9'%)P.".:T1#&$9]J *?QW%''IQ3 ;[4!<=\TXX["D_"D-"4H /4XIV > MW-(0!U&:!"$4G?%.X[BCCTXH&! '>FC&>M..,<"F@ 'B@$.QQG--S[XII;G& M*3_>YHW%8E'-(1VZTW.![4F23Q0 R1S ZLOKVKTKPMJB30Q1L_..E>;NH8?PJ)<'H.:GP"F".:I"/+/&\8W#/%< M%C>/X]C+D9KSN^4K;;NU:(DZ7PO QM"5Y%;L+K'(=QJ+P! +C2G ' M-0^(;&[T]C* 2I/84-#-*1E<94T)'F,D\5G:/=I/"%(;")L!=WTH2!LT64 CG-277S6I ]*QE\1637;&9-@0[JN*)9RSGRMJ:=,)+=<>E>5:I/#_ &Q&XZ9%>B>' MKR":(#S4'U-$UIH"-F(MY^".*DG1MX(Z4IQG*NOUS67J7B"#3D9)&#-CL:QA M%W*;-,KN ;FM&VTX2PC>*3%)AG)S7#)'N&W8V?I2D26K!AQ4.F5=GT/I&HKJ$*#/45IS6H4?> MKP73?&-WIX7RW(Q]:Z*#XD321XGWLWJ,UGR:AAIV TY-1ABD50=U=SH'V9HTE=E M ([UP>G:9;.V9ER175V*Q.%@C&T>IH; U]=O(4C;[.N\XXQ7"0ZQK27,GEV$ MQ7L1BN]BTZ*,C>P8^QK+O%&KQS,LD,L?U-<_IOC:\@,T37T3-@5+12B>SZ1J%CJREY MKU("0S-@X8C\:(KA[.?SXV.X=\TT,^H+5=,L; M&]?^R3%KABI[IHT(M(EFE8;<=*SO$\\%TK% .!7*ZMXT#Z/MM6P^.QJ+PQJZ7ELW]HL M#D]S6;.J#U,VS^S"^;S64#/>NBNKVU72VCBB!X^\!5'6QH$,?F1J-Y]"*Y@Z MQE_)B!$1K-G5$VM!\+/KYE(8#'K65X@\*3Z #('SSVKT?X?X2"1HB"?:LCQX MM[=KL$3XW?W332%*2OJ>9VD<[2"9HF91WK6EOXGBV[-I%=G8:(D?A-I94Q(% M[BN+TNU2YOF29"ZY["FC-SCU.3NYYEN6*,5&>M0#4[J-P1.QQ[U]%1_"[1]2 MT99$B5)67JV*XS5?@C>&0M9S1[?08_QK5'#4U>AP-GXON(<*^]A6HOB57&]L MC-2WGPGUNT4L06QZ+_\ 7KFKW0-3LRR/:S''?8:3$DSM['Q5"83&7QFK%J(+ MR;8K!/ V7@D!'JIK3M-5D4A=?+^[WJ*0QV\0(0AC MUI%I&;8RK;WXB9N];L[!ERK=JYR6T:XF\Z/AJF@GGMG"3 L/:E2;T4X%:FG7RHRV MS###BMF*..W0A %SZUSVI6,BNT]M_K/44[7"YJZE($M6PMBS MG/D%=0;YO?BI(YM-1N"I^A%+4-&:D$A2S4 V"!701R29(%*I7.F0SCVNMA!"CO6O=W\0MV)(.!ZU+>IHHZ&)8_+*LS8ALO,'^L'TI%MOL_.:D#YH9/4B>]1(7!8U:R=H%,![K\_!XIPP!UIJ@D M<]*:X /%%P'=.^:>'XIJ8["AL9ZHKG M,<9-)@8EPK#@U5+;>^:M7,C.":HK\Y/:I>P TGH:C^_U.*?F,-C'--E*^@#5#,^:TK4J3BJ]N M% P1S5F"(!\BHN!JI!&\745F7ED0/E7-7XP^/E1C]!4C2-&N)(GY]JF^@UJ8 M.CQ%M2"9PN>E:>JSR+\BHVW'I2N58XYMWG-L MX.:GM[ZXM) Y+,!VK2BBM0Q+KACZU:CT3^T&VPLHS1<3DR2S\0Q3*!(N/K6A MNLKY<>8JFL:\\,2V0^<;CZ@5@W GMF^0D8II7&JAU5QX?+Y:!@P]JSWL;VU_ MY8,:SK+6M5@QMG&T=LUOV_B\H,7:EOH#5:%J=S%FDN,_,"M20:@%78_)KH/[ M2T;4N#'M8]S_ /JJO=^'(9(6GMW7'4 $4G8UC9F:_E3(3D"N1U.W82L0.,]: MUKIY+.7:ZMU]*V+;3$OK925ZBLW+EU9O&GSZ'-Z19L\>XK6LT:*N.,UU%GHL M=I9.=O:N9N#&;AUVD8)J54NR:N'Y$8]T%#\5/:!=F!S2!L_>%5<8F,G&:=Y:_P!ZFE>X MZ4W\#0!],8+=>/I1R#BH(9R3R0:L@Y&:U1DQ.>U/[4PYSQ3A\U,5PY[=:,O_ M !#'TI?NF@DMUI6&.!###5G:A9QNIP,\5>$;9SN%/:VW(>16YCW2$<\TD@:*,'S0Y(YI MIM)IW 3I2PJ[N$0=:Z73-,=%WR8'UJR+#-.T_P#LZ-;@J"P'>HY-8-[?" DJ M"<<4[6M9CBMF@C^\.*QO#Z?:M3C+G#%JSEYFL3O].\ 6>J*'DGD'XG_&NDL_ M!.C6!&[YB/54^,;!HBSY&-U%Q-6-CP==EK>-2>:[B8G@ M^U>6^$;K9+%'GO7J9^>-3[5-@3&I(QX-2[21FH0NT\U.N2O'2E9E#0<4A'<4 MC ]J3<<8H'8:<=^M,)IS>]1'-*]A#A]*:S8;&*;N(/)XIC*SG<#Q33&BRK$" MA_)D&&49^E1JXQ@U&_WLBF!6N]'AN%)50#["L"ZT>2#)'2NK2Y$8PU07(-PI M H$SB\M%)M-6@S$?* ?K2:I83Q.TO\(JI8ZE$,K)QBFF0RU/.#'M9!^54OLZ MRJ2H ^E+>7EO*"(R-WUIVGD[?FJT9O1F7=V[QJ2PXKFKEV64^F:[O5 GD'OQ M7'PV$MY?; #M)]*HE,2R6YFP(QP:Z"TTB12:G5 !U&*H15,$B#TIC2(W ZU28[$(BR.:C:+/:GLS*>HH\ MY>YHV$R+9M["G*Y7@"E+@]",5&6 [TA%E9L4Y9 [AO4CPO\2JJG]:6T:VVJTV#^%<1_:DU_<')Z&M) MC=RQA8V ^M(#T&"_T&.+;(0&_P!T5#<7F@D$J?\ QT5P4>AZC<-DW*#/O_\ M7K7L_"ETP_>7<7_?0_QI@9WB?5K06SK;J/;BO/%G:>Z!2J^W KG(O#5T MD>^&=.GK_P#7K-FTW47E,623]*3 U'U'[2^02/I6[HFI"SDW2PFLU MS/UJPMZLK".-23GM6TNU>W7<3G/K69X;T$RVB7 M3<=^:Z7 4;5(XK%C$(&M+M/?I30AH4 MG[M3Q#%(HP.*54 MAAWJD0QV21S1_*F DBG#.*T)%^E'\Z.O3BDYJA"_7K1]:/KUI#FD [!/TI,8 MI02*.6Z4 (!Z48]>M+C'2DS^= >>M,*FG_6D.: &4ASV%/VGK3:!B"EH/M2 M8/0T"&DD\&F3Q%(]RT]U*\DT[.]-IIL9TWA#59(56(G@GUKT9PK6RO&?F(YK MQ:UNS93J5. #7IWAO68]158BPR!ZUFQHUT/&&ZT,A/44^>,I+\O-)N/>LW8I M N1VJ9 3]*@).,YJ:!B2*I7 X'X@1XV8&:\RU3BTKU/X@*?DQ7ENJ@_935Q6 MI+W.^^&3Q_82">6Y\]5VX]*\L\!ZG!I]MNE< YP36YXI\>&ZM! M;Z4I:7H< FM+:@'8\BJ3ZU.X]C**V71F(^@I$-K$VX.V*E_L"0$L\Z'Z$5%* MMM:@B16;'I5)$LQ]3FBDN0R,U:ND7 5\>PY7I0H) M#N:DM\UQ\I ]15NSLH85%UN)8T,-OI6BT$6=6U=KPK& M% XXJ"VM$^\>:SF^=MPXJQ%<2?=6JY@L:3RV\*XP-P]JRKJ<3'I4@M9[J?& M>M6+C1I;906., _A62R,HP:L6K2QD%3\M18:1?O= M+5DRO%9(L)B^U&.?K6Q)>F:/8O#"HK.3R;@-(13L.Q0^RZA:L&#L,<\,:VM+ M\7WE@X#_ # <F:;XVAGM074;R/05 M)+<7.L,/)X7V->500W,9!C/ [5W?A77DLN1 MFK@?S3R-H]!3H_\ 2XQ,I!0] *3R_GV@$?6@"18E4_NJOHT\<8) ]15-8GA MYSGZ58>[(BPQ#>PZU,AHW=-GMA"9)I6R/>DN/$I)\JPRS#CFN>@L;^^E!@!2 M'/.177:7H5E:@.W,F.>:J)G)ZF=/9ZKKUGY4S&-6[JQ!JG;?"VW=2;BZE[\BW:1G7@9QFM1Q9Y%XN^%-C#:%[9OF_&O%=3T.33 M;XQ=<&O)8F;!(X!KR235H]5UH>8A&YNA%0S>-NI@R6]QC*BH/-E M8^4!EJ].NM$M_LFZ.,]*XO3+2(^(?+D4E=W2@SFS+CL[ESM*#)JP=)DC&93M M^AKN]7TJ*WLC<6\3#:,\BN+B:_U)F"J6"^BT-$TYW(XG>)@I)*^YKL=&\-W> MJV;7$)VH.N#BN$F>6*;RG4JP/<5Z;X-U:YM]&DB3!R/2LVNYUQEV..\06+6> M5\UV8'D$FJ%I<3?9]FP?6NGO+.:\O6:XB?:6]*UG\.6D.B-<#A@N<$BI:.A/ MJ:?PRU%;28K,20QKTGQ#>:;]C5VC3G_9%>4?#VU%_FZMI9AWE0PQ@"L%/!EMHUSOM\/N/\5;VCZ?&=.!M[B/ M?C@;A5"]@UF.X7<-RY[+5I-'/*3-V_@OTT$?9.'QP <5EZ'O+5+:::T-DMO8SQ@@8 R#0RXM6,W4O MA_X><#_P"O M71W-[+:Z:HD0LX7G I%+N?/^H^"[^VG,,2@CMS6)?>#M2C&9(@/I7JM]XA9= M7^>SE*YZA#_A73V-[HVIH%N+=U/OQ_2FANQ\QW>FW%D3N4CZ54668' D8:Y\'=3MI'>WY4=!@?XTS)V;T/.5U>^5P_F#(14PB MA!A5"C@ #.!R>I.2Z'+ M$$55EOTLFX_XUS5SX+\1::Q^SC>H_O,:]Z9I3)]]0OO2/ M'OX?:1WIV%S,^>]WB&VRLUN@ [C_ /57+ZW-.[,9UP>^*^F=0LM$$9^TR1J3 MZL!7 :WX*T[5)&:TGB*GH X-0T4IL\9T)K<7&6SP?2O0H+R%X55#GCO5ZQ^% M+*Q*. ?J*FNOACK:)FTG3/X?XTDD/FT,MA(S97;^=21K)_'@?2JLO@SQ99R? M/(K*/1?_ *]0S+JU@,7%O(Y_V4-:+8B^H[6Y%MK)G0#<.]<:VL2R0NK$_G6C MJ]S=RPMYB,J^A&*Y=L\X-97.^,?=+6DRD79()Y->H6B@Z>K9R<5YKHT*&7.1 M7HUG)FU5%8=/6J1SS33)XB<'(%#9)YXI%CD Z@TA5SU(JTE(NI;FVL !4=X8U7.<&N?N=5MXG*[AN^M!1UGVB#^ M\:LQNCC@\5R6G7'VMN'!_&NGM[=U0$L,4,"RV!TH7.>*C(.>"*<#MI 2%F/% M,((/-)YGS4I)84T ]7]10Q)Z#BH0&SS4A)5,YXH:U Y%0W))C)J&2]C4]0* M26^BDAVK]ZDP,N9OGP:JSOL^Z*GN,X+=ZIKF3.ZI %+-U%),_EQD^E(I97Y^ M[6?J=WM!16'(HL!DW]\URQC'8U1C#*>:%1O.+9ZU854,S+RC "M+29;F M1N'Q4RB4CLM0CM[)2]I@XZ9%:6B:<=7LV>9$S7+:L\T>FEED7=BJN@>,[G38 MS$^""?2H42F^Q8\2Z*EC,3DCGM6/I]_<6LX,9) ]ZT/$/B.._P!I922?2L5) M/DWKQ5./K5*]2W9V,6<')J+86 MZ, *HS[K:3S589%(M5+';ZWH\%ZD;P $CKQ4>GJD>VW'WAQ4?A+46U&*19". M!Q4,PFL]5:3^#-<]2YZN#ES,WI9?(A,;=Q7)W]KEF< #-=!\U^F]2.*Q=6D- MO&0QK&+U.O'Q2B_WK313MXKT*6Q\ZM9D2PDMQ4NP MH*=$K%N*=+E1\PJY,BHO>(BV[@J*1[6-UR0*(YXNC4YMYY!&VLTR[:&?-IJM M]T"J$NG2)]T"MP%@?:G-M857,(Y1XWC/(IN]O[HKH9+*.0G%0_V6*.8#V*UG MCW_*Q-:\<@*>]<]Y9MSG&*TK.Z# UU)&9>R&/-2@<4Q\8R!2QMS3L@M<0L= MV*F!(' J-EYS0K$]L4,-!/XLY-2@_+U.:9@>E/7TQFH: S[T*5_>*-OTKD?$ M5O8263A H?U KN;FWWITS7)>(=)DEM'$*G=[5DT4KGELL:6\A"\G/&:5?M5)''M1RIC3/9O"/BB.]CVELD>IKLM\TJY*#8>]?//AO49+*? XR:]TTJ M\EN-,C8YP1UK&4;&\9%MRGW=Q&:XOQI:+]DW5V2^XS7/>*XO-M, 9K)2UL.6 MQY]H+^3J,?/RAJ]BM'$UNA4Y&*\4@D^SZJJ_[5>OZ#)YMD#TXJ[&<31;;_#R M:3=@8/6F_=<]J?P><4F:(11N^_Q0P 'M37EV]!FH6EXS^E0QCR0/I3&9.QJ% MG)IO)[8HL"0YBA/!YIO(IK'_ &?QIN\XZ9H2&UH.;&.33 W-58\+$#^E,\_Y^!6J9E)7 M+,L/F'#'BI8K6VLU\Y<;J@DF/E],5G0W$]Q=>45.W/6J(L6;Z^>XDVKTZ<4Z MQTMG?>V>:U(-,4)N9>:F$BP\#M0D.Q+;VZPJ 5&![5+).B_ZO%49+LD56,K- M2LA(T3<+CKS4#W S]XU1\QLX-'FCH1^- RT9@>I--,YZ"JID';FF^:,TQW+) MF<_2DW#J#S5,4;_QH$3D^] (]>*@#X]Z# M)WQ^% :$Q(_A)H$@!Y8U6,Y/\&*42[N"N/>AH$7 \9YWG-+O/9C^=4]^#@"G M"0CMFE:PK&@DC?Q,0/K5A9O[KD_C64+@CJ*=]KQR!BBX>AL+M=QX>\&Z=; MPY,R2GTS3YAG*V3W2(%M2SG'0FM33[?67N0TEJNT]\?_ %J[M-*MH0-ML% [ MU>@2&/'2LW-E*-SB+S2&NF"SILSZ"M#1?!6GQ2^:SDGKS6]?VPD!D7L*SK*\ MD6Y5C:!-HGV:$#R^E(D.#G)YI4DWC)'XTXR@=!FI8T/"'O3\8^E M0>>?2CSC18"RN.U+D?C5<.3[5)NXZ4P)@ >IIQ4+R34*28.,9J9ON@]:5R61 M7Z>=9%1R,5Y?K\ ANL 5ZV$WP8QVZ5YYXLL2+G?C&*M:DLY9 0,FG?*3UJ,2 M[CLZ8I^.U:H@4[>_%+QBDQCJ,TO;@4[" =J3;CIS2C/<8IU+J T*/QH(&>3 MBG48]J!C< TNT8I:2@0FT"DX[:GMAA@#UI@(V\K@T^#)E%"!LY#Q]$65*\MU"/,)5AQ7KOC M>,^4#UXKQ36+W$CIFM(H1E^>T4XB21@I/.#7;^&FM=-83'$K,.CC-<%:6TM[ M?(B@G+ 5[AX1\$>5%'-=?,I4'FKD[+0"""QU#Q'*SYAGG=EKDUE?/##&I"G R* MTS'J6JS!RI5#_=KH=1^'TD47VE,ACR>:RSK@T>/[$\67'&ZJ5F TZ5!9KF:X MDR?4UGO';F0[6W#WHGO5N_F>7'H*AMHKB]G\B&$G/\0K1(DD>2W@& J[OI5& M:YW?> ]JT[K1KFV&QHRTIZ"L6ZT[5HN9+%POK5QT)T96GCC8$D"L^2%6. > M*M,Y<^4XVMZ5%(@C4C=S57!7Z%9K1(QN!JL^ W!.:GB\X2$NI*TD]PF2HBY] M:D?4K@.7&1@5IQK JCGFJ5N^UOF7.:GG'R@H*FPRTEP87W*!M'>IY-42X7!/ M2J:,OV;#?>]*I*=C'M=!HEM!*5>1AP M:-@)FTE$MQ)SDBL:6QG\PE@1'ZUWUSJ-A;VJ@A6P*P;O6[29"B1+1<9FV6JO MIJ[(OF/O6@=;O+\!)H4"^N*Y^YQ+."HV\U>6VD\M3YI6AA8Z/2K*QFN$+M^\ M)^[6SK7A=KA4DA 4+_=XKE[.X-M&/+7?(.AJ6;Q#JB#;(KJOO2'8[GPA>KYW MV&5B2G'-=K+9(O[Q^(NYKR_P9JT,-\960.Y[5Z%9O)K5L?%]U"%!!V"@=CU+[# M%%$4C11QV%9RV,D,I8$G-7UXL=H2T)."95&>O-4I,2C8@N_! M6GO8^=< ;RN3D5X=JFG6]IXT$,.-@?T^M>\^(-=C:T**0M>)ZE9-=>(//5\? M-UHNF7?0[74$6WTX; #E:\RT>:V3Q66NCM3=S7?O.+6SVR/YN17#Z?I3WOB0 MOY9"EJ%835]SL_$OB+2H](>WMV#97T%++".RMRIC&<5 M<^&$,;17!?'^<47L0J;6QQGBK_C_ )&V!3N["N_^&<5F^G%KANA[UQ?C"(OJ MTR*G&[K6WX,T2_FMOW4C*A/.*5KFL5)'K)A\/W?[MV53Z@"H[SP7;W]FRV\C M&%A[TWP[X3S,#+<;CZ$UUU]9SVVFM!;YSC@BIL:J MM7/$5[JNJV2PK'C'<5JVFG7\3N]VC..V:HZAK\6F-^^@ &<QM&6+4E16Z#(%;7A_5H-9T]56(;6%4==\$:7F332L92<6SI;+5]-URU41.-K#CI2MX?T_>&RN:Y)?!,\%L#8Z@5 ' 4_ M_6KG;Z#Q'I5ZN)I9E!]J38E"+V9Z5J6B&XM]D+MQTP36-IWA^_L;WS=SE0>A M)K*7X@7^FVRB?3F.!U(_^O5S1_B4FI7:PRV_E@]R/_KT(3BT:&K:]=64H5HE M..Y%3Z3JT>KOYPDF@:*I01/,T8*IK&D/NM%:1?]HFK2 M^*-2QMNK9-W<$?\ UJZ2"ZMQ$/-Q^-037ND[_F5"?6JY1UEC'#%)"C=&&*AI( M:FSE/$O@/2],W"%RW'I_]>N6T;PE+J%X\=JF<>U>O6N@2QVS#4)#(Q'5JYS4 MKV/PPS3VB[F)Z"LY)(WC(X'Q!X4N]*W&12&';FN=BL1*I:7AA78:UXPFUN)H MY;8H3_$:Y0R21OY:J6W=ZSL;*6A4DM#*VP#BM*VTF."W\YC@CFC[,]NOFMGG MM4UE#=:M<+:1JP5CC(IH4I(SYWENIEC@RW.*]3\%_#G[0(KJZB&TC)RII^@^ M")/#X$TUJ;G=SSVKTC1O$MNNRU> 0@<8K1(YI2ZEVRL(-%01VT28_P!VMBWN M#,,, *AG\FYA,D;C&.HK(:]M+56$UZL9[9IW,MV;%Q;IRSR$#ZU0O-2L[.RD M FRV#CFN U.!M5OY+^&.6:5D+JV'@S3K95GB@12 M.>*7-<'%+8T8TC6U1D<[L5-97,XDPPROO4D:*5VJG2GHIA;.W-5%&3>I:,\3 M'#1J3[BE:RM)XSYEM"?J@J';O&X+@T%RD+;VV\5K;0:1Y5\2=+LK?3YI(556 M] ,=J\2AA67>SD@ UZM\1+B:9)D#$KFO.M#MQ+O?Q:6%XN9;-3GUK/N_!NC M7P(%E&A]>:9RR5SQI?$FFRG;YAS5VWGM+@?))74^(?A_I-G:23*Z1L!GK7CF MI22V,Y%I,9 #VJD"1T_B+;;VVXL0OUKRK5+AGN6*2-C/K6[>:_=74'DRQDX] M:YV>-Y9>%P3VIV+L=;X+$LK'YB?QKTU%18 -QW?6O//!=K+$26!%>A#_ %>, M?C4B!<=R:-C/>I S96X(/ M2J@+ _(,U/(V3R*B:98U)/%2!#J%S'!:EL_/BN0N+A[J7<">M:&H7PN)&B%4 M4C\LXQF@-21!D8?BI-NT97I00-H/6G9'ET[@1';(>33A$N/E)S3!UZ8IV['M M2; AD8!MN3N]*ZCPS8>>CM*2,5RJ_/<@8SSUKNM"S#;MQG(I;@KF+KEWL9X$ MLH M(QC\:87'#W%+M4]>/I32WH,T]?IFBXA50@_*3BK*-QS4:].E*3CVI,8R4J3P MQS5:XC#1'DFI77)J&X)6$C'XTA#CK7'>%Y")& M[UTGB"7.E'Z5SU%=G;A9N$M"#2KUO+*P?,M4/$2R^1N(ZU%X=F"J0?6M37,3 M6H&*P4;2/:J15>%V<19#-S@]VAF0[3UKE/MCQR&K,>L%>"?PK23N'Q:LTTTA.3DU5DCFB M]/;3G[2?A3/L$O]\TK!9'JE_$2G2J5LYCD -;!0,.3FLF[7 MRY"0*ZUIJ.=N":7 MIWS386'E<1J5UY+,I.!7I>HPC[.^#V->3Z]!ME9[K<#D9J> M,^4.!5-CL?(;-689/,'S?+4AN/8EN:KRD8QWJULSQG\:K3)M/K3V&B.T$BW2 M<=Z]]T!G_L.+C^&O K>Z$4ZEAD9KVGPUKEG-I\4(G7?C[M1)7-$SH$=]V,53 MUNW,MJ<3^-3<&-5L'GK4A?UJ-MO8YIA!['-,$R1B2.G%1Y(Z M49/Q561\' .:&03%@>M-QFJ^3GK4R\#.F M"[4\;\FK1FR>8G:%K3T_3E4+,:S(T+$,[<5I"X*1;5;BK(+UQJN979O:E^3'+T 2-.2>E)EV' JLTL2 MG_6"HFOU7HU%@+P5Q288'-9CZHQZ"F'4)FZ*:+ALL)<$1]CQ4/]BL.LN:D71_62@!1>)V-(;P=J=_9('_+2E_LL M#_EI1H T72GZU*KJRU&; =-^/>GI:[/X\TF&A)$F&R>E$C,#\O2FR*47Y6W4 MD8+U,9+%.VPBLG4(U?/F'%:,K>7]T5/:V,>IG8[!: .,^PR^=O@!85IP M"<$"9,5U4V@FUB/EC=CN*R?*96_>+^= "SA8K/>A^;%4+#Q1<65VB'[N[GFK MTJAX]N<"N9U+3?WN]),8HL,]OTS6;?5K5$C(W[1GFGO!*DG KQK0=Q:9JT5Y9(Y(WD=*REN7%ED!C$0PK$N5^SR;O4UO\NA.*Q+Z/+?,>]38 M=S3L6,EH&%+SFDTX;;48Z5,0&Z&E8+D)SVH4FI/+'IQ2Z@/MV.<8YKGO$]D9E9L=C70( M0'X/XTR_A66SDSR=IK1$-'BAA9+IP>F:><@\5;U.%H+N0]MQJHOS^*,9%4*PXG--.:7&.M&1ZTK!83)[]*.>U.VC&#Q0(-I'6@MG@TA)QUI@Z]: @D].*,8Z4['O01GOB@!GTZTNT]32[:0 MY''6@".7E."^O-(W'?\*$2-;(/RTUQN7CK3U 8=<4N!ZTV616, MK6MZLGH:]A\+ZA'J<)#GD"O('48XK7T#6WTV7;NX)K-H=SU>XC9)C@?+3K=L M2 4EI<1WFG+*'!8CI2PIA\D\^E2AF#XS1GM\@=J^=]:WG49%]Z^DO$Z;[8Y. M.*^;O$!\O5Y<'^*MH"9L^$UA%[#YA^?<,#\:^D+)Q%I,9D 5=@P?PKYC\.*# M?13-+C:P./QKVR_UR6[T:&WM\Y"@9%*0&?K0N=5U@VT +1D]:Z/0M#&E0AKD M8(YY%4_"]L8IEGF.9/0UT>NH]QI\DB-LPIK/J-'/^+?%$$%GY=KM9AP1FO&] M5O([NX::4[7ST%5/$E[=QWLJ>3A"34QTU4C\QY.?2M4R3TP>*;/4_$4#1D&$$9KUTZ9I M.MZ8>>R13YV$+GM0"L8^\EL"KBML7)JN+(^GUJ M2=I9E.<_2J#*T9P3BDP-!KV2X&UB?SIT$*[\EJI0PM(WR&M!X3%#DM@TAW+' MDH95YK6, ,(Y[5AV=G<7)S'EN>M;\6@W;)EY648[T!AJW_8L8*BV^?/7%,+FGX(T]I+W>W2O6OM0MK+RHQE\< M5R/A;1C9*LKMC/:NGN(RT9*#/O4@++/)FX&T=J1D3R-JFF:@S(WSO423* MBY)R*AZ#N.&8XSD_+6)>S!VQ:N6?/(IVHZH6F$*=&XS5K3=&6!OM#2;MW.*3 M8>A=\/O);E99A\U=)<>(4"8SAL>M8V44=,"JDT*S2 JU4F!K6TQU28I,=J>M M:J^&M+V>89OF^E0F3+L]ZSKO6K@.88I"WN*.81K:SIL:#$#;JYVW>ZTV MZ\X1 @5HV,LV";B0GTS5NSN(C=XEC#)GO5+DXP1ZUQ=MX'TZY_>F-(W/.:IZM9:GIL#V]FSB(#AA1<- M&>AO>V4^8V903Z8KA?&WA*;4+<-;C(SG@5A^'/#VI7]WYTNINNTYVD]?TKKO M$/B"ZT+3E06S3X&,T7'RWV*G@]!H]FEM*?WH[5<\2C4KIHS;H2![UPUKXCOK MN_6Y^QLHSG;7H6G>+K$HJZ@%@/;=2N*5%[DVB7EU;1(MVF% YIFJ^)-(CO%C ME8;C]*WTGT[4(?W#JP/0BL2_\$P7TXFW $>]6D9VY=RJR+B2/:/QIT?AF65AYS$#OQ71FZ=FPIS4@:3 M&2*7-8#'7P?: ;_-)(]12K.+%O)2)2%XS1JWB*/35^<@5YYXC\<17T#P6S". M0_Q"L)2U-(QN=+K^NI&K*Q ;'8UY;J^HM6+S M^3)C-1>YJDRC*"W"J,4Z.V58S(^,CFHKN1+%-_F;SZ59T31KWQ'<(T6Y8MP! M I)!S-%>**\UR<6UE%N(/->R>"O !M;".YNEVW YVXK4\-?#ZWTJ%)]X$A R MK7=D_V.^786..M4/%NF/=A3;2GGT-6O'$>U&N$.R11Q7E' M]HZO>NV+AP%^E2S6,-+G6Z=X4O+>99V8FNXTO3;::,)9>$M8U.YUE M+.XD M6^.O&\VC855Z^]5I_B/J3 QM8.!ZX_\ KUDRK#XH?%TH0^]6I=#90:1RMOK, M_B:\\EDX<^M=KH_P[<,ER1P#GI6KH/PJCLYTOH[H8ZA0?_K5Z!!;/:6_E#YN M,5=KD.HUH5-.GMX+=8&;E1BK7V6)WWQG)/M5>*R592T@QFMB(*L8 3CUI-7% MS7(X4*+@BG27"V:,\IP,5)(Z10-*QP%&:\C^(7CE5MVAM)-S@X( I6%8S?'_ M (RWW,UG"V<\=:\E>[EMG9I!G=ZTZ[NWNYCAZ#I+36RR8R:!U(!4D]*D'^SUJKLV'[U!9\<#%- 6/FW5*"<6Q6#*TMU"2@'% 6U M.$U1MVHN1ZU&I/>J[2-+>ECT)ZU:8#'!S5#8V0@]>*:I/X4A!!]:=D8H$2*3 MVJQ%UJ*)&G82-BNFUTDZ63[5S/AQ"LAW<]=+.IG@ /I7%V4I23CUKHXKPJ@WFN=_$>W3?N&3>1-!<$XXS4L+A>;90G9?,;'7-4)7(?WI&8F=LMCFFOU]:VL<\ M796)([IUJ['J# ?,:R^?3-.QQU_"E8@W8=6V]#^M7$U8M_\ KKEU7/1L4_YQ M_'BG89U0OV;I_.G?;)/0?G7+^;(!PY^M,\V;_GL:5K@?1:%>PJI=PAP35H$' MMBE=-T===C,Q(F\B45O02>:@S6'=H8W! S5RQN"I]:FU@9ILF#[4HQ_#Q0&W MC/Z4#GVHN HQGWIQ;%-!YZ?C3^/2G<- %.!QUZ4@^E*.OK[4,$-GB$L+#VKS M7Q5I("LRCG/I7J ((P1BL;7=,6ZMSA<5E)!<\"GS!<;3ZU<@(D%7/$6E-;W; MD+P.]9%K.8R1UK)E(U,G&!4#Y'WJ!,5.[&?:F/(93]W%+H6BM-M/W15S0+R2 MVU!64D8/K4?V7<,GBF1.MK,&V]#0[6*3/>/#-Z]W: N&=06WG M2//#,.]<%+/)).6#$\U: MIZ3J$=UIT2%1D**MLR*-H7\:QE&QLAS?..:@>+CGI3TD*]LTK2 CI687*IC MZ4F['2G/)STJ,N#VQ5( )W?6H99&3BI@WM^-#('Y*YJBGL4=VX_-3>,U::$# MH*A,?/\ 2I>Y(QB,<"H]^00.*L&/VQ2!0>-N*$!QFLB7[2QSQ4-A-&,B09KH M]0TAKK=M[]ZS;?PK,&),A%6B64KA8F!(%4%C'VA2.F:V[W2_LD))DSCM6#O8 M7 P.]6C-FW?2^7:IMZU'#<,\(%-N7\RV4,N,57MI6+!%3\:O4AEO:N&7;PI-4_(HK3R".$Q2;V' 7\: *Z:3"O45,MA".W%2!W]*7YS0"8+;1+T%2 M^7$!P.:C"MC).* K9ZT(9+LCQTYIO[L=JCPV>M/"X'/- AX91U%!8=148'OF MC SUH&.#9Z4F><4O ]J3//3\:!"-C\::?]JI,#TI#QVS2 CV_E2$#M4O;I3" M,^U,",* >*1@.N.:D/TH SVH!W*S9[U-8S>3+FG-'QTS3881OYH;!;'9Z>ZW M-N,]#535=-@ R!5:RN7A0!!D4^]O&DA)?Y<4KW*1SETD(RB\&N*UNY>VGVJW M%6=7UYX;UT3G!K"N/MFIOO6)C5I".D\+"WO)V^TX.!D5U.G:@MGJOEAAY0. M,UYE$NH6'S(&2I1JET&W%VW>M2XC3/I+3YXKRVW(P'%9FJ0@=#WKR[PYXON[ M<+$9&.379W/B#R[999Q@$9YJ+%7.LTQ#]D /2IFV(>%-E2K$ <]ZDCB+=L4YXR!Z4#&YY4"HL6 MMAJO%CA:D=1);,%]*:\2 94_A3HR=A7%4B6>:>)[;RBS8[US,17'3FO0_%VG ME[?M+T%'7H,T?A5"#J*;L4]*=2TT S %)@'K3S2 M8/84F(3&*6E7KZTX@?\ UJ &'I3!C/%28/IBC'M0 @IW'<49X^[29QU&: Z" M$X^E)D&AO7]*;@D^E =!:80#P.M2=J;CGI26X6&8 ZTN,=>E.Q[9I3P.F:M( M0S:#]*KS "12.U3Y.?Z4%-XSC%1)#N=]X2U16\N$^GK79G_CX!%>,Z/J#6-Z MK= #7L&C74=[:++G)Q692(/$$/F6C9]*^:/$D8&M2C_:KZAU4;K5QC/%?-7B MRV9-8F?'\5:P8V9^C9_M2&/^$L,_G7T=8:1;0Z1#*B?,4&?RKYJTV\%M?QR% M<[6!KZ%\'^,+/4+>.VN=J *!DU4D2C0TF6(:L$D&!GO6-\0_%HTK=;0,,,IZ M&M'Q@;:QL'OK&X&_&1MKP37=2OM7NB\Q9@#U-2E23G)S4'F <# MI4@@7&.]6[/P]J&H3*L,#%3W%6@*\-VL?W5)H(GO&VJI ->G^&?A.+@;[^;R MA_M'_P"M78GP#X=M(=GVN(..^3_A5-DGB5KX9=X#(S#/TI8K9K5]N:]$\0Z% M;:?;.]K?AP/X1_\ JKSK[]7-,LH=V\PB+-4!CV7A3[0H>[.Z0]3BNGTO1+73NJ9JP#Y3X7E?6K/G* MX]: +@\EEPJXI)))4B(5OEJL,IR*G52R98\5#&<[J2B0Y<=*P+^\"Q&.,'=6 MUXCU.WL0 Q S7+V6HV=Y>8=EP34L"_I-BMROF3#D&MPRQP+M Z577RHP%MW& M#Z5+%;\[G.X5%AC6F\T8 J2-5CB+D\BH;BYBM#G:*QKJ]N+N4>0"$[XH$6KJ M]>\8Q#H#4UI9(H#,.:2SM@F&=>:NM,J+@+0KC&3E>!BG6Z98$]*A!,AZ9JU' M\@IAJ+*=G2JWVQT;Y#3N-02/0[?6(R!N_G6A'JMM=)]G8#!XZUYE]HF5>'- O[J,[ ME<@BEZH5DMIPH7G@5M16=OM\R&^"M MV HDU:\LN,M.M',-5>7J<]X174]&OHX+J0M&G'>O8K.\AN81M(Z>M>,-0T.81I"TJYJE(F;YW<]>O+9'7.,U0$"(>%YKF="^(4=\P2 M]B$"XZL*Z)_%6@ ?+>1%O3FM%(S<;$AG,9Q@T];B)OO(:J#Q%IDO*E&'K3)] M?TM%RC(3Z5?,+D+;2+N^53BIHO+?JIKGY/%]I']V%6J >-XB#BU"_A_]>I<@ M4&=:L<4?S*0#[UDZIK*VJ,-XX]ZXK6/&%XZGR(V7Z"N,O-=E%&?:HU9LM$5UN0[Y M;H*EN]6MHH0%4[OK6=-;SYPJD9K?\(>!)O$-Z$GD*+UY-6HDN21!X7T&3Q)J MR"53Y#'H17T#X=\,V'A^T"1QC.,]!2>'_!%MX>LU6-0T@'WA6Y(DAMV!4[L< M55C/F*\NJ0P\.P"_6F)-!/\ O$8'\:\S\<0:^JDV*2GYOX<5/X)76RL0O?,' M/(;%*P:'IZ003CYQTJ:"WCCD^6N+\8>)W\.1(53)(YKGO#?Q/?5-16V,7).. ME2]!\MS0^)EVL%K)@'=C@UX?I.LW9OBA;Y2:][\;::FI:%+=.<$+FO"-#LHS MJ9&0<-0:+1'O7ACP]IZ6$6H21YD(R3Q796KQO'B$A17/Z1"_]@1HI_AJ$0ZC M$^8M^W/:FD92=F=0;>4'.\&G+&&&T]:Q4U2[@7]_$V/4TO\ PD04Y\JJY3-& MM<(+2W>7'09KS/7/&L7F/%*F0"1UKT&+5HM2@>*0!=PQ7 ^(_AXM\6DMY^6. M>#_]:BQK%V.4_MH:E<>5" W%=9H?A*XE(E+>_2N>TCP+>:;J22.6=5/K7K^ MGW/D0*@AQ@5*6I8!TIIW!&+X^\8G2EDM8V MX92.#7@%S?2W%])*2?F)/-:WB'7)]?NS,Q. >E<_=W4:1[53YO6F.Y%86WK6UIWCB_L%6-9,*/:)LI(10!]!QW6 MEWF&0 $^]6?L<;CAUQ7@=OKFI6WW9G.*U[7QUJ,!^=F;\*0'L+Z:@Y!&:@:! MTZ=*X6Q^(SC'FIGV(K<&KB-9U6WAWK'@D4 87B&< M-)Q6/9G>3@5/<3_;'R13X(Q%VQ4L!K)@Y'6E3ISS4I8,<4F .V: & +GD4\_ M=XZ4TKZ4UGVC!H C+*N?6K&G64FH3!<' ]J2SL9+^X4(IQGFNZM[6UT6V$LB MJ&Q28#XHK?3-'(('F 5P&IWYO92'.<>]7-F*GCY.,4:@.48JPF!]ZA(^1QF MIY$"IQ2"Q7=USBG1(&Z57*DR_P!*N1_*O(Q0QHJ74JP_6J^Y98\]Z;J6Z3A: MH1W1B'ED?C0F4V=#H\?SG-;6LG&F$=L5F^'!YF3C-7M<;;:,/TK*H== Y" X MFR.F:U[B53"H YK)@YEZ=ZU98]T(XQ7-)ZGJ1?NEF-]UCM]JH26ZLIR.:G@< MA?+HERO&*WIR//KQOJ8+Z>-Y)J&2T*@X%;T<8+9(S4C6L;#/'TKIW//D)OE&:KR12I_ 30 S MQBD\M?2DWL.JXI/,/I0!]#@Y_B!^AJ=,XQGBL"SN&#_>)K9C<.O7FNUF387, M ="16/O:&3@XK>"_(M+ANU'E@++-&>0AU^F:\X> 1R';6YJ>JRW ML['>3GWK)>,YR:R92'(5"_-0Q'5:0)\O/2C:O0'BHV* 2N!RYHO8#SQ"RMP"*LVTVV[C9SG!%;.KZ;'"["!&Z+J$L$P$3$UZIHE]YMHK2-\^*S:N:*3- M[85'45!(<=^:C:X9OO'%1[\]3Q6#1=KB,QS1_O!WJ4PM8FW8'48 MI1(V/E.!5; )SFJMW3[5BVB?;K@J[MC/K M78V.AHEL' S]318GF,KS7/W@:!N/;-:S6BEMI6K0TZ*)0RC)JU ES.B&-1PH%+M3T%5RDN1QTOA\31A=OZ5/9>%UC8$@8KJ=J9X IY B7>*> MVA-SEM0LDM4(&!Q7(R2#SF (ZUU7B&Y#LB D5*Z2?Q"BPT3>8IY_AI?-4#BH!%Q1M"\YYIV F^T9Z"E%QV MYJ!9%[TI9".M(9*;@]^:3S&JOY@4X'-.W\<4F*Q-O;UH_>-T;BHMW&>] 9J$ MPV)MC]CB@(W<\U'O=N*;NDSCG%,5RS@GJ#2_C M3 K$9I"&[TADHYH9/7K4!D9*03DT7L*Y+CU(H'L1BH^.QI=O?-.X[DASV-,Z MGC@T 'N:7KUI6&:-I=)&H5NOK5+6[EW3;&PY]*9\NW&:8L43-\S9^II#1S%M MX9>ZOO-FY4FNST_2[&QAV&')^E6+:*W0 J1FKT8C8CI1SV*L4AH]A>MM> X/ MM4DGP[T^ZC_YQ6Y;HO' %6F8AZG']DCS\O'2O2Y928V7<6R.YK!=1:3>9L')]*.<6IY7<>$;^V4NT;MCT6L M>2TO4;'V>88_V37TIIWV>ZL@SPQL2.ZBD;1[&X)WVT0_X"*%,#YQM[W4K-@8 MQ(A'J#6S;^.==ML 7&,>Y_QKVBX\"Z5> @QH,^G%<[J'PJL?F,()_P"!&CF3 MZ".3LOBCJ<1_TB8L/J:ZK3_BQ9$*+I6;UY-2PQ[55D%[GN]C\0M%O%&S"9]3_]:MB#6--N_N7$2Y]7%?,+07=J?G:1#[$B MG1ZI=QG NI1C_;-+D12G8^K(_LK#*W4)^CBE+(L@"NK?0U\QVWBS4K4C9S$Y7/<]QJI#/%)_%^M6BH=>#Q56L #W.: M=3(X0#U-.EC/&VF I4XSF@9QP0*0 !>3S1M4]34]2>@X=>#2\?C3 %]:#[4P M''/UH.[')IN6'04FZD,=\V.O%(.>AQ49Z]:.>YIV$2$8I*;C(Y-+@#H:0=!V MWWI*9TZ&E '7/-)(8\ D<&DI,@=Z#SUJDQ6$X+8IDS&,@>M2 5')\QXYI/4 M02Q'R!(#S7:^#]691' S@<]S7'+]W'Z4L%P]K.)%8C'I4\A5SW2^A1K,D2*< MCUKY]\6VF_49@!WKKT\83B+8TIZ=S7,7SF]N&D89SWJDA\QPQBA@G E7G-:T MEZ;2!6M,AO:J>L6X6\4"M73+)&56>,'-+#;7.W# MM='.M<_?7(C8H#GZ58N]0 M8V^P.I]*!N=V>U6;BPW=W'-5S$Z'(.?I5J:U\L''2 MJ\9(R!S57 B^T,3L;I0;<.-PXIZPJTN3UI9SY? I,!EO1L=BV:ZK1_B5= [;@+CW44KA8[56ED;8%*X]13KMYH+5CO' J; M2M*>*YI+R4!FS65;Z5,D8DC;!K ML+WPQ=2S$B)CS5673)[&/,B$ >M)H$827VIV9'SG J_'XOEC&)"3^=5;F[RV MP*#GVJ'^S$F^9AC-*P[FQ;Z[#JDPB;Y2>YZ5T^GP00QX\Z,D_P"T*X)--0': M"5]P:;+'=6A_?QZ[J$1PY; ]:V[#Q M$I"^:XS0T!U"Y3I4@?/UJE;ZE;7(^^/SJV55AE3Q2L%P)/3-4YU8$"1M@%2DL3P:JJSKR!3P^[[W% ]28YQP:4<#FHCMQUI MAD;IVI7"PLARRC%9JO[U M)G=WQ3$=,FLP;-KCYNYJ>&[TB4YN8]QKD^3QFG+$QZ$_G2+4[:'>):>%[]/+ M\D!B/4?X5D7OPTMIV::Q=5SR.16-;QM$P8.WYUL0:W+;@#S6X]ZT4A7*0\+Z MAI0*,^]?:GVWV2VDSIVG_"MVU\1"0CS-K?45K_VA;7$6&ABZ?W15Y_+50/85RL";RV>:5[B MYQ9-0N2Q(D&WTJK)Z40RD[C^=/CE5HNV:AH?M!LL*;"<@5R\FKPV MEZ0PS@UO73'8JS1<"1A^-,G4^OK7Q1I%\ /,B&?5A5U6LI&WPW$/X,*^1;37;G=_Q] M2#Z-70VGBN_MU!2YE./]HTFBD['T%KWA>V\0*!.R/CI@BL/1_AC:Z3J NHT' M!SVKS:P^*&IVK8,A(]Q7:Z5\5#-M$TJ\]>!4\I2G8Z'QM#.OA^:*%&(VXP!7 MSSI&G:JFJDK%(@W=U-?2-MXQTK4(=MQ)&<]CBD^R:%>-NA6$'_9 H40<[EOP M[&5T"+S6 <+SFN+\6?$0^&[X0 Y'MFNX%F_D^7%G9CC%<7XB^&\6N7/FS*Q/ MU-5L0]2UX4\:0>*YO)D&>*Z6]L[&WSN*J/80,PXXP:.8J,3>AM[6YS]DN(MP]&%36UIJ,VZCJ#6&EI)T;'I4N5RN4U8+?,/[S!:E$21]17EO_ LF6/51:F0!I+J,08,#6>K8.EUN7FBP-V1BG1(S'(/%(R*WRYY^M5M0OH]-L)'+88*2 M*OE)V,SQ7XDBT6W*M(H8CUKYS\1ZS/JE_(2Q,;&K_C3Q+:VU&XP:Y M*:\*P^4W7UJB2*6X6V!0'K6=(=QW$YS1(OF'.2:11L/K3N*PJMQQTI&0OT.* M>2I^M-6/>>N*5QEBSB^;&*U5LE9-V.:CLX .*UHU&W%)]QW,9[$MU&:A:S5 M?X3^5=%Y2CIS49@5CT%.]Q'.FU<_",?PFMQK3 SBH'A[;:5@,-HV0Y0D5:M]6U&T \J4C'N:LO:CJ*B-N.XI@6 M/^$GUB<;7F./J:A1Y[J7,CV*M)%@<#\:=P)(X#$.>34A)/6D#;%P M>:>H2)R M,?W3BN2A3#YSDT) 31 )'AN6I.<]:4@;NM# >M-+4!><4#W-,R>G:E51ZT[# M'X.:LQJ<9ID:"KL<"D>]3<+7!-W:G2' ZT]E"+5)FW/@FBX[$Z1;CN[U!?3F M E5H0%.:T=-'G7Z)UR:-A7N=+ MX8@*(WRD?45!KTN0ZY&:Z>.%+&VS@+D5Q&H$SWKY)QFL)GI4(W1FVR_O,GUK M6D8K",\UG/\ N9 !5GS/D'.:YY+4[DK!:LS777C-7+E3N&*SX3_I&:UE19$R M3S6T-#GKPTN5#T^7K3#NQ[U8P >::<'BNA/0\BJ[,@4/W-(S3#^+CTJRL?I3 MXK4-)DU2(1# I<_-TJT;&*0< 5:^RQA,]*HSS+#T:F,JSZ/&V>@JM_8B?WU_ M2EN-1)!&ZJ7VL_\ /0_G2L!ZNB(A^7BM2V9=H]:RUAD)YK0MPR ]*]"Q@7P MY/6F3P"1.E.1QVJ3=D86LVF4<_)^XN>G -;-G]1G!;WJ""4S*!5H(85W'M2 +XU+)$XZ>MT_S)\N>>*3D)(K7.@K]H^0J8O05S^M MZ%:H65R%89B!Y)JKKDEC=C/F$/CH*(L'GW95E M?/ [5QL2M#.Q RN>*T[>\D609X6J81/2+>[6\7&#Q4C_ "#VK(T.\CE4^68V,&M81F3M4@TP/ M&2!DU:C*IFV3MPU:VUZN8R ?K3\N/I7G]O-=63ALG'UKH[/Q(L@"28JDA&]D'MS0>/O:-!6%^E4]2ODBMR!]X5.UU7&9Y,D=*A&(VSG=[&D!A?;-6@EQ&C[!Z M*:OQ:S,W%PC ^X-=);ZA&D.TP1D^ZBJ5[#!?_>14/^R*+@-MH)+D!EF0 ]B: MO#179 M&Q5"WU!IA\K$_C4QD<]S3$7/L-KZ"E%I;#IBJ.^3IDT8DZY/YTK7&F7OL]MG MH*>(;1>& -4/GQU--PQ[FJ2&:P2S'4"E"VA/ &*R,D?Q&G \<,2:E6>0#DG'UH!FNL$ X.*>;.!NV:QOM+YX-6(=09:EAH79 M-*C=>%JC-I3(IV*?RJY'JX!YJY'JMNWW\46 Y-[6>-CA6_*A79#\RG-==/=6 M3I_#^0KG[^2$%M@&*$A%5IEQTI(W\PX/2J+7B1MZT?VBK\1=:=@L:9M]PX85 M3GT^ZZQFHX);EYAP:WX9'2/]ZHJ&F4CES/>6S88GBKMKJ\O&X%NF:FQ9U.D:B\S@2 X]ZW[C'D[@>*YQ[BWAB7R,;N]7+?4Q+&$)YH ML38L0EGE'IFIM9MHWM5VCFDA;)''-37L,K0C<.*30T0:7+Y$ 3O6CYLC&LNS M^695/3-=&(%* K2"PR%'(!W"IO/FA;.<@4@C1?XCFG+LW='D^U2+)M'W%_*G^<3U4 4TPY3&N?!6@7I_?VN6/? _PK&O?A)I M%PI-M&JD^N*[47 5<#%1>;(6^4G\ZI28N4\>UCX/7\)9K5UV]@ /\:Y6Z\!Z MS9YW*Q ]%KZ22?'#?,?0T.(9OOPQG_@(IJ86/E.XT:]A.#:S$CT0U7%M-"-S M6\JD>JFOJ_[!IC?ZZVAY_P!@5@>(O"FFS64D\<* 8[+5*0K'SFE],AP 15R/ M6;I.LG'UK>O-#M?.94]?2L^?PSE=R$U28AT&N/MRSY'UJY!XDAS@J:Q3H,\: M$C/ZU3:WNH#S'3$=S'J=G*N[(!/J:4W5JYX(_.N"WOW9@?K3ENIX_NLQ_&D% MCO1Y;#AA^=&".AXKBXM2ND/!)_&KL.N3(1OZTQ)G3AY,< T@&3T.:R(_$J]' M JY'K<$G<4K 7. >5.:&([BB.\CE7C%.*E_NXIV"XPXQ28/;I3MA7ZTX$XY% M*P$?'88IN1GIS3SD]1BDP?2DP8W/K2G@>.:T$A>0_-P*I7<.W(J;C2)M%NO)W< M5K+=M.V ":QM,55#$UJ65_;136W+E3C'I6!/$ML3QBNODUJV- MH54C./:N3O2;IB13!HS4?=-\M/G8*<."33%B>&7)%2LXD/2J)>A5P">E3H#C MGI4JP#JM(T;CH*D2)4( IRNI/ JL-X/S<58C8?Q<4BU<&*9^Z=WK3?*+?>&? MI5AB@CR,5%%-+SM4&D(?;7,ML^82RD5LV_C;7+(!!<_NQVR?\:PF>0$G:,U3 M;=+/M/>J);/6O#GQ5L;=6&J1F0GTS_A5R\\6Z+XC8P0Q;-W0M_\ JKR3[&D8 M!:I4,\8_<9![$4,$>I0>#K"==ZRQ9/3YA5'4?"MQ;IF)@Z^B\UQ5KK&IVO61 M^/\ :KH=+\=W-N^+A0R_[7-(H@DA-N-DL+AAW(JJS/T3@5T]UXGTO5+?&$$Q M[ "J5OIJ78RAY/2D!SDL.\?O*IM86[GY4.[UKK;OP]>1IN9,+60\8MGVN.E& MP&.;*]@Y@?%31:QJ]J0))"5'UK668,,( :BEB+_P#\J6J EM/&"CY+E&/X&M M>WURQE^Y\I]S7-/9*RX* -]*IR:;,IRK,/H:3!'H2W<E8:/1"(P/NFH^2>.!7+V/C'>P68 ?E726NK M:;=(,2_O#VHL*Y8"#'%)L&>!4FP]>,4\*>XI-%$(09Y%2*@[BE.<].*D3/84 M"N.CBR>>E6@B(.*KL6"_+UI$E8??XJ0+0;/&*8\*,,]Z:LZ]#3G)8>U" 2-$ M1AZUI1SN%QSBLR/Y6QUK5@*@9')JT(IWZEX6)]*YU)5@+#I727DN[*URNIJT M;C(QFJ2$9NJDR?,HJ&TD1$&_K5NZ95M@6Q7,7.H-YQC3I5V O:Q?1JN <_2N M-FFWS$D<9K3OBX&6).?6LHXB7 <5%YA!QBD*L_(H D-W.QY:IH;SRSEL MYJJ"R=12[PW!'%%P-N#6%^ZA8-V.:VK#7]4LSNBN@!_O?_7KC & R@X]:023 M?PN?SH ]8L?BIK5HRI+<;E'H37=:%\7+>5 +L_-[DU\XK6 M*GV-(#ZYM?'6D7J@;T&?]JKA.CZDF7GAP>Q<5\DP:S+;\BXD'_ JU(O$\H3* M7LV_TWFBQ2?8^H[?1M'MVWV_ELW^R13-6TTZK;&!!@8XKY\T?XA:WIYRA,B_ M[39KKM-^,-]O"SHBCOT_PI-%HHM87-H:EY/;V"-<2L !ZFO#_B+X MX\R\-O:R91A@[3FI_'OCZ2]AFL;5_88->2EI/F>Z8ENO)S5)$L>\\=JS2OR7 MYK)N94G!49B 713E..".*NM[ 5$0OXTK@5R%8X MQ2EO(^Z.M/( .ZG924?-VHN!&-LG+"HGE".(T&2?2GN23L6MG1= :Y=9V7*@ MY.: )-!T:2:7?,IV]>16[J6H06%DULI&<>M3ZMJ<&EV"K"%#@8->=7U]-?71 MD)."?6@+"2,T\K$],TY(%[4B[L M!3N T@'CM2!<'@5,J9;WJ=8@3R*& R,$#@5820@\#FI5AP.12-\HZ<5):(+B MXPIW=:S$N/WASS4U[+S@52B!WD@5(,T?M7[O Z54<"6J\LY5\4Y)O6FB"%XV M+[4!KK_#NCA%2ZD7ISG%9^AV*ZA/@CI[5U-U>IIEDUL 0*;V!%?Q#JZE51# MT]*YZ/YCO8<&J\D[3RDDYYJ^JDP@**YYGJX=Z%*ZA#MN7H*KB91\OI5]E*H= MW6LN13N/&*Q]3LN68F7S,UI1R IZUCID#VK5L>1ZUK%&-9Z"D,QY!Q4T=N3S MCBKNU-O &:1I@B]JW1XE760U(D0ZD8G MG:?>JT#H:6H:O(N0A)^E8DE_/*?FS4X#8^89^M(57^$"G= 1*&<9:E\M?0T\ M'::=YI]!2;ML![A+)&HXJHTQW9!XI#'Z$FHF"J>37I7.>)?MY*R-7NX+<#!%8RD4B?3[M(0N] MAQ5?6=;15(20#CUKF;C4L9*,?SKGM0N9;A_OM^=9\PT/U#57FN %?^*M?4D2 M3PZ"1\VWK7%3+)#(C-TS7;#;=:"J9ZK4MZ%)'G6&6?:.YK?L-&-SM) -8^I0 M_9+K ]:Z?PK/)+*%QGBLY#-VPTO[+$. ,5>8N> :F:-]V#Q1Y..M0RT0!#U( MIP/M5K,83!IHV'ITJ!HK.N[[PS0IV=.*N 1U$\:8RIYI 5)4\QMS=12">1. MV!2R#'6J^&8\]*&V!J0LDR8<@DUD:OIG!9%[=J=YK1-P>*O>?YMF^>>*:9+/ M/Y0T4I#>M6X1YD?!J*\CWW+[?6H5=XFJ@5SL_#EO(NX@UTC,?NGK7*^'-5CC M.)SMS7;I#9WD(,;_ #&HD:)E'&$R>:B3YWQTJU+:2V[8493U-+$D+GK@TE<; M=C1M[<11"1B"/2GM,K'Y>*C5)(DW)\WUJ)A)*V6&WZ5HD8LDE3SEQ69<69&2 M%YK5B&W[U6=J.N,#%6!QLJ2*<,":=#L0Y(KH[G3T925&?PK%GL&&=HI-@QT. MIRPRC#'RQ716>M6\PQN /O7$O<20R^4Z_+ZU(?LW!25@WL:+@>@Y##>K _0T MH)/!!KDM.U.X@=0Q)C':(PP/)_6K=W&I/R5 M4$)'>G<7(V/8'KD?G495CR#2F/YOO4NP=S1S#5-@JYXS01M-*1@=:9U/)XHN M/E8\..]*P.,YH"Q#^*@^7_>HN)Q:& '/6I0H/<5$=G]ZG! ?XOUIVN9/<=@9 MIK9SP*D6 CG-*=V> *5K%(1=P')JK\1WSVY&QL?0US3ZK>.,;FQ]:=@/1CJ%K;G[ZY'O5.[U;[1 MQ%(#]#7#*T\RY>1OSK8T>VRW+D_4U+&C;MX)I) S'(-;5M8.Y&T@?C3[6UB$ M*D'FK\,>WD'I421?4L1:;Y2;G(Z>M182.7Y2*6XE=X]I) J&RB22X"NYJ1&Y M87\,6!)UK5NKV*> !"#6'+IB8W(QJ.(F%L;B?K3T'8MP B\![9KHWF!0;37+ MPR&2Y&/6N@2!R@S2M<+C_.!X[TY7XQWJ$P.#R.*EC1?XCQ4M#N2*6'>E^?KF MG;K2,O%9TWC.^N <#&?0TTA.1Z8? M*SEIH_\ OH5'?W5O]A:/SD(QTW5Y'+K-W,V?.U8\1D!PQXJPZR. M/A@2:[Z.":7@H-OTJ8Z=:A=TV!ZT[DGF;Q2)_P LW/X4B17#'Y48?A7H4QTR M(80*Q]P*JQ"UWDE5 /M1<9QJ27=N+P4P*B,#1<.6%*Z&V=Q%?P2? MQK^=3D(PW"1?SK@8<[OED?\ .KBSW,?*NQ_&@6C.O+!3US3MX?@ UR UF\A. M&4&KL'B0])@%%*P'0^2>N:<#MK,BUNSEP#)U]ZNI(]QR#3'N#9(I(-OFXQ2LKCK3[7/FX<8%(74Y/Q-@7J\5F#..M/>/Y=Q-5S+&IP6I;BU)$.XXIK$ M[]N#4:EEIHKPS["<<"I&82?<'-4O.7)S6OH M<<4\^'Z46"Y BS8QM;\JBF>2'KD9KT>WTVS^S9('3TKD?$T5O"P\JF)LPUCD MEYS4P@9%R:B2;;&,5I6J^?;L6JA-D%C&;F78IP?>M*;29[>/S""P]JR[8^3= M_*2.:[VSDV*QPYF4?*T39_W:B>(]>E=\UA97(^5%Y]JK-X4M7R MS.0*ER*29Q1^6.HX7/..*Z>;P_&L_EQDE:?)X96-,]":+@U30-NC;IZ&NGDTBXV;E4_D:@,$ MT(VR*<4]0,BVUB]LF_?,[#\ZZ"R\6PL0K@_B*H^7"X^Z#]14+V,+?=X/L*/4 M#LK;5+6X ;S47/J<5=\Z%ON3(?HU>9S:8^H! MB1@?G2E,CFN&M?%VH6^%N(@(QW_R*V+?QA:38#/C/TJ7$$S:\ME;.:F\XJO( M-5;;4K.XQYKK*2N4 -&X$:L9&R,BM"-'9<*<50C\P,-R@5HK\R?+5(" MM,^P[6Z^M<_J\R*N68?G6IJ^I6UK;N';]X!7G-YJ$U]*0A)&?6K0F,NKN2>8 MQJW%-CL\?O&(I3;"% _\1ZU'YKGBJ3 J:HZL !VK*5USBM>Z@R,OD5BN564C MM3 E.:A/6@ ;ELU(F['!XJ(+D\4_ Y-%P''#<4TDKQFF]Z! MUYH 4DGK2[.,TA '2DR: %#D# /%*H)Z&@!<<]:;0 [DG&:0K@T#&>:4XSQ3 M "IQS2!"#N!I3CL:0'%- 3QSS#@,0*L)=;>IJEN#=>*/+)ZGBBX&M'=H><\U M>BU>ZB&V.4@'WKF]C+W.*<)F7H2:+AO-9FHSAY,*W%4!),Y^ M\S8J&(XJMIUH!SBNAC5%C '6I&4Q;+CD57 MEL@WW16@VW/)IZJO>AB,&6Q<#@36O+IY%5)K1HURW2AZ 9KRJK>41R>]-D7R. MGS9].:N1Z=+>R;(%W$]\5V/A_P #H 9-1)4#IG-*XSD]#TR>]O%S$P4GJ17= MR-;Z1I[Q,ZARO'--UO6=+T6T:*RV&5>!P*\WOM7GU:8O([+Z &F*Q%?7$UU> M298E,G%1 ;1C'-2(I_C''K3L+FG8"(!AUI"".M3$+VH*KVH AP<<4T9JP N/ M>FM'0@(\GH*FB5R>M"I5R"+C@4V)$L9*K\U4[J3 /-6Y1L7BL6ZDRQP>:FY= MNHQ_GYJOGG XI5;'WN*2=TV\'FDV,:\)V^832V=G+?2#RU) ZT^QMYKR98L' M83UKM+*RM]!AW-C+#N*:T)%@,.CV*LV%?'-%O+^\:MV[;9-Y/RUSS/2H-V-*X Z5F M31E.36HNV8;E.152["A<"L;ZG5,GO66S?-@5;MFV#GBM8F55 M^Z=#Y8R$!J=<3%DQDU3 R>:Z(GCU?B'.=WWN:0 X]JD(':FG% M,.@QDR*@:,]JM<8INT'K0%RMLR,4WR3ZU99%%,^3U-&@KV/9)/F' Q5*2-B< M#GWK1D*,/E-/BMBPR17?S=C%(HV=LX?D9K9&(D!:HU(AIQ=)U(STK&4C2*90 MUC5X[6R=EQD"O,Y];FU*8@$@ UL^+;TQ/) #7*Z+'N=RU8RDF6DS6\UO*P1^ M-1A@!DC-.8G?M(XJM<.4.%Z5FRK%+5)=X4+V-=)H4QFMTAZ\=*Y6Z!QD%M2$-Q]VM'X@0%[M2@XQ7,Z,PAN!O.*K1 MHD]<@G-Q&'"?C4H&>HJKHTF^Q4KR,5;>18U)8XJ.5LI,3$?0TG[H>EU M4)&QI\,;L,N!79VEC-! LL4Y;CH*X:V7:ZX-=]I$Y\A%Z\4G$OFL2Q:Q)#*( MKB([?4UIEK.Y7,MR8 MP]L0:JQW5U"=LD8VCO6A;SZ=,,3OM?TXJMB",:RV?]1FI5US;UAJR-/@D&86 M!%,:PME.)&P?I1<+"KXBB(PT(%!UFV?K"!41TVS;I(?RIITJ(]&-2PL++<6% MRI5HE4G^*L6[TB MNAN ?85JMIL8&W>:I3Z=/&P-OEZFP[$,,4\"C]V744\W M*)F(Q@5RESK,JRLH4\&N[N$%S:%CQQ7FNNE;61BIYS2:[#5B0ZW-G& M#]:/[:F[ FN>6]9VY'%2->",X%+E97-&QLMK-QZ&F?VOP:ROMP(X%,>^; M&,4U%ASP-.379O<57;Q#/TYK+:4O][BHR/RJDC*4X]#6_P"$@N,=S2KXDN5/ MQ;1N6@#)D\TG" @5V?YR14'FLO;FHY)#(1NXI6N.YZ+I=\MPBJ&Y M-=#!$Y' SFO,](U);613GI[UU\'BE4CXQQ[U%F-2[G60Z=Y@.\XJG]B2VN2W MF\ USLGC9ONJ!GZUG7>N:B4,PC^0]\U+BQN2/3[:\M$MSYDBYQ6)?ZQ9*Q"L MO6N0TW78;B/9<2%'/&,T^_TJ:5/,@8L#S328KW.HM]:AC7> #CO5G_A-HXQC M:#^%<5<%OY<@(-4_)D=\KDBG8F]CMY?&;29V)67<^);QLE0P]JRHHXPN V M7]*7+^9AE&*0[B2Z[J$AY9A5=KJ[FZRL,U8N4& 5 J!/F.W%*PKL:JR?QDO[ MU*JCNN:D"LHP!2#.>*=A$R(@&G%,;T*[ CJ*5@HCRI^:@"!B$/W:039X$>*6..62 M8 K\M7+B*&W0,3S0QZ%=89'Y=2J^M.,MK;#YI03Z5FW&MROF%4&WIG-4Q9RW M3[B30(U9M?<#;!#N^E9TDU]>-DAD![5>MK,0<]3[U89ATVBF%C)2S=?ODFD> MVE_A)K5()!XYJ&-F1_WHPO:EJSZ=YF(]JZZ MUT6&(;F_E3;J*!,KFFK F<6-.=3P32BPD8X8$#UK;GV1GY:JW$[K'PO%5= 1 MV]G'"N3R:KWTH. !6K8Q"XMF9CBLN^CV-\O-4)H?ID!:<';FM6Y\R-P%4BJN MB,?M"C%;%_D2 D5F"1ER[]F67%9\S1E2"!6VQ$R;7X%<[J2F.1@O2@:*3Q*9 M %YS72:):I"X*D0B$>M,#4@\1 M7*8$^6])O#%U&LZ\,Z-J[F:UN8R#T4$U\ZCSD?,/:J+VLW]REL!SG]F7<#;HKEACTJS#JVIV9 ;>X%:;1 M2K]Y:C=E9=K**3"YU-^SI&/E6K>-HP!Q5=WV\>M%P*K*9FV 5I:/X7N[ MFZ20QMY1/)I=,T^::?>4^7Z5Z)I=V+*T$;(.!UIW%8R[_P $Q/:Y102!S7D^ MMZ*;*[DR.AKVN]\2QVT3 />(M1DO;N0JHY/K5+4#GLJ 1TJ'DMTIS1.# MEA2(=I^:GJ [D#I^-1ECGUIYDWMM44A7!YI@)13B 1Q3<'I1< IVX8Z4W##K M1@_A2 ,4H..U&[ Q0 3TJ@#OTI3UZ8H&0?>ALYYH #T^[BC<,8Q0=V.1Q0%/ M7M2 !]*56(-+T'R\TU,^]!_VN*0#MF 3#M5- M6YQ3BLAY7I0P++Q;VPASFM*Q\,3W!5R#@UEVC2(^<9KK[#79(XU01C(]ZG5 M:VF>!H)X<2$!C5MOA4S_ #1OU]ZJP>);B%PVP8'O726/Q#CC 64 8]Z38'+W M'PVU"#/EHS >]9K^%-6M>MLYKUVS\>6,Z ,%Y]Q6DNKZ;?#'R<_2E<+'@IM[ MN!]LT3#ZUJZ?:[V5BN/:O6;_ ,*:??1^9$XW'MBN2O/#]Q8SGRDR@]J5]1D$ M42HHXQ4C3#;M _&H3YB\.N*;N ZU5Q6 LV?6I%E07U]-(I\SC\:YV7<[^M*UA%0+<75QF;+ ]S6@FCJ1O#8QV MJ[:0#:"PQ5M@JCY35 8[V[$; G3O4)LG!SBM@,<\"FMD]N:=P1B/ P_AQ4>Q MNXQ6TT.[[PQ4+6P-&@&3M.:>,CWJ\;/GVH-K_=YH K0CYNGX5IQ*-G3%5D@V MGCK5G)2$[NN*'Y"1FW\I!P.*R'?<>E6KJ<4UOF;(Z4NYMNTCBF2MQB,6;IFM)A_ MH_ YK.0A&^7FM.,[XQ6,ST*,N@6MP8UVD4VYG[M_'>MX MGFSWN1?A2'Z5(8W'44TJ>]6T3NAE(2>PI^WBC%2%B/!ZTF/]BI,4T M0QJ#P-U6VAE$6]4.*CAN[0-\H_6M+^VK3[.8MOS8]:WYR>6S,'SMTFUQMJ2\ MDCM+FVXB3/7-9D MEC<&^WLIQGTK;C^1 !Q4-E#)0 Y.:R;R4>9]ZM6905)KF]1<+-0M0N23'],#(>@Q1Y MB= .: &2JJ]#6IX';%T6-F-5:PCHX;29DW;C4Z1R)P234RRO&FU>E3P@R=10 M!F3633 \]:SY?#TTC91R*ZAH^R]:DB60#!HN'4YJ#3;VSY$S-[58_M*2([)K MS7 M8P]JS?M.IZ2WS.2HXZ&E8+G5C0MJY+;JL6NGI&?G05F:;XG$D2B8?-[FMVWU M*"X'(S^- 7$N4M4@(,:CWKSOQ'%$UQF,#'M7P0RKE".E<]/;NC$]!4J:AY;A7/ MZU?FEBN(>!VJD3<5C65M+,6V@FM;6(]DC'M5KPKYT*:=<0^<.E)#4V3UH$0)?>4>M2F\^T# %9LZ@-S4T,B6_S$9I]!B3A@W2F1J6/( MS3WO$D?@<5/"R'HM2(?! JD,3^%:44:LOWL523:6QBK\$:8Y%(;'+;1ALDBK MJ NNQC\E0XC09(S2JS9S_#Z4,!L]I&AS&!N]J2VU:[L7S)N9!V-6U>+'W>:" MDYIT$$-UDQ2 9]*YRYTF Y:,8;M5-+J]TQN&)% M [G72:--"WFAR14!?#;7ZTS2/$[W,BPW!RI]ZV+K38YU,\?W<9I,31D-*L?! M;.:58% \T-^%#6B2' (XIZ1$?)GBD GWA][%,[_>Q4DD.WH:B\HD\F@"9"/[ MU2AH0;#QC^]FG%\#K2>3GH:/)&/>@+7$""3OBH3&P?&:> M0\9I2S*,D<4 3A3';%QU'>L"YFGN7P"2!70;O,LF %8T"NDAP* &V]H%PS#) MJZ'"# 7%.\Q=OW3FF@@GE330PRS]L4HB]6I^3CI2>5)(>N!2N!&X"_=?-26E M@]V_SG %68;!,[V(XJOJVJ_9(=MIPW0XIAJ27EV+&)K93DXK*M2\C$R9%1VS M/>,)9\EJOR!0!M%(3#RMISFGC&/6F*Q88-/"@#B@-0Q[T=^M-R">*<,?C3 " M/?%*..]&!1@=Z0"YSQG\:-K+_'FD(XXI%5ST- "F1@.N:/D ME,$,DM+=AR@IVFV5NEV"J@'UJ7Y"/F%/M0BS9 I#*7B2$A%+08Z-V?(/%8NIDK( MV&K8E=57(%85\=[DGI30&OS5@ZI"1(QW5NQ-ER*S=40$-QS3 I:'I?]H7J#..:]@M MO"Z0V2-G^$5Y;X8N/L]^O^]7LYU)5TY"S#[H[TQ'$:_:RV\$@3/ ZUYCM>@^)_$&3)$IX/O7GC%YI2?4T(9HZ='\PPV3Z5IO$?,4DXJGID'E.KL: MFO[AFF79TH$/U67_ $=0#1IJO(%&:K7&7B&ZI;*X:$C/04F,Z&,B!>3FH9KW M?P*KFX\X<<5"XV\CK6;$2-(W7-,60MWIF[*\TZ';W%(8_..]/E(%L6]NM-(# M53O+G9"T=4K 94K&XEZYP:W+6,K O/:LC3H/,M.9/3BDV8''6@,1PW- #4^4\U+YHZ$<>M-;&.10-F/F M'RT #B+'"AC4<9NXWS#.T?TI^^'_ )9)@T;96^Z<4P-O3/%NJZ65W7;R*O\ M#7;:9\6(G&RZM!]2/_KUY>(\#Y^336A1NHH ]P@\7>'M1QYGE(Q^M:<5EH>H MIF&:/GTS7SW]BBC^<9S]:M6VJ:G9D&TF**/K1:X'M]]X-A$9>+$F>PKC]0\, MRJ6Q&5K'TCXD:M92*+N4N@XZFO0M*\>Z-J@6.YA^9NI+46 \ZDT*6,Y#'Z5& MUM/$,-&<>M>U)8Z'J*[X54$^XJE?^&K4)G 9>P HL!XP\5P[86,UL:+H[2OF M=,_6NW.BP1/D1':/:IE2VB& F*7*!+:65A;VRA44MBH)5A,OW0%H1X1)P*N! M;:1.5^:G9@8NH6%I<1' 4'%>5:YH%RES(Z*0F>M>SM;VZ-\PS1?6%E:C2'YL[-PKL_%'A=UG,D0X'/2N2$KV[E'0\<4("K+"&;Y! MAO2H&MI!]XFM-L']ZHP:9YF\_/S3$9A5E[4W<0:US$C#D5&UFAY%(#-+$T;O M>K;VRCH*@,// H :%!&:9O'I3U<]J %#XZ\TX\ MC.<>U-8KCCK3: #)%.7GOBA<=Q2[0.30 A'S=:<2%'K3.,T[:&Z<4 (G+5,6 MP.M,VX''6D^HYH"X>:RMQQ6SITRY7<:QPI;J*L1 J>>E*P'9P26Y7YF!J1UL MY!A"N:Y-)6'0\5:AN4!^4$'ZU/*-&\+,YW)-CVJ99;N _).U88OY=VU36QIZ MS3??;-3R@;VG^)+Z#"L[$"MV'Q,90!,F1W)K$BLD" L*E\F,#&WBERCZ&_\ M;;"?LN:46ME+R)%^E<^D-NOW5(JPDL*'A3GZU2$:[Z=9_P#/1148L;3/^M45 M2WI)3'C&.30P-);.QC.YI5:I?M>G0=(T:N>*#?R?EIWEP]Q0@-Q]=MD&(XA^ M%9=UJ\\Q/EL5!["JC"W'W$P:9L9ONG%*X$$LERY^>0_C2IY:C+8SZT^563F0 MYK+U"\C\HJ@^:B]P(M4F#/M1LU!96Y8Y/-0VJ-,V6Z5KQ!8AP*H0%/+7@_A4 M7+'DXIY?*M0 MS%0 >*FDB '-4BWSX/2E)&E.;)Y'R>N:DBRQP#FJVW/W>E:&EPAYA63.E5&: M47AV:XM_.3/TJE/IMY:GE&P*],T4I%IZJ5R<58FMK6[4ATY-):&::>><_A34 ME8<.*3<"W%:IW)0[--;GOB@D9I&QW%/J4';K3E 7.OT;5'OY M=OF[:V?+E6<'S217$>"X))[S!.:]3.E!+3>>N*3-+:#K)U8 'FIKU8$CW2Q! MQZ&J.EC_ $D*3@9KH-8L%DL 4(SBH9-C@M4U+355HTLT#^MR(TK,.]/P0:H!#@=%Q0V N=OXT[/KS39,[.3Q4;@0,V[@#-;OAR'%Q MDG-8()S\O%=+X;C+SU#'$[%,>7@578,'Z5-M*,!FH)Y61JR9H+<9\KI7)ZG. M5D92GXUT_GM(,&N?U>WD8L13)3Z%#3OGEX&:]0T*T/DHQ].E>=>'KBVM)O\ M2HF;GL*]ET6[TR[MD2)=C$?Q50,41+D?+GVJ;RS_ ,\]E76TUPXD2XCVCW%3 MAH,8GFC/_ A0!G1Q -G=FK2KQ]RI2VG0_.98R/\ >%1/K>G)P&7'UIL6H[ [ M+FGQQ2$YVGZ56/B+2TY&,_6J\OC2PA'RC)'H:2&C>3P%8S:I=Z(VUX6D![TO_"<' M[JYV_C4$^K)J0Y'YT- :$6N)>K\Y"Y[52OD67+1\_2LI+!GGRC 5=R]H-K9/ MTHL"NBE'&PD.Z/;[T,%9B"<5I1SQS95\53N-/?>74C;28[&!J5I+OWQ$D#TI MNF7TBR[)@<#UK;9/+C(8]JPYXRTAV<'-""Q+JMNES"S(>2*@\,V[6TK;^,FI MHG$:8,5YI MXB,QU%B&^6F(>MG9VXYE5JC>XL8CD!7/I6+*CR02.::;5C]* 5S+FD:0]*1=S<'FM3["3TIPLL=!S0!FI& V<5>B' MHN*F%H0>E6(X"O6@+"Q*#_#BKJ?*.F:B2/%3JIQP<4@:!6YY&:E+\<+^%(H M-(6';K0@)(V'=:E+;AP-M5@^.M2;B>]%@) 2.#S[TKQPR+AXPU19/K2;O?%) MH"C-IOE2>;%+LYZ"NAL=6D-C]E.2Q&-U8EP^4('6ETQV%RH/K1818O#<6#;M MY.>U1IK4K#;Y)SZUHZV%V)FLN(8 I:#)O[2D[J:47[^F:@D1F/RD"FB*0=#1 M8&:45\Y[&K N'/8BLE!,IX/-65:;N:5@+_GR^A%6([EE&6CS6;YL_*8=32;4$/6&D:\B=<% *RQYQ[TIC9A[T,.IJIJEM;Q%& YJHVKV.[HHS6; M+I[3=3S55M 9CN)Y%"0'21SQ2#QIAJ4&50<) M%M%.4!?O012 0\-D"ER3UXIP.!SUIC9)I[@'X8IP/M^- M)M..32\^O%(8X/CC;FES3<-V-'/:F(6E!(IHSGFG%2.II!U$+YXV_C2KM'\- M)13"P_<#T6D@4B7/Z4@)'2GPG,G'6E8$&HG-L^1V-<;I9_XF+X&.:[:^3-HY M//!KB-/;9J3Y/>J*.R60>1@IGCK4(.3PM.C?=#[8IOFA.G%2 ]XV9>$S6/=V MEX7)%LVWUKNO"(M+N\VW(!'O7IW_ C^E3V>%50".IQ3$?-'EW*R )"37::) MX;FU&-1*3$".IJ3Q_:QZ#(K64B'/]T@_RKD+3QSJJ 1B4X_&J3"QJ^+=$CT= ML"X$AK#T2Y#LR,,9INIZO+J)WW+%C5.SF0-E%*XJF!TEWX0-S&;A)\YYQFL5 MX9]+?R2A8'O6W:>(O*01D]/>J^HWHN_G5AG'K4C(K="PW;<$UFZC(P9E,?'K M4?\ :5Q YW/\M1W&HB:,[CS0@(+1Q%,'5NAK;N_$\XMA&KDX%*U(-1:"(JIQ3V&6[D(I( SBJ42"S<^U M8MU,;BYVJO!JUJ5V"NR,\TEA!O D8KA<=-OXTQV(& :09/)/ M%)@@)YZ9IV1CIFF_3BC.>G6E88'U_2E!XZ8I/YT$X^]0 X,2>E,.-_2G*V:8 MR'=G/% ;#9B,CC-:VDG#J0/PK'E;D;:V=(W>8M("/7)Y3*$5#S52RTV>X/S* M5KI+JT5Y5D89Q3A<+$,**I"9EOH++'DM69/9/"V I:NG:YDD&,\5#M!/S"J MY=HY,?ZLFH2&S@KCVKKC!&X^48-59=*W_,,9I <\H4'E<5-OXXXJSE. )Z"C\*!M%!Z'=ZTZ,W<+;K>7;CWH ][FT)T7?;.9AZBLJ=;^U8[[=E4 M=Z\[TSQ_XATG"-ZT"+ U1.DCC-2+?;C\K M9%7+5?#.O\VICB;_ &F J2X\).$)LKF(GMA@?ZTKC,Z5K>9")HP2?6L*Z\*Z M?J!.Q%C)[UJSZ-J%I)_I"M)[J*<)HXEQY+JWN* ./OO +QQGR7W#V-<[<^%[ MNV)_=,:]0_M&53PP">AH:<7 R66F(\;GM;R#K;M4(D8<.-I]*]=N+*"8?,H- M8UWX:L9R3L 8_2F(\[+Q]R*: K'A/QKJ[KP<.L>/TK$N=&NK7/<#VIV&9SP( M>O%0FT!^[\U63$P^^I_*D641] 12 SS9.&SM.*0V[#VK4\YI.!Q2>7_>.: , MK8WH:3?MX*UK8C7JN:@DL_..Y>!Z4 4 X';-*&]:L-8.HR*@:%QQ0 8!Y_2D M)/88IN"M/#9^]0 Y22.E2H!G&W-1J&)XZ5:AC/!IB+,$"XY7-2FV7M^521@[ M>*4 [J5P(?L9(R&Q[4D=NV[&,5<4'O4T2<^M)C*\5J=X_G72:7B'J=U9)5P, MBG17$L1XS4@=BLVY1BIT*[,L*Y./5I$ZYJ];ZRLA"L:8S:+IGCBE^7'W?QJ* M&:U;EL'\:N[H63"D?G2 KIO*) M;YF%,E>* \L"?K0 C0AA]W;[U&[K N=V<57GU= ,9S6/F(;DXZ M?C3>3S3SG'7BF;L"F 9-. XSG\*BW9-&_!H FWX[4<-VQ3-V>M(S8]Z0#BI' M2D#*H^84*Y(Q4,_UQ3&4KVY+915K,VL>=E:AC!.0.:KS;DI+4:12Q(_RK":= M'X>FG;>V1FHGU.6V/6HV\37N,*W'XT&B1J+X3C;E[H)[9I9O#T$"Y^TA_P : MP7U>_G;)8_K3Q=73C!>DQI&B-,AW\S #TJ4Z39D+E2*DB5B-9'S MAOF'I39[&TN8SOA4,:_"F[E]:C;]RV)48D=>*3[1;?W#33&:/@C4!:W MN2?SKUV*^6ZM>&ZBOG_3Y&28&,XKUKPQ<;[- YRU:6+OH;2PE)0PR.:W[1WN M4V.3@"LI_EP<9K0TV<%\8K-HEG)^*-+VR22*O%<,'*LPKU_Q!$)+*0^U>1W: MK#(_&*1)BZC*,-SS6*6)-:4N%)Q]:U1X;?GM4 MFWN*5Q"?=J">0!>M3-C'I6?<,.<5((DA(9N376Z!E),BN,M6_>#ZUW.AH."3 MVJ&M!K].D9$]ZIL^]L@'%9W ZR/^=59Y%BAW(,&J"7CRMAG&:>X;FJ;J>3K(WYTGVET^\Q/U-1I'+MR7 M!%5)W;?M*D_A1:P&B+]"<$@U*RF5D&XGBKUKM>V8^U M*P% P[Y3L)X/:K$LQBAVYY%5H;@IRR'*< 56N9DN%V2\T VS"BGWR;2:N%Q;LNT]:K7&GLA,L3 *.U5T ME9CB3)Q1=$W9W5JR260(/S$5P^NQ;KUL]:W-#O1]I"-]WTK*\3-_I[,B''KB MG<6IBI9*>33]RQ< XIL=R<$&F"(O)N?[M6B@EB289+9_&HK=!%)Q5AHE!^3I M3)=I7"#!H:'?0M%%E2LV:W\MZN6[[2 U.N4\PY%(=D4!'NX-!CQP*L1Q^6!3$5?LZ@T-;@U;V[C2M%CK2 J"$ 4 MX(O2IWB8+GM4:H330">4HZ4NQ<>]/VGM32/4HH#<<%7 M&*<% IHQBE!STH!$G Z4X8;DU!N&:7=@T@)R!BF8&<4W>,?-S3&F4=J:!+H2 M$8I0P7H:A$H;H*M)L#'BIDQ#]ZD)[D0BSP:T;6T$:B3 M'3O54*TC?+T]*TFG2"Q*MUQTH"QFZK<[RH!S4,1Q&#FJ32>?*=H-7E4"+'>D M,1G)/%3(6-0K@=15A&Q0*Y/&/45*#CI42MGM4RD&C4+CPP]!4BGC.*:@3M3B MX7@"D&X[;NZC%.$0J'S7[ U(KN>O2F,&C /% PO0TI8 9(.*1#&_W1CZT"'A M_P#9!_"D:..0?,J_E03C@4PMS2#T(FL(7ZJ!43:7'V8CZ&K><]:?MXS2"YF' M2=AW+/)Q_MFIHKFZ@.%9FQZ\U;R >E2%T ^08-,&R ZW=(,,@_*B+5DG;$VU M?PQ3]JR'YQFH9]*MIAPO- &JD5C,F5D!8^]4[FUE5OW*Y3UQ6(;&>RDWHWRC MM6G9>)O) MG!RW&: %Y'!ZTX+WJQ<6Q2,7&0V[G JNKANQ!]Z '4H /6FE@# M@C-+VYH 4@#I24NTXSVHW*>@Q2L,;M[T$\4OX4W@GIS3$)UZFI8?']UJ#DG^(T[E'8V2@ MVP]<42P@GGBF:>W^B!\CI4-S=?O, MN3:3*\]ZB-M'CS1]Z@14U">YO)"UR[L#_>-9@MXE;(QFM2:1Y>'Y J!HH"/E M&&JT%S,F!\P8'%7+>-7'( J"0%9@GK5^.T?&VWR$L1FG= 8*\ M,!6I#$KJ.*H1HHEVMR2>*W;2T:-=[\KBF%B%+5-_2J.L0!,;:OR2$76U>F:; MJ$!F0$"A6$!3N!/;,"W/%7MR@<5EID=C4P< MXI- ;]EAHZG.%-4M.D'E8JR59CQQ]:$,'/&:IS7&T8SBG7%TD0*'EJRV9IW' M7%)@26T!N+@ELD5LH/)38*2UCCB@!Q\U*S;FI-@')I1Q1N ^Z,4F>](!_P![ MK3:9O&<$4_'&:!B@]J0CG%-)QVI005R#B@ ($8R.M(&,AI$#73[$4@_2MNPT MD@*S]:8:%"WL3(6.BT[@,0 &IO*604PH'^YP:1$DB;<31S *U@I MYJK/:%!QD5H?;5'!!)I1+'+PXXH3 S8DXP:D\LC[N:T?*@QD 4*L8Z#%%P92 M6 -]^HI;*$@D-@^QK39$<=A5&XC"YQ0(IQ&>T;,5Q*OT.:PE^8_-4N..*&,]%LOBI=L D\<9!ZDH*Z33O$&D:P0+EXE)ZXP*\4*@C! MJ/R-IW0DAOK20(]YU'P_I]Q;&2P?>Q' #9KB;[3]0LI#E7 %3 M,<#ZUUMA\3(+A0NKQM*W3(!JD!0?6)X!A^,>U-74S.?O=:Z^VO?!VM_*T(1C M_>(_PI;GP':72F73+B%5/0;EIB.9CE8#@YILD22_>4&]8TLYR9%_P!D M9K-%Y+&^R6WE##J2II@)+HUO-U4 U5?PM#(,A:OB[7=T(/O5E+Q^SC\Z+ '7BSM0X%9J,?H*I%'7[ZMCZ4 0-;@\"FBUP: MN+C''%+@GI0Q,KI"%-6XHP1S2#:O;FGJZ^AJ=1:DH&*E1,U&/]H58C=>F*&- M@(QG%:5E8Y;(R:K0P-)("HP*Z>QB5%''.*5P0D.EQLF6%.;1XC_#6B&XP!0& M(/S^D M^U,IXIL=T4&2ZV_=-4I)+]3]UORKH4U)5X<9HEOXF7E: .<-U>;,,"!ZU7;S M9?XF-;D\GFC'\-5A$%^[0%S+73R3DY-6X[%57)'-6\G'%-+\8-("LR*!Z569 MCNQGBKE1* M!FIP,IBHBNR@+HEVHJYSS4$F",AOUJ.0[^%I5 *[2/FHLS.;1>TVT%PV3VK5 MU&;R[+R@>@IWAZ$1QN7%9E]+YU\T0Z9H$F&FL>XSS7<>'$627!4'CTKDK54A M&TCDUV?A-3]HSBH9>MC:O;)85\U1@TRPN"QPQ/6M/4.4P>E9$:*L@P.]2C*3 M-FXB!B!%5XG*MM-6(RQC ;IBHG50V11H2F.EA#@$&HFWHF!3U8S'#=* M=RM>I"LC=SSZ4V6$7 Q(H_*IF"#D#FHF,AZFA,>ABW?ANSN,Y R:S_\ A#;/ M/_UZZ?9@Y/-.RG]TT[D\IX7;AHY 3Q7I/A:Z(BC':O.70QD$G-=KX8?Y8SFN MI$GK-I"+B/.,U(L7D,2@YJEIMP1'@&KP)DSVJ&!DZW=N+5P?2O*=4FW2-GBO M2?$#[() 3VKRR]D7S#DYJ6@,:7>SGCBH3$^>!5X@ [J>I5NU4@N5K>-E.<5< MW C '-.50>G%(5 -:!<09!Y%*TG'-#=*C"\\G-2(,DG@<5(K$5'M.<@\5*JY M[T@ 9SQ3N._6F'*GBGH=QQBBX$-P6QSQ67*Y)(KO%=!86\=PZJ MZCDV@KEM&F=(55V)/O736[[QUJ;68 M[ED%I..]3I*84V=,U'%C=4

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image6.jpg begin 644 image6.jpg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�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end GRAPHIC 12 image00007.jpg begin 644 image00007.jpg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�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htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2018
May 04, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name BIOSIG TECHNOLOGIES, INC.  
Document Type S-1  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   34,619,071
Amendment Flag false  
Entity Central Index Key 0001530766  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Filer Category Smaller Reporting Company  
Entity Well-known Seasoned Issuer No  
Document Period End Date Mar. 31, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED BALANCE SHEETS - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Current assets:      
Cash $ 1,035,100 $ 1,547,579 $ 1,055,895
Prepaid expenses 119,111 116,938 134,263
Total current assets 1,154,211 1,664,517 1,190,158
Property and equipment, net 19,457 18,716 24,188
Deposits 22,477 17,084 27,612
Total assets 1,196,145 1,700,317 1,241,958
Current liabilities:      
Accounts payable and accrued expenses, including $27,375 and $15,755 to related parties as of December 31, 2017 and 2016, respectively 338,811 473,098 373,103
Dividends payable 482,636 447,901 359,891
Warrant liability 0 2,358,240 1,937,234
Derivative liability 0 685,922 288,934
Total current liabilities 821,447 3,965,161 2,959,162
Convertible Preferred Stock 965,000 985,000 1,070,000
Stockholders’ deficit      
Preferred stock  
Common stock, $0.001 par value, authorized 200,000,000 shares, 29,321,204 and 22,588,184 issued and outstanding as of December 31, 2017 and 2016, respectively 30,498 29,321 22,588
Additional paid in capital 55,381,386 53,215,635 41,019,251
Commitments and contingencies 115,470 29,985 0
Accumulated deficit (56,117,658) (56,524,786) (43,829,043)
Total stockholders’ deficit (590,302) (3,249,844) (2,787,204)
Total liabilities and stockholders’ deficit 1,196,145 1,700,317 1,241,958
Series C Preferred Stock [Member]      
Current liabilities:      
Dividends payable   419,283 359,891
Series D Preferred Stock [Member]      
Stockholders’ deficit      
Preferred stock 1 $ 1 $ 0
Series E Preferred Stock [Member]      
Stockholders’ deficit      
Preferred stock $ 1    
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Accounts payable and accrued expenses, related parties (in Dollars) $ 7,236 $ 27,375 $ 15,755
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000 1,000,000
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000 200,000,000
Common stock, shares issued 30,497,707 29,321,204 22,588,184
Common stock, shares outstanding 30,497,707 29,321,204 22,588,184
Series C Preferred Stock [Member]      
Preferred stock, shares issued 965 985 1,070
Preferred stock, shares outstanding 965 985 1,070
Preferred stock, liquidation preference (in Dollars) $ 965,000 $ 985,000 $ 1,070,000
Preferred stock, shares authorized 4,200 4,200 4,200
Series A Preferred Stock [Member]      
Preferred stock, shares authorized 200 200 200
Preferred Stock, shares outstanding   0  
Series B Preferred Stock [Member]      
Preferred stock, shares authorized 600 600 600
Preferred Stock, shares outstanding     0
Series D Preferred Stock [Member]      
Preferred stock, liquidation preference (in Dollars) $ 1,030,500 $ 2,001,000 $ 0
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 $ 0.001
Preferred stock, shares authorized 1,400 1,400 1,400
Preferred Stock, shares issued 687 1,334 0
Preferred Stock, shares outstanding 687 1,334 0
Series E Preferred Stock [Member]      
Preferred stock, liquidation preference (in Dollars) $ 1,500,000    
Preferred stock, par value (in Dollars per share) $ 0.001    
Preferred stock, shares authorized 1,000 1,000 1,000
Preferred Stock, shares issued 1,000    
Preferred Stock, shares outstanding 1,000    
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Operating expenses:        
Research and development $ 862,420 $ 1,338,604 $ 4,756,468 $ 2,654,501
General and administrative 1,771,796 1,557,341 8,138,117 8,499,304
Depreciation 2,903 3,069 11,698 10,475
Total operating expenses 2,637,119 2,899,014 12,906,283 11,164,280
Loss from operations (2,637,119) (2,899,014) (12,906,283) (11,164,280)
Other income (expense):        
Gain (loss) on change in fair value of derivatives 0 (373,611) 210,465 (422,908)
Interest income 85 0 75 1
Loss before income taxes (2,637,034) (3,272,625) (12,695,743) (11,587,187)
Income taxes (benefit) 0 0 0 0
Net loss (2,637,034) (3,272,625) (12,695,743) (11,587,187)
Preferred stock dividend (305,046) (23,745) (119,877) (110,023)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (2,942,080) $ (3,296,370) $ (12,815,620) $ (11,697,210)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.09) $ (0.14) $ (0.50) $ (0.60)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 29,944,445 23,051,872 25,550,686 19,490,767
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock [Member]
Series D Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Common Stock [Member]
Series D Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Common Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Common Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Series D Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series D Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Common Stock Subscription [Member]
Series D Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Common Stock Subscription [Member]
Series D Preferred Stock [Member]
Common Stock Subscription [Member]
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Common Stock Subscription [Member]
Series C Preferred Stock [Member]
Common Stock Subscription [Member]
Retained Earnings [Member]
Series D Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Retained Earnings [Member]
Series D Preferred Stock [Member]
Retained Earnings [Member]
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Retained Earnings [Member]
Series C Preferred Stock [Member]
Retained Earnings [Member]
Series D Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Series D Preferred Stock [Member]
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Series C Preferred Stock [Member]
Total
Balance, Value at Dec. 31, 2015                 $ 16,826         $ 29,314,399                   $ 32,241,856         $ (2,910,631)
Balance, shares (in Shares) at Dec. 31, 2015                 16,825,703                                        
Sale of common stock                 $ 3,798         5,222,570                             $ 5,226,368
Sale of common stock (in Shares)                 3,798,417                                       3,798,417
Common stock issued for services                 $ 1,335         2,469,715                             $ 2,471,050
Common stock issued for services (in Shares)                 1,335,000                                        
Common stock issued upon conversion of preferred stock and accrued dividends             $ 58 $ 267       $ 90,365 $ 400,733                           $ 90,423 $ 401,000  
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)             58,185 267,334                                          
Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance                                                         0
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares                           103,096                             103,096
Stock based compensation                 $ 304         3,528,396                             3,528,700
Stock based compensation (in Shares)                 303,545                                        
Preferred Stock dividend                           (110,023)                             (110,023)
Net loss                                               (11,587,187)         (11,587,187)
Balance, Value at Dec. 31, 2016                 $ 22,588         41,019,251                   (43,829,043)         $ (2,787,204)
Balance, shares (in Shares) at Dec. 31, 2016                 22,588,184                                       22,588,184
Sale of common stock                 $ 4,131         6,007,098                             $ 6,011,229
Sale of common stock (in Shares)                 4,131,536                                       4,131,536
Sale of preferred stock   $ 1                 $ 1,929,959                             $ 1,929,960      
Sale of preferred stock (in Shares)   1,334                                                      
Common stock issued for services                 $ 2,272         3,384,345                             $ 3,386,617
Common stock issued for services (in Shares)                 2,271,788                                        
Common stock issued upon conversion of preferred stock and accrued dividends             $ 24 $ 57       31,844 84,943                           31,868 85,000  
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)             24,021 56,669                                          
Common stock received and canceled in connection with short term swing profit reimbursement                 $ (11)         11                              
Common stock received and canceled in connection with short term swing profit reimbursement (in Shares)                 10,744                                       10,744
Common stock subscription received                                     $ 29,985                   $ 29,985
Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance                           1,049,216                             (1,049,216)
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares                           20,757                             20,757
Fair value of warrant issued to acquire research and development                           543,927                             543,927
Stock based compensation                 $ 260         1,362,593                             1,362,853
Stock based compensation (in Shares)                 259,750                                        
Preferred Stock dividend                           (119,877)                             (119,877)
Net loss                                               (12,695,743)         (12,695,743)
Balance, Value at Dec. 31, 2017   $ 1             $ 29,321         53,215,635         29,985         (56,524,786)         $ (3,249,844)
Balance, shares (in Shares) at Dec. 31, 2017   1,334   0         29,321,204                                       29,321,204
Sale of common stock   $ 0   $ 0         $ 200         299,785         29,985         0         $ 270,000
Sale of common stock (in Shares)   0   0         200,000                                        
Sale of preferred stock   $ 0   $ 1         $ 0         1,492,968         0         0         1,492,969
Sale of preferred stock (in Shares)   0   1,000         0                                        
Common stock issued for services   $ 0   $ 0         $ 100         141,900         0         0         142,000
Common stock issued for services (in Shares)   0   0         100,000                                        
Common stock issued upon conversion of preferred stock and accrued dividends $ 0 $ 0 $ 0 $ 0 $ 210 $ 647 $ 7 $ 13   $ 261,825 $ (647) $ 8,269 $ 19,987   $ 0 $ 0 $ 0 $ 0   $ 0 $ 0 $ 0 $ 0   $ 262,035   $ 8,276 $ 20,000  
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares) 0 (647) 0 0 209,574 647,000 6,595 13,334                                          
Common stock subscription received   $ 0   $ 0         $ 0         0         115,470         0         115,470
Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance                                                         0
Fair value of warrant issued to acquire research and development   0   0         0         0         0         3,044,162         3,044,162
Stock based compensation   0   0         0         246,710         0         0         246,710
Preferred Stock dividend   0   0         0         (305,046)         0         0         (305,046)
Net loss   0   0         0         0         0         (2,637,034)         (2,637,034)
Balance, Value at Mar. 31, 2018   $ 1   $ 1         $ 30,498         $ 55,381,386         $ 115,470         $ (56,117,658)         $ (590,302)
Balance, shares (in Shares) at Mar. 31, 2018   687   1,000         30,497,707                                       30,497,707
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) - $ / shares
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Preferred Stock [Member] | Series D Preferred Stock [Member]      
Conversion of preferred stock $ 1.50   $ 1.50
Preferred Stock [Member] | Series D Preferred Stock [Member] | Settlement of Preferred Stock [Member]      
Conversion of preferred stock     $ 1.55
Common Stock [Member] | Series D Preferred Stock [Member]      
Common stock issued 1.25    
Common Stock [Member] | Series C Preferred Stock [Member]      
Common stock issued   $ 1.50  
Common Stock [Member] | Series C Preferred Stock [Member] | Settlement of Preferred Stock [Member]      
Common stock issued $ 1.25 $ 1.37  
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $ (2,637,034) $ (3,272,625) $ (12,695,743) $ (11,587,187)
Adjustments to reconcile net loss to cash used in operating activities:        
Depreciation 2,903 3,069 11,698 10,475
Equipment distribution as officer compensation 0 0 3,210 0
Change in derivative liabilities 0 373,611 (210,465) 422,908
Equity based compensation 388,710 560,746 4,749,470 5,999,750
Fair value of issued warrant to acquire research and development 0 543,927 543,927 0
Changes in operating assets and liabilities:        
Prepaid expenses (2,173) (27,514) 17,325 (102,955)
Payment of long term deposit (5,393) 0 10,528 0
Accounts payable (134,714) 209,466 102,338 149,661
Deferred rent payable 427 (521) (2,342) (104)
Net cash used in operating activities (2,387,274) (1,609,841) (7,470,054) (5,107,452)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchase of property and equipment (3,644) (1,620) (9,436) (16,255)
Net cash used in investing activity (3,644) (1,620) (9,436) (16,255)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from sale of common stock 270,000 1,799,692 6,011,229 5,226,368
Proceeds from common stock subscription 115,470 0 29,985 0
Net cash provided by financing activities 1,878,439 1,799,692 7,971,174 5,226,368
Net increase in cash and cash equivalents (512,479) 188,231 491,684 102,661
Cash and cash equivalents, beginning of the period 1,547,579 1,055,895 1,055,895 953,234
Cash and cash equivalents, end of the period 1,035,100 1,244,126 1,547,579 1,055,895
Supplemental disclosures of cash flow information:        
Cash paid during the period for interest 0 0 0 0
Cash paid during the period for income taxes 0 0 0 0
Non cash investing and financing activities:        
Reclassify derivative liability to equity     20,757 103,096
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock 0 0 1,049,216 0
Accrual of dividend payable charged to additional paid in capital 305,046 23,745 0 0
Series D Preferred Stock [Member]        
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from sale of preferred stock 1,929,960   1,929,960 0
Non cash investing and financing activities:        
Common stock issued upon conversion preferred stock and accrued dividends 262,035 0 0 0
Series E Preferred Stock [Member]        
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from sale of preferred stock 0 0 0 0
Series C Preferred Stock [Member]        
Non cash investing and financing activities:        
Common stock issued upon conversion preferred stock and accrued dividends 28,276   116,868 491,423
Embedded Derivative Financial Instruments [Member]        
Adjustments to reconcile net loss to cash used in operating activities:        
Change in derivative liabilities     20,583  
Non cash investing and financing activities:        
Reclassify derivative liability to equity 3,044,162 0 0 0
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock     0  
Embedded Derivative Financial Instruments [Member] | Series D Preferred Stock [Member]        
Non cash investing and financing activities:        
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock     397,162  
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]        
Non cash investing and financing activities:        
Reclassify derivative liability to equity $ 0 $ 0 $ 20,757 $ 103,096
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Significant Accounting Policies [Text Block]
NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.

At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).

Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420 and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively.

Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 
 
March 31,
2018
   
March 31,
2017
 
Series C convertible preferred stock
   
643,333
     
713,333
 
Series D convertible preferred stock
   
687,000
     
-
 
Series E convertible preferred stock
   
1,000,000
     
-
 
Options to purchase common stock
   
8,230,319
     
8,245,190
 
Warrants to purchase common stock
   
12,237,628
     
10,419,655
 
Totals
   
22,798,280
     
19,378,178
 

Stock Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested.

As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as non-current.

Registration Rights

On February 16, 2018, in connection with the Company’s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018.

Adoption of Accounting Standards

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.

When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.

Business and organization

BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.  At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively.

Prepaid Expenses

Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

Long-Lived Assets

The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.  Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.

At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).

Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468 and $2,654,501 for the year ended December 31, 2017 and 2016, respectively.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as non-current.

Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 
 
2017
 
 
2016
 
Series C convertible preferred stock
 
 
656,667
 
 
 
713,333
 
Series D convertible preferred stock
   
1,334,000
     
-
 
Options to purchase common stock
 
 
8,510,319
 
 
 
8,245,190
 
Warrants to purchase common stock
 
 
12,789,086
 
 
 
9,128,189
 
Totals
 
 
23,290,072
 
 
 
18,086,712
 

Stock based compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash.

As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.

Registration Rights

The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  

Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on March 31, 2017. On June 8, 2017, the Company filed the required registration statement and on September 19, 2017 was declared effective. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

On November 3, 2017, in connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Substantial Doubt about Going Concern [Text Block]
NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As of March 31, 2018, the Company had cash of $1,035,100 and working capital of $332,764. The Company raised approximately $1,500,000 through the sale of Series E preferred stock and warrants and $385,000 through the sale of common stock and warrants during the three months ended March 31, 2018 and approximately $4,675,000 subsequent to March 31, 2018 (See Note 11). During the three months ended March 31, 2018, the Company used net cash in operating activities of $2,387,274.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months.

The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at March 31, 2018 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.

Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As of December 31, 2017, the Company had cash of $1,547,579 and working capital deficit (current liabilities in excess of current assets) of $2,300,644 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised $6,041,214 through the sale of common stock and warrants (See Note 8) and $1,929,960 through the sale of Series D preferred stock and warrants (Note 6) in 2017. Subsequent to December 31, 2017, the Company raised $1,500,000 from the sale of Series E preferred stock and warrants and $270,000 from the sale of common stock (Note 13). As of December 31, 2017, excluding the derivative and warrant liabilities, the Company’s working capital would have been $743,518. During the year ended December 31, 2017, the Company used net cash in operating activities of $7,470,054.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months.

The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at December 31, 2017 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.

Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2017
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]
NOTE 3 – RELATED PARTY TRANSACTIONS

The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009.  No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. As of December 31, 2017 and 2016, all advances had been repaid.

Accrued expenses related primarily to travel reimbursements due related parties as of December 31, 2017 and 2016 was $27,375 and $15,755, respectively.

On May 4, 2016, Mr. Londoner and Mr. Chaussy were granted 250,000 and 200,000 shares of common stock at a cost basis of $1.93 per share for their 2016 performance, respectively. The granted shares vested immediately.

On December 8, 2016, Mr. Londoner and Mr. O’Donnell each were granted 41,500 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017.

On December 8, 2016 Mr. Cash and Mr. Tanaka each were granted 20,875 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017.

On December 22, 2016 Mr. Zeldis and Mr. Weild each were granted options to purchase 50,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term.

On December 22, 2016 Mr. Gallagher and Mr. Foley each were granted options to purchase 25,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term.

On April 1, 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from Mr. Londoner.

On June 16, 2017 Mr. Cash was granted 100,000 shares of common stock at a cost basis of $1.37 per share in connection with his severance settlement. The granted shares vested immediately.

On November 8, 2017, Mr. Londoner, Mr. Chaussy and Mr. O’Donnell were granted 450,000, 250,000 and 200,000 shares of common stock at a cost basis of $1.52 per share for their 2017 performance, respectively. The granted shares vested immediately.

On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors,  the Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company’s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned.  Mr. Filler is the general counsel and partner of Sherpa. 

On November 9, 2017, Mr. Londoner, Mr. O’Donnell and Mr. Weild, as members of the board of directors, were granted each 50,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board and committee service. The granted shares vested immediately.

On November 9, 2017, Mr. Tanaka, Mr. Filler and Mr. Foley, as members of the board of directors, were granted each 30,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board service. The granted shares vested immediately.

On December 22, 2017 Mr. Gallagher and Mr. Fischer were granted options to purchase 39,926 and 65,972 shares of common stock at a cost basis of $1.37 per share for their 2017 board service. The granted options vested as of December 22, 2017 and are exercisable for a ten year term.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
PROPERTY AND EQUIPMENT
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Abstract]    
Property, Plant and Equipment Disclosure [Text Block]
NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows:

 
 
March 31,
2018
   
December 31,
2017
 
Computer equipment
 
$
90,703
   
$
87,059
 
Furniture and fixtures
   
12,975
     
12,975
 
Subtotal
   
103,678
     
100,034
 
Less accumulated depreciation
   
(84,221
)
   
(81,318
)
Property and equipment, net
 
$
19,457
   
$
18,716
 

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

Depreciation expense was $2,903 and $3,069 for the three months ended March 31, 2018 and 2017, respectively.

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment as of December 31, 2017 and 2016 is summarized as follows:

 
 
2017
   
2016
 
Computer equipment
 
$
87,059
   
$
84,704
 
Furniture and fixtures
   
12,975
     
10,117
 
Subtotal
   
100,034
     
94,821
 
Less accumulated depreciation
   
(81,318
)
   
(70,633
)
Property and equipment, net
 
$
18,716
   
$
24,188
 

During the year ended December 31, 2017, the Company distributed equipment with a book value of $3,210 to a prior employee in connection with a settlement agreement.

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

Depreciation expense was $11,698 and $10,475 for the years ended December 31, 2017 and 2016, respectively.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Payables and Accruals [Abstract]    
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following:

 
 
March 31,
2018
   
December 31,
2017
 
Accrued accounting and legal
 
$
151,745
   
$
93,595
 
Accrued reimbursements
   
10,510
     
2,600
 
Accrued consulting
   
12,650
     
109,059
 
Accrued research and development expenses
   
148,932
     
246,030
 
Accrued office and other
   
644
     
7,912
 
Deferred rent
   
997
     
569
 
Accrued settlement related to arbitration
   
13,333
     
13,333
 
 
 
$
338,811
   
$
473,098
 

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following:

 
 
2017
   
2016
 
Accrued accounting and legal
 
$
93,595
   
$
120,464
 
Accrued reimbursements
   
2,600
     
43,116
 
Accrued consulting
   
109,059
     
1,192
 
Accrued research and development expenses
   
246,030
     
181,884
 
Accrued office and other
   
7,912
     
10,202
 
Deferred rent
   
569
     
2,912
 
Accrued settlement related to arbitration
   
13,333
     
13,333
 
 
 
$
473,098
   
$
373,103
 

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
SERIES C 9% CONVERTIBLE PREFERRED STOCK
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]    
Preferred Stock [Text Block]
NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK

On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. 

As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.

In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

Series C Preferred Stock issued and outstanding totaled 965 and 985 as of March 31, 2018 and December 31, 2017, respectively.  As of March 31, 2018 and December 31, 2017, the Company has accrued $432,660 and $419,283 dividends payable on the Series C Preferred Stock.

NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK

Series C 9% Convertible Preferred Stock

On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:

 ●
incur additional indebtedness;
permit liens on assets;
repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;
pay cash dividends to our stockholders; and
engage in transactions with affiliates.

Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.

In the event that:

  (i)  
we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,
(ii)  
we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,
(iii)  
we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,
 (iv)  
we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,
(v)  
we are party to a change of control transaction,
(vi)  
we file for bankruptcy or a similar arrangement or are adjudicated insolvent,
(vii)  
we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,

The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity.

In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. 

As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.

In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense.

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There was no established market for the Company’s common stock.  As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.

Issuances:

During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock.

During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910.

On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000.  

2017 and 2016 conversions: 

In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2017, the Company issued an aggregate of 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends.

In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

For the year ended December 31, 2017, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $20,757 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.74% to 1.06%, a dividend yield of 0%, and volatility of 151% to 166%.

Series C Preferred Stock issued and outstanding totaled 985 and 1,070 as of December 31, 2017 and 2016, respectively.  As of December 31, 2017 and 2016, the Company has accrued $419,283 and $359,891 dividends payable on the Series C Preferred Stock.

Registration Rights Agreement

In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.

Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.

The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.  At December 31, 2017 and 2016, the Company estimated the liability at $-0-.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
WARRANT AND DERIVATIVE LIABILITIES
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Disclosure Text Block [Abstract]    
Derivatives and Fair Value [Text Block]
NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES

Series C 9% Convertible Preferred Stock and related warrants

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.

The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%.

Series D Convertible Preferred Stock and related warrants

At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively.

The Company valued the reset provisions of the Series D Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%.

At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES

Series C 9% Convertible Preferred Stock and related warrants

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.

The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%.

Series D Convertible Preferred Stock and related warrants

At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively.

The Company valued the reset provisions of the Series D Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%.

At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The Company recorded a gain from change in fair value of derivatives of $210,465 for year ended December 31, 2017. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDER EQUITY
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Stockholders' Equity Note [Abstract]    
Stockholders' Equity Note Disclosure [Text Block]
NOTE 8 – STOCKHOLDER EQUITY

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2018 and December 31, 2017, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock and (2018) 1,000 shares of Series E Preferred Stock. As of March 31, 2018 and December 31, 2017, there were no outstanding shares of Series A and Series B preferred stock.

Series C Preferred Stock

In February 2018, the Company issued 9,919 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

In March 2018, the Company issued 10,010 shares of its common stock in exchange for 10 shares of the Company’s Series C Preferred Stock and accrued dividends.

Series D Preferred Stock

In January 2018, the Company issued an aggregate of 235,911 shares of its common stock in exchange for 180 shares of the Company’s Series D Preferred Stock and accrued dividends.

In February 2018, the Company issued an aggregate of 131,432 shares of its common stock in exchange for 100 shares of the Company’s Series D Preferred Stock and accrued dividends.

In March 2018, the Company issued an aggregate of 489,231 shares of its common stock in exchange for 367 shares of the Company’s Series D Preferred Stock and accrued dividends.

Series E Preferred Stock

On February 16, 2018, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the “Preferred Shares”) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.75 per share (the “Warrants”), in exchange for aggregate consideration of $1,492,969, net of transaction expenses of $7,031 (the “Transaction”).

The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type.  The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the “ROFR”) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement))  Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering.

In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.

The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.  The Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.

In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the “Consent”) with the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Holders”).  Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction.  In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the “Consent Warrants”).  The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. 

Common stock

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2018 and December 31, 2017, the Company had 30,497,707 and 29,321,204 shares issued and outstanding, respectively.

During the three months ended March 31, 2018, the Company issued 100,000 shares of its common stock for services totaling $142,000 ($1.42 per share).

During the three months ended March 31, 2018, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 180,000 shares of common stock and 90,000 warrants for aggregate proceeds of $270,000.

During the three months ended March 31, 2018, the Company issued 20,000 shares of common stock and 10,000 warrants for a previously received common stock subscription of $29,985.

NOTE 8 – STOCKHOLDER EQUITY

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2017 and 2016, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock and (in 2017) 1,400 shares of Series D Preferred Stock. As of December 31, 2017 and 2016, there were no outstanding shares of Series A and Series B preferred stock.

Series C Preferred Stock

In February 2016, the Company issued 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2017, the Company issued 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends.

In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends.

Cumulatively from January 1, 2017 to December 31, 2017, the Company exchanged 85 shares of the Company’s Series C Preferred Stock and dividends with a recorded value of $116,868 for 80,690 shares of common stock.

As of December 31, 2017 and 2016, the Company has 985 and 1,070 Series C Preferred Stock issued and outstanding.

Series D Preferred Stock

On November 3, 2017, the Board of Directors authorized the issuance of up to 1,400 shares of Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and accordingly, the Company filed the Certificate of Designations for the Series D Preferred Stock with the Secretary of State of the State of Delaware.  Pursuant to such Certificate of Designations, in the event of the Company’s liquidation or winding up of its affairs, the holders of Preferred Shares will be entitled to a liquidation preference of the stated value per Preferred Share of $1,500 (the “Stated Value”) plus any accrued but unpaid dividends or any other fees due the holder.

A holder of Preferred Shares is entitled at any time to convert any whole or partial number of shares of Preferred Shares into shares of Common Stock determined by dividing the Stated Value of the Preferred Shares being converted by the conversion price of $1.50 per share (the “Conversion Price”).  The Conversion Price is subject to “full ratchet” anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the Conversion Price as well as other customary anti-dilution protection.

A holder of the Preferred Shares shall be entitled to receive cumulative dividends at the rate per Preferred Share (as a percentage of the Stated Value per Preferred Share) of 9% per annum, with respect to the Series D Preferred Stock on each date that such Holder converts Preferred Shares into Common Stock (with respect only to Preferred Shares being converted).  The Company may pay such dividends, at its option, in cash, Common Stock or a combination thereof.  Payment of dividends in shares of Common Stock is subject to the satisfaction of certain equity conditions set forth in the Certificate of Designations.  Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion.

On November 3, 2017,  the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold an aggregate of 1,334 shares (the “Preferred Shares”) of its Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of the Company’s common stock, par value $0.001 per share at an exercise price of $1.75 per share (the “Class A Warrants”), in exchange for aggregate net cash proceeds of $1,929,960, net of expenses of $70,040. Contemporaneously with the entry into the Purchase Agreement, the Company and the Purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of the Common Stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price (the “Class B Warrants”). Class A Warrants are exercisable immediately and expire on May 3, 2021, and have an exercise price of $1.75 per share.  The Class B Warrants are exercisable immediately and expire on November 3, 2020, and have an exercise price of $1.50.  The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect.

On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment.

In connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

As of December 31, 2017, the Company has 1,334 Series D Preferred Stock issued and outstanding and has accrued $28,618 dividends payable on the Series D Preferred Stock.

Common stock

On November 18, 2016 at the Special Meeting, the stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 200,000,000 shares (the “Certificate Amendment”). The Certificate Amendment had been previously approved by the Company’s Board on September 7, 2016, subject to stockholder approval. Immediately following the Special Meeting on November 18, 2016, the Company filed the Certificate Amendment with the Secretary of State of the State of Delaware.

As of December 31, 2017 and 2016, the Company had 29,321,204 and 22,588,184 shares issued and outstanding, respectively.

During the year ended December 31, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share).

During the year ended December 31, 2016, the Company issued an aggregate of 545,000 shares of common stock for services rendered totaling $1,051,850 ($1.93 average per share).

During the year ended December 31, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 3,798,417 shares of common stock and 2,040,504 warrants for aggregate proceeds of $5,226,368, net of $490,543 in expenses.

During the year ended December 31, 2016, the Company issued 220,000 shares of common stock as vested previously issued restricted stock units

During the year ended December 31, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

During the year ended December 31, 2017, the Company issued an aggregate of 1,825,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $2,705,250 ($1.48 average per share).

During the year ended December 31, 2017, the Company issued an aggregate of 446,788 shares of its common stock for services totaling $681,367 ($1.53 per share).

During the year ended December 31, 2017, the Company issued an aggregate of 135,000 and 124,750 shares of its common stock for vested restricted stock units and stock based compensation previously accrued in 2016.

During the year ended December 31, 2017, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 4,131,536 shares of common stock and 2,246,300 warrants for aggregate proceeds of $6,011,229, net of $186,075 in expenses.

In April 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from an officer and member of the Company’s Board of Directors.

In connection with the securities purchase agreements described above, the Company entered into registration rights agreements with the purchasers in such private placements pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued such investors. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the termination date of such private placement and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and within 180 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 180 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that the Company will not be required to make any payments any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that the Company will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that the Company is unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended.

Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreements shall be 3% to 6% of the aggregate purchase price paid by the purchasers and (iii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreements, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.

The Company filed registration statements, which was declared effective to satisfy the requirements under the registration rights agreements with the purchasers of its common stock and warrants prior to April 6, 2017. The final closing under the April 6, 2017 Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]    
Shareholders' Equity and Share-based Payments [Text Block]
NOTE 9 – OPTIONS AND WARRANTS

Options

On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years.

The following table presents information related to stock options at March 31, 2018:

Options Outstanding
   
Options Exercisable
 
           
Weighted
       
           
Average
   
Exercisable
 
Exercise
   
Number of
   
Remaining Life
   
Number of
 
Price
   
Options
   
In Years
   
Options
 
$
1.01-2.00
     
3,545,540
     
7.2
     
2,483,540
 
 
2.01-3.00
     
4,384,779
     
3.4
     
4,384,779
 
 
3.01-4.00
     
300,000
     
7.0
     
300,000
 
         
8,230,319
     
5.2
     
7,168,319
 

A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at December 31, 2017
   
8,510,319
   
$
2.11
     
5.2
   
$
27,045
 
Grants
   
50,000
   
$
1.42
     
10.0
   
$
-
 
Exercised
   
-
                         
Canceled
   
(330,000
)
   
1.66
                 
Outstanding at March 31, 2018
   
8,230,319
   
$
2.12
     
5.2
   
$
158,930
 
Exercisable at March 31, 2018
   
7,168,319
   
$
2.20
     
4.7
   
$
104,305
 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.57 as of March 31, 2018, which would have been received by the option holders had those option holders exercised their options as of that date.

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the three months ended March 31, 2018 and 2017 was estimated using the Black-Scholes pricing model.

On February 15, 2018, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.42 per share for a term of ten years with vesting immediately.

The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018:

Risk-free interest rate
   
2.65
%
Dividend yield
   
0
%
Stock price volatility
   
94.10
%
Expected life
 
5 years
 
Weighted average grant date fair value
 
$
1.01
 

The fair value of all options vesting during the three months ended March 31, 2018 and 2017 of $246,710 and $42,984, respectively, was charged to current period operations.  Unrecognized compensation expense of $783,894 and $979,812 at March 31, 2018 and December 31, 2017, respectively, will be expensed in future periods.

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018: 

Exercise
   
Number
 
Expiration
Price
   
Outstanding
 
Date
$
0.001
     
383,320
 
January 2020
$
1.50
     
7,615,982
 
February 2018 to May 2021
$
1.75
     
500,000
 
August 2021
$
1.84
     
35,076
 
January 2020
$
1.95
     
1,689,026
 
October 2018 to September 2019
$
2.00
     
100,000
 
August 2018
$
2.02
     
30,755
 
January 2020
$
2.50
     
100,000
 
August 2018
$
2.75
     
228,720
 
August 2019 to September 2019
$
3.67
     
214,193
 
December 2018 to January 2019
$
3.75
     
1,340,556
 
April 2019 to March 2020
         
12,237,628
 
 

On January 5, 2018, the Company issued 100,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on January 5, 2021, in connection with the sale of the Company’s common stock.

On February 14, 2018, the Company entered into a consent agreement with the holders of the Company’s Series D Convertible Preferred Stock.  Pursuant to the consent, the Series D Holders consented to the Series E Preferred Stock transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the transaction.  In consideration for their entry into the consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of common stock.  The consent warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share. The warrants contain certain anti-dilutive provisions (see Note 8).

On February 16, 2018, the Company issued an aggregate of 500,000 warrants to purchase the Company’s common stock at $1.75 per share, expiring on August 16, 2021, in connection with the sale of the Company’s Series E preferred stock.  The warrants contain certain anti-dilutive provisions (see Note 8).

A summary of the warrant activity for the three months ended March 31, 2018 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
Grants
   
700,000
   
$
1.68
     
3.0
     
-
 
Exercised
   
-
                         
Expired
   
(1,251,458
)
 
$
1.50
     
-
     
-
 
Outstanding at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
 
                               
Vested and expected to vest at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
Exercisable at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 

NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

Options

On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan.

During the year ended December 31, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers, directors and key consultants.

During the year ended December 31, 2016, the Company granted an aggregate of 723,545 stock grants to officers, employees and key consultants under the plan. See Note 8.

During the year ended December 31, 2017, the Company granted an aggregate of 1,680,898 options to officers, directors and key consultants.

During the year ended December 31, 2017, the Company granted an aggregate of 2,009,750 stock grants to officers, employees and key consultants under the plan. See Note 8.

The following table presents information related to stock options at December 31, 2017:

Options Outstanding
   
Options Exercisable
 
           
Weighted
       
           
Average
   
Exercisable
 
Exercise
   
Number of
   
Remaining Life
   
Number of
 
Price
   
Options
   
In Years
   
Options
 
$
1.01-2.00
   
 
3,825,540
   
 
6.8
   
$
2,662,707
 
 
2.01-3.00
     
4,384,779
     
3.7
     
4,384,779
 
 
3.01-4.00
     
300,000
     
7.3
     
300,000
 
         
8,510,319
     
5.2
     
7,347,486
 

A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at January 1, 2016
   
7,780,190
   
$
2.30
     
6.4
   
$
-
 
Grants
   
905,000
     
1.71
     
10.0
   
$
-
 
Exercised
   
-
             
-
     
-
 
Canceled
   
(440,000
)
   
2.24
             
-
 
Outstanding at December 31, 2016
   
8,245,190
   
$
2.24
     
5.7
   
$
-
 
Grants
   
1,680,898
     
1.50
     
10.0
   
$
-
 
Exercised
   
-
                         
Canceled
   
(1,415,769
)
 
$
2.17
                 
Outstanding at December 31, 2017
   
8,510,319
   
$
2.11
     
5.2
   
$
27,045
 
Exercisable at December 31, 2017
   
7,347,486
   
$
2.19
     
4.8
   
$
25,394
 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.44 as of December 31, 2017, which would have been received by the option holders had those option holders exercised their options as of that date.

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the years ended December 31, 2017 and 2016 was estimated using the Black-Scholes pricing model.

On May 18, 2016, the Company granted an aggregate of 685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent.

On December 22, 2016, the Company granted an aggregate of 150,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.36 per share for a term of ten years with vesting immediately.

On December 29, 2016, the Company granted 5,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.35 per share for a term of ten years with vesting immediately.

The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016:

         
Risk-free interest rate
 
 
1.08% - 2.04
%
Dividend yield
 
 
0
%
Stock price volatility
 
 
109.3% to 122.82
%
Expected life
5 – 10 years
 
Weighted average grant date fair value
 
$
1.47
 

On February 8, 2017, the Company granted an aggregate of 130,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.55 per share for a term of ten years with vesting immediately.

On November 8, 2017, the Company granted 200,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020.

On November 8, 2017, the Company granted 475,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 237,500 vesting immediately and 237,500 at one year anniversary.

On November 24, 2017, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years, vesting immediately.

On November 24, 2017, the Company granted 420,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years with 120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent.

On November 24, 2017, the Company granted 300,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.50 per share for a term of ten years with 150,000 vesting immediately and 150,000 performance contingent.

On December 22, 2017, the Company granted 105,898 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.37 per share for a term of ten years, vesting immediately.

The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2017:

         
Risk-free interest rate
 
 
2.01% - 2.34
%
Dividend yield
 
 
0
%
Stock price volatility
 
 
95.72% to 107.17
%
Expected life
5 – 10 years
 
Weighted average grant date fair value
 
$
1.17
 

The fair value of all options vesting during the year ended December 31, 2017 and 2016 of $1,269,591 and $2,801,948, respectively, was charged to current period operations.  Unrecognized compensation expense of $979,812 and $310,817 at December 31, 2017 and 2016, respectively, will be expensed in future periods.

Restricted Stock

The following table summarizes the restricted stock activity for the two years ended December 31, 2017:

Restricted shares issued as of January 1, 2016
 
 
175,000
 
Granted
 
 
180,000
 
Vested
   
(220,000
)
Total restricted shares issued as of December 31, 2016
 
 
135,000
 
Granted
 
 
-
 
Vested
 
 
(135,000
)
Vested restricted shares as of December 31, 2017
 
 
-
 
Unvested restricted shares as of December 31, 2017
 
 
-
 

On September 7, 2016, the Company granted 180,000 restricted stock units (“RSU”) to a consultant vesting monthly over one year beginning October 7, 2016.

Stock based compensation expense related to restricted stock grants was $93,261 and $213,174 for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017, the stock-based compensation relating to restricted stock of $-0- remains unamortized. 

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017: 

Exercise
   
Number
 
Expiration
Price
   
Outstanding
 
Date
$
0.001
     
383,320
 
January 2020
$
1.50
     
8,667,440
 
February 2018 to May 2021
$
1.84
     
35,076
 
January 2020
$
1.95
     
1,689,026
 
October 2018 to September 2019
$
2.00
     
100,000
 
August 2018
$
2.02
     
30,755
 
January 2020
$
2.50
     
100,000
 
August 2018
$
2.75
     
228,720
 
August 2019 to September 2019
$
3.67
     
214,193
 
December 2018 to January 2019
$
3.75
     
1,340,556
 
April 2019 to March 2020
         
12,789,086
 
 

On February 9, 2016, the Company issued 25,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services.

On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services.

On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 18,040 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services.

On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 17,996 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services.

On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company’s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services.

On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company’s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company’s common stock.

On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company’s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company’s common stock.

On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company’s common stock.

On October 28, 2016, the Company issued an aggregate of 173,284 warrants to purchase the Company’s common stock at $1.50 per share, expiring on October 28, 2019, in connection with the sale of the Company’s common stock.

On November 23, 2016, the Company issued an aggregate of 50,002 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 23, 2019, in connection with the sale of the Company’s common stock

On December 16, 2016, the Company issued an aggregate of 456,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 16, 2019, in connection with the sale of the Company’s common stock

On December 22, 2016, the Company issued an aggregate of 115,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 22, 2019, in connection with the sale of the Company’s common stock

On February 9, 2017, the Company exchanged 38,572 warrants with an exercise price of $2.10 with 45,001 warrants with an exercise price of $1.50, all other terms and conditions the same, to 2016 investors to adjust offered terms in connection with the Company’s equity raise with other investors.

On February 10, 2017, the Company issued an aggregate of 300,628 warrants to purchase the Company’s common stock at $1.50 per share, expiring on February 10, 2020, in connection with the sale of the Company’s common stock.

On March 10, 2017, the Company issued an aggregate of 197,159 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 10, 2020, in connection with the sale of the Company’s common stock.

On March 15, 2017, the Company issued 630,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 15, 2020, to Mayo Foundation in connection with a know-how licensing agreement (See Note 10). The fair value of the of the issued warrants of $543,927, determined using the Black-Scholes option model with an estimated volatility of 105.22%, risk free rate of 1.599%, dividend yield of -0- and fair value of the Company’s common stock of $1.37, was charged to current period operations as acquired research and development.

On March 31, 2017, the Company issued an aggregate of 157,250 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 31, 2020, in connection with the sale of the Company’s common stock.

On April 6, 2017, the Company issued an aggregate of 288,300 warrants to purchase the Company’s common stock at $1.50 per share, expiring on April 6, 2020, in connection with the sale of the Company’s common stock.

On May 5, 2017, the Company issued an aggregate of 6,667 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 5, 2020, in connection with the sale of the Company’s common stock.

On May 17, 2017, the Company issued an aggregate of 186,957 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 17, 2020, for placement agent services in connection with the sale of the Company’s common stock.

On June 20, 2017, the Company issued 10,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 20, 2020, in connection with the sale of the Company’s common stock.

On June 30, 2017, the Company issued an aggregate of 108,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 30, 2020, in connection with the sale of the Company’s common stock.

On July 13, 2017, the Company issued an aggregate of 133,501 warrants to purchase the Company’s common stock at $1.50 per share, expiring on July 13, 2020, in connection with the sale of the Company’s common stock.

On August 18, 2017, the Company issued an aggregate of 175,500 warrants to purchase the Company’s common stock at $1.50 per share, expiring on August 18, 2020, in connection with the sale of the Company’s common stock.

On September 18, 2017, the Company issued an aggregate of 51,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on September 18, 2020, in connection with the sale of the Company’s common stock.

On October 11, 2017, the Company issued an aggregate of 193,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on October 11, 2020, in connection with the sale of the Company’s common stock.

On November 3, 2017, the Company issued an aggregate of 667,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 3, 2021, in connection with the sale of the Company’s Series D preferred stock.  The warrants contain certain anti-dilutive provisions (see Note 8).

On November 3, 2017, the Company issued an aggregate of 780,506 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 3, 2020 in exchange for the return and cancellation of previous issued 780,505 warrants.  The transaction was in connection with the sale of the Series D preferred stock.  Both the issued and canceled warrants contain certain anti-dilutive provisions (see Note 8).

On November 6, 2017, the Company issued an aggregate of 206,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 6, 2020, in connection with the sale of the Company’s common stock.

On November 6, 2017, due to certain anti-dilutive provisions embedded in the November 3, 2017 warrants issued in connection with the sale of Series D preferred stock (see above), exercise price of the previously issued 667,000 warrants were reset to $1.50 and an additional 111,167 warrants were issued with an exercise price of $1.50 per share, expiring May 3, 2021.

On December 29, 2017, the Company issued an aggregate of 230,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 29, 2020, in connection with the sale of the Company’s common stock.

Stock based compensation related to warrants issued for services was $0 and $56,931 for the years ended December 31, 2017 and 2016, respectively.

A summary of the warrant activity for the years ended December 31, 2017 and 2016 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at January 1, 2016
   
7,078,685
   
$
2.02
     
3.0
     
497,933
 
Grants
   
2,049,504
   
$
1.74
     
2.5
     
-
 
Exercised
   
-
           
$
-
     
-
 
Canceled
   
-
           
$
-
     
-
 
Outstanding at December 31, 2016
   
9,128,189
   
$
1.96
     
2.1
   
$
494,099
 
Grants
   
4,479,974
     
1.50
     
3.0
     
-
 
Exercised
   
-
                         
Canceled
   
(819,077
)
 
$
1.50
                 
Outstanding at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
 
                               
Vested and expected to vest at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
Exercisable at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.44 as of December 31, 2017, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENT
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Fair Value Disclosures [Abstract]    
Fair Value Disclosures [Text Block]
NOTE 10 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of March 31, 2018 and December 31, 2017, the Company did not have any items that would be classified as level 1 or 2 disclosures.

As of March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.

The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of March 31, 2018:

 
 
Warrant
Liability
   
Derivative
 
Balance, December 31, 2017
 
$
2,358,240
   
$
685,922
 
Total (gains) losses
               
Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018
   
(2,358,240
)
   
(685,922
)
Balance, March 31, 2018
 
$
-
   
$
-
 

NOTE 10 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of December 31, 2017 and 2016, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company.

As of December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.

The derivative and warrant liability as of December 31, 2017, in the amount of $685,922 and $2,358,240, respectively, has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2017:

 
 
Warrant
Liability
   
Derivative
 
Balance, December 31, 2015
 
$
1,621,199
   
$
285,157
 
Total (gains) losses
               
Transfers out due to conversion of Series C Preferred Stock
   
-
     
(103,096
)
Mark to market to December 31, 2016
   
316,035
     
106,873
 
Balance, December 31, 2016
   
1,937,234
     
288,934
 
Initial fair value of derivative at date of issuance of Series D Preferred Stock
   
-
     
397,162
 
Initial fair value of warrant liability at date of issuance
   
652,054
     
-
 
Transfers out due to conversion of Series C Preferred Stock
   
-
     
(20,757
)
Mark to market to December 31, 2017
   
(231,048
)
   
20,583
 
Balance, December 31, 2017
   
2,358,240
     
685,922
 
Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016
 
$
231,048
   
$
(20,583
)

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
NOTE 11 – COMMITMENTS AND CONTINGENCIES

Operating leases

On February 8, 2017, the Company entered into a lease amendment agreement, whereby the Company agreed to extend the lease for office space in Los Angeles, California, commencing September 1, 2017 and expiring on August 31, 2019.  In connection with the lease, the Company is obligated to lease parking spaces at an aggregate approximate cost of $978 per month.  In addition, the Company entered into a lease for storage space with the Los Angeles, California building commencing on December 1, 2017 and expiring on August 31, 2019.

Future minimum lease payments under these three agreements are as follows:

Year Ending December 31,
     
2018
 
$
112,994
 
2019
   
76,995
 
 
 
$
189,989
 

Licensing agreements

On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale.  The agreement expires in ten years from the effective date.

The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined.

In consideration, the Company issued 630,000 warrants to acquire the Company’s common stock at an exercise price of $1.50, expiring on March 15, 2020.

Employment agreements

On July 14, 2014, the Company’s Board of Directors (the “Board”) increased the size of the Board to eight members and appointed Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer.

In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.

In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.

Effective July 15, 2017, the Company elected not to continue under the above described agreement and accordingly terminated employment with Mr. Cash.

As of December 31, 2017, there are no outstanding employment agreements.

Litigation

The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business.  Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.  There was no outstanding litigation as of December 31, 2017.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
NOTE 12 – INCOME TAXES

At December 31, 2017, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $24,000,000, expiring in the year 2036, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.  During the year ended December 31, 2017, the Company has increased the valuation allowance from $5,500,000 to $8,200,000.We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns.  ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.  

Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement.  The Company had no tax positions relating to open income tax returns that were considered to be uncertain.

The Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2013.

 
 
2017
 
 
2016
 
Statutory rate on pre-tax book loss
 
 
(34.00
)%
 
 
(34.00
)%
(Gain) loss on change in fair value of derivatives
 
 
(0.56
)%
 
 
1.24
%
Stock based compensation
 
 
12.72
%
 
 
17.6
%
Fair value of warrant to acquire research and development
   
1.46
%
   
0.00
%
Other
 
 
0.09
%
 
 
0.09
%
Valuation allowance
 
 
20.29
%
 
 
15.07
%
 
 
 
0.00
%
 
 
0.00
%

The Company’s deferred taxes as of December 31, 2017 and 2016 consist of the following:

 
 
2017
   
2016
 
Non-Current deferred tax asset:
           
 Net operating loss carry-forwards
 
$
8,200,000
   
$
5,500,000
 
 Valuation allowance
   
(8,200,000
)
   
(5,500,000
)
 Net non-current deferred tax asset
 
$
-
   
$
-
 

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2018
Table Text Block [Abstract]  
Schedule of Subsequent Events [Table Text Block]
NOTE 13 – SUBSEQUENT EVENTS

Adoption of Accounting Standards

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.

When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018.  As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

Series E Preferred Stock Issuance

On February 16, 2018, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the “Preferred Shares”) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.75 per share (the “Warrants”), in exchange for aggregate consideration of $1,500,000 (the “Transaction”). The sale of the Preferred Shares and Warrants were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”) provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.

The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type.  The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the “ROFR”) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement))  Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering.

In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations.

The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share.  The Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.

In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the “Consent”) with the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Holders”).  Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction.  In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the “Consent Warrants”).  The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share.  The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect.  The issuance of the Consent Warrants to the Series D Holders was in reliance on the exemption from registration under the Securities Act provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.

Common Stock Issuance

On January 5, 2018, the Company entered into a unit purchase agreements with certain accredited investors pursuant to which the Company issued 200,000 shares of our common stock and 100,000 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring January 5, 2021, in exchange for aggregate consideration of $299,985, net of expenses of $15 (of which $29,985 were received as common stock subscriptions as of December 31, 2017).

In January and February 2018, the Company issued an aggregate of 367,343 shares of common stock in exchange for 280 shares of our Series D 9% Convertible Preferred Stock and accrued dividends.

On February 14, 2018, the Company issued an aggregate of 9,919 shares of common stock in exchange for 10 shares of our Series C 9% Convertible Preferred Stock and accrued dividends.

On February 1, 2018, the Company granted 200,000 restricted stock units to consultants for services rendered, of which 100,000 vest upon date of grant and 100,000 shares vest at the one-year anniversary of the date of grant provided the consultants are providing services through the vesting date.

Options

On February 15, 2018, the Company granted our board member, Andrew L. Filler 50,000 options to purchase common stock in connection with his appointment as chairman of our Nominating and Corporate Governance Committee at the exercise price of $1.42 per share for a term of ten years, vesting immediately.

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
3 Months Ended
Mar. 31, 2018
Disclosure Text Block [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.

The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

The condensed balance sheet as of December 31, 2017 has been derived from audited financial statements.

Operating results for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2017 filed with the Company’s Form 10-K/A with the Securities and Exchange Commission on March 26, 2018.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
NOTE 11 – SUBSEQUENT EVENTS

In April 2018, the Company issued an aggregate of 577,339 shares of its common stock in exchange for 454 shares of the Company’s Series D Preferred Stock and accrued dividends.

In April 2018, the Company issued an aggregate of 351,021 shares of its common stock in exchange for 370 shares of the Company’s Series C Preferred Stock and accrued dividends.

On April 30, 2018 the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 3,193,004 shares of  the Company’s common stock  and warrants to purchase an aggregate of 1,596,506 shares of the Company’s common stock, at an exercise price of $1.75 per share, in exchange for aggregate consideration of $4,789,502, net of transaction expenses of approximately $1,000 (the “April 2018 private placement”), of which $115,470 was received as common stock subscriptions as of March 31, 2018.

In connection with the April 2018 private placement, the Company issued additional warrants to purchase an aggregate of 83,334 shares of the Company’s common stock, at an exercise price of $1.50 per share to the Series E holders. In addition, 500,000 warrants to purchase the Company’s common stock at an exercise price of $1.75 per share previously issued to the Series E holders were reset to an exercise price of $1.50 per share.

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accounting Policies, by Policy (Policies)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Basis of Accounting, Policy [Policy Text Block]  
Business and organization

BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
Revenue Recognition, Policy [Policy Text Block]  
Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Use of Estimates, Policy [Policy Text Block]
Use of estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]  
Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.  At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively.
Prepaid Expenses Policy [Policy Text Block]  
Prepaid Expenses

Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments.
Property, Plant and Equipment, Policy [Policy Text Block]  
Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]  
Long-Lived Assets

The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.  Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]
Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2018 and December 31, 2017, the Company did not have any derivative instruments that were designated as hedges.

At March 31, 2018 and December 31, 2017, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).
Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.

At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).
Research and Development Expense, Policy [Policy Text Block]
Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $862,420 and $1,338,604 for the three months ended March 31, 2018 and 2017, respectively.
Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468 and $2,654,501 for the year ended December 31, 2017 and 2016, respectively.
Income Tax, Policy [Policy Text Block]
Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as non-current.
Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as non-current.
Earnings Per Share, Policy [Policy Text Block]
Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted loss per share as of March 31, 2018 and 2017 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 
 
March 31,
2018
   
March 31,
2017
 
Series C convertible preferred stock
   
643,333
     
713,333
 
Series D convertible preferred stock
   
687,000
     
-
 
Series E convertible preferred stock
   
1,000,000
     
-
 
Options to purchase common stock
   
8,230,319
     
8,245,190
 
Warrants to purchase common stock
   
12,237,628
     
10,419,655
 
Totals
   
22,798,280
     
19,378,178
 
Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 
 
2017
 
 
2016
 
Series C convertible preferred stock
 
 
656,667
 
 
 
713,333
 
Series D convertible preferred stock
   
1,334,000
     
-
 
Options to purchase common stock
 
 
8,510,319
 
 
 
8,245,190
 
Warrants to purchase common stock
 
 
12,789,086
 
 
 
9,128,189
 
Totals
 
 
23,290,072
 
 
 
18,086,712
 
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

As of March 31, 2018, the Company had 8,230,319 options outstanding to purchase shares of common stock, of which 7,168,319 were vested.

As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested.
Stock based compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash.

As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.
Registration Rights Policy [Policy Text Block]
Registration Rights

On February 16, 2018, in connection with the Company’s private placement of Series E Preferred Stock and warrants, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered.  The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered thereby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Company has estimated the liability under the registration rights agreement at $-0- as of March 31, 2018.
Registration Rights

The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  

Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on March 31, 2017. On June 8, 2017, the Company filed the required registration statement and on September 19, 2017 was declared effective. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

On November 3, 2017, in connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]
Adoption of Accounting Standards

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features.

When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.

On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162.

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]
Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed financial statements, except as disclosed.
Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 
 
March 31,
2018
   
March 31,
2017
 
Series C convertible preferred stock
   
643,333
     
713,333
 
Series D convertible preferred stock
   
687,000
     
-
 
Series E convertible preferred stock
   
1,000,000
     
-
 
Options to purchase common stock
   
8,230,319
     
8,245,190
 
Warrants to purchase common stock
   
12,237,628
     
10,419,655
 
Totals
   
22,798,280
     
19,378,178
 
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

 
 
2017
 
 
2016
 
Series C convertible preferred stock
 
 
656,667
 
 
 
713,333
 
Series D convertible preferred stock
   
1,334,000
     
-
 
Options to purchase common stock
 
 
8,510,319
 
 
 
8,245,190
 
Warrants to purchase common stock
 
 
12,789,086
 
 
 
9,128,189
 
Totals
 
 
23,290,072
 
 
 
18,086,712
 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
PROPERTY AND EQUIPMENT (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Abstract]    
Property, Plant and Equipment [Table Text Block]
Property and equipment as of March 31, 2018 and December 31, 2017 is summarized as follows

 
 
March 31,
2018
   
December 31,
2017
 
Computer equipment
 
$
90,703
   
$
87,059
 
Furniture and fixtures
   
12,975
     
12,975
 
Subtotal
   
103,678
     
100,034
 
Less accumulated depreciation
   
(84,221
)
   
(81,318
)
Property and equipment, net
 
$
19,457
   
$
18,716
 
Property and equipment as of December 31, 2017 and 2016 is summarized as follows:

 
 
2017
   
2016
 
Computer equipment
 
$
87,059
   
$
84,704
 
Furniture and fixtures
   
12,975
     
10,117
 
Subtotal
   
100,034
     
94,821
 
Less accumulated depreciation
   
(81,318
)
   
(70,633
)
Property and equipment, net
 
$
18,716
   
$
24,188
 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Payables and Accruals [Abstract]    
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Accounts payable and accrued expenses at March 31, 2018 and December 31, 2017 consist of the following:

 
 
March 31,
2018
   
December 31,
2017
 
Accrued accounting and legal
 
$
151,745
   
$
93,595
 
Accrued reimbursements
   
10,510
     
2,600
 
Accrued consulting
   
12,650
     
109,059
 
Accrued research and development expenses
   
148,932
     
246,030
 
Accrued office and other
   
644
     
7,912
 
Deferred rent
   
997
     
569
 
Accrued settlement related to arbitration
   
13,333
     
13,333
 
 
 
$
338,811
   
$
473,098
 
Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following:

 
 
2017
   
2016
 
Accrued accounting and legal
 
$
93,595
   
$
120,464
 
Accrued reimbursements
   
2,600
     
43,116
 
Accrued consulting
   
109,059
     
1,192
 
Accrued research and development expenses
   
246,030
     
181,884
 
Accrued office and other
   
7,912
     
10,202
 
Deferred rent
   
569
     
2,912
 
Accrued settlement related to arbitration
   
13,333
     
13,333
 
 
 
$
473,098
   
$
373,103
 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]    
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
The following table presents information related to stock options at March 31, 2018:

Options Outstanding
   
Options Exercisable
 
           
Weighted
       
           
Average
   
Exercisable
 
Exercise
   
Number of
   
Remaining Life
   
Number of
 
Price
   
Options
   
In Years
   
Options
 
$
1.01-2.00
     
3,545,540
     
7.2
     
2,483,540
 
 
2.01-3.00
     
4,384,779
     
3.4
     
4,384,779
 
 
3.01-4.00
     
300,000
     
7.0
     
300,000
 
         
8,230,319
     
5.2
     
7,168,319
 
The following table presents information related to stock options at December 31, 2017:

Options Outstanding
   
Options Exercisable
 
           
Weighted
       
           
Average
   
Exercisable
 
Exercise
   
Number of
   
Remaining Life
   
Number of
 
Price
   
Options
   
In Years
   
Options
 
$
1.01-2.00
   
 
3,825,540
   
 
6.8
   
$
2,662,707
 
 
2.01-3.00
     
4,384,779
     
3.7
     
4,384,779
 
 
3.01-4.00
     
300,000
     
7.3
     
300,000
 
         
8,510,319
     
5.2
     
7,347,486
 
Share-based Compensation, Stock Options, Activity [Table Text Block]
A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2018 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at December 31, 2017
   
8,510,319
   
$
2.11
     
5.2
   
$
27,045
 
Grants
   
50,000
   
$
1.42
     
10.0
   
$
-
 
Exercised
   
-
                         
Canceled
   
(330,000
)
   
1.66
                 
Outstanding at March 31, 2018
   
8,230,319
   
$
2.12
     
5.2
   
$
158,930
 
Exercisable at March 31, 2018
   
7,168,319
   
$
2.20
     
4.7
   
$
104,305
 
A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at January 1, 2016
   
7,780,190
   
$
2.30
     
6.4
   
$
-
 
Grants
   
905,000
     
1.71
     
10.0
   
$
-
 
Exercised
   
-
             
-
     
-
 
Canceled
   
(440,000
)
   
2.24
             
-
 
Outstanding at December 31, 2016
   
8,245,190
   
$
2.24
     
5.7
   
$
-
 
Grants
   
1,680,898
     
1.50
     
10.0
   
$
-
 
Exercised
   
-
                         
Canceled
   
(1,415,769
)
 
$
2.17
                 
Outstanding at December 31, 2017
   
8,510,319
   
$
2.11
     
5.2
   
$
27,045
 
Exercisable at December 31, 2017
   
7,347,486
   
$
2.19
     
4.8
   
$
25,394
 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
The following assumptions were used in determining the fair value of employee options for the three months ended March 31, 2018:

Risk-free interest rate
   
2.65
%
Dividend yield
   
0
%
Stock price volatility
   
94.10
%
Expected life
 
5 years
 
Weighted average grant date fair value
 
$
1.01
 
The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016:

         
Risk-free interest rate
 
 
1.08% - 2.04
%
Dividend yield
 
 
0
%
Stock price volatility
 
 
109.3% to 122.82
%
Expected life
5 – 10 years
 
Weighted average grant date fair value
 
$
1.47
 
         
Risk-free interest rate
 
 
2.01% - 2.34
%
Dividend yield
 
 
0
%
Stock price volatility
 
 
95.72% to 107.17
%
Expected life
5 – 10 years
 
Weighted average grant date fair value
 
$
1.17
 
Nonvested Restricted Stock Shares Activity [Table Text Block]  
The following table summarizes the restricted stock activity for the two years ended December 31, 2017:

Restricted shares issued as of January 1, 2016
 
 
175,000
 
Granted
 
 
180,000
 
Vested
   
(220,000
)
Total restricted shares issued as of December 31, 2016
 
 
135,000
 
Granted
 
 
-
 
Vested
 
 
(135,000
)
Vested restricted shares as of December 31, 2017
 
 
-
 
Unvested restricted shares as of December 31, 2017
 
 
-
 
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]
The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2018:

Exercise
   
Number
 
Expiration
Price
   
Outstanding
 
Date
$
0.001
     
383,320
 
January 2020
$
1.50
     
7,615,982
 
February 2018 to May 2021
$
1.75
     
500,000
 
August 2021
$
1.84
     
35,076
 
January 2020
$
1.95
     
1,689,026
 
October 2018 to September 2019
$
2.00
     
100,000
 
August 2018
$
2.02
     
30,755
 
January 2020
$
2.50
     
100,000
 
August 2018
$
2.75
     
228,720
 
August 2019 to September 2019
$
3.67
     
214,193
 
December 2018 to January 2019
$
3.75
     
1,340,556
 
April 2019 to March 2020
         
12,237,628
 
 
The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017:

Exercise
   
Number
 
Expiration
Price
   
Outstanding
 
Date
$
0.001
     
383,320
 
January 2020
$
1.50
     
8,667,440
 
February 2018 to May 2021
$
1.84
     
35,076
 
January 2020
$
1.95
     
1,689,026
 
October 2018 to September 2019
$
2.00
     
100,000
 
August 2018
$
2.02
     
30,755
 
January 2020
$
2.50
     
100,000
 
August 2018
$
2.75
     
228,720
 
August 2019 to September 2019
$
3.67
     
214,193
 
December 2018 to January 2019
$
3.75
     
1,340,556
 
April 2019 to March 2020
         
12,789,086
 
 
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
A summary of the warrant activity for the three months ended March 31, 2018 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
Grants
   
700,000
   
$
1.68
     
3.0
     
-
 
Exercised
   
-
                         
Expired
   
(1,251,458
)
 
$
1.50
     
-
     
-
 
Outstanding at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
 
                               
Vested and expected to vest at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
Exercisable at March 31, 2018
   
12,237,628
   
$
1.85
     
1.7
   
$
1,134,548
 
A summary of the warrant activity for the years ended December 31, 2017 and 2016 is as follows:

 
             
Weighted-Average
       
 
       
Weighted-Average
   
Remaining
   
Aggregate
 
 
 
Shares
   
Exercise Price
   
Contractual Term
   
Intrinsic Value
 
Outstanding at January 1, 2016
   
7,078,685
   
$
2.02
     
3.0
     
497,933
 
Grants
   
2,049,504
   
$
1.74
     
2.5
     
-
 
Exercised
   
-
           
$
-
     
-
 
Canceled
   
-
           
$
-
     
-
 
Outstanding at December 31, 2016
   
9,128,189
   
$
1.96
     
2.1
   
$
494,099
 
Grants
   
4,479,974
     
1.50
     
3.0
     
-
 
Exercised
   
-
                         
Canceled
   
(819,077
)
 
$
1.50
                 
Outstanding at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
 
                               
Vested and expected to vest at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
Exercisable at December 31, 2017
   
12,789,086
   
$
1.82
     
1.7
   
$
551,636
 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENT (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Fair Value Disclosures [Abstract]    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of March 31, 2018:

 
 
Warrant
Liability
   
Derivative
 
Balance, December 31, 2017
 
$
2,358,240
   
$
685,922
 
Total (gains) losses
               
Transfers out due to the adoption of ASU 2017-11 effective January 1, 2018
   
(2,358,240
)
   
(685,922
)
Balance, March 31, 2018
 
$
-
   
$
-
 
The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2017:

 
 
Warrant
Liability
   
Derivative
 
Balance, December 31, 2015
 
$
1,621,199
   
$
285,157
 
Total (gains) losses
               
Transfers out due to conversion of Series C Preferred Stock
   
-
     
(103,096
)
Mark to market to December 31, 2016
   
316,035
     
106,873
 
Balance, December 31, 2016
   
1,937,234
     
288,934
 
Initial fair value of derivative at date of issuance of Series D Preferred Stock
   
-
     
397,162
 
Initial fair value of warrant liability at date of issuance
   
652,054
     
-
 
Transfers out due to conversion of Series C Preferred Stock
   
-
     
(20,757
)
Mark to market to December 31, 2017
   
(231,048
)
   
20,583
 
Balance, December 31, 2017
   
2,358,240
     
685,922
 
Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016
 
$
231,048
   
$
(20,583
)
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Future minimum lease payments under these three agreements are as follows:

Year Ending December 31,
     
2018
 
$
112,994
 
2019
   
76,995
 
 
 
$
189,989
 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2013.

 
 
2017
 
 
2016
 
Statutory rate on pre-tax book loss
 
 
(34.00
)%
 
 
(34.00
)%
(Gain) loss on change in fair value of derivatives
 
 
(0.56
)%
 
 
1.24
%
Stock based compensation
 
 
12.72
%
 
 
17.6
%
Fair value of warrant to acquire research and development
   
1.46
%
   
0.00
%
Other
 
 
0.09
%
 
 
0.09
%
Valuation allowance
 
 
20.29
%
 
 
15.07
%
 
 
 
0.00
%
 
 
0.00
%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
The Company’s deferred taxes as of December 31, 2017 and 2016 consist of the following:

 
 
2017
   
2016
 
Non-Current deferred tax asset:
           
 Net operating loss carry-forwards
 
$
8,200,000
   
$
5,500,000
 
 Valuation allowance
   
(8,200,000
)
   
(5,500,000
)
 Net non-current deferred tax asset
 
$
-
   
$
-
 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
3 Months Ended 12 Months Ended
Jan. 01, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]            
Cash, Uninsured Amount       $ 1,297,579 $ 805,895  
Retainage Deposit       100,000    
Research and Development Expense   $ 862,420 $ 1,338,604 $ 4,756,468 $ 2,654,501  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)   8,230,319   8,510,319 8,245,190 7,780,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)   7,168,319   7,347,486 7,028,639  
Registration Payment Arrangement, Accrual Carrying Value   $ 0        
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity $ 3,044,162     $ 20,757 $ 103,096  
Minimum [Member]            
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]            
Property, Plant and Equipment, Estimated Useful Lives       3    
Maximum [Member]            
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]            
Property, Plant and Equipment, Estimated Useful Lives       5    
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 22,798,280 19,378,178 23,290,072 18,086,712
Series C Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 643,333 713,333 656,667 713,333
Series D Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 687,000 0 1,334,000 0
Employee Stock Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 8,230,319 8,245,190 8,510,319 8,245,190
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 12,237,628 10,419,655 12,789,086 9,128,189
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 16, 2018
Nov. 03, 2017
May 03, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Cash and Cash Equivalents, at Carrying Value       $ 1,035,100 $ 1,244,126 $ 1,547,579 $ 1,055,895 $ 953,234
Working Capital (Deficit)       (332,764)   (2,300,644)    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants           6,041,214    
Proceeds from Issuance or Sale of Equity           6,011,229 5,226,368  
Net Cash Provided by (Used in) Operating Activities       (2,387,274) $ (1,609,841) (7,470,054) $ (5,107,452)  
Subsequent Event [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants           1,500,000    
Proceeds from Issuance or Sale of Equity           270,000    
Working Capital Excluding Derivative and Warrant Liabilities [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Working Capital (Deficit)           (743,518)    
Series D Preferred Stock [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants   $ 1,929,960       $ 1,929,960    
Series E Preferred Stock [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants $ 1,492,969     1,500,000        
Series E Preferred Stock [Member] | Subsequent Event [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants $ 1,500,000              
Common Stock and Warrant [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Proceeds from Issuance or Sale of Equity       $ 385,000        
Series C and D Preferred Stock [Member] | Subsequent Event [Member]                
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]                
Proceeds from Issuance or Sale of Equity     $ 4,675,000          
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
RELATED PARTY TRANSACTIONS (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 22, 2017
Nov. 24, 2017
Nov. 09, 2017
Nov. 08, 2017
Nov. 01, 2017
Jun. 16, 2017
Apr. 01, 2017
Feb. 08, 2017
Dec. 29, 2016
Dec. 22, 2016
Dec. 08, 2016
May 04, 2016
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Due to Related Parties, Current (in Dollars)                           $ 27,375 $ 15,755
Stock Issued During Period, Shares, Share-based Compensation, Gross                           124,750  
Shares Issued, Price Per Share (in Dollars per share) $ 1.37   $ 1.49 $ 1.52   $ 1.37                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 105,898 300,000   475,000       130,000 5,000 150,000     50,000 1,680,898 905,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) $ 1.37 $ 1.50   $ 1.57       $ 1.55 $ 1.35 $ 1.36     $ 1.42 $ 1.50 $ 1.71
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years 10 years   10 years       10 years 10 years 10 years          
Stock Repurchased and Retired During Period, Shares             10,744             10,744  
Stock Issued During Period, Shares, New Issues           100,000               4,131,536 3,798,417
Chief Executive Officer [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross     50,000 450,000             41,500 250,000      
Shares Issued, Price Per Share (in Dollars per share)                     $ 1.36 $ 1.93      
Chief Financial Officer [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross       250,000               200,000      
Shares Issued, Price Per Share (in Dollars per share)                       $ 1.93      
Director [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross     50,000 200,000             41,500        
Shares Issued, Price Per Share (in Dollars per share)                     $ 1.36        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 39,926                 50,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)                   $ 1.36          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                   10 years          
Former Chief Executive Officer and President [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross                     20,875        
Shares Issued, Price Per Share (in Dollars per share)                     $ 1.36        
Director #2[Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross                     20,875        
Shares Issued, Price Per Share (in Dollars per share)                     $ 1.36        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 65,972                 25,000          
Former Director [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                   50,000          
Director #3 [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross     30,000                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                   25,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)                   $ 1.36          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                   10 years          
Affiliated Entity [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Related Party Transaction, Description of Transaction         Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company’s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned                    
Director #4 [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross     30,000                        
Director #5 [Member]                              
RELATED PARTY TRANSACTIONS (Details) [Line Items]                              
Stock Issued During Period, Shares, Share-based Compensation, Gross     30,000                        
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
PROPERTY AND EQUIPMENT (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
PROPERTY AND EQUIPMENT (Details) [Line Items]        
Loss Contingency, Damages Paid, Value     $ 3,210  
Depreciation $ 2,903 $ 3,069 $ 11,698 $ 10,475
Minimum [Member]        
PROPERTY AND EQUIPMENT (Details) [Line Items]        
Property, Plant and Equipment, Useful Life 3 years   3 years  
Maximum [Member]        
PROPERTY AND EQUIPMENT (Details) [Line Items]        
Property, Plant and Equipment, Useful Life 5 years   5 years  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 103,678 $ 100,034 $ 94,821
Less accumulated depreciation (84,221) (81,318) (70,633)
Property and equipment, net 19,457 18,716 24,188
Computer Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 90,703 87,059 84,704
Furniture and Fixtures [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 12,975 $ 12,975 $ 10,117
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Schedule of Accounts Payable and Accrued Liabilities [Abstract]      
Accrued accounting and legal $ 151,745 $ 93,595 $ 120,464
Accrued reimbursements 10,510 2,600 43,116
Accrued consulting 12,650 109,059 1,192
Accrued research and development expenses 148,932 246,030 181,884
Accrued office and other 644 7,912 10,202
Deferred rent 997 569 2,912
Accrued settlement related to arbitration 13,333 13,333 13,333
$ 338,811 $ 473,098 $ 373,103
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 01, 2018
Nov. 03, 2017
Jun. 16, 2017
Mar. 15, 2017
Mar. 31, 2015
May 11, 2013
Jan. 09, 2013
Mar. 31, 2018
Feb. 28, 2018
Jul. 31, 2017
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2016
May 31, 2016
Feb. 28, 2016
Feb. 28, 2013
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2015
Jul. 31, 2013
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2013
Dec. 31, 2014
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Temporary Equity, Redemption Price Per Share (in Dollars per share)             $ 1.50                                  
Class of Warrant or Rights, Granted                                 700,000       4,479,974 2,049,504    
Warrant, Description of Warrant             after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.                                  
Class of Warrant or Right, Outstanding               12,237,628       9,128,189         12,237,628       12,789,086 9,128,189   7,078,685
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)                                 $ 3,044,162       $ 543,927      
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)   $ 397,162     $ 1,242,590     $ 0       $ 288,934         0   $ 1,242,590   $ 685,922 $ 288,934    
Stock Issued During Period, Shares, New Issues     100,000                                   4,131,536 3,798,417    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                         $ 6,041,214      
Conversion of Stock, Shares Issued               10,010 9,919                              
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars) $ 3,044,162                                       $ 20,757 $ 103,096    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate       1.599%                                        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                         0.00% 0.00%    
Dividends Payable, Current (in Dollars)               $ 482,636       359,891         $ 482,636       $ 447,901 $ 359,891    
Warrants at $2.61 [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Class of Warrant or Rights, Granted             1,330,627                                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)             $ 2.61                                  
Warrants, Term of Warrants             5 years                                  
Minimum [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                         5 years 5 years    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                 2.65%              
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                 0.00%              
Maximum [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                 5 years       10 years 10 years    
Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Temporary Equity, Shares Authorized             4,200                                  
Preferred Stock, Dividend Rate, Percentage             9.00%                                  
Preferred Stock, Liquidation Preference, Value (in Dollars)             $ 1,000                                  
Temporary Equity, Par Value (in Dollars)             $ 1,000                                  
Preferred Stock, Dividend Payment Terms             payable quarterly                                  
Preferred Stock, Voting Rights             The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.                                  
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description1             The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including: ●incur additional indebtedness;●permit liens on assets;●repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;●pay cash dividends to our stockholders; and●engage in transactions with affiliates                                  
Convertible Preferred Stock, Terms of Conversion             Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:  (i)  we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii)  we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii)  we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv)  we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v)  we are party to a change of control transaction,(vi)  we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii)  we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%                                  
(in Dollars)               $ 965,000       $ 1,070,000         $ 965,000       $ 985,000 $ 1,070,000 $ 2,781,000  
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)                                             1,242,590  
Stock Issued During Period, Shares, New Issues           450                           2,181        
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)                                       $ 1,814,910        
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)           $ 450,000                                    
Conversion of Stock, Shares Issued               10,010 9,919 19,844 60,846 18,188 54,759 197,713 54,859           80,690      
Conversion of Stock, Shares Converted               10 10 20 65 20 70 236 75           85      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                         2 years      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                         0.00%      
Temporary Equity, Shares Outstanding               965       1,070         965       985 1,070    
Temporary Equity, Shares Issued               965       1,070         965       985 1,070    
Dividends Payable, Current (in Dollars)                       $ 359,891                 $ 419,283 $ 359,891    
Registration Payment Arrangement, Term                                         In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014      
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description             The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.                                  
Dividends Payable (in Dollars)               $ 432,660                 $ 432,660       $ 419,283      
Series C Preferred Stock [Member] | Minimum [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                         0.74%      
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate                                         151.00%      
Series C Preferred Stock [Member] | Maximum [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                         1.06%      
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate                                         166.00%      
Bridge Loan [Member] | Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Debt Conversion, Converted Instrument, Shares Issued                               600                
Options Held [Member] | Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Adjustments to Additional Paid in Capital, Other (in Dollars)                                             1,303,671  
(in Dollars)                                             1,303,671  
Warrant [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)                                             4,097,444  
Warrant [Member] | Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)                                             1,064,739  
(in Dollars)                                             1,064,739  
Issuance Costs [Member] | Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
(in Dollars)                                             $ 412,590  
Embedded Derivative Financial Instruments [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)                                 3,044,162 $ 0     $ 0 0    
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate   130.00%     141.00%                           141.00%   131.00%      
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)                                 $ 0 $ 0     $ 20,757 $ 103,096    
Full-Ratchet Anti-Dilution Protection Provision [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)             $ 1.50                                  
Class of Warrant or Right, Outstanding             2,315,301                                  
Full-Ratchet Anti-Dilution Protection Provision [Member] | Series C Preferred Stock [Member]                                                
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)             $ 1.50                                  
Class of Warrant or Right, Outstanding             2,315,301                                  
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)
3 Months Ended 12 Months Ended
Jan. 01, 2018
Nov. 03, 2017
Mar. 15, 2017
Mar. 31, 2015
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]                  
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)   $ 397,162   $ 1,242,590 $ 0   $ 1,242,590 $ 685,922 $ 288,934
Derivative Liability, Current (in Dollars)   $ 652,054   $ 4,097,444 0   $ 4,097,444 2,358,240 1,937,234
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate     0.00%            
Derivative, Gain (Loss) on Derivative, Net (in Dollars)         0 $ (373,611)   210,465 (422,908)
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars) $ 3,044,162             $ 20,757 103,096
Embedded Derivative Financial Instruments [Member]                  
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]                  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate   1.74%              
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate   0.00%   0.00%     0.00% 0.00%  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate   130.00%   141.00%     141.00% 131.00%  
Derivative, Gain (Loss) on Derivative, Net (in Dollars)               $ (20,583)  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term               0 years  
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)         $ 3,044,162 $ 0   $ 0 $ 0
Embedded Derivative Financial Instruments [Member] | Minimum [Member]                  
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]                  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate       0.56%     0.56% 1.39%  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term               1 year 156 days  
Embedded Derivative Financial Instruments [Member] | Maximum [Member]                  
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]                  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate       0.89%     0.89% 1.89%  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term               3 years 131 days  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCKHOLDER EQUITY (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 16, 2018
Feb. 14, 2018
Nov. 06, 2017
Nov. 03, 2017
Jun. 16, 2017
Apr. 01, 2017
Mar. 15, 2017
May 11, 2013
Jan. 09, 2013
Mar. 31, 2018
Feb. 28, 2018
Jan. 31, 2018
Jul. 31, 2017
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2016
May 31, 2016
Feb. 28, 2016
Mar. 31, 2018
Jul. 31, 2013
Dec. 31, 2017
Dec. 31, 2016
Dec. 22, 2017
Nov. 18, 2017
Nov. 17, 2017
Nov. 09, 2017
Nov. 08, 2017
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Preferred Stock, Shares Authorized                   1,000,000         1,000,000       1,000,000   1,000,000 1,000,000          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                   $ 0.001         $ 0.001       $ 0.001   $ 0.001 $ 0.001          
Conversion of Stock, Shares Issued                   10,010 9,919                                
Stock Issued During Period, Shares, New Issues         100,000                               4,131,536 3,798,417          
Class of Warrant or Rights, Granted                                     700,000   4,479,974 2,049,504          
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                         $ 6,041,214            
Payments of Stock Issuance Costs (in Dollars)                                         $ 186,075 $ 490,543          
Warrants, Fair Value of Warrants Granted (in Dollars)             $ 543,927                                        
Common Stock, Shares Authorized                   200,000,000         200,000,000       200,000,000   200,000,000 200,000,000   200,000,000 50,000,000    
Common Stock, Shares, Outstanding                   30,497,707         22,588,184       30,497,707   29,321,204 22,588,184          
Common Stock, Shares, Issued                   30,497,707         22,588,184       30,497,707   29,321,204 22,588,184          
Stock Issued During Period, Shares, Share-based Compensation, Gross                                         124,750            
Shares Issued, Price Per Share (in Dollars per share)         $ 1.37                                   $ 1.37     $ 1.49 $ 1.52
Stock Issued During Period, Value, Issued for Services (in Dollars)                                     $ 142,000   $ 3,386,617 $ 2,471,050          
Proceeds from Issuance or Sale of Equity (in Dollars)                                         $ 6,011,229 $ 5,226,368          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                         0.00% 0.00%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate             105.22%                                        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate             1.599%                                        
Share Price (in Dollars per share)             $ 1.37               $ 1.44             $ 1.44          
Stock Issued During Period, Shares, Restricted Stock Award, Gross                                         135,000            
Stock Repurchased and Retired During Period, Shares           10,744                             10,744            
Common Stock, Par or Stated Value Per Share (in Dollars per share)                   $ 0.001         0.001       $ 0.001   $ 0.001 $ 0.001          
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)                   $ 29,985                 $ 29,985                
Phantom Share Units (PSUs) [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Stock Issued During Period, Shares, Conversion of Convertible Securities                                           220,000          
Class A Warrant Adjustment [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)     $ 1.50                                                
Warrant Adjustment, Additional Shares Issued Upon Exercise     111,167                                                
Services Provided [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Shares Issued, Price Per Share (in Dollars per share)                   $ 1.42         1.93       $ 1.42     $ 1.93          
Stock Issued During Period, Shares, Issued for Services                                     100,000     545,000          
Stock Issued During Period, Value, Issued for Services (in Dollars)                                     $ 142,000     $ 1,051,850          
Private Placement [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Class of Warrant or Rights, Granted                                         2,246,300 2,040,504          
Exercise of Options [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Stock Issued During Period, Shares, Share-based Compensation, Gross                                           83,545          
Stock Issued During Period, Value, Stock Options Exercised (in Dollars)                                           $ 100,000          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                           0.00%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                                           122.82%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                           1.08%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                           5 years          
Share Price (in Dollars per share)                             $ 1.84             $ 1.84          
Common Stock Issued for Services [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Shares Issued, Price Per Share (in Dollars per share)                                         $ 1.53            
Stock Issued During Period, Shares, Issued for Services                                         446,788            
Stock Issued During Period, Value, Issued for Services (in Dollars)                                         $ 681,367            
Sale of Warrants in Connection With Series E Preferred Stock[Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Class of Warrant or Rights, Granted 500,000                                                    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.75                                                    
Common Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.001                                                    
Consent Agreement, Series D Holders [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Class of Warrant or Rights, Granted 100,000 100,000                                                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.50 $ 1.50                                                  
Securities Purchase Agreements [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Stock Issued During Period, Shares, New Issues                                     180,000                
Class of Warrant or Rights, Granted                                     90,000                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                     $ 270,000                
Common Stock Subscription [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Stock Issued During Period, Shares, New Issues                                     20,000                
Class of Warrant or Rights, Granted                                     10,000                
Series A Preferred Stock [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Preferred Stock, Shares Authorized                   200         200       200   200 200          
Preferred Stock, Shares Outstanding                                         0            
Series B Preferred Stock [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Preferred Stock, Shares Authorized                   600         600       600   600 600          
Preferred Stock, Shares Outstanding                             0             0          
Series C Preferred Stock [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Preferred Stock, Shares Authorized                   4,200         4,200       4,200   4,200 4,200          
Conversion of Stock, Shares Issued                   10,010 9,919   19,844 60,846 18,188 54,759 197,713 54,859     80,690            
Conversion of Stock, Shares Converted                   10 10   20 65 20 70 236 75     85            
Convertible Preferred Dividends, Net of Tax (in Dollars)                                         $ 116,868            
Temporary Equity, Shares Issued                   965         1,070       965   985 1,070          
Temporary Equity, Shares Outstanding                   965         1,070       965   985 1,070          
Preferred Stock, Dividend Rate, Percentage                 9.00%                                    
Convertible Preferred Stock, Terms of Conversion                 Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:  (i)  we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii)  we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii)  we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv)  we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v)  we are party to a change of control transaction,(vi)  we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii)  we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%                                    
Stock Issued During Period, Shares, New Issues               450                       2,181              
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)               $ 450,000                                      
Dividends Payable (in Dollars)                   $ 432,660                 $ 432,660   $ 419,283            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                         0.00%            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                         2 years            
Series D Preferred Stock [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Preferred Stock, Shares Authorized       1,400           1,400         1,400       1,400   1,400 1,400          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)       $ 0.001           $ 0.001         $ 0.001       $ 0.001   $ 0.001 $ 0.001          
Preferred Stock, Shares Outstanding                   687         0       687   1,334 0          
Conversion of Stock, Shares Issued                   489,231 131,432 235,911                              
Conversion of Stock, Shares Converted                   367 100 180                              
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)       1,500                                              
Preferred Stock, Conversion Price (in Dollars per share)       $ 1.50                                              
Preferred Stock, Dividend Rate, Percentage       9.00%                                              
Convertible Preferred Stock, Terms of Conversion       Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion                                              
Stock Issued During Period, Shares, New Issues       1,334                                              
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)       $ 1,929,960                                 $ 1,929,960            
Payments of Stock Issuance Costs (in Dollars)       $ 70,040                                              
Preferred Stock, Shares Issued                   687         0       687   1,334 0          
Dividends Payable (in Dollars)                                         $ 28,618            
Series D Preferred Stock [Member] | Sale of Class A Warrants [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Class of Warrant or Rights, Granted       667,000                                              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)       $ 1.75                                              
Series D Preferred Stock [Member] | Exchange of Outstanding Warrants for Class B Warrants [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)       $ 1.50                                              
Warrants, Fair Value of Warrants Granted (in Dollars)       $ 780,506                                              
Series E Preferred Stock [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Preferred Stock, Shares Authorized                   1,000         1,000       1,000   1,000 1,000          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.001                 $ 0.001                 $ 0.001                
Preferred Stock, Shares Outstanding                   1,000                 1,000                
Stock Issued During Period, Shares, New Issues 1,000                                                    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) $ 1,492,969                                   $ 1,500,000                
Payments of Stock Issuance Costs (in Dollars) $ 7,031                                                    
Preferred Stock, Shares Issued                   1,000                 1,000                
2012 Equity Incentive Plan [Member]                                                      
STOCKHOLDER EQUITY (Details) [Line Items]                                                      
Stock Issued During Period, Shares, Share-based Compensation, Gross                                           790,000          
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)                                           $ 1,419,200          
Shares Issued, Price Per Share (in Dollars per share)                             $ 1.80           $ 1.48 $ 1.80          
Stock Issued During Period, Shares, Issued for Services                                         1,825,000            
Stock Issued During Period, Value, Issued for Services (in Dollars)                                         $ 2,705,250            
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)
3 Months Ended 12 Months Ended
Feb. 16, 2018
Feb. 15, 2018
Feb. 14, 2018
Jan. 05, 2018
Dec. 29, 2017
Dec. 22, 2017
Nov. 24, 2017
Nov. 08, 2017
Nov. 06, 2017
Nov. 03, 2017
Oct. 11, 2017
Sep. 18, 2017
Aug. 18, 2017
Jul. 13, 2017
Jun. 30, 2017
Jun. 20, 2017
May 17, 2017
May 05, 2017
Apr. 06, 2017
Mar. 31, 2017
Mar. 15, 2017
Mar. 10, 2017
Feb. 10, 2017
Feb. 09, 2017
Feb. 08, 2017
Dec. 29, 2016
Dec. 22, 2016
Dec. 16, 2016
Nov. 23, 2016
Oct. 28, 2016
Sep. 19, 2016
Sep. 07, 2016
Aug. 30, 2016
Aug. 24, 2016
Jun. 01, 2016
May 18, 2016
Apr. 29, 2016
Apr. 19, 2016
Apr. 01, 2016
Mar. 09, 2016
Feb. 09, 2016
Oct. 19, 2012
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award                                                                                   the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           105,898 300,000 475,000                                 130,000 5,000 150,000                               50,000   1,680,898 905,000
Share Price (in Dollars per share)                                         $ 1.37                                                 $ 1.44
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period           10 years 10 years 10 years                                 10 years 10 years 10 years                                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period                                                                                     0   0 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                                                                         0.00% 0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                                         105.22%                                                  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                         1.599%                                                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)                                                                                         $ 1.47 $ 1.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares             150,000 237,500                                                                            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)           $ 1.37 $ 1.50 $ 1.57                                 $ 1.55 $ 1.35 $ 1.36                               $ 1.42   $ 1.50 $ 1.71
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights   vesting immediately         150,000 vesting immediately and 150,000 performance contingent 237,500 vesting immediately and 237,500 at one year anniversary                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)                                                                                       $ 42,984    
Share-based Compensation (in Dollars)                                                                                     $ 388,710 $ 560,746 $ 4,749,470 $ 5,999,750
Class of Warrant or Rights, Granted                                                                                     700,000   4,479,974 2,049,504
Warrants, Fair Value of Warrants Granted (in Dollars)                                         $ 543,927                                                  
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate                                         0.00%                                                  
Class of Warrant or Rights, Cancelled                                                                                     1,251,458   (819,077) 0
Restricted Stock Units (RSUs) [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                                                               1 year                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                                                               180,000                            
Share-based Compensation (in Dollars)                                                                                         $ 93,261 $ 213,174
Warrants at $1.95 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Rights, Granted                                                             35,000   152,513       567,866 84,980 100,327 100,000 25,000          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                                             $ 1.95   $ 1.95       $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95   $ 1.95   $ 1.95  
Warrant, Expriation Date                                                             Sep. 19, 2019   Aug. 30, 2019                          
Warrants at $1.50 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Rights, Granted       100,000 230,334       206,668 780,506 193,334 51,668 175,500 133,501 108,334 10,000 186,957 6,667 288,300 157,250 630,000 197,159 300,628 45,001     115,000 456,668 50,002 173,284             96,256 17,996 18,040 12,000 6,000          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)       $ 1.50 $ 1.50       $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50     $ 1.50 $ 1.50 $ 1.50 $ 1.50             $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50   1.50 $ 1.50 $ 1.50  
Warrant, Expriation Date       Jan. 05, 2021 Dec. 29, 2020         Nov. 03, 2020 Oct. 11, 2020 Sep. 18, 2020 Aug. 18, 2020 Jul. 13, 2020 Jun. 30, 2020 Jun. 20, 2020 May 17, 2020 May 05, 2020 Apr. 06, 2020 Mar. 31, 2020   Mar. 10, 2020 Feb. 10, 2020       Dec. 22, 2019 Dec. 16, 2019 Nov. 23, 2019 Oct. 28, 2019               Apr. 19, 2019 Apr. 01, 2019 Mar. 09, 2019 Feb. 09, 2019          
Class of Warrant or Rights, Cancelled                   780,505                                                                        
Warrants at $2.10 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Rights, Granted                                               38,572                     38,572                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                               $ 2.10                     $ 2.10                      
Warrant, Expriation Date                                                                     Jun. 01, 2019                      
Warrants at $1.75 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                                                                     $ 1.75      
Minimum [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                                                                     0.00%      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                                                                                     94.10%   109.30% 95.72%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                                                                     2.65%      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                                                                         5 years 5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)                                                                                     $ 1.01      
Minimum [Member] | Warrants at $1.50 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Warrant, Expriation Date                                                                         Oct. 23, 2018                  
Maximum [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                                                                                         122.82% 107.17%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                                                                     5 years   10 years 10 years
Maximum [Member] | Warrants at $1.50 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Warrant, Expriation Date                                                                         Apr. 29, 2019                  
Series D Preferred Stock [Member] | Warrants at $1.50 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Rights, Granted                 111,167 667,000                                                                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                 $ 1.50 $ 1.50                                                                        
Warrant, Expriation Date                 May 03, 2021 May 03, 2021                                                                        
Series E Preferred Stock [Member] | Warrants at $1.75 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Rights, Granted 500,000                                                                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.75                                                                                          
Services Provided [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross             50,000 200,000                                                                            
Stock Issued During Period, Shares, Issued for Services                                                                                     100,000     545,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period             10 years 10 years                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares               50,000                                                                            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)             $ 1.45 $ 1.57                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights               50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020                                                                            
Services Provided #2 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross             420,000                                                                              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period             10 years                                                                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares             120,000                                                                              
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)             $ 1.45                                                                              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights             120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent                                                                              
Warrant [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation (in Dollars)                                                                                         $ 0 $ 56,931
Consent Agreement, Series D Holders [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Class of Warrant or Rights, Granted 100,000   100,000                                                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.50   $ 1.50                                                                                      
Options at $1.42 [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   50,000                                                                                        
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)   $ 1.42                                                                                        
2012 Equity Incentive Plan [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Stock Issued During Period, Shares, Issued for Services                                                                                         1,825,000  
2012 Equity Incentive Plan [Member] | Officers Directors and Key Consultants [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                                                                                         1,680,898 750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period                                                                                           100,000
Stock Issued During Period, Shares, Issued for Services                                                                                         2,009,750 723,545
2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                                                                                   15,186,123        
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award                                                                                   the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.        
Common Stock, Capital Shares Reserved for Future Issuance                                                                                   227,388        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                                                                   65,000                     685,000  
Share Price (in Dollars per share)                                                                                     $ 1.57   $ 1.44  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)                                                                   $ 1.33                     $ 1.84  
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                                                                   10 years                     10 years  
Stock Issued During Period, Shares, Conversion of Convertible Securities                                                                                         83,545  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period                                                                                         100,000  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                                                                       0.00%                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                                                                       122.82%                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                                                                       1.08%                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term                                                                       5 years                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)                                                                       $ 1.84                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)                                                                                     $ 246,710   $ 1,269,591 $ 2,801,948
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)                                                                                     $ 783,894   $ 979,812 $ 310,817
2012 Equity Incentive Plan [Member] | Maximum [Member] | Employee Stock Option [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                                                                                   10 years        
2012 Equity Incentive Plan [Member] | Share-based Compensation Award, Tranche One [Member] | Employee Stock Option [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares                                                                   12,500                        
2012 Equity Incentive Plan [Member] | Share-based Compensation Award, Tranche Two [Member] | Employee Stock Option [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares                                                                   37,500                        
2012 Equity Incentive Plan [Member] | Share-based Compensation Award, Tranche Three [Member] | Employee Stock Option [Member]                                                                                            
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                                                                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares                                                                   15,000                        
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Number of Options 8,230,319 8,510,319 8,245,190   7,780,190
Options Outstanding,Weighted Average Remaining Life 5 years 73 days 5 years 73 days 5 years 255 days 6 years 146 days  
Options Exercisable, Number of Options 7,168,319 7,347,486      
Options at $1.01-$2.00 [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share) $ 1.01        
Options Outstanding, Number of Options 3,545,540 3,825,540      
Options Outstanding,Weighted Average Remaining Life 7 years 73 days 6 years 292 days      
Options Exercisable, Number of Options 2,483,540 2,662,707      
Options at $1.01-$2.00 [Member] | Minimum [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share)   $ 1.01      
Options at $1.01-$2.00 [Member] | Maximum [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share)   $ 2.00      
Options at $2.01-$3.00 [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share) $ 2.01        
Options Outstanding, Number of Options 4,384,779 4,384,779      
Options Outstanding,Weighted Average Remaining Life 3 years 146 days 3 years 255 days      
Options Exercisable, Number of Options 4,384,779 4,384,779      
Options at $2.01-$3.00 [Member] | Minimum [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share)   $ 2.01      
Options at $2.01-$3.00 [Member] | Maximum [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share)   $ 3.00      
Options at $3.01-$4.00 [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share) $ 3.01        
Options Outstanding, Number of Options 300,000 300,000      
Options Outstanding,Weighted Average Remaining Life 7 years 7 years 109 days      
Options Exercisable, Number of Options 300,000 300,000      
Options at $3.01-$4.00 [Member] | Minimum [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share)   $ 3.01      
Options at $3.01-$4.00 [Member] | Maximum [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price (in Dollars per share)   $ 4.00      
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Compensation, Stock Options, Activity - USD ($)
3 Months Ended 12 Months Ended
Dec. 22, 2017
Nov. 24, 2017
Nov. 08, 2017
Feb. 08, 2017
Dec. 29, 2016
Dec. 22, 2016
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-based Compensation, Stock Options, Activity [Abstract]                    
Options Outstanding, Shares (in Shares)             8,510,319 8,245,190   7,780,190
Options Outstanding, Weighted-Average Exercise Price             $ 2.11 $ 2.24   $ 2.30
Options Outstanding, Weighted-Average Remaining Contractual Term             5 years 73 days 5 years 73 days 5 years 255 days 6 years 146 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)             $ 27,045 $ 0   $ 0
Options Exercisable, Shares (in Shares)             7,168,319 7,347,486 7,028,639  
Options Exercisable, Weighted-Average Exercise Price             $ 2.20 $ 2.19    
Options Exercisable, Weighted-Average Remaining Contractual Term             4 years 255 days 4 years 292 days    
Options Exercisable, Aggregate Intrinsic Value (in Dollars)             $ 104,305 $ 25,394    
Options Granted, Shares (in Shares) 105,898 300,000 475,000 130,000 5,000 150,000 50,000 1,680,898 905,000  
Options Granted, Weighted-Average Exercise Price $ 1.37 $ 1.50 $ 1.57 $ 1.55 $ 1.35 $ 1.36 $ 1.42 $ 1.50 $ 1.71  
Options Granted, Weighted-Average Remaining Contractual Term             10 years 10 years 10 years  
              $ 0 $ 0  
Options Exercised, Shares (in Shares)             0 0 0  
Options Exercised, Weighted-Average Exercise Price               $ 0 $ 0  
Options Canceled, Shares (in Shares)             (330,000) (1,415,769) (440,000)  
Options Canceled, , Weighted-Average Exercise Price             $ 1.66 $ 2.17 $ 2.24  
Options Outstanding, Shares (in Shares)             8,230,319 8,510,319 8,245,190  
Options Outstanding, Weighted-Average Exercise Price             $ 2.12 $ 2.11 $ 2.24  
Options Outstanding, Aggregate Intrinsic Value (in Dollars)             $ 158,930 $ 27,045 $ 0  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares
3 Months Ended 12 Months Ended
Mar. 15, 2017
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]        
Dividend yield     0.00% 0.00%
Stock price volatility 105.22%      
Weighted average grant date fair value (in Dollars per share)     $ 1.47 $ 1.17
Minimum [Member]        
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]        
Dividend yield   0.00%    
Stock price volatility   94.10% 109.30% 95.72%
Expected life     5 years 5 years
Weighted average grant date fair value (in Dollars per share)   $ 1.01    
Maximum [Member]        
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]        
Stock price volatility     122.82% 107.17%
Expected life   5 years 10 years 10 years
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - shares
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Nonvested Restricted Stock Shares Activity [Abstract]    
Restricted shares issued 135,000 175,000
Granted 0 180,000
Vested (135,000) (220,000)
Total restricted shares issued 0 135,000
Unvested restricted shares 0  
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Jan. 05, 2018
Dec. 29, 2017
Nov. 06, 2017
Nov. 03, 2017
Oct. 11, 2017
Sep. 18, 2017
Aug. 18, 2017
Jul. 13, 2017
Jun. 30, 2017
Jun. 20, 2017
May 17, 2017
May 05, 2017
Apr. 06, 2017
Mar. 31, 2017
Mar. 15, 2017
Mar. 10, 2017
Feb. 10, 2017
Feb. 09, 2017
Dec. 31, 2016
Dec. 22, 2016
Dec. 16, 2016
Nov. 23, 2016
Oct. 28, 2016
Sep. 19, 2016
Aug. 30, 2016
Apr. 29, 2016
Apr. 19, 2016
Apr. 01, 2016
Mar. 09, 2016
Feb. 09, 2016
Dec. 31, 2014
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Number Outstanding 12,237,628 12,789,086                                     9,128,189                       7,078,685
Warrants at $0.001 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 0.001 $ 0.001                                                              
Number Outstanding 383,320 383,320                                                              
Expiration Date January 2020 January 2020                                                              
Warrants at $1.50 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50   $ 1.50 $ 1.50 $ 1.50 $ 1.50     $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50  
Number Outstanding 7,615,982 8,667,440                                                              
Expiration Date February 2018 to May 2021 February 2018 to May 2021                                                              
Warrants at $1.84 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 1.84 $ 1.84                                                              
Number Outstanding 35,076 35,076                                                              
Expiration Date January 2020 January 2020                                                              
Warrants at $1.95 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 1.95 $ 1.95                                               $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95  
Number Outstanding 1,689,026 1,689,026                                                              
Expiration Date October 2018 to September 2019 October 2018 to September 2019                                                              
Warrants at $2.00 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 2.00 $ 2.00                                                              
Number Outstanding 100,000 100,000                                                              
Expiration Date August 2018 August 2018                                                              
Warrants at $2.02 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 2.02 $ 2.02                                                              
Number Outstanding 30,755 30,755                                                              
Expiration Date January 2020 January 2020                                                              
Warrants at $2.50 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 2.50 $ 2.50                                                              
Number Outstanding 100,000 100,000                                                              
Expiration Date August 2018 August 2018                                                              
Warrants at $2.75 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 2.75 $ 2.75                                                              
Number Outstanding 228,720 228,720                                                              
Expiration Date August 2019 to September 2019 August 2019 to September 2019                                                              
Warrants at $3.67 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 3.67 $ 3.67                                                              
Number Outstanding 214,193 214,193                                                              
Expiration Date December 2018 to January 2019 December 2018 to January 2019                                                              
Warrants at $3.75 [Member]                                                                  
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price (in Dollars per share) $ 3.75 $ 3.75                                                              
Number Outstanding 1,340,556 1,340,556                                                              
Expiration Date April 2019 to March 2020 April 2019 to March 2020                                                              
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]        
Warrants Outstanding, Shares 12,789,086 9,128,189   7,078,685
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share) $ 1.82 $ 1.96   $ 2.02
Warrants Outstanding, Weighted-Average Remaining Contractual Term 1 year 255 days 1 year 255 days 2 years 36 days 3 years
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars) $ 551,636 $ 494,099   $ 497,933
Warrants Granted, Shares 700,000 4,479,974 2,049,504  
Warrants Granted, Weighted-Average Exercise Price (in Dollars per share) $ 1.68 $ 1.50 $ 1.74  
Warrants Granted, Weighted-Average Remaining Contractual Term 3 years 3 years 2 years 6 months  
Warrants Exercised, Shares 0 0 0  
Warrants Canceled, Shares 1,251,458 (819,077) 0  
Warrants Canceled, Weighted-Average Exercise Price (in Dollars per share) $ 1.50 $ 1.50    
Warrants Outstanding, Shares 12,237,628 12,789,086 9,128,189  
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share) $ 1.85 $ 1.82 $ 1.96  
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars) $ 1,134,548 $ 551,636 $ 494,099  
Vested and expected to vest at December 31, 2017 12,237,628 12,789,086    
Vested and expected to vest at December 31, 2017 (in Dollars per share) $ 1.85 $ 1.82    
Vested and expected to vest at December 31, 2017 1 year 255 days 1 year 255 days    
Vested and expected to vest at December 31, 2017 (in Dollars) $ 1,134,548 $ 551,636    
Warrants Exercisable, Shares 12,237,628 12,789,086    
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share) $ 1.85 $ 1.82    
Warrants Exercisable, Weighted-Average Remaining Contractual Term 1 year 255 days 1 year 255 days    
Warrants Exercisable, Aggregate Intrinsic Value (in Dollars) $ 1,134,548 $ 551,636    
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENT (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Nov. 03, 2017
Dec. 31, 2016
Mar. 31, 2015
Fair Value Disclosures [Abstract]          
Embedded Derivative, Fair Value of Embedded Derivative Liability $ 0 $ 685,922 $ 397,162 $ 288,934 $ 1,242,590
Derivative Liability, Current $ 0 $ 2,358,240 $ 652,054 $ 1,937,234 $ 4,097,444
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016 $ 0 $ (373,611) $ 210,465 $ (422,908)
Initial fair value of warrant liability at date of issuance 0 0 1,049,216 0
Warrant [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Balance 2,358,240 1,937,234 1,937,234 1,621,199
Transfers out due to conversion of Series C Preferred Stock (2,358,240)   0 0
Mark to market to December 31, 2016     (231,048) 316,035
Balance 0   2,358,240 1,937,234
Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016     231,048  
Initial fair value of warrant liability at date of issuance     652,054  
Warrant [Member] | Series D Preferred Stock [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Initial fair value of warrant liability at date of issuance     0  
Embedded Derivative Financial Instruments [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Balance 685,922 $ 288,934 288,934 285,157
Transfers out due to conversion of Series C Preferred Stock (685,922)   (20,757) (103,096)
Mark to market to December 31, 2016     20,583 106,873
Balance $ 0   685,922 $ 288,934
Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016     (20,583)  
Initial fair value of warrant liability at date of issuance     0  
Embedded Derivative Financial Instruments [Member] | Series D Preferred Stock [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Initial fair value of warrant liability at date of issuance     $ 397,162  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended 12 Months Ended
Jan. 05, 2018
$ / shares
shares
Dec. 29, 2017
$ / shares
shares
Dec. 22, 2017
shares
Nov. 24, 2017
shares
Nov. 08, 2017
shares
Nov. 06, 2017
$ / shares
shares
Nov. 03, 2017
$ / shares
shares
Oct. 11, 2017
$ / shares
shares
Sep. 18, 2017
$ / shares
shares
Aug. 18, 2017
$ / shares
shares
Jul. 14, 2017
Jul. 13, 2017
$ / shares
shares
Jun. 30, 2017
$ / shares
shares
Jun. 20, 2017
$ / shares
shares
May 17, 2017
$ / shares
shares
May 05, 2017
$ / shares
shares
Apr. 06, 2017
$ / shares
shares
Mar. 31, 2017
$ / shares
shares
Mar. 15, 2017
$ / shares
shares
Mar. 10, 2017
$ / shares
shares
Feb. 10, 2017
$ / shares
shares
Feb. 09, 2017
$ / shares
shares
Feb. 08, 2017
shares
Dec. 29, 2016
shares
Dec. 22, 2016
$ / shares
shares
Dec. 16, 2016
$ / shares
shares
Nov. 23, 2016
$ / shares
shares
Oct. 28, 2016
$ / shares
shares
Apr. 29, 2016
$ / shares
shares
Apr. 19, 2016
$ / shares
shares
Apr. 01, 2016
$ / shares
shares
Mar. 09, 2016
$ / shares
shares
Feb. 09, 2016
$ / shares
shares
Jul. 15, 2014
USD ($)
$ / shares
shares
Mar. 31, 2018
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
shares
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Agreement Term                                     10 years                                    
Class of Warrant or Rights, Granted                                                                     700,000 4,479,974 2,049,504
Number of Directors                     8                                                    
Qualified Financing Amoun (in Dollars) | $                                                                   $ 3,500,000      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     105,898 300,000 475,000                                   130,000 5,000 150,000                   50,000 1,680,898 905,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years 10 years 10 years                                   10 years 10 years 10 years                        
Chief Executive Officer [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Deferred Compensation Arrangement with Individual, Requisite Service Period                                                                   3 years      
Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                                                                   1,265,769      
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares                                                                   $ 2.21      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                                                                   10 years      
Signing Bonus [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Other Commitment (in Dollars) | $                                                                   $ 30,000      
Warrants at $1.50 [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Class of Warrant or Rights, Granted 100,000 230,334       206,668 780,506 193,334 51,668 175,500   133,501 108,334 10,000 186,957 6,667 288,300 157,250 630,000 197,159 300,628 45,001     115,000 456,668 50,002 173,284 96,256 17,996 18,040 12,000 6,000        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares $ 1.50 $ 1.50       $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50   $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50     $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50   $ 1.50 $ 1.50  
Minimum [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Royalty Percentage of Net Sales                                     1.00%                                    
Minimum [Member] | Annual Salary [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Other Commitment (in Dollars) | $                                                                   $ 275,000      
Maximum [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Royalty Percentage of Net Sales                                     2.00%                                    
Share-based Compensation Award, Tranche One [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number                                                                   542,473      
Share-based Compensation Award, Tranche One [Member] | Options Vesting in Eleven Equal Installments [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                                                                   45,206      
Share-based Compensation Award, Tranche One [Member] | Final Installment of Vested Options [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                                                                   45,207      
Share-based Compensation Award, Tranche Two [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                                                                   180,824      
Share-based Compensation Award, Tranche Three [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                                                                   180,824      
Share-based Compensation Award, Tranche Four [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                                                                   180,824      
Share-based Compensation Award, Tranche Five [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                                                                   180,824      
Stock Value Outstanding (in Dollars) | $                                                                   $ 150,000,000      
Parking Space Leases [Member]                                                                          
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]                                                                          
Operating Leases, Rent Expense, Minimum Rentals (in Dollars) | $                                                                       $ 978  
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases
Dec. 31, 2017
USD ($)
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]  
2018 $ 112,994
2019 76,995
$ 189,989
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]    
Operating Loss Carryforwards $ 24,000,000  
Operating Loss Carryforwards, Expiration Date 1 2036 years  
Deferred Tax Assets, Valuation Allowance $ 8,200,000 $ 5,500,000
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Schedule of Effective Income Tax Rate Reconciliation [Abstract]    
Statutory rate on pre-tax book loss (34.00%) (34.00%)
(Gain) loss on change in fair value of derivatives (0.56%) 1.24%
Stock based compensation 12.72% 17.60%
Fair value of warrant to acquire research and development 1.46% 0.00%
Other 0.09% 0.09%
Valuation allowance 20.29% 15.07%
0.00% 0.00%
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)
Dec. 31, 2017
Dec. 31, 2016
Schedule of Deferred Tax Assets and Liabilities [Abstract]    
Net operating loss carry-forwards $ 8,200,000 $ 5,500,000
Valuation allowance (8,200,000) (5,500,000)
Net non-current deferred tax asset $ 0 $ 0
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUBSEQUENT EVENTS (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 16, 2018
Feb. 15, 2018
Feb. 14, 2018
Feb. 01, 2018
Jan. 05, 2018
Jan. 01, 2018
Dec. 22, 2017
Nov. 24, 2017
Nov. 08, 2017
Nov. 03, 2017
Jun. 16, 2017
Feb. 08, 2017
Dec. 29, 2016
Dec. 22, 2016
May 11, 2013
Apr. 30, 2018
Mar. 31, 2018
Feb. 28, 2018
Jan. 31, 2018
Jul. 31, 2017
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2016
May 31, 2016
Feb. 28, 2016
Feb. 27, 2018
Mar. 31, 2018
Jul. 31, 2013
Dec. 31, 2017
Dec. 31, 2016
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)           $ 3,044,162                                             $ 20,757 $ 103,096
Stock Issued During Period, Shares, New Issues                     100,000                                   4,131,536 3,798,417
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                                 $ 0.001         $ 0.001         $ 0.001   $ 0.001 $ 0.001
Class of Warrant or Rights, Granted                                                     700,000   4,479,974 2,049,504
Common Stock, Par or Stated Value Per Share (in Dollars per share)                                 $ 0.001         0.001         $ 0.001   $ 0.001 $ 0.001
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                                         $ 6,041,214  
Proceeds from Issuance or Sale of Equity (in Dollars)                                                         6,011,229 $ 5,226,368
Payments of Stock Issuance Costs (in Dollars)                                                         $ 186,075 $ 490,543
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)                                 $ 29,985                   $ 29,985      
Conversion of Stock, Shares Issued                                 10,010 9,919                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross             105,898 300,000 475,000     130,000 5,000 150,000                         50,000   1,680,898 905,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)             $ 1.37 $ 1.50 $ 1.57     $ 1.55 $ 1.35 $ 1.36                         $ 1.42   $ 1.50 $ 1.71
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period             10 years 10 years 10 years     10 years 10 years 10 years                                
Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)                                     $ 3,044,162                      
Stock Issued During Period, Shares, New Issues     9,919                                                      
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                                         $ 1,500,000  
Proceeds from Issuance or Sale of Equity (in Dollars)                                                         270,000  
Conversion of Stock, Shares Issued                                                   367,343        
Stock Issued During Period, Shares, Issued for Services       200,000                                                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   50,000                                                        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)   $ 1.42                                                        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period   10 years                                                        
Consent Agreement, Series D Holders [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Class of Warrant or Rights, Granted 100,000   100,000                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.50   $ 1.50                                                      
Consent Agreement, Series D Holders [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Class of Warrant or Rights, Granted 100,000                                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.50                                                          
Unit Purchase Agreements [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)                                                         $ 29,985  
Unit Purchase Agreements [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, New Issues         200,000                                                  
Class of Warrant or Rights, Granted         100,000                                                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)         $ 1.50                                                  
Proceeds from Issuance or Sale of Equity (in Dollars)         $ 299,985                                                  
Payments of Stock Issuance Costs (in Dollars)         $ 15                                                  
Share-based Compensation Award, Tranche One [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, Issued for Services       100,000                                                    
Share-based Compensation Award, Tranche Two [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, Issued for Services       100,000                                                    
Series E Preferred Stock [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, New Issues 1,000                                                          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.001                               $ 0.001                   $ 0.001      
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) $ 1,492,969                                                   $ 1,500,000      
Payments of Stock Issuance Costs (in Dollars) $ 7,031                                                          
Series E Preferred Stock [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, New Issues 1,000                                                          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.001                                                          
Class of Warrant or Rights, Granted 500,000                                                          
Common Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.001                                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.75                                                          
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) $ 1,500,000                                                          
Series D Preferred Stock [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, New Issues                   1,334                                        
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                   $ 0.001             $ 0.001         $ 0.001         $ 0.001   $ 0.001 $ 0.001
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                   $ 1,929,960                                     $ 1,929,960  
Payments of Stock Issuance Costs (in Dollars)                   $ 70,040                                        
Conversion of Stock, Shares Issued                                 489,231 131,432 235,911                      
Conversion of Stock, Shares Converted                                 367 100 180                      
Series D Preferred Stock [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Conversion of Stock, Shares Issued                               577,339                            
Conversion of Stock, Shares Converted                               454                   280        
Series C Preferred Stock [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Stock Issued During Period, Shares, New Issues                             450                         2,181    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                             $ 450,000                              
Conversion of Stock, Shares Issued                                 10,010 9,919   19,844 60,846 18,188 54,759 197,713 54,859       80,690  
Conversion of Stock, Shares Converted                                 10 10   20 65 20 70 236 75       85  
Series C Preferred Stock [Member] | Subsequent Event [Member]                                                            
SUBSEQUENT EVENTS (Details) [Line Items]                                                            
Conversion of Stock, Shares Issued                               351,021                            
Conversion of Stock, Shares Converted     10                         370                            
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 22,798,280 19,378,178 23,290,072 18,086,712
Series C Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 643,333 713,333 656,667 713,333
Series D Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 687,000 0 1,334,000 0
Series E Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 1,000,000 0    
Employee Stock Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 8,230,319 8,245,190 8,510,319 8,245,190
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities 12,237,628 10,419,655 12,789,086 9,128,189
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 103,678 $ 100,034 $ 94,821
Less accumulated depreciation (84,221) (81,318) (70,633)
Property and equipment, net 19,457 18,716 24,188
Computer Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 90,703 87,059 84,704
Furniture and Fixtures [Member]      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 12,975 $ 12,975 $ 10,117
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Schedule of Accounts Payable and Accrued Liabilities [Abstract]      
Accrued accounting and legal $ 151,745 $ 93,595 $ 120,464
Accrued reimbursements 10,510 2,600 43,116
Accrued consulting 12,650 109,059 1,192
Accrued research and development expenses 148,932 246,030 181,884
Accrued office and other 644 7,912 10,202
Deferred rent 997 569 2,912
Accrued settlement related to arbitration 13,333 13,333 13,333
$ 338,811 $ 473,098 $ 373,103
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Number of Options 8,230,319 8,510,319 8,245,190   7,780,190
Options Outstanding, Weighted Average Remaining Life 5 years 73 days 5 years 73 days 5 years 255 days 6 years 146 days  
Options Exercisable, Number of Options 7,168,319 7,347,486      
Options at $1.01-$2.00 [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share) $ 1.01        
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share) $ 2.00        
Options Outstanding, Number of Options 3,545,540 3,825,540      
Options Outstanding, Weighted Average Remaining Life 7 years 73 days 6 years 292 days      
Options Exercisable, Number of Options 2,483,540 2,662,707      
Options at $2.01-$3.00 [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share) $ 2.01        
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share) $ 3.00        
Options Outstanding, Number of Options 4,384,779 4,384,779      
Options Outstanding, Weighted Average Remaining Life 3 years 146 days 3 years 255 days      
Options Exercisable, Number of Options 4,384,779 4,384,779      
Options at $3.01-$4.00 [Member]          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share) $ 3.01        
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share) $ 4.00        
Options Outstanding, Number of Options 300,000 300,000      
Options Outstanding, Weighted Average Remaining Life 7 years 7 years 109 days      
Options Exercisable, Number of Options 300,000 300,000      
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)
3 Months Ended 12 Months Ended
Dec. 22, 2017
Nov. 24, 2017
Nov. 08, 2017
Feb. 08, 2017
Dec. 29, 2016
Dec. 22, 2016
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]                      
Options Outstanding, Shares             8,230,319 8,510,319 8,245,190   7,780,190
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)             $ 2.12 $ 2.11 $ 2.24   $ 2.30
Options Outstanding, Weighted-Average Remaining Contractual Term             5 years 73 days 5 years 73 days 5 years 255 days 6 years 146 days  
Options Outstanding, Aggregate Intrinsic Value (in Dollars)             $ 158,930 $ 27,045 $ 0   $ 0
Options Exercisable, Shares             7,168,319 7,347,486 7,028,639    
Options Exercisable, Weighted-Average Exercise Price (in Dollars per share)             $ 2.20 $ 2.19      
Options Exercisable, Weighted-Average Remaining Contractual Term             4 years 255 days 4 years 292 days      
Options Exercisable, Aggregate Intrinsic Value (in Dollars)             $ 104,305 $ 25,394      
Options Granted, Shares 105,898 300,000 475,000 130,000 5,000 150,000 50,000 1,680,898 905,000    
Options Granted, Weighted-Average Exercise Price (in Dollars per share) $ 1.37 $ 1.50 $ 1.57 $ 1.55 $ 1.35 $ 1.36 $ 1.42 $ 1.50 $ 1.71    
Options Granted, Weighted-Average Remaining Contractual Term             10 years 10 years 10 years    
Options Exercised, Shares             0 0 0    
Options Canceled, Shares             (330,000) (1,415,769) (440,000)    
Options Canceled, Weighted-Average Exercise Price (in Dollars per share)             $ 1.66 $ 2.17 $ 2.24    
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares
3 Months Ended 12 Months Ended
Mar. 15, 2017
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]        
Risk-free interest rate 1.599%      
Dividend yield     0.00% 0.00%
Stock price volatility 105.22%      
Weighted average grant date fair value (in Dollars per share)     $ 1.47 $ 1.17
Minimum [Member]        
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]        
Risk-free interest rate   2.65%    
Dividend yield   0.00%    
Stock price volatility   94.10% 109.30% 95.72%
Expected life     5 years 5 years
Weighted average grant date fair value (in Dollars per share)   $ 1.01    
Maximum [Member]        
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]        
Stock price volatility     122.82% 107.17%
Expected life   5 years 10 years 10 years
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Jan. 05, 2018
Dec. 29, 2017
Nov. 06, 2017
Nov. 03, 2017
Oct. 11, 2017
Sep. 18, 2017
Aug. 18, 2017
Jul. 13, 2017
Jun. 30, 2017
Jun. 20, 2017
May 17, 2017
May 05, 2017
Apr. 06, 2017
Mar. 31, 2017
Mar. 15, 2017
Mar. 10, 2017
Feb. 10, 2017
Feb. 09, 2017
Dec. 31, 2016
Dec. 22, 2016
Dec. 16, 2016
Nov. 23, 2016
Oct. 28, 2016
Sep. 19, 2016
Aug. 30, 2016
Apr. 29, 2016
Apr. 19, 2016
Apr. 01, 2016
Mar. 09, 2016
Feb. 09, 2016
Dec. 31, 2014
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Number of Warrants Outstanding 12,237,628 12,789,086                                     9,128,189                       7,078,685
Warrants at $0.001 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 0.001 $ 0.001                                                              
Number of Warrants Outstanding 383,320 383,320                                                              
Expiration Date, Warrants January 2020 January 2020                                                              
Warrants at $1.50 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50   $ 1.50 $ 1.50 $ 1.50 $ 1.50     $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50  
Number of Warrants Outstanding 7,615,982 8,667,440                                                              
Expiration Date, Warrants February 2018 to May 2021 February 2018 to May 2021                                                              
Warrants at $1.75 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 1.75                                                                
Number of Warrants Outstanding 500,000                                                                
Expiration Date, Warrants August 2021                                                                
Warrants at $1.84 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 1.84 $ 1.84                                                              
Number of Warrants Outstanding 35,076 35,076                                                              
Expiration Date, Warrants January 2020 January 2020                                                              
Warrants at $1.95 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 1.95 $ 1.95                                               $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95  
Number of Warrants Outstanding 1,689,026 1,689,026                                                              
Expiration Date, Warrants October 2018 to September 2019 October 2018 to September 2019                                                              
Warrants at $2.00 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 2.00 $ 2.00                                                              
Number of Warrants Outstanding 100,000 100,000                                                              
Expiration Date, Warrants August 2018 August 2018                                                              
Warrants at $2.02 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 2.02 $ 2.02                                                              
Number of Warrants Outstanding 30,755 30,755                                                              
Expiration Date, Warrants January 2020 January 2020                                                              
Warrants at $2.50 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 2.50 $ 2.50                                                              
Number of Warrants Outstanding 100,000 100,000                                                              
Expiration Date, Warrants August 2018 August 2018                                                              
Warrants at $2.75 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 2.75 $ 2.75                                                              
Number of Warrants Outstanding 228,720 228,720                                                              
Expiration Date, Warrants August 2019 to September 2019 August 2019 to September 2019                                                              
Warrants at $3.67 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 3.67 $ 3.67                                                              
Number of Warrants Outstanding 214,193 214,193                                                              
Expiration Date, Warrants December 2018 to January 2019 December 2018 to January 2019                                                              
Warrants at $3.75 [Member]                                                                  
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]                                                                  
Exercise Price, Warrants (in Dollars per share) $ 3.75 $ 3.75                                                              
Number of Warrants Outstanding 1,340,556 1,340,556                                                              
Expiration Date, Warrants April 2019 to March 2020 April 2019 to March 2020                                                              
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]          
Warrants Outstanding, Shares 12,237,628 12,789,086 9,128,189   7,078,685
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share) $ 1.85 $ 1.82 $ 1.96   $ 2.02
Warrants Outstanding, Weighted-Average Remaining Contractual Term 1 year 255 days 1 year 255 days 2 years 36 days 3 years  
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars) $ 1,134,548 $ 551,636 $ 494,099   $ 497,933
Warrants Vested and expected to vest, Shares 12,237,628 12,789,086      
Warrants Vested and expected to vest, Weighted-Average Exercise Price (in Dollars per share) $ 1.85 $ 1.82      
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term 1 year 255 days 1 year 255 days      
Warrants Vested and expected to vest, Aggregate Intrinsic Value (in Dollars) $ 1,134,548 $ 551,636      
Warrants Exercisable, Shares 12,237,628 12,789,086      
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share) $ 1.85 $ 1.82      
Warrants Exercisable, Weighted-Average Remaining Contractual Term 1 year 255 days 1 year 255 days      
Warrants Exercisable, Aggregate Intrinsic Value (in Dollars) $ 1,134,548 $ 551,636      
Warrants Granted, Shares 700,000 4,479,974 2,049,504    
Warrants Granted, Weighted-Average Exercise Price (in Dollars per share) $ 1.68 $ 1.50 $ 1.74    
Warrants Granted, Weighted-Average Remaining Contractual Term 3 years 3 years 2 years 6 months    
Warrants Exercised, Shares 0 0 0    
Warrants Canceled, Shares (1,251,458) 819,077 0    
Warrants Canceled, Weighted-Average Exercise Price (in Dollars per share) $ 1.50 $ 1.50      
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Warrant [Member]      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Balance $ 2,358,240 $ 1,937,234 $ 1,621,199
Transfers out (2,358,240) 0 0
Balance 0 2,358,240 1,937,234
Embedded Derivative Financial Instruments [Member]      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Balance 685,922 288,934 285,157
Transfers out (685,922) (20,757) (103,096)
Balance $ 0 $ 685,922 $ 288,934
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUBSEQUENT EVENTS (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2018
Feb. 16, 2018
Feb. 14, 2018
Nov. 03, 2017
Jun. 16, 2017
May 11, 2013
Apr. 30, 2018
Mar. 31, 2018
Feb. 28, 2018
Jan. 31, 2018
Jul. 31, 2017
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2016
May 31, 2016
Feb. 28, 2016
Feb. 27, 2018
Mar. 31, 2018
Jul. 31, 2013
Dec. 31, 2017
Dec. 31, 2016
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Conversion of Stock, Shares Issued               10,010 9,919                        
Stock Issued During Period, Shares, New Issues         100,000                             4,131,536 3,798,417
Class of Warrant or Rights, Granted                                   700,000   4,479,974 2,049,504
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                       $ 6,041,214  
Payments of Stock Issuance Costs (in Dollars)                                       186,075 $ 490,543
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)               $ 29,985                   $ 29,985      
Subsequent Event [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Conversion of Stock, Shares Issued                                 367,343        
Stock Issued During Period, Shares, New Issues     9,919                                    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                                       1,500,000  
April 2018 Private Placement [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)               $ 115,470                   115,470      
April 2018 Private Placement [Member] | Subsequent Event [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Stock Issued During Period, Shares, New Issues 3,193,004                                        
Class of Warrant or Rights, Granted 1,596,506                                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.75           $ 1.75                            
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) $ 4,789,502                                        
Payments of Stock Issuance Costs (in Dollars) $ 1,000                                        
Series D Preferred Stock [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Conversion of Stock, Shares Issued               489,231 131,432 235,911                      
Conversion of Stock, Shares Converted               367 100 180                      
Stock Issued During Period, Shares, New Issues       1,334                                  
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)       $ 1,929,960                               $ 1,929,960  
Payments of Stock Issuance Costs (in Dollars)       $ 70,040                                  
Series D Preferred Stock [Member] | Subsequent Event [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Conversion of Stock, Shares Issued             577,339                            
Conversion of Stock, Shares Converted             454                   280        
Series C Preferred Stock [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Conversion of Stock, Shares Issued               10,010 9,919   19,844 60,846 18,188 54,759 197,713 54,859       80,690  
Conversion of Stock, Shares Converted               10 10   20 65 20 70 236 75       85  
Stock Issued During Period, Shares, New Issues           450                         2,181    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)           $ 450,000                              
Series C Preferred Stock [Member] | Subsequent Event [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Conversion of Stock, Shares Issued             351,021                            
Conversion of Stock, Shares Converted     10       370                            
Series E Preferred Stock [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Stock Issued During Period, Shares, New Issues   1,000                                      
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)   $ 1,492,969                               $ 1,500,000      
Payments of Stock Issuance Costs (in Dollars)   $ 7,031                                      
Series E Preferred Stock [Member] | Subsequent Event [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Stock Issued During Period, Shares, New Issues   1,000                                      
Class of Warrant or Rights, Granted   500,000                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 1.75                                      
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)   $ 1,500,000                                      
Series E Preferred Stock [Member] | April 2018 Private Placement [Member] | Subsequent Event [Member]                                          
SUBSEQUENT EVENTS (Details) [Line Items]                                          
Class of Warrant or Rights, Granted             83,334                            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.50           $ 1.50                            
EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 483 284 1 false 85 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://BIOS/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONDENSED BALANCE SHEETS Sheet http://BIOS/role/ConsolidatedBalanceSheet CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONDENSED BALANCE SHEETS (Parentheticals) Sheet http://BIOS/role/ConsolidatedBalanceSheet_Parentheticals CONDENSED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONDENSED STATEMENTS OF OPERATIONS (unaudited) Sheet http://BIOS/role/ConsolidatedIncomeStatement CONDENSED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 004 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://BIOS/role/ShareholdersEquityType2or3 CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) Sheet http://BIOS/role/ShareholdersEquityType2or3_Parentheticals CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) Statements 6 false false R7.htm 006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://BIOS/role/ConsolidatedCashFlow CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Statements 7 false false R8.htm 007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 008 - Disclosure - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS Sheet http://BIOS/role/GOINGCONCERNANDMANAGEMENTSLIQUIDITYPLANS GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS Notes 9 false false R10.htm 009 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://BIOS/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://BIOS/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://BIOS/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 12 false false R13.htm 012 - Disclosure - SERIES C 9% CONVERTIBLE PREFERRED STOCK Sheet http://BIOS/role/SERIESC9CONVERTIBLEPREFERREDSTOCK SERIES C 9% CONVERTIBLE PREFERRED STOCK Notes 13 false false R14.htm 013 - Disclosure - WARRANT AND DERIVATIVE LIABILITIES Sheet http://BIOS/role/WARRANTANDDERIVATIVELIABILITIES WARRANT AND DERIVATIVE LIABILITIES Notes 14 false false R15.htm 014 - Disclosure - STOCKHOLDER EQUITY Sheet http://BIOS/role/STOCKHOLDEREQUITY STOCKHOLDER EQUITY Notes 15 false false R16.htm 015 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Sheet http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTS OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Notes 16 false false R17.htm 016 - Disclosure - FAIR VALUE MEASUREMENT Sheet http://BIOS/role/FAIRVALUEMEASUREMENT FAIR VALUE MEASUREMENT Notes 17 false false R18.htm 017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://BIOS/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 018 - Disclosure - INCOME TAXES Sheet http://BIOS/role/INCOMETAXES INCOME TAXES Notes 19 false false R20.htm 019 - Disclosure - SUBSEQUENT EVENTS Sheet http://BIOS/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 20 false false R21.htm 020 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://BIOS/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 21 false false R22.htm 021 - Disclosure - SUBSEQUENT EVENTS Sheet http://BIOS/role/SUBSEQUENTEVENTS0 SUBSEQUENT EVENTS Notes 22 false false R23.htm 022 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://BIOS/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 23 false false R24.htm 023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 24 false false R25.htm 024 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://BIOS/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://BIOS/role/PROPERTYANDEQUIPMENT 25 false false R26.htm 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://BIOS/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://BIOS/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES 26 false false R27.htm 026 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) Sheet http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) Tables http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTS 27 false false R28.htm 027 - Disclosure - FAIR VALUE MEASUREMENT (Tables) Sheet http://BIOS/role/FAIRVALUEMEASUREMENTTables FAIR VALUE MEASUREMENT (Tables) Tables http://BIOS/role/FAIRVALUEMEASUREMENT 28 false false R29.htm 028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://BIOS/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://BIOS/role/COMMITMENTSANDCONTINGENCIES 29 false false R30.htm 029 - Disclosure - INCOME TAXES (Tables) Sheet http://BIOS/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://BIOS/role/INCOMETAXES 30 false false R31.htm 030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 31 false false R32.htm 031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Sheet http://BIOS/role/ScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareTable SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Details http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 32 false false R33.htm 032 - Disclosure - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) Sheet http://BIOS/role/GOINGCONCERNANDMANAGEMENTSLIQUIDITYPLANSDetails GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) Details http://BIOS/role/GOINGCONCERNANDMANAGEMENTSLIQUIDITYPLANS 33 false false R34.htm 033 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://BIOS/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://BIOS/role/RELATEDPARTYTRANSACTIONS 34 false false R35.htm 034 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://BIOS/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://BIOS/role/PROPERTYANDEQUIPMENTTables 35 false false R36.htm 035 - Disclosure - PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment Sheet http://BIOS/role/PropertyPlantandEquipmentTable PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment Details http://BIOS/role/PROPERTYANDEQUIPMENTTables 36 false false R37.htm 036 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities Sheet http://BIOS/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities Details http://BIOS/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables 37 false false R38.htm 037 - Disclosure - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) Sheet http://BIOS/role/SERIESC9CONVERTIBLEPREFERREDSTOCKDetails SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) Details http://BIOS/role/SERIESC9CONVERTIBLEPREFERREDSTOCK 38 false false R39.htm 038 - Disclosure - WARRANT AND DERIVATIVE LIABILITIES (Details) Sheet http://BIOS/role/WARRANTANDDERIVATIVELIABILITIESDetails WARRANT AND DERIVATIVE LIABILITIES (Details) Details http://BIOS/role/WARRANTANDDERIVATIVELIABILITIES 39 false false R40.htm 039 - Disclosure - STOCKHOLDER EQUITY (Details) Sheet http://BIOS/role/STOCKHOLDEREQUITYDetails STOCKHOLDER EQUITY (Details) Details http://BIOS/role/STOCKHOLDEREQUITY 40 false false R41.htm 040 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) Sheet http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSDetails OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 41 false false R42.htm 041 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Sheet http://BIOS/role/ScheduleofSharebasedCompensationSharesAuthorizedunderStockOptionPlansbyExercisePriceRangeTable OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 42 false false R43.htm 042 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Compensation, Stock Options, Activity Sheet http://BIOS/role/SharebasedCompensationStockOptionsActivityTable OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Compensation, Stock Options, Activity Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 43 false false R44.htm 043 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Sheet http://BIOS/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 44 false false R45.htm 044 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity Sheet http://BIOS/role/NonvestedRestrictedStockSharesActivityTable OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 45 false false R46.htm 045 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range Sheet http://BIOS/role/ScheduleofWarrantsorRightsSharesAuthorizedbyExercisePriceRangeTable OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 46 false false R47.htm 046 - Disclosure - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights Sheet http://BIOS/role/ScheduleofStockholdersEquityNoteWarrantsorRightsTable OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights Details http://BIOS/role/OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 47 false false R48.htm 047 - Disclosure - FAIR VALUE MEASUREMENT (Details) Sheet http://BIOS/role/FAIRVALUEMEASUREMENTDetails FAIR VALUE MEASUREMENT (Details) Details http://BIOS/role/FAIRVALUEMEASUREMENTTables 48 false false R49.htm 048 - Disclosure - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Sheet http://BIOS/role/FairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Details http://BIOS/role/FAIRVALUEMEASUREMENTTables 49 false false R50.htm 049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://BIOS/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://BIOS/role/COMMITMENTSANDCONTINGENCIESTables 50 false false R51.htm 050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases Sheet http://BIOS/role/ScheduleofFutureMinimumRentalPaymentsforOperatingLeasesTable COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases Details http://BIOS/role/COMMITMENTSANDCONTINGENCIESTables 51 false false R52.htm 051 - Disclosure - INCOME TAXES (Details) Sheet http://BIOS/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://BIOS/role/INCOMETAXESTables 52 false false R53.htm 052 - Disclosure - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation Sheet http://BIOS/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation Details http://BIOS/role/INCOMETAXESTables 53 false false R54.htm 053 - Disclosure - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities Sheet http://BIOS/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities Details http://BIOS/role/INCOMETAXESTables 54 false false R55.htm 054 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://BIOS/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://BIOS/role/SUBSEQUENTEVENTS 55 false false R56.htm 055 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Sheet http://BIOS/role/ScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareTable0 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Details http://BIOS/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 56 false false R57.htm 056 - Disclosure - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment Sheet http://BIOS/role/ScheduleofPropertyPlantandEquipmentTable PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment Details http://BIOS/role/PROPERTYANDEQUIPMENTTables 57 false false R58.htm 057 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities Sheet http://BIOS/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable0 ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities Details http://BIOS/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables 58 false false R59.htm 058 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Sheet http://BIOS/role/ScheduleofSharebasedCompensationSharesAuthorizedunderStockOptionPlansbyExercisePriceRangeTable0 OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Details 59 false false R60.htm 059 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity Sheet http://BIOS/role/ScheduleofSharebasedCompensationStockOptionsActivityTable OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity Details 60 false false R61.htm 060 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Sheet http://BIOS/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable0 OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Details 61 false false R62.htm 061 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range Sheet http://BIOS/role/ScheduleofWarrantsorRightsSharesAuthorizedbyExercisePriceRangeTable0 OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range Details 62 false false R63.htm 062 - Disclosure - OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights Sheet http://BIOS/role/ScheduleofStockholdersEquityNoteWarrantsorRightsTable0 OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights Details 63 false false R64.htm 063 - Disclosure - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Sheet http://BIOS/role/FairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable0 FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Details http://BIOS/role/FAIRVALUEMEASUREMENTTables 64 false false R65.htm 064 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://BIOS/role/SUBSEQUENTEVENTSDetails0 SUBSEQUENT EVENTS (Details) Details http://BIOS/role/SUBSEQUENTEVENTS 65 false false All Reports Book All Reports bios-20180331.xml bios-20180331.xsd bios-20180331_cal.xml bios-20180331_def.xml bios-20180331_lab.xml bios-20180331_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 84 0001185185-18-000924-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001185185-18-000924-xbrl.zip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end

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